fingolimod hydrochloride has been researched along with sphingosine in 1352 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (sphingosine) | Trials (sphingosine) | Recent Studies (post-2010) (sphingosine) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 8,325 | 117 | 3,459 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | sphingosine (IC50) |
|---|---|---|---|
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 6.3125 | |
| cAMP-dependent protein kinase catalytic subunit alpha | Rattus norvegicus (Norway rat) | 0.098 | |
| Sphingosine kinase 2 | Homo sapiens (human) | 1.56 | |
| Sphingosine kinase 1 | Homo sapiens (human) | 3.86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 56 (4.14) | 18.2507 |
| 2000's | 478 (35.36) | 29.6817 |
| 2010's | 773 (57.17) | 24.3611 |
| 2020's | 45 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Amari, M; Chiba, K; Enosawa, S; Hoshino, Y; Kakefuda, T; Naoe, S; Shinomiya, T; Suzuki, S | 1 |
| Chiba, K; Fujita, T; Hoshino, Y; Masubuchi, Y; Ohtsuki, M; Sasaki, S; Suzuki, C; Yanagawa, Y | 1 |
| Amano, Y; Chiba, K; Hoshino, Y; Masubuchi, Y; Ohtsuki, M; Suzuki, C | 1 |
| Amano, Y; Chiba, K; Higashi, H; Hoshino, Y; Kakefuda, T; Kataoka, H; Kawaguchi, T; Ohtsuki, M; Rahman, F; Suzuki, S; Teshima, K | 1 |
| Amemiya, H; Chiba, K; Enosawa, S; Hoshino, Y; Kakefuda, T; Suzuki, S | 1 |
| Kawasaki, T; Kozutsumi, Y; Nakamura, S | 1 |
| Amari, M; Amemiya, H; Chiba, K; Enosawa, S; Hoshino, Y; Kakefuda, T; Li, XK; Mitsusada, M; Naoe, S; Shinomiya, T; Suzuki, S; Takahara, S | 1 |
| Amemiya, H; Enosawa, S; Kakefuda, T; Li, XK; Suzuki, S | 1 |
| Amemiya, H; Enosawa, S; Kakefuda, T; Li, XK; Mitsusada, M; Suzuki, S; Takahara, S | 1 |
| Amari, M; Amemiya, H; Enosawa, S; Li, XK; Naoe, S; Shinomiya, T; Suzuki, S | 1 |
| Enosawa, S; Li, XK; Shinomiya, T; Suzuki, S | 1 |
| Enosawa, S; Kakefuda, T; Kobayashi, E; Mitsusada, M; Miyata, M; Suzuki, S | 1 |
| Afford, SC; Antoniou, EA; D'Silva, M; McMaster, P; Pirenne, J; Suzuki, S; Xu, M | 1 |
| Amemiya, H; Li, XK; Shinomiya, T; Suzuki, S | 1 |
| Chueh, SC; Kahan, BD; Stepkowski, SM; Tian, L; Wang, M; Wang, ME | 1 |
| Doi, K; Kawai, S; Kido, K; Muramatsu, K; Shigetomi, M | 1 |
| Amemiya, H; Chiba, K; Hoshino, Y; Kakefuda, T; Kataoka, H; Kawaguchi, T; Rahman, F; Suzuki, S | 1 |
| Kahan, BD; Okamoto, M; Qu, X; Stepkowski, SM; Tejpal, N; Wang, ME; Yu, J | 1 |
| Chiba, K; Hoshino, Y; Kataoka, H; Kawaguchi, T; Masubuchi, Y; Ohtsuki, M; Yanagawa, Y | 1 |
| Chiba, K; Kataoka, H; Kawaguchi, T; Masubuchi, Y; Sugahara, K; Yanagawa, Y | 1 |
| Chikahisa, L; Hirata, A; Kanemaru, K; Nagano, T; Nakata, M; Noguchi, S; Okazaki, E; Oyama, Y | 1 |
| Antoniou, EA; D'Silva, M; Drayson, M; Howie, AJ; McMaster, P | 1 |
| Amemiya, H; Hiromitsu, K; Li, XK; Suzuki, K; Suzuki, S; Yan, H | 2 |
| Fukao, K; Jinzenji, Y; Otsuka, M; Sakurayama, N; Suzuki, S; Takada, Y; Taniguchi, H; Yuzawa, K | 1 |
| Amemiya, H; Kawabe, A; Kazui, T; Li, XK; Suzuki, K; Suzuki, S | 1 |
| Dohi, K; Fukuda, Y; Miyata, Y; Ohdan, H; Shintaku, S | 1 |
| Afford, SC; Antoniou, EA; D'Silva, M; McMaster, P; Pirenne, J; Xu, M | 1 |
| Kahan, BD; Troncoso, P | 1 |
| Kahan, BD | 5 |
| Kahan, BD; Okamoto, M; Qu, X; Stepkowski, SM; Tejpal, N; Wang, M; Yu, J | 1 |
| Fujiwara, I; Mizuta, N; Nakajima, H; Oka, T; Sun, E | 1 |
| Antoniou, S; D'Silva, M; Gunson, B; McMaster, P; Pirenne, J; Xu, M | 1 |
| Fujiwara, I; Matsuda, T; Mizuta, N; Nakajima, H; Oka, T | 1 |
| Hashimoto, K; Kimura, M; Kubo, M; Li, X; Nakayama, T; Shimizu, C; Sugaya, K; Suzuki, S | 1 |
| Amemiya, H; Funeshima, N; Kawabe, A; Kazui, T; Li, XK; Suzuki, K; Suzuki, S | 1 |
| Asahara, T; Dohi, K; Fan, XH; Fudaba, Y; Fukuda, Y; Miyata, Y; Noriyuki, T; Ohdan, H; Shibata, S; Shintaku, S; Yamamoto, H; Yoshioka, S | 1 |
| Chiba, K; Masubuchi, Y; Yanagawa, Y | 1 |
| Chueh, SC; Clark, J; Kahan, BD; Qu, X; Stepkowski, SM; Troncoso, P; Wang, ME | 1 |
| Adachi, K; Fujita, T; Kiuchi, M; Kohara, T; Masubuchi, Y; Mishina, T; Teshima, K | 1 |
| Koyasu, S; Matsuda, S; Minowa, A; Suzuki, S | 1 |
| Azuma, H; Ichimaru, N; Matsumiya, K; Nonomura, N; Okuyama, A; Suzuki, S; Takahara, S; Toki, K; Wang, JD | 1 |
| Hamada, Y; Nagasawa, K; Sakano, Y; Toshima, T; Watanabe, H | 1 |
| Kimura, F; Luo, ZJ; Miyasaka, M; Tanaka, T | 1 |
| Furukawa, Y; Hara, M; Hwang, MW; Iwasaki, A; Matsumori, A; Okada, M; Ono, K; Sasayama, S | 1 |
| Fujimura, A; Hozumi, Y; Kobayashi, E; Miyata, M | 1 |
| Suzuki, S | 1 |
| Fukai, M; Furukawa, H; Horiuchi, H; Iida, J; Jin, MB; Kishida, A; Magata, S; Matsushita, M; Nomura, M; Omura, T; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S; Yamashita, K; Yokota, R | 1 |
| Amemiya, H; Enosawa, S; Funeshima, N; Li, XK; Suzuki, S; Tamura, A | 1 |
| Amemiya, H; Enosawa, S; Funeshima, N; Hayashi, S; Kazui, T; Kita, Y; Li, XK; Suzuki, K; Suzuki, S; Tamura, A | 1 |
| Fujiwara, I; Matsuda, T; Mizuta, N; Nakajima, H; Oka, T; Yamagishi, H | 1 |
| Arendse, H; Auer, R; Davison, G; Ehrhart, F; Fullard, L; Kraus, G; Markgraaff, N; Quesniaux, V; Schuurman, HJ | 1 |
| Hikita, N; Ikeda, E; Kurose, S; Mochizuki, M; Tokiwa, M | 1 |
| Amemiya, H; Enosawa, S; Funeshima, N; Kitajima, M; Li, XK; Suzuki, S; Tamura, A | 1 |
| Brinkmann, V; Chiba, K; Feng, L; Pinschewer, D | 1 |
| Fujita, M; Fukai, M; Furukawa, H; Hayashi, T; Ishikawa, H; Jin, MB; Kishida, A; Magata, S; Masuko, H; Nagashima, K; Ogata, K; Omura, T; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S; Yamashita, K | 1 |
| Fujimura, A; Hashizume, K; Kanno, T; Kitoh, Y; Kobayashi, E; Miyashita, F; Mizuta, K; Mori, M; Ohmori, M | 1 |
| Napoli, KL | 1 |
| Imayoshi, T; Matsuura, M; Okumoto, T | 1 |
| Isobe, M; Kitabayashi, H; Sekiguchi, M; Suzuki, J; Watanabe, N; Yazaki, Y | 1 |
| Fujita, T; Hirose, R; Kohno, T; Kurio, W; Matsumoto, N; Shimizu, T; Uchida, S; Watabe, K; Yanada, K | 1 |
| Kahan, BD; Stephkowski, SM; Wang, M; Yuzawa, K | 1 |
| Amemiya, H; Enosawa, S; Funeshima, N; Li, XK; Ohba, M; Okuyama, T; Suzuki, S; Tamura, A | 1 |
| Gao, W; Ge, Q; Sun, E; Zeng, Y; Zhang, L; Zhao, M | 1 |
| Chiba, K; Kobayakawa, T | 1 |
| Hong, JC; Kahan, BD; Katz, SM | 1 |
| Brinkmann, V; Hengartner, H; Ochsenbein, AF; Odermatt, B; Pinschewer, DD; Zinkernagel, RM | 1 |
| Chiba, K; Itoh, T; Kamba, R; Nakamura, M; Soga, H; Yagi, H; Yaguchi, K | 1 |
| Enosawa, S; Ikekita, M; Nagahara, Y; Shinomiya, T; Suzuki, S | 1 |
| Baumlin, Y; Hof, A; Hof, RP; Kraus, G; Nikolova, Z; Rudin, M | 1 |
| Bari, S; Groth, CG; Korsgren, O; Nava, S; Song, Z; Sundberg, B; Wennberg, L; Wijkström, M; Zhang, J | 1 |
| Adachi, K; Aoki, Y; Arita, M; Chiba, K; Fujita, T; Hanano, T; Hoshino, Y; Kiuchi, M; Kohara, T; Minoguchi, M; Mishina, T; Nakao, N; Ohtsuki, M; Sasaki, S; Teshima, K | 1 |
| Ikekita, M; Nagahara, Y; Shinomiya, T | 2 |
| Chiba, K; Hoshino, Y; Yanagawa, Y | 1 |
| Ji, P; Koshiba, T; McMaster, P; Pirenne, J; Tanaka, K; Van Damme, B; Waer, M | 1 |
| Baumlin, Y; Hof, A; Hof, RP; Nikolova, Z | 3 |
| Chiba, K; Imayoshi, T; Matsuura, M; Okumoto, T | 1 |
| Azuma, H; Katsuoka, Y; Kusaka, M; Suzuki, S; Takahara, S; Ueda, H | 1 |
| Böhler, T; Budde, K; Friedrich, M; Neumayer, HH; Reinhold, S; Schmouder, R; Schötschel, R; Schütz, M; Waiser, J | 1 |
| Amemiya, H; Goto, T; Kimura, H; Kokubo, T; Lei, G; Miyamoto, M; Suzuki, S | 1 |
| Chiu, B; Chueh, SC; Lai, MK; Li, YC; Tsai, CC | 1 |
| Amemiya, H; Enosawa, S; Kita, Y; Li, XK; Ogoshi, S; Ohba, M; Sasakuri, S; Suzuki, S; Tamura, A | 1 |
| Bernhard, M; Hedinger, R; Kraus, G; Kunkler, A; Menninger, K; Quesniaux, VF; Schuurman, HJ; Vedrine, C | 1 |
| Aizu-Yokota, E; Hasegawa, M; Kasahara, T; Momoi, T; Sakurai, S; Sonoda, Y; Yamamoto, D | 1 |
| Amari, M; Amemiya, H; Enosawa, S; Fujino, M; Funeshima, N; Guo, L; Kakefuda, T; Li, XK; Naoe, S; Suzuki, S; Tamura, A | 1 |
| Kelly, DA; van Mourik, ID | 1 |
| Pohanka, E | 1 |
| Amemiya, H; Enosawa, S; Funeshima, N; Kita, Y; Li, XK; Nagai, H; Ogoshi, S; Ohba, M; Okuyama, T; Sasaguri, S; Suzuki, S; Zhang, H | 1 |
| Hwang, MW; Ito, H; Matsumori, A; Miyamoto, T; Nishio, R; Sasayama, S | 1 |
| Hammond-McKibben, D; Hugo, R; Lake, P; Tart-Risher, N; Weetall, M; Zhang, J | 1 |
| Hof, RP; Nikolova, Z | 1 |
| Audet, M; Gaschen, L; Menninger, K; Quesniaux, V; Schuurman, HJ | 1 |
| Diaz-Romero, J; Vogt, G; Weckbecker, G | 1 |
| Higuchi, S; Ikekita, M; Matsuoka, Y; Nagahara, Y; Saito, K; Shinomiya, T | 1 |
| Morley, SJ; Pain, VM | 1 |
| Brinkmann, V; Chen, S; Feng, L; Pinschewer, DD | 1 |
| Dumont, FJ | 2 |
| Morel, D | 1 |
| Thervet, E | 1 |
| Amano, T; Fujino, M; Guo, L; Li, XK; Suzuki, S | 1 |
| Brinkmann, V; Förster, R; Henning, G; Hohenberger, W; Junt, T; Lipp, M; Nakano, H; Ohl, L; Reiterer, P | 1 |
| Little, MT; Sale, GE; Storb, R; Storer, B; Xun, CQ; Yu, C; Zaucha, JM; Zellmer, E | 1 |
| Bai, Y; Boros, P; Bromberg, JS; Honig, S; Liu, J; Qin, L; Wang, Y | 1 |
| Kongkanand, A; Matsumiya, K; Nishimura, K; Nonomura, N; Okuyama, A; Permpongkosol, S; Takahara, S; Tsujimura, A; Wang, JD | 1 |
| Amano, T; Fujino, M; Funeshima, N; Guo, L; Kawasaki, M; Kitazawa, Y; Li, XK; Suzuki, S | 1 |
| Azuma, H; Fukui, R; Hoshiga, M; Ichimaru, N; Ishihara, T; Itoh, Y; Katsuoka, Y; Morimoto, J; Nonomura, N; Okuyama, A; Otsuki, Y; Suzuki, S; Takahara, S; Wang, JD | 1 |
| Brunkhorst, R; Budde, K; Choudhury, S; Kraus, G; Lücker, PW; Mayer, T; Nashan, B; Neumayer, HH; Schmouder, RL; Skerjanec, A | 1 |
| Bergstrom, J; Card, D; Hajdu, R; Hale, J; Keohane, C; Lynch, CL; Mandala, S; Milligan, J; Parsons, W; Quackenbush, E; Rosen, H; Rosenbach, M; Rupprecht, K; Shei, GJ; Thornton, R; Xie, J | 1 |
| Fujimura, A; Hirata, D; Iwamoto, M; Kamimura, T; Kano, S; Kobayashi, E; Masuyama, J; Minota, S; Okazaki, H; Sato, H; Yoshio, T | 1 |
| Arima, N; Chiba, K; Heining, P; Jusko, WJ; Li, H; Meno-Tetang, GM | 1 |
| Albert, R; Baumruker, T; Brinkmann, V; Bruns, C; Cottens, S; Davis, MD; Foster, CA; Heise, CE; Hiestand, P; Hof, R; Lynch, KR; Prieschl, E; Zollinger, M | 1 |
| Brinkmann, V; Deleo, J; Fu, F; Hoover, J; Hopf, C; Hu, S; Lake, P; Li, S; Shi, VC; Wang, S | 1 |
| Koshiba, T; Lu, Y; Mathieu, C; Overbergh, L; Pirenne, J; Rutgeerts, O; Tanaka, K; Van Damme, B; Waer, M; Yan, Y | 1 |
| Honda, K; Kiyochi, H; Kobayashi, N; Sakagawa, T | 2 |
| Inobe, M; Konishi, K; Murakami, M; Todo, S; Uede, T; Yamada, A | 1 |
| Hatori, M; Ichimaru, N; Morozumi, K; Okuyama, A; Suzuki, K; Suzuki, S; Takahara, S; Tanaka, T; Wang, J; Yamanaka, H | 1 |
| Hayashi, S; Ida, M; Ito, Y; Kageyama, Y; Kazui, T; Kita, Y; Li, X; Matsushita, K; Nogimura, H; Ohi, S; Suzuki, K; Suzuki, S; Takahashi, T | 1 |
| Amersi, FF; Anselmo, D; Brinkmann, V; Busuttil, RW; Coito, AJ; Farmer, DG; Gao, F; Katori, M; Ke, B; Kupiec-Weglinski, JW; Lassman, C; Shen, XD | 1 |
| Sykes, M | 1 |
| Brinkmann, V; Lynch, KR | 1 |
| Boehler, T; Budde, K; Neumayer, H; Schuetz, M; Waiser, J | 1 |
| Mabuchi, A; Tawadrous, MN; Wheatley, AM; Zimmermann, A | 1 |
| Amersi, FF; Anselmo, DM; Brinkmann, V; Busuttil, RW; Coito, AJ; Farmer, DG; Gao, F; Katori, M; Ke, B; Kupiec-Weglinski, JW; Lassman, C; Ma, J; Shen, XD | 1 |
| Audet, M; Bernhard, M; Brinkmann, V; Gaschen, L; Kunkler, A; Maurer, C; Menninger, K; Quesniaux, V; Schuurman, HJ; Vedrine, C | 1 |
| Hof, RP; Matsumoto, Y | 1 |
| Baumlin, Y; Hof, A; Hof, RP; Matsumoto, Y | 1 |
| Im, DS | 1 |
| Gottschalk, R; Maki, T; Monaco, AP | 1 |
| Lee, YS; Magae, J; Matsuda, T; Mizuta, N; Nakajima, H | 1 |
| Cai, DH; Chen, H; Zhang, H; Zhao, DM | 1 |
| Ida, M; Kageyama, Y; Kazui, T; Kita, Y; Li, XK; Nogimura, H; Ohi, S; Suzuki, K; Suzuki, S | 1 |
| Chen, ZK; Min, ZL; Shen, SQ; Sun, EW; Zhang, L; Zhu, T | 1 |
| Bromberg, JS; Fu, S; Gunn, MD; Honig, SM; Mao, X; Randolph, GJ; Yopp, A | 1 |
| Asavaroengchai, W; Bronson, R; Kim, YM; Sachs, T; Sykes, M | 1 |
| Forrest, MJ; Koprak, SL; Nomura, N; Quackenbush, EJ; Rosen, H; Xie, JH | 1 |
| Amemiya, H; Fujino, M; Funeshima, N; Kimura, H; Kitazawa, Y; Li, XK; Suzuki, S | 1 |
| Koshiba, T; Pirenne, J; Rutgeerts, O; Van Damme, B; Waer, M | 1 |
| Goetschy, JF; Hagiwara, S; Movva, NR; Welsch, CA | 1 |
| Ikekita, M; Matsuoka, Y; Nagahara, Y; Shinomiya, T | 1 |
| Bennet, W; Goto, M; Groth, CG; Korsgren, O; Maeda, A; Wennberg, L; Zhang, J | 1 |
| Lee, YS; Magae, J; Nakajima, H; Tsuruga, M | 1 |
| Brinkmann, V; Chen, M; Ellett, JD; Fialkow, LB; Lynch, KR; Nadler, JL; Wu, R; Yang, Z | 1 |
| Azuma, H; Horie, S; Katsuoka, Y; Muto, S; Otsuki, Y; Takahara, S | 1 |
| Azuma, T; Hasegawa, T; Kimura, T; Nakai, H; Okada, A; Sasaki, T; Usui, N | 1 |
| Böhler, T; Brookman, L; Brunkhorst, R; Budde, K; L Schmouder, R; Mayer, T; Nashan, B; Nedelman, J; Neumayer, HH; Skerjanec, A; W Lücker, P | 1 |
| Ji, P; Koshiba, T; Pirenne, J; Rutgeerts, O; Sefrioui, H; Van Damme, B; Waer, M | 1 |
| Kahan, BD; Ortiz, AM; Troncoso, P | 1 |
| Aki, FT; Kahan, BD | 1 |
| Liao, J; Rosen, H | 1 |
| Brinkmann, V; Claffey, K; Estrada-Hernandez, T; Hla, T; Paik, JH; Sanchez, T; Venkataraman, K; Wu, MT | 1 |
| Huang, HZ; Milekhin, V; Wang, MH; Zhang, H | 1 |
| Alfonso, C; Rosen, H; Sanna, G | 1 |
| Baumruker, T; Billich, A; Bornancin, F; Dévay, P; Mechtcheriakova, D; Urtz, N | 1 |
| Chodoff, L; Ferguson, RM; Gonwa, TA; Kahan, BD; Karlix, JL; Leichtman, AB; Mulgaonkar, S; Schmouder, RL; Skerjanec, A | 1 |
| Braun, WE | 1 |
| Hogan, WJ; Kuhr, CS; Lee, RS; Little, MT; Sale, GE; Storb, R; Zellmer, E | 1 |
| Barbour, SE; Milstien, S; Paugh, SW; Payne, SG; Spiegel, S | 1 |
| Brinkmann, V; Kemeny, DM; Manlius, C; Sawicka, E; Trifilieff, A; Walker, C; Zuany-Amorim, C | 1 |
| Hoffmann, F; Ignatius, R; Müller, A; Zhang, EP | 1 |
| Bromberg, JS; Chen, D; Ding, Y; Fu, S; Mao, M; Mao, X; Yopp, AC; Zhang, N | 1 |
| Böhler, T; Budde, K; Neumayer, HH; Schumann, B; Schütz, M; Waiser, J | 1 |
| McDonald, RA; Nemeth, TL; Smith, JM | 1 |
| Goetzl, EJ; Gräler, MH | 1 |
| Ahn, MY; Alfonso, C; Chun, J; Gray, N; Jo, E; Lefebvre, S; Liao, J; Peterson, MS; Rosen, H; Sanna, MG; Webb, B | 1 |
| Allende, ML; Brinkmann, V; Cinamon, G; Cyster, JG; Lesneski, MJ; Lo, CG; Matloubian, M; Proia, RL; Xu, Y | 1 |
| Bergstrom, J; Card, D; Doherty, G; Forrest, M; Hajdu, R; Hale, J; Keohane, C; Mandala, S; Meyers, C; Milligan, J; Mills, S; Nomura, N; Proia, RL; Rosen, H; Rosenbach, M; Shei, GJ; Singer, II; Sun, SY; Tian, M; West, S; White, V; Xie, J | 1 |
| Chen, ZH; Guo, H; Min, ZL; Shen, SQ; Sun, EW; Zhang, L; Zhu, T | 1 |
| Barshes, NR; Goodpastor, SE; Goss, JA | 1 |
| Böhler, T; Budde, K; Neumayer, HH; Schuetz, M; Waiser, J | 1 |
| Böhler, T; Budde, K; Dragun, D; Haller, H; Luft, FC; Neumayer, HH; Nieminen-Kelhä, M; Schneider, W; Waiser, J | 1 |
| Boehmler, AM; Brinkmann, V; Kanz, L; Kimura, T; Kuçi, S; Möhle, R; Seitz, G; Wiesner, T | 1 |
| Burne, MJ; Garcia, JG; Hassoun, PM; McVerry, BJ; Pearse, D; Peng, X; Rabb, H; Sammani, S; Tuder, RM | 1 |
| Boehler, T; Budde, K; Dragun, D; Fritsche, L; Neumayer, HH; Peters, H | 1 |
| Ferguson, R | 1 |
| Kover, KL; Moore, WV; Popovic, J | 1 |
| Goetzl, EJ | 1 |
| Cottens, S; Hering, BJ; Kenyon, NM; Kenyon, NS; Kirchhof, N; Lake, P; Mullon, C; Ricordi, C; Wijkstrom, M | 1 |
| Barilla, D; Kovarik, JM; Kraus, G; Schmouder, R; Wang, Y | 1 |
| Barilla, D; Hunt, T; Kovarik, JM; Riviere, GJ; Schmouder, R; Wang, Y | 1 |
| Brock, J; Kotsch, K; Lehmann, M; Nickel, P; Reinke, P; Risch, K; Ritter, T; Schroeder, G; Siepert, A; Volk, HD | 1 |
| Ann Keohane, C; Bergstrom, J; Card, D; Chrebet, G; Hajdu, R; Hale, JJ; Jackson, JJ; Koo, GC; Koprak, SL; Mandala, S; Milligan, J; Mills, SG; Neway, W; Rosen, H; Rosenbach, M; Shei, GJ | 1 |
| Fürstner, A; Laurich, D; Seidel, G | 1 |
| Argraves, KM; Obeid, LM; Taha, TA | 1 |
| Butler, J; LaMontagne, K; Lana, D; Round, O | 1 |
| Cao, W; Hu, X; Huang, W; Li, D; Zhang, Y | 1 |
| Calne, SR | 1 |
| Böhler, T; Budde, K; Dragun, D; Neumayer, HH; Schütz, M; Waiser, J | 1 |
| Cinamon, G; Cyster, JG; Lesneski, MJ; Low, C; Lu, T; Matloubian, M; Proia, RL; Xu, Y | 1 |
| Goetschy, JF; Movva, NR; Roth, LW; Welsch, CA | 1 |
| Borra, RC; Bueno, V; Franco, M; Oliveira, CM; Pestana, JO; Schor, N; Silva, HT | 1 |
| Bueno, V; Lima, RS; Nogueira-Martins, MF; Pestana, JO; Silva, HT | 1 |
| Brinkmann, V; Cyster, JG; Hla, T | 1 |
| Kabelitz, D; Kunzendorf, U; Ziegler, E | 1 |
| Birnbaum, F; Braunstein, S; Claas, F; Mayer, K; Reinhard, T; Reis, A; Sundmacher, R | 1 |
| Djanani, AM; Feistritzer, C; Kaneider, NC; Lindner, J; Mosheimer, BA; Sturn, DH; Wiedermann, CJ | 1 |
| Baumann, DR; Cannet, C; Foster, CA; Hiestand, P; Rausch, M; Rudin, M | 1 |
| Boira, JG; Charpentier, B; Kahan, BD; Madsen, S; Mourad, G; Mulgaonkar, S; Nashan, B; Pellet, P; Tedesco-Silva, H; Vanrenterghem, Y; Weimar, W | 2 |
| Fujishiro, J; Inoue, S; Kobayashi, E; Murakami, T; Shimizu, H; Yoshino, H | 1 |
| Gunn, MD; Kelsoe, G | 1 |
| Bromberg, JS; Ding, Y; Fu, S; Honig, SM; Krieger, NR; Randolph, GJ; Yopp, AC | 1 |
| Takeya, H | 1 |
| Cerio, J; Gabardi, S | 1 |
| Chun, J; Hale, J; Lariosa-Willingham, K; Lin, FF; Mandala, S; Rao, TS; Tham, CS; Webb, M; Yu, N | 1 |
| Barbour, SE; Milstien, S; Payne, SG; Spiegel, S | 1 |
| Ito, T; Kai, Y; Kishi, D; Kiyono, H; Matsuda, H; Mizushima, T; Nezu, R; Tamagawa, H | 1 |
| Fan, ST; Ho, JW; Lee, TK; Man, K; Ng, IO; Ng, KT; Sun, CK; Wang, XH; Wong, YC; Xu, R | 1 |
| Dai, XW; Fan, ST; Lee, TK; Li, XL; Lo, CM; Man, K; Ng, KT; Sun, CK; Zhao, Y | 1 |
| Feng, L; Garcia, G; Guan, H; Han, S; Li, P; Wang, G; Zhang, X; Zheng, B | 1 |
| Heemann, U; Liu, S; Lutz, J; Ouyang, N; Song, E; Wang, M | 1 |
| Bergstrom, JD; Card, D; Chrebet, GL; Hajdu, R; Hale, JJ; Mandala, S; Milligan, JA; Neway, WE; Rosenbach, M; Shei, GJ; Thornton, RA; Yan, L | 1 |
| Fujita, T; Hirayama, K; Kohno, T; Matsumoto, A; Tsuji, T; Watabe, K | 1 |
| Kawachi, H; Krämer, S; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y | 1 |
| Allende, ML; Hajdu, R; Kawai, H; Keohane, CA; Mandala, S; Mi, Y; Olivera, A; Proia, RL; Rosenbach, M; Sasaki, T; Spiegel, S; van Echten-Deckert, G | 1 |
| Lee, WJ; Lee, YM; Lim, JS; Oh, S; Suh, PG; Yoo, HS | 1 |
| Isoyama, N; Kishi, Y; Matsumura, M; Naito, K; Takahara, S; Takai, K; Tsuchida, M; Uchiyama, K | 1 |
| Kovarik, JM; Schmouder, RL; Slade, AJ | 1 |
| Elices, MJ | 1 |
| Clemens, JJ; Davis, MD; Lynch, KR; Macdonald, TL | 2 |
| Fujita, M; Fukai, M; Furukawa, H; Horiuchi, H; Jin, MB; Magata, S; Nagashima, K; Nomura, M; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S; Yamashita, K; Yokota, R | 1 |
| Emre, S; Krieger, NR | 1 |
| Adachi, K; Chiba, K; Chino, M; Kiuchi, M; Maeda, Y; Mitsutomi, N; Sato, N; Sugahara, K; Takeda, S; Tanaka, Y; Tomatsu, A | 1 |
| Fan, ST; Ho, JW; Lee, TK; Man, K; Ng, IO; Ng, KT; Poon, RT; Sun, CK; Wang, XH; Xu, R | 1 |
| Brinkmann, V | 3 |
| Arai, S; Ishii, K; Kiriyama, M; Sugiyama, S | 1 |
| Fan, ST; Ho, JW; Lee, TK; Li, XL; Lo, CM; Man, K; Ng, KT; Sun, CK; Zhao, Y | 1 |
| He, JH; Lin, ZB; Zhang, HN | 1 |
| Enosawa, S; Fukuchi, K; Hakamata, Y; Iwanami, S; Kaneko, T; Kishi, T; Kobayashi, E; Kudou, S; Kuriyama, K; Matsumoto, K; Morishita, Y; Murakami, T; Shimizu, H; Takahashi, M; Takeyoshi, I; Yasue, T | 1 |
| Heufler, C; Hofer, S; Kaneider, N; Konwalinka, G; Mayer, G; Mosheimer, B; Müller, H; Neuwirt, H; Tiefenthaler, M | 1 |
| Baczkowska, T; Durlik, M | 1 |
| Goto, R; Ichimaru, N; Kangawa, K; Kawano, Y; Moriyama, T; Nakahama, H; Okuyama, A; Sada, M; Shi, Y; Takahara, S; Yazawa, K; Yoshihara, F | 1 |
| Filipec, M; Forrester, JV; Muckersie, E; Robertson, M; Sedláková, K | 1 |
| Brinkmann, V; Koyrakh, L; Roman, MI; Wickman, K | 1 |
| Böhler, T; Budde, K; Neumayer, HH; Waiser, J | 1 |
| Lowe, PJ; Meno-Tetang, GM | 1 |
| Cyster, JG | 1 |
| Dilzer, SC; Kovarik, JM; Lasseter, KC; Schmouder, RL; Serra, D; Wang, Y; Wiegand, H | 1 |
| Itoh, M; Kataoka, H; Kuno, A; Nakao, H; Ogawa, K; Ohara, H; Okamoto, T; Sano, H; Shirai, T; Tang, M; Yamada, T | 1 |
| Brinkmann, V; Chun, J; Giebing, G; Jankowski, J; Jankowski, V; Keul, P; Levkau, B; Schäfers, M; Schönfelder, G; Tölle, M; Van der Giet, M; von Wnuck Lipinski, K; Zidek, W | 1 |
| Fujita, T; Hayashi, M; Hirayama, K; Hirose, M; Iwatsuki, R; Kohno, T; Matsumoto, A; Tsuji, T; Watabe, K; Yoshikawa, H | 1 |
| Itoh, S; Katsuoka, Y; Nomi, H; Shibahara, N; Takahara, S; Ueda, H | 1 |
| Bonasio, R; Gauguet, JM; Halin, C; Mandala, S; Mempel, TR; Proia, RL; Quackenbush, E; Scimone, ML; von Andrian, UH | 1 |
| Gottschalk, R; Maki, T; Monaco, AP; Ogawa, N | 1 |
| Cui, Y; Hajdu, R; Hale, J; Keohane, CA; Mandala, S; Neway, W; Nichols, E; Porter, G; Vora, KA; Zaller, D | 1 |
| Bendszus, M; Stoll, G | 1 |
| Felipe, CR; Garcia, R; Machado, PG; Medina-Pestana, JO; Park, SI; Schmouder, R; Skerjanec, A; Tedesco-Silva, H | 1 |
| Cai, JQ; Dong, WP; Tan, JM; Wang, JB; Wang, YF | 1 |
| Chiba, K | 3 |
| Cozzi, E; Schuurman, HJ; Smith, HT | 1 |
| Beckmann, JH; Brinkmann, V; Förster, R; Hoffmann, MW; Pabst, O; Rodriguez-Barbosa, JI; Yan, S | 1 |
| Chan, FL; Chua, CW; Ho, J; Lee, DT; Ling, MT; Man, K; Wang, X; Wong, YC; Zhou, C | 1 |
| Fukuzawa, M; Hagiwara, N; Ikeda, T; Inoue, M; Koshinaga, T; Sugito, K | 2 |
| Albert, R; Brinkmann, V; Cooke, N; Francotte, E; Guerini, D; Hinterding, K; Knecht, H; Müller-Hartwieg, C; Simeon, C; Streiff, M; Wagner, T; Welzenbach, K; Zécri, F; Zollinger, M | 1 |
| Burcin, TL; Engelhard, VH; Kharel, Y; Lee, S; Ley, K; Lynch, KR; Macdonald, TL; Morris, MA; Pearson-White, S; Setiady, Y; Sheasley-O'neill, SL; Snyder, AH; Tung, KS; Zhu, R; Zigler, MA | 1 |
| Albert, R; Anderson, KC; Brinkmann, V; Catley, L; Chauhan, D; Hamasaki, M; Hideshima, T; Ishitsuka, K; Kumar, S; Mitsiades, CS; Podar, K; Raje, N; Richardson, PG; Roccaro, AM; Shiraishi, N; Tai, YT; Yasui, H | 1 |
| Bromberg, JS; Ding, Y; Ledgerwood, L; Mao, M; Ochando, JC; Yopp, AC | 1 |
| Bernhardt, G; Czeloth, N; Förster, R; Genth, H; Hofmann, F | 1 |
| Bandhuvula, P; Oskouian, B; Saba, JD; Tam, YY | 1 |
| DA, WM; Huang, WR; Wang, LS | 1 |
| Hla, T | 1 |
| Fan, ST; Ho, JW; Lee, TK; Man, K; Poon, RT; Sun, CK | 1 |
| Abe, M; Brinkmann, V; Coates, PT; Colvin, BL; De Creus, A; Lan, YY; Thomson, AW | 1 |
| Baumruker, T; Billich, A; Bornancin, F; Kinzel, B; Mechtcheriakova, D; Müller, M; Reuschel, R; Urtz, N; Zemann, B | 1 |
| Baumruker, T; Billich, A; Ettmayer, P; Guerini, D; Mechtcheriakova, D; Nussbaumer, P; Streiff, MB | 1 |
| Budde, K; Cole, E; Hsu, CH; Neumayer, HH; Schmouder, R; Skerjanec, A; Tedesco, H | 1 |
| Brinkmann, V; Gibb, DR; Ley, K; Morris, MA; Picard, F; Straume, M | 1 |
| Eberhardt, W; Huwiler, A; Pfeilschifter, J; Ren, S; Xin, C | 2 |
| Forrest, MJ; Lin, J; Mandala, S; Matheravidathu, SS; Quackenbush, EJ; Singer, II; Tian, M; Wickham, LA | 1 |
| Ahn, KO; Bang, BK; Choi, BS; Kim, J; Kim, JS; Kim, JY; Kim, YS; Li, C; Lim, SW; Yang, CW; Yang, HJ | 1 |
| Chu, AC; Fan, ST; Ho, JW; Lee, TK; Man, K; Ng, IO; Ng, KT; Poon, RT; Sun, CK; Sun, HC; Tang, ZY; Wang, XH; Xu, R; Xu, Y | 1 |
| Albert, R; Brinkmann, V; Dubois, G; Edwards, M; Jarai, G; Newson, C; Nicholls, A; Sawicka, E; Thomas, M; Walker, C | 1 |
| Brinkmann, V; Clarkson, MR; Fernandes, S; Habicht, A; Henderson, J; Jurewicz, M; Sayegh, MH; Yang, J; Yuan, X | 1 |
| Senior, K | 1 |
| Brinkmann, V; Del Rio, ML; Domínguez-Perles, R; Muñoz-Luna, A; Parrilla-Paricio, P; Peñuelas-Rivas, G; Ramírez-Romero, P; Rodríguez-Barbosa, JI | 1 |
| Domínguez, J; Kahan, BD; Ortiz, AM; Troncoso, P | 1 |
| Chen, Y; Fairchild, RL; Heeger, PS; Valujskikh, A; Zhang, Q | 1 |
| Billy, E; Butler, J; Hla, T; LaMontagne, K; Liau, G; Littlewood-Evans, A; O'Reilly, T; Probst, B; Sanchez, T; Schnell, C; Theuer, A; Wood, A; Wood, J; Wyder, L | 1 |
| Awad, AS; Foss, FW; Huang, L; Li, L; Lynch, KR; Macdonald, TL; Okusa, MD; Ye, H | 1 |
| Bernhardt, G; Förster, R; Herbrand, H; Müller, W; Pabst, O; Schippers, A; Willenzon, S; Worbs, T | 1 |
| Chiba, K; Fukunari, A; Kataoka, H; Koyama, M; Shimano, K; Sugahara, K; Teshima, K | 1 |
| Hartmann, S; Kovarik, JM; Picard, F; Riviere, GJ; Schmidt, HH; Schmouder, RL; Voss, B; Wagner, F; Weiss, M | 1 |
| Fan, ST; Ho, JW; Lam, KS; Lee, TK; Li, XL; Lo, CM; Man, K; Ng, KT; Sun, CK; Xu, A; Zhao, Y | 1 |
| Kin-Wah Lee, T; Ling, MT; Man, K; Wang, X; Wong, YC; Zhou, C | 1 |
| Bittman, R; Sun, C | 1 |
| Fujita, T; Hirose, R; Kohno, T; Kurio, W; Kusumoto, H; Matsumoto, N; Shimizu, T; Uchida, S; Watabe, K; Yamaguchi, S; Yanada, K | 1 |
| Harada, T; Kanekake, H; Nishikido, M | 1 |
| Chiba, K; Maeda, Y; Matsuyuki, H; Sugahara, K | 1 |
| Baumruker, T; Brinkmann, V | 1 |
| Cassidy, MP; He, H; Milstien, S; Paugh, SW; Selley, DE; Sim-Selley, LJ; Spiegel, S | 1 |
| Fujii, R; Kanai, T; Makita, S; Nemoto, Y; Okamoto, R; Oshima, S; Totsuka, T; Tsuchiya, K; Watanabe, M | 1 |
| Chen, YJ; Gregory, CR; Kyles, AE | 1 |
| Isoyama, N; Matsumura, M; Naito, K; Takai, K; Tsuchida, M | 1 |
| Ijzermans, JN; Mol, WM; Vaessen, LM; van Besouw, NM; Weimar, W | 1 |
| Bergmann, S; Frink, M; Kaudel, CP; Klempnauer, J; Krettek, C; Pape, HC; Schmiddem, U; Winkler, M | 1 |
| Kaneko, T; Kawana, H; Kobayashi, E; Murakami, T; Takahashi, M; Yasue, T | 1 |
| Brammer, C; Cose, S; Khanna, KM; Lefrançois, L; Masopust, D | 1 |
| Heining, P; Jusko, WJ; Li, H; Lowe, P; Meno-Tetang, GM; Mis, S; Pyszczynski, N | 1 |
| El Alwani, M; Hannun, YA; Obeid, LM; Wu, BX | 1 |
| Ferguson, R; Knoflach, A; Kunzendorf, U; Mulgaonkar, S; Oppenheimer, F; Patel, Y; Russ, G; Tedesco, H; Walker, R | 1 |
| Lynch, SV; Salm, P; Taylor, PJ; Warnholtz, CR | 1 |
| Bastien, MC; DiMarco, J; Hunt, TL; Kovarik, JM; Schmouder, R; Serra, D; Wang, Y | 1 |
| Ito, T; Matsuda, C; Matsuda, H; Miao, G; Nishida, T; Nozawa, M; Sawa, Y; Song, J; Tanemura, M | 1 |
| Andoh, A; Bamba, S; Deguchi, Y; Fujiyama, Y; Inatomi, O; Tsujikawa, T; Yagi, Y | 1 |
| Massberg, S; von Andrian, UH | 1 |
| Antel, J; Comi, G; Haas, T; Kappos, L; Karlsson, G; Korn, AA; Montalban, X; O'Connor, P; Polman, CH; Radue, EW | 1 |
| Kihara, A | 1 |
| Barbour, SE; Chalfant, CE; Griffiths, R; Milstien, S; Oskeritzian, CA; Payne, SG; Spiegel, S; Subramanian, P | 1 |
| Aradhye, S; Budde, K; Charpentier, B; Eisenberger, U; Eris, J; Hmissi, A; Klempnauer, J; Nashan, B; Pallardo, LM; Rostaing, L; Salvadori, M; Schena, FP | 1 |
| Billich, A; Charron, G; Guerini, D; Hanessian, S | 1 |
| Hammad, H; Hijdra, D; Hoogsteden, HC; Idzko, M; Kool, M; Lambrecht, BN; Müller, T; Soullié, T; van Nimwegen, M; Willart, MA | 1 |
| Böhler, T; Budde, K; Glander, P; Liefeldt, L; Neumayer, HH; Peters, H; Schütz, M; Waiser, J | 1 |
| Fukuzawa, M; Hagiwara, N; Ikeda, T; Inoue, M; Koshinaga, T; Kusafuka, T; Sugito, K | 1 |
| Weissert, R | 1 |
| Aoyama, K; Asakura, S; Hashimoto, D; Koyama, M; Matsuoka, K; Sakoda, Y; Tanimoto, M; Teshima, T | 1 |
| Heusch, G; Keul, P; Levkau, B; Lucke, S; Schuchardt, M; Tölle, M; van der Giet, M; von Wnuck Lipinski, K | 1 |
| Aicher, A; Brinkmann, V; Chun, J; Dimmeler, S; Haendeler, J; Keul, P; Levkau, B; Reinhold, J; Rochwalsky, U; Seeger, F; Spyridopoulos, I; Urbich, C; Walter, DH; Zeiher, AM | 1 |
| Brinkmann, V; Hofmann, M; Zerwes, HG | 1 |
| Bueno, V; Burdmann, EA; Cury, PM; Silva, FR; Silva, LB | 1 |
| Böhler, T; Budde, K; Neumayer, HH; Schütz, M; Waiser, J | 1 |
| Miller, D | 1 |
| Huwiler, A; Pfeilschifter, J | 2 |
| Ito, T; Matsuda, C; Nishida, T; Nozawa, M; Sawa, Y; Song, J; Tanemura, M | 1 |
| Foster, C; Kovarik, JM; Lorber, MI; Tedesco-Silva, H | 1 |
| Cibrik, D; Esmeraldo, Rde M; Gugliuzza, KK; Kahan, BD; Lord, H; Mulgaonkar, S; Pescovitz, MD; Rajagopalan, PR; Rees, MA; Salvadori, M; Slade, JM; Tedesco-Silva, H | 1 |
| Chun, J; Keller, CD; Kleuser, B; Radeke, HH; Rivera Gil, P; Schäfer-Korting, M; Tölle, M; van der Giet, M | 1 |
| Fan, ST; Ho, JW; Lee, TK; Lo, CM; Man, K; Ng, KT; Poon, RT; Sun, CK; Zhao, Y | 1 |
| Bruns, CJ; Graeb, C; Guba, M; Heeschen, C; Ischenko, I; Jauch, KW; Joka, M; Papyan, A; Schmid, G; Schrepfer, S | 1 |
| Chen, YJ; Downes, S; Gregory, C; Kyles, A | 1 |
| Gonzalez-Cabrera, PJ; Hla, T; Rosen, H | 1 |
| Bueno, V; Burdmann, EA; Franco, M; Gallo, AP; Silva, LB | 1 |
| Bartlett, M; Hartmann, S; Kovarik, JM; Neddermann, D; Port, A; Riviere, GJ; Schmouder, RL; Wang, Y | 1 |
| Gohda, M; Higuchi, M; Ishikawa, I; Kiyono, H; Kunisawa, J; Kurashima, Y; Miura, F; Ogahara, I | 1 |
| Hla, T; Lin, CY; Liu, CH; Lynch, KR; Macdonald, TL; Oo, ML; Thangada, S; Wu, MT | 1 |
| Assmann, G; Biessen, EA; Bot, M; Brinkmann, V; Brodde, M; Nofer, JR; Salm, P; Taylor, PJ; van Berkel, T | 1 |
| Cahalan, SM; Gonzalez-Cabrera, PJ; Rosen, H; Sanna, MG | 1 |
| Daniel, C; Geisslinger, G; Radeke, HH; Sartory, N; Stein, JM; Zahn, N | 1 |
| Alperovich, G; Bolaños, N; Carrera, M; Cruzado, JM; Franquesa, M; Gomà, M; Grinyó, JM; Herrero-Fresneda, I; Lloberas, N; Poveda, R; Rama, I; Torras, J | 1 |
| Baumruker, T; Billich, A; Brinkmann, V | 1 |
| Nagahara, Y; Shinomiya, T; Tanaka, M | 1 |
| Kawai, R; Kovarik, JM; Mee-Lee, D; Picard, F; Riviere, GJ; Schmidli, H; Schmouder, RL; Slade, A; Sugita, Y; Voss, B | 1 |
| Chiba, K; Kataoka, H; Maeda, Y; Matsuyuki, H; Shimano, K; Sugahara, K | 1 |
| Huang, ZF; Xia, SS; Xiong, HB; Ye, QF | 1 |
| Cremer, M; Ferguson, R; Grinyó, J; Jardine, A; Juarez, F; Klinger, M; Mulgaonkar, S; Oppenheimer, F; Ostrowski, M; Preiss, R; Torres, A; Walker, R | 1 |
| Budde, K; Daig, U; Krämer, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Wang-Rosenke, Y | 1 |
| Kleuser, B; Levkau, B; Tölle, M; van der Giet, M | 1 |
| Bergmann, S; Frink, M; Kaudel, CP; Klempnauer, J; Krettek, C; Probst, C; Schmiddem, U; van Griensven, M; Winkler, M | 2 |
| Böhler, T; Budde, K; Martini, S; Peters, H | 1 |
| Dev, KK; Mullershausen, F; Osinde, M | 1 |
| Don, AS; Martinez-Lamenca, C; Proia, RL; Roberts, E; Rosen, H; Webb, WR | 1 |
| Chun, J | 1 |
| Goetzl, EJ; Huang, MC; Liao, JJ | 1 |
| Fischereder, M | 1 |
| Berg, KM; Bittman, R; Kapitonov, D; Milstien, S; Miner, AS; Payne, SG; Ratz, PH; Spiegel, S; Watterson, KR | 1 |
| Cai, M; Liu, J; Shen, Y; Wang, C; Wang, X; Xia, W; Xie, H; Zhang, Q; Zheng, S | 1 |
| Daniel, C; Geisslinger, G; Radeke, HH; Sartory, NA; Schmidt, R; Stein, JM; Zahn, N | 1 |
| Camp, SM; Chiang, ET; Dudek, SM; Garcia, JG; Natarajan, V; Singleton, PA; Usatyuk, PV; Zhao, Y | 1 |
| Bi, Y; He, X; Liu, L; Shang, W; Wang, C; Wang, D | 1 |
| Bassilana, F; Cortes-Cros, M; Craveiro, LM; Dev, KK; Guerini, D; Mullershausen, F; Osinde, M; Schwab, ME; Seuwen, K; Shin, Y; Sivasankaran, R; Thallmair, M; Wishart, WL | 1 |
| Burton, JM; O'Connor, P | 1 |
| Amagai, T; Itoi, M; Kubo, H; Mori, K; Tsukamoto, N | 1 |
| Gonsette, RE | 1 |
| Budde, K; Glander, P; Liefeld, L; Martini, S; Neumayer, HH; Offermann, G; Schmidt, S; van der Giet, M; Westhoff, TH; Zidek, W | 1 |
| Anada, Y; Igarashi, Y; Kihara, A | 1 |
| Baumruker, T; Billich, A; Bornancin, F; Mechtcheriakova, D; Sobanov, J; Wlachos, A; Zlabinger, G | 1 |
| Blazar, BR; Brinkmann, V; Ehrhardt, MJ; Lees, CJ; Panoskaltsis-Mortari, A; Serody, JS; Taylor, PA; Tolar, J; Weigel, BJ | 1 |
| Anderson, CC; Emamaullee, JA; James Shapiro, AM; Merani, S; Truong, W | 1 |
| Gohda, M; Higuchi, M; Ishikawa, I; Kiyono, H; Kunisawa, J; Kurashima, Y; Shimizu, M; Takayama, N | 1 |
| Delbridge, MS; El Nahas, AM; Haylor, JL; Raftery, AT; Shrestha, BM | 1 |
| Hartung, HP; Hohlfeld, R; Klatt, J | 1 |
| Balatoni, B; Beerli, C; Billich, A; Foster, CA; Hiestand, PC; Howard, LM; Persohn, E; Reuschel, R; Schwartz, M; Schweitzer, A | 1 |
| Schluesener, HJ; Zhang, Z | 1 |
| Frink, M; Hildebrand, F; Kaudel, CP; Klempnauer, J; Krettek, C; Pape, HC; van Griensven, M; Winkler, M | 1 |
| Guo, D; He, S; Tan, W; Wang, F | 1 |
| Blaser, BW; Bloomfield, CD; Byrd, JC; Caligiuri, MA; Chen, CS; Cortes, J; Druker, BJ; Eiring, AM; Gambacorti-Passerini, C; Liu, S; Marcucci, G; Muthusamy, N; Neviani, P; Notari, M; Oaks, JJ; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Verrills, NM | 1 |
| Bittman, R; Coelho, RP; Payne, SG; Sato-Bigbee, C; Spiegel, S | 1 |
| Byrd, JC; Chen, CS; Dalton, JT; Frissora, F; Jarjoura, D; Lehman, A; Liu, Q; Ma, Y; Muthusamy, N; Perrotti, D; Santhanam, R; Zhao, X | 1 |
| Bea, F; Blessing, E; Dengler, TJ; Grone, HJ; Hansson, GK; Katus, HA; Klingenberg, R; Nofer, JR; Preusch, M; Rudling, M | 1 |
| Brown, BA; Kantesaria, PP; McDevitt, LM | 1 |
| Balatoni, B; Foster, CA; Hiestand, PC; Koziel, A; Lambrou, GN; Schönborn, V; Storch, MK; Swoboda, EM; Weissert, R | 1 |
| del Rio, ML; Förster, R; Pabst, O; Penuelas-Rivas, G; Ramirez, P; Rodriguez-Barbosa, JI | 1 |
| Gohda, M; Higuchi, M; Ishikawa, I; Kim, N; Kiyono, H; Kunisawa, J; Kurashima, Y; Ogahara, I; Shimizu, M | 1 |
| Karliner, JS; Kelley, M; Li, L; Tao, R; Vessey, DA; Zhang, J | 1 |
| Bittman, R; Li, Z | 1 |
| Antel, JP; Jung, CG; Kennedy, TE; Kim, HJ; Miron, VE; Soliven, B | 1 |
| Bernhardt, G; Czeloth, N; Förster, R; Küster, B; Müller, W; Schippers, A; Wagner, N | 1 |
| Augé, N; Böhler, T; Canivet, C; Etienne, L; Galvani, S; Guillebaud, J; Kamar, N; Nègre-Salvayre, A; Rostaing, L; Salvayre, R; Thiers, JC; Thomsen, M | 1 |
| Bilbe, G; Dev, KK; Hoyer, D; Kuhn, RR; Mattes, H; Mir, A; Mullershausen, F | 1 |
| Fauser, U; Schluesener, HJ; Zhang, Z | 1 |
| Cremer, M; Hmissi, A; Lang, P; Mayer, H; Schena, FP; Shoker, A; Sommerer, C; Szakaly, P; Tedesco-Silva, H; Yoshimura, N | 1 |
| Kennedy, PC; Kharel, Y; Lynch, KR; Macdonald, TL; Schaffter, L; Snyder, AH; Sun, Q; Zhu, R | 1 |
| Bueno, V; Cury, PM; da Silva, LB; Palma, PV | 1 |
| Brinkmann, V; Chun, J; Ip, PC; Potts, EM; Salomone, S; Tyndall, S; Waeber, C | 1 |
| Cinamon, G; Cyster, JG; Foss, FW; Lam, OM; Zachariah, MA | 1 |
| Allende, ML; Bromberg, JS; Ding, Y; Esses, SJ; Garin, A; Ginhoux, F; He, X; Lal, G; Ledgerwood, LG; Lira, SA; Merad, M; Ochando, JC; Peche, H; Schuchman, EH; Yang, Y; Zhang, N | 1 |
| Herzinger, T; Kleuser, B; Korting, HC; Schäfer-Korting, M | 1 |
| Hagiwara, N; Ikeda, T; Inoue, M; Koshinaga, T; Kusafuka, T; Sugito, K | 2 |
| Da, WM; Zhu, HY | 1 |
| Delbridge, MS; El Nahas, AM; Haylor, J; Raftery, AT; Shrestha, BM | 1 |
| Illana Esteban, C | 1 |
| Campbell, P; Grynoch, R; Murray, AG; Sis, B; Solez, K | 1 |
| Brunati, AM; Carraro, A; Cillo, U; D'Amico, F; Gringeri, E; Massimino, ML; Nalesso, G; Pagano, MA; Tibaldi, E; Toninello, A | 1 |
| Almony, A; Blinder, KJ; Brennan, DC; Saab, G; Schuessler, R | 1 |
| Barbet, I; Goldwater, DR; Kovarik, JM; Lu, M; Maton, S; Riviere, GJ; Schmouder, RL | 1 |
| Hunt, TL; Kovarik, JM; Maton, S; Neddermann, D; Riviere, GJ; Schmouder, RL | 1 |
| Kleuser, B; Kleuser, U; Kürschner, U; Schäfer-Korting, M; Schüppel, M | 1 |
| Coisne, C; Engelhardt, B; Lyck, R | 1 |
| Fauser, U; Schluesener, HJ; Zhang, Z; Zhang, ZY | 2 |
| Byrd, JC; Chen, CS; Cheng, AL; Hung, JH; Kulp, SK; Lu, YS; Ma, YH; Muthusamy, N; Wang, DS; Wang, YC | 1 |
| Hao, Y; Xie, M; Zhou, JH; Zhu, GQ | 1 |
| Brinkmann, V; Gfeller, P; Katopodis, A; Li, J; Metzler, B; Mueller, M; Nuesslein-Hildesheim, B; Wieczorek, G | 1 |
| Cui, NQ; Li, DH; Liu, HB; Wang, Q; Xue, XP | 1 |
| Cho, JY | 1 |
| Fujita, T; Hirose, R; Matsumoto, N; Sasaki, S | 1 |
| Billich, A; Högenauer, K; Nussbaumer, P; Pally, C; Streiff, M; Wagner, T; Welzenbach, K | 1 |
| Kreuwel, HT; Redmond, WL; Sherman, LA; Wei, CH | 1 |
| Gohda, M; Higuchi, M; Ishikawa, I; Kagiyama, Y; Kiyono, H; Kunisawa, J; Kurashima, Y; Miura, F; Ogahara, I | 1 |
| Chwalla, I; Krump-Konvalinkova, V; Siess, W | 1 |
| Foster, CA; Hiestand, PC; Meier, DP; Rausch, M | 1 |
| Chiba, K; Kataoka, H | 1 |
| Bueno, V; Cury, PM; Gallo, AP; Lopes, CT; Palma, PV | 1 |
| Horga, A; Montalban, X | 1 |
| Bueno, V; Cordeiro, JA; Cury, PM; Lucas da Silva, LB; Ribeiro, DA | 1 |
| Mansoor, M; Melendez, AJ | 1 |
| Rouse, BT; Sehrawat, S | 1 |
| Hupfeld, CJ; Kendall, MR | 1 |
| Angioni, C; Brenneis, C; Coste, O; Geisslinger, G; Marian, C; Pierre, S; Popp, L; Schmidt, H; Scholich, K | 1 |
| Antel, JP; Miron, VE | 1 |
| Hunt, TL; Kovarik, JM; Maton, S; Neddermann, D; Riviere, GJ; Schmouder, RL; Slade, A | 1 |
| Igarashi, Y; Kohno, T | 1 |
| Fujita, T; Nagaoka, Y; Otsuki, K; Uesato, S | 1 |
| Balatoni, B; Baumruker, T; Bornancin, F; Foster, CA; Howard, LM; Kinnunen, A; Mechtcheriakova, D; Sobanov, J; Storch, MK; Wlachos, A | 1 |
| Milstien, S; Paugh, SW; Spiegel, S; Takabe, K | 1 |
| Igarashi, Y; Kihara, A | 1 |
| Chi, YY; Li, QY; Liu, SQ | 1 |
| Giese, T; Meuer, S; Morath, C; Sommerer, C; Zeier, M | 1 |
| Cai, M; Shen, Y; Wang, C; Wang, X; Xia, W; Xie, H; Zheng, S; Zhou, L | 1 |
| Kabashima, K; Kobayashi, T; Nakashima, D; Sakabe, J; Sugita, K; Tokura, Y; Yoshiki, R | 1 |
| Lynch, KR; Macdonald, TL | 1 |
| Antel, JP; Miron, VE; Schubart, A | 1 |
| Arai, K; Asakawa, Y; Fujita, T; Goto, S; Hashimoto, T; Hori, H; Momose, K; Nagasawa, H; Nakata, E; Nakayama, S; Okamoto, Y; Okuno, Y; Sasaki, Y; Tanimoto, K; Uto, Y | 1 |
| Garber, K | 1 |
| Benedetti, MD; Invernizzi, P; Monaco, S; Poli, S | 1 |
| Brinkmann, V; Lan, YY; Thomson, AW; Tokita, D; Wang, HC; Wang, Z; Zhan, J | 1 |
| Bevan, MJ; Fink, PJ | 1 |
| Altman, JD; Moseley, NB; Premenko-Lanier, M; Pruett, ST; Romagnoli, PA | 1 |
| Anada, Y; Igarashi, Y; Kihara, A; Yamanaka, M | 1 |
| Borriello, G; Cefaro, LA; Gasperini, C; Pozzilli, C; Prosperini, L; Tosto, G | 1 |
| Antel, JP; Hall, JA; Kennedy, TE; Miron, VE; Soliven, B | 1 |
| Ciesek, S; Manns, MP; Pietschmann, T; Steinmann, E; Wedemeyer, H | 1 |
| Copland, DA; Dick, AD; Nicholson, LB; Raveney, BJ | 1 |
| Antel, J; Bar-Or, A; Brinkmann, V; Goebels, N; Kappos, L; Kristofic, C; Kuhle, J; Lindberg, RL; Mehling, M; Vedrine, C | 1 |
| Davis, MD; Kehrl, JH | 1 |
| Awad, AS; Bajwa, A; Jo, SK; Kharel, Y; Lynch, KR; Okusa, MD; Vergis, AL; Ye, H | 1 |
| Abdollahi, A; Domhan, S; Zeier, M | 1 |
| Fujii, T; Kanai, T; Nakamura, T; Nemoto, Y; Okamoto, R; Sakamoto, N; Tomita, T; Totsuka, T; Tsuchiya, K; Watanabe, M | 1 |
| Bode, C; Gräler, MH; Sensken, SC | 1 |
| Brewer, JM; Bundick, RV; Choo-Kang, BS; Garside, P; Gibson, VB; Hutchison, S; Leishman, AJ; McInnes, IB | 1 |
| Baumann, M; Heemann, U; Liu, S; Lutz, J; Roos, M; Schmaderer, C; Strobl, M | 1 |
| Dole, K; Jin, Y; Kovarik, JM; Lasseter, KC; Maton, S; Pommier, F; Riviere, GJ; Schmouder, RL | 1 |
| Berdyshev, EV; Bittman, R; Dudek, SM; Garcia, JG; Gorshkova, I; Lu, X; Mirzapoiazova, T; Natarajan, V; Skobeleva, A | 1 |
| Antel, J; Comi, G; de Vera, A; Kappos, L; Montalban, X; O'Connor, P; Pohlmann, H; Radue, EW | 1 |
| Bueno, V; Cordeiro, JA; Cury, PM; Oshima, CT; Salinas, NR | 1 |
| Bäumer, W; Kietzmann, M; Kleuser, B; Lüth, A; Mischke, R; Reines, I; Tschernig, T | 1 |
| Aoki, J; Arima, N; Kano, K; Kitamura, H; Makide, K | 1 |
| Egen, JG; Germain, RN; Ishii, M; Klauschen, F; Meier-Schellersheim, M; Proia, RL; Saeki, Y; Vacher, J | 1 |
| Schluesener, HJ; Zhang, Z; Zhang, ZY | 1 |
| Bueno, V; Lopes, CT; Oshima, CT; Palma, PV; Salinas, NR | 1 |
| Adams, DR; Butera, S; Folks, T; Garcia-Lerma, JG; Kersh, EN; Luo, W; Mitchell, J; Otten, R | 1 |
| Drennan, MB; Elewaut, D; Hogquist, KA | 1 |
| Davis, MD; Hwang, IY; Kehrl, JH; Park, C; Sinha, RK | 1 |
| Fukuda, K; Fukushima, A; Kumagai, N; Nishida, T; Nishino, K; Sumi, T; Ueno, H | 1 |
| Fujii, T; Watanabe, M | 1 |
| Bernier, SG; Doyle, E; Evindar, G; Halley, K; Hannig, G; Hutchings, A; Kavarana, MJ; Kelley, MS; Lorusso, J; Morgan, BA; Saha, AK; Satz, AL; Taghizadeh, N; Westlin, WF; Wright, AD | 1 |
| Bester, M; Gerloff, C; Heesen, C; Leypoldt, F; Moeller, F; Münchau, A | 1 |
| Bittman, R; Liu, J; Lu, X; Shuyu, E; Sun, C; Tigyi, G; Valentine, WJ | 1 |
| Auge, N; Böhler, T; Canivet, C; Etienne, L; Galvani, S; Kamar, N; Nègre-Salvayre, A; Rostaing, L; Salvayre, R; Thomsen, M | 1 |
| Bittman, R; Futerman, AH; Lahiri, S; Laviad, EL; Lu, X; Park, H | 1 |
| Aronovich, A; Bitcover, R; Blazar, BR; Cohen, S; Eventov-Friedman, S; Hecht, G; Katchman, H; Klionsky, Y; Milstein, O; Reisner, Y; Rosen, C; Shezen, E; Tal, O; Tchorsh-Yutsis, D; Yagita, H | 1 |
| Bonz, A; Burkard, N; Ertl, G; Frantz, S; Hofmann, U; Ritter, O; Thoma, A; Vogt, C | 1 |
| Billich, A; Cetin, C; Guerini, D; Mullershausen, F; Seuwen, K; Zecri, F | 1 |
| Binder, E; Budde, K; Khadzhynov, D; Krämer, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Wang-Rosenke, Y | 1 |
| Peyruchaud, O | 1 |
| Arita, N; Fujino, T; Kamada, K; Miyazaki, T; Nose, M; Soga, Y; Takubo, N; Tsubaki, T; Yamamoto, H | 1 |
| Chan, KW; Chiu, YT; Chua, CW; Ling, MT; Man, K; Wang, X; Wong, YC; Yuen, HF | 1 |
| Dikow, R; Gross, ML; Hug, F; Schaier, M; Sommerer, C; Vorwalder, S; Waldherr, R; Zeier, M | 1 |
| Jin, J; Kim, SM; Kim, YS; Lee, C; Lee, J; Park, J; Yang, SH | 1 |
| Bittman, R; Camp, SM; Chiang, ET; Dudek, SM; Garcia, JG; Harbeck, M; Lu, X; Mirzapoiazova, T; Moreno-Vinasco, L; Natarajan, V; Roe, M; Sammani, S; Sun, C | 1 |
| Cumberbatch, M; Dearman, RJ; Kimber, I | 1 |
| Chow, WN; Colello, RJ; Graf, MR; Graham, RS; Lee, KD; Mathern, BE; Sato-Bigbee, C; Young, HF | 1 |
| Davis, MD; Foss, FW; Kennedy, PC; Kharel, Y; Lynch, KR; Macdonald, TL; Mathews, TP; Snyder, AH | 1 |
| Gidday, JM; Park, TS; Wacker, BK | 1 |
| Bae, H; Dukala, D; Jung, CG; Kakazu, R; Kim, HJ; Soliven, B; Wollmann, R | 1 |
| Goda, N; Kataoka, N; Makino, H; Nishishita, S; Omori, K; Sarai, K; Sasaki, M; Shikata, K; Shikata, Y; Wada, J; Watanabe, N | 1 |
| Eaton, R; Gonzalez, MI; Marshall, I; Papadopoulos, D; Patel, R; Philpott, KL; Reynolds, R; Richardson, JC; Rundle, J; Stretton, J | 1 |
| Shen, ZJ; Shi, GH; Wang, H; Wang, XH; Xu, D; Zhou, PJ | 1 |
| Dürr, C; Eller, K; Gastl, G; Gerlach, UV; Markut, L; Rosenkranz, AR; Sixt, M; Wolf, AM; Wolf, D; Zeiser, R | 1 |
| Yamamura, T | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Wiendl, H | 1 |
| Czech, B; Huwiler, A; Kahles, T; Mazaheri-Omrani, N; Neumann-Haefelin, T; Pfeilschifter, J; Pfeilschifter, W; Rami, A; Strobel, MA | 1 |
| Legge, KL; McGill, J | 1 |
| Li, GQ; Liu, SM; Ou, WC; Tan, MQ; Xiong, LG | 1 |
| Berin, MC; Blázquez, AB; Bromberg, JS; Getachew, H; Knight, AK; Lira, SA; Mayer, L | 1 |
| Beckmann, N; Blé, FX; Cannet, C; Frossard, N; Gérard, C; Trifilieff, A; Zurbruegg, S | 1 |
| Banerjee, A; Bankovich, AJ; Beilke, JN; Chun, J; Cyster, JG; Enders, A; Goodnow, CC; Jenne, CN; Lanier, LL; Miller, SA; Pereira, JP; Reiner, SL; Rivera, R; Roots, CM; Watson, SR; Weinmann, AS; Xu, Y | 1 |
| Eschenhagen, T; Friedrich, FW | 1 |
| Chung, DH; Hwang, SJ; Kim, HY; Kim, JH; Kim, S | 1 |
| Knudsen, E; Maghazachi, AA; Rolin, J; Sand, KL | 1 |
| Cartwright, E; Egom, EE; Ke, Y; Lei, M; Mohamed, TM; Musa, H; Solaro, RJ; Wang, T | 1 |
| Asahara, T; Itamoto, T; Kobayashi, T; Kuroda, S; Miyata, Y; Ogawa, T; Ohdan, H; Tanimoto, Y; Tashiro, H; Ushitora, Y | 1 |
| Gasperini, C; Ruggieri, S | 2 |
| Friedlander, RM; Lin, N | 1 |
| Hasegawa, Y; Rolland, W; Sozen, T; Suzuki, H; Zhang, JH | 1 |
| Xie, M; Zhou, JH | 1 |
| Marsolais, D; Oldstone, MB; Rosen, H; Walsh, KB; Welch, MJ | 1 |
| Adamowicz, JJ; Berdyshev, EV; Diab, KJ; Garrison, J; Gu, Y; Hubbard, WC; Kamocki, K; Petrache, I; Rajashekhar, G; Rush, NI; Schweitzer, KS; Skobeleva, A | 1 |
| Cao, X; Sun, Y; Zhang, A; Zhang, J; Zhang, N | 1 |
| Hendriks, RW; Hoogsteden, HC; KleinJan, A; Lambrecht, BN; Leman, K; van Nimwegen, M; Willart, M | 1 |
| Beerli, C; Bruns, C; Burkhart, C; Metzler, B; Morris, RE; Pally, C; Wagner, J; Weckbecker, G; Wieczorek, G | 1 |
| Zéphir, H | 1 |
| Arslanian, C; Belfort, R; Bueno, V; Commodaro, AG; Lopes, CT; Peron, JP; Rizzo, LV | 1 |
| Antel, J; Aradhye, S; Comi, G; Kappos, L; Karlsson, G; Montalban, X; O'Connor, P; Pohlmann, H; Radue, EW | 1 |
| Hibi, T; Kanai, T; Watanabe, M | 1 |
| Botchwey, EA; Lynch, KR; Macdonald, TL; Ogle, RC; Peirce, SM; Petrie Aronin, CE; Sadik, KW; Sefcik, LS; Tholpady, A; Tholpady, SS; Wamhoff, BR | 1 |
| Bäck, N; Bittman, R; Blom, T; de Lera, A; Diczfalusy, U; Ikonen, E; Kovanen, PT; Li, Z; Mutka, AL | 1 |
| Brooks, SF; Chun, J; Fontaine, BA; Luster, AD; Shea, BS; Tager, AM | 1 |
| Agoropoulou, C; Burtin, P; Calabresi, P; Hohlfeld, R; Kappos, L; Leyk, M; O'Connor, P; Polman, C; Radue, EW; Selmaj, K; Zhang-Auberson, L | 1 |
| Aradhye, S; Barkhof, F; Capra, R; Cohen, JA; Comi, G; de Vera, A; Gallo, P; Hartung, HP; Izquierdo, G; Jin, J; Kappos, L; Khatri, BO; Montalban, X; Pelletier, J; Stites, T; Tiel-Wilck, K; Wu, S | 1 |
| Carroll, WM | 1 |
| Hasegawa, T; Hayashi, K; Koide, Y; Konno, T; Mochizuki, N; Mori, K; Murakami, A; Ohnuma, S; Sakurai, A; Sasamori, J; Sato, Y; Takahashi, A; Takakura, N; Takasugi, H; Takeda, S; Watanabe, Y | 1 |
| Huang, MX; Ito, T; Song, JH; Wei, JM | 1 |
| McFadden, G; Werden, SJ | 1 |
| Arrighi, JF; Bombrun, A; Burgat-Charvillon, F; Cambet, Y; Covini, D; Crosignani, S; Donini, C; Eligert, V; Françon, B; Maio, M; Marin, D; Martin, T; Martinou, I; Nichols, A; Novo-Perez, L; Quattropani, A; Rivron, D; Sauer, W; Schott, O; Simpson, D; Swinnen, D; Vitte, PA | 1 |
| Hinterding, K; Högenauer, K; Nussbaumer, P | 1 |
| Cyster, JG; Pereira, JP; Xu, Y | 1 |
| Dragun, D; Fuller, TF; Hegner, B; Hoff, U; Kong, L; Luft, FC; Naether, M; Nieminen-Kelhä, M; Nolting, J; Wagner, P | 1 |
| Czech, B; Neumann-Haefelin, T; Pfeilschifter, W | 1 |
| Li, F; Li, Q | 1 |
| Link, H; Martin, R | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kawashima, H; Konuma, N; Koshinaga, T; Masuko, T; Ohashi, K; Sugito, K; Uekusa, S | 1 |
| Amano, E; Amano, H; Ando, S; Hirose, S; Hou, R; Lin, Q; Minowa, K; Morimoto, S; Nakano, S; Nakiri, Y; Ohtsuji, M; Takasaki, Y; Tokano, Y; Tsurui, H; Watanabe, T | 1 |
| Martin, R | 1 |
| Angyal, A; Egelston, C; Glant, TT; Kobezda, T; László, A; Mikecz, K; Olasz, K | 1 |
| Bluestone, JA; Penaranda, C; Ruddle, NH; Tang, Q | 1 |
| Bueno, V; Cordeiro, JA; Lopes, CT; Rosin, FC | 1 |
| Bueno, V; Cury, PM; de Paula, DM; Lopes, CT; Valero-Lapchik, VB | 1 |
| Bueno, V; Cordeiro, JA; de Franco, MF; Lopes, CT; Pletiskaitz, TM | 1 |
| Bajwa, A; Dondeti, KR; Haase, VH; Huang, L; Jo, SK; Lynch, KR; Macdonald, TL; Okusa, MD; Rosin, DL; Ye, H | 1 |
| Castilló, J; Horga, A; Montalban, X | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T | 2 |
| Gold, R; Haghikia, A | 1 |
| Coolen, C; Jones, C; Lopez, AF; Ma, Y; Pham, D; Pitson, SM; Woodcock, JM | 1 |
| Antel, JP; Darlington, PJ; Jarjour, AA; Kennedy, TE; Ludwin, SK; Miron, VE; Soliven, B | 1 |
| Imado, T; Iwasaki, T; Kitano, S; Miyazawa, K; Sano, H; Tsunemi, S | 1 |
| Oberpichler-Schwenk, H | 1 |
| Hecht, B | 1 |
| Cardani, AN; Crihfield, A; Derecki, NC; Kipnis, J; Lynch, KR; Quinnies, KM; Yang, CH | 1 |
| Mann, H | 1 |
| Alinari, L; Baiocchi, RA; Byrd, JC; Chen, CS; Dalton, JT; Lapalombella, R; Lin, T; Liu, Q; Mani, R; Muthusamy, N; Yan, F; Zhang, X | 1 |
| Chiba, K; Maeda, Y; Sato, N; Seki, N; Sugahara, K | 1 |
| Marriott, JJ; O'Connor, PW | 1 |
| Arndt, T; Hedrich, HJ; Jörns, A; Lenzen, S; Meyer Zu Vilsendorf, A; Rath, KJ; Terbish, T; Wedekind, D | 1 |
| Kleuser, B; Lüth, A; Nieuwenhuis, B; Potteck, H; van der Giet, M | 1 |
| Gräler, MH | 1 |
| Chen, X; Jiang, H; Liang, Y; Liu, L; Meng, X; Pan, S; Song, X; Wang, J; Yin, D; Zheng, T | 1 |
| Vasiliou, S | 1 |
| Harp, JR; Onami, TM | 1 |
| Chen, Y; Duan, L; Fang, M; Feng, W; Gong, F; Heng, Y; Ma, Y; Tan, Z; Xiong, P; Xu, Y; Yin, H; Zheng, F | 1 |
| Frey, O; Kamradt, T | 1 |
| Hosch, W; Korporal, M; Max, R; Schwarz, A; Wildemann, B | 1 |
| Ashman, LK; Carpenter, H; Guthridge, MA; Horan, M; McDougall, F; Neviani, P; Perrotti, D; Powell, JA; Roberts, KG; Sim, AT; Smith, AM; Thomas, D; Verrills, NM | 1 |
| Aktas, O; Hartung, HP; Kieseier, B; Küry, P | 1 |
| Bittman, R; Lim, KG; Long, J; Loveridge, C; Pitson, SM; Pyne, NJ; Pyne, S; Tigyi, G; Tonelli, F | 1 |
| Nau, JY | 1 |
| Blaho, VA; Guo, C; Hla, T; Im, DS; Khanna, KM; Lefrancois, L; Oo, ML; Thangada, S | 1 |
| Bauersachs, J; Bonz, A; Burkard, N; Ertl, G; Frantz, S; Hofmann, U; Hu, K; Ritter, O; Walter, F | 1 |
| Brinkmann, V; Hess, C; Kappos, L; Kuhle, J; Lindberg, R; Mehling, M; Raulf, F | 1 |
| Antel, J; Bar-Or, A; Haegert, DG; Johnson, TA; Keezer, M; Lapierre, Y; Shames, I | 1 |
| Isoyama, N; Matsumura, M; Matsuyama, H; Takai, K; Tsuchida, M | 1 |
| Brinkmann, V; Connor, LM; Harvie, MC; Kirman, JR; Le Gros, G; Quinn, KM; Rich, FJ | 1 |
| Bee, T; Chung, SK; Don, AS; Jary, E; Morris, JC; Seo, KC; Walker, SR | 1 |
| Slavin, AJ; Zamvil, SS | 1 |
| Bagayoko, ND; Botchwey, EA; Cui, Q; Khan, Y; Naden, KB; Petrie Aronin, CE; Rios, PD; Sefcik, LS; Shin, SJ; Zawodny, SR | 1 |
| Alewijnse, AE; De Vries, HE; Dijkstra, CD; Lakeman, K; Peters, SL; Reijerkerk, A; Ronken, E; Van Der Valk, P; Van Doorn, R; Van Het Hof, B; Van Horssen, J; Verzijl, D; Witte, M | 1 |
| Engelhard, VH; Enriquez, HL; Fu, YX; Thompson, ED | 1 |
| Banwell, B; Yiu, EM | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Warnke, C; Wiendl, H | 1 |
| Ley, K; McDuffie, M; Morris, MA; Nadler, JL | 1 |
| Cho, WY; Jo, SK; Kim, HK; Kim, MG; Ko, YS; Lee, HY; Lee, SY | 1 |
| Kabashima, K; Sakabe, J; Sugita, K; Tanizaki, H; Tokura, Y; Yoshiki, R | 1 |
| Berdyshev, EV; Bittman, R; Byun, HS; Gorshkova, I; Goya, J; Natarajan, V; Prestwich, GD | 1 |
| Barske, C; Bouhelal, R; Dev, KK; Dubois, C; Gasparini, F; Guerini, D; Haessig, S; Mattes, H; Mir, AK; Orain, D; Osinde, M; Picard, A; Tasdelen, E | 1 |
| Rabasseda, X | 1 |
| Morrow, T | 1 |
| Antel, JP; Bar-Or, A; Blain, M; Durafourt, BA; Johnson, TA; Lambert, C | 1 |
| Edwards, J; Fujiwara, Y; Long, JS; Pyne, NJ; Pyne, S; Tannahill, CL; Tigyi, G | 1 |
| Fontoura, P; Garren, H | 1 |
| Aktas, O; Hartung, HP; Hohlfeld, R; Ingwersen, J; Kieseier, B; Küry, P | 1 |
| Fox, EJ | 1 |
| Aronin, CE; Awojoodu, AO; Botchwey, EA; Lynch, KR; Mac Gabhann, F; MacDonald, TL; Peirce, SM; Sefcik, LS; Shin, SJ; Wamhoff, BR | 1 |
| Di, W; Qi, Y; Wadham, C; Wang, L; Warren, A; Xia, P; Zhang, N | 1 |
| Kalinowska-Łyszczarz, A; Losy, J | 1 |
| Chiba, K; Fukunari, A; Kataoka, H; Koyama, M; Seki, N; Shimano, K; Sugahara, K; Sugita, T | 1 |
| Guo, D; He, S; Qian, K; Tan, W; Wang, F; Zhu, X | 1 |
| Belfort, R; Bueno, V; Commodaro, AG; Rizzo, LV | 1 |
| Bohler, T; Brizuela, L; Cuvillier, O; Doumerc, N; Golzio, M; Malavaud, B; Pchejetski, D; Salunkhe, V; Sauer, L; Teissié, J; Waxman, J | 1 |
| Chun, J; Noguchi, K | 1 |
| Aradhye, S; Baumruker, T; Billich, A; Brinkmann, V; Burtin, P; Francis, G; Heining, P; Schmouder, R | 1 |
| Gschwind, HP; Hartmann, S; Jin, Y; Sayer, C; Zécri, F; Zollinger, M | 1 |
| Borell, H; Jin, Y; Patten, CJ; Zimmerlin, A; Zollinger, M | 1 |
| Choi, JW; Chun, J; Lee, CW | 1 |
| Ratner, M | 1 |
| Alizzi, K; Cacciato, PM; Eberhard, M; Faggio, C; Ferlinz, K; Föller, M; Lang, F | 1 |
| Chiang, ET; Dudek, SM; Garcia, JG; Simmons, JT; Wang, L | 1 |
| Hisano, Y; Kawahara, A; Kobayashi, N; Nishi, T; Yamaguchi, A | 1 |
| Lai, WQ; Leung, BP; Wong, WS | 1 |
| Engel, DR; Franken, L; Hirner, A; Kalff, JC; Knolle, PA; Koscielny, A; Kurts, C; Limmer, A; Maurer, J; Schiwon, M; Schumak, B; Sparwasser, T; Wehner, S | 1 |
| Gold, R | 1 |
| Dawson, G; Qin, J | 1 |
| Bieberich, E | 1 |
| Racke, MK | 1 |
| Antel, JP; Bar-Or, A; Johnson, TA; Lapierre, Y | 1 |
| Jeffery, DR; Markowitz, CE; Reder, AT; Tobias, K; Weinstock-Guttman, B | 1 |
| Claas, RF; Ferreirós, N; Hegen, B; Huwiler, A; Labocha, S; Meyer Zu Heringdorf, D; Pfeilschifter, J; Ter Braak, M; van Echten-Deckert, G | 1 |
| Bode, C; Gräler, M; Heusch, G; Keul, P; Levkau, B; Lucke, S; von Wnuck Lipinski, K | 1 |
| Baek, KJ; Jeong, YM; Kim, DS; Kim, SY; Kwon, NS; Lee, JE; Park, KC; Yun, HY | 1 |
| Fiedler, M; Martin, M; Mory, C; Prescher, A; Uhlmann, D | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Choi, JW; Chun, J; Gardell, SE; Herr, DR; Kennedy, G; Lee, CW; Lu, M; Noguchi, K; Rivera, R; Teo, ST; Yung, YC | 1 |
| Jadidi-Niaragh, F; Mirshafiey, A | 1 |
| Hobeika, E; Jäck, HM; Kahn, ML; Mathews, M; Porstner, M; Reth, M; Roth, E; Sandrock, L; Schuh, W; Winkelmann, R | 1 |
| Aronovich, A; Bachar-Lustig, E; Bitcover, R; Cohen, S; Eventov-Friedman, S; Feine, I; Katchman, H; Reisner, Y; Rosen, C; Shezen, E; Tal, O; Tchorsh-Yutsis, D; Zangi, L; Zlotnikov Klionsky, Y | 1 |
| Lock, JF; Malinowski, M; Martus, P; Neuhaus, P; Stockmann, M | 1 |
| Antel, JP; Dukala, D; Kim, HJ; Ludwin, SK; Miron, VE; Proia, RL; Soliven, B; Traka, M | 1 |
| Bolli, MH; Lescop, C; Nayler, O | 1 |
| Alsharif, N; Brinkmann, V; Guo, S; Hwang, SK; Kim, HH; Liao, JK; Lo, EH; Qin, T; Shin, HK; Waeber, C; Wei, Y; Yemisci, M; Yung, LM | 1 |
| Awad, AS; Bolton, WK; Huang, L; Khutsishvili, K; Lynch, KR; Okusa, MD; Rouse, MD | 1 |
| Habashita, H; Hagiya, H; Kurata, H; Kurono, M; Kusumi, K; Minami, M; Mizuno, H; Nakade, S; Ono, T; Otsuki, K; Seko, T; Terakado, M | 1 |
| Filippi, M | 1 |
| Casper, RF; Dertinger, SD; Fanton, JK; Jacob, DS; Jurisicova, A; Lawson, MS; Murphy, MK; Pau, KY; Tilly, JL; Toscano, NP; Zelinski, MB | 1 |
| Schluesener, HJ; Zhang, ZY; Zug, C | 1 |
| Brinkmann, V; Merkler, D; Pinschewer, DD | 1 |
| Antel, J; Bar-Or, A; Johnson, TA; Kappos, L; Mehling, M | 1 |
| Barkhof, F; Hohlfeld, R; Polman, C | 1 |
| Brinkmann, V; Hla, T | 1 |
| Chun, J; Miron, V; Soliven, B | 1 |
| Antel, J; Hohlfeld, R | 1 |
| Nishi, S | 1 |
| Benson, EL; Heuvelman, DM; Masferrer, JL; Radi, ZA | 1 |
| Chang, HY; Jennings, PC; Jones, KT; Stewart, J; Verrills, NM | 1 |
| Durovic, B; Eichin, D; Fritz, S; Gasser, O; Hess, C; Hilbert, P; Kappos, L; Klimkait, T; Kuhle, J; Lindberg, RL; Mehling, M | 1 |
| Berman-Booty, LD; Byrd, JC; Chen, CS; Chou, CC; Hung, JH; Kogure, T; Kulp, SK; Ma, Y; Muthusamy, N; Omar, HA; Patel, T; Terracciano, L; Wang, D | 1 |
| Weinstock-Guttman, B; Yeh, EA | 1 |
| Bassetti, M; Ginocchio, F; Mancardi, GL; Uccelli, A | 1 |
| Bähr, M; Diem, R; Hein, K; Hillgruber, C; Kretzschmar, B; McRae, BL; Rau, CR; Sättler, MB | 1 |
| Dumont, AG; Reynoso, DG; Trent, JC | 1 |
| Gutbier, B; Hellwig, K; Hippenstiel, S; Hocke, AC; Müller, HC; N'Guessan, PD; Peters, H; Rosseau, S; Schmiedl, A; Schönrock, SM; Suttorp, N; Tschernig, T; Witzenrath, M | 1 |
| Carmona, O; Cocco, E; Drulovic, J; Duddy, M; Eggers, C; Gold, R; Haghikia, A; Zéphir, H | 1 |
| Oberlies, NH; Pearce, CJ; Strader, CR | 1 |
| Hoshikawa, S; Ito, S; Mori, K; Morohoshi, K; Nakagawa, Y; Osone, M; Ozaki, H; Takahashi, Y; Yoshida, K | 1 |
| Al-Izki, S; Baker, D; Giovannoni, G; Jackson, SJ; Pryce, G | 1 |
| Bendall, LJ; Bradstock, KF; Hewson, J; Wallington-Beddoe, CT | 1 |
| Bittman, R; Li, Z; Lim, KG; Lu, X; Pyne, NJ; Pyne, S; Tonelli, F | 1 |
| Berthele, A; Buck, D; Cepok, S; Hemmer, B; Hohlfeld, R; Korn, T; Kowarik, MC; Kümpfel, T; Pellkofer, HL | 1 |
| Li, N; Li, PL; Wang, Z; Xia, M; Zhu, Q | 1 |
| Bromberg, JS; Ding, Y; Shi, Q; Xu, J; Yin, N; Zhang, N | 1 |
| Ishii, K; Kim, SU; Satoh, J; Sugiyama, S; Tabunoki, H; Yoshino, T | 1 |
| Chun, J; Cohen, JA | 1 |
| Hussar, DA | 1 |
| Blaho, V; Chang, SH; Han, DK; Hla, T; Hwang, SI; Oo, ML; Rezaul, K; Thangada, S; Wu, MT | 1 |
| Cserti-Gazdewich, C; Dhabangi, A; Finney, CA; Hawkes, CA; Kain, DC; Kain, KC; Liles, WC; Musoke, C; Oravecz, T | 1 |
| Heytens, E; Oktay, K; Soleimani, R | 1 |
| Bueno, V; Franco, M; Gomes, GN; Haidar, AA; Hirata, AE; Pedregosa, JF | 1 |
| Kieseier, BC; Wiendl, H | 1 |
| Barkhof, F; Cohen, JA; Comi, G; Francis, G; Hartung, HP; Holdbrook, F; Kappos, L; Khatri, B; Montalban, X; Pelletier, J; Stites, T; Wu, S; Zhang-Auberson, L | 1 |
| Bastien, MC; Ettenger, R; Hoyer, PF; Kovarik, JM; Schmouder, R | 1 |
| Bittman, R; Lim, KG; Pyne, NJ; Pyne, S; Sun, C | 1 |
| Antel, JP; Bar-Or, A; Blain, M; Durafourt, BA; Evans, BL; Johnson, TA; Lapierre, Y | 1 |
| Chen, L; Di, J; Li, DJ; Li, W; Lin, Y; Ren, L; Shan, B; Sun, Y; Wang, W | 1 |
| Fujita, T; Kohno, T; Tsuji, T; Yoshida, Y | 2 |
| David, M; Huang, T; Kennedy, PC; Lynch, KR; Macdonald, TL; Mathews, TP; Peyruchaud, O; Tomsig, JL; Zhu, R | 1 |
| Habashita, H; Hagiya, H; Komiya, T; Kurata, H; Kurono, M; Kusumi, K; Minami, M; Mizuno, H; Nakade, S; Ono, T; Otsuki, K; Shioya, H; Suzuki, R; Takada, Y | 1 |
| Berger, JR; Espinosa, PS | 1 |
| Eshhar, Z; Marcus, A; Waks, T | 1 |
| Aktas, O; Boyko, A; Hartung, HP; Ingwersen, J; Kieseier, B; Kuery, P | 1 |
| Allen, JD; Alling, N; Haass, NK; Jackson, EA; Martinello-Wilks, R; McGowan, EM; Yagoub, D | 1 |
| Ross, AP; Singer, B; Tobias, K | 1 |
| Yeung, BK | 1 |
| Bauer, H; Liesz, A; Mracsko, E; Schwarting, S; Sommer, C; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Cartwright, EJ; Chacko, S; Chirico, D; Egom, EE; Fath-Ordoubadi, F; Ke, Y; Lei, M; Liu, W; Mamas, MA; Mohamed, TM; Shaheen, M; Shi, Y; Solaro, RJ; Stringer, SE; Wang, T; Wang, X | 1 |
| Milstien, S; Nagahashi, M; Spiegel, S; Stevenson, CE; Takabe, K | 1 |
| Csépány, T | 1 |
| Bittman, R; Fujiwara, Y; Godwin, VI; Liu, J; Osborne, DA; Parrill, AL; Tigyi, G; Valentine, WJ; Van Brocklyn, J | 1 |
| Hasegawa, Y; Lekic, T; Manaenko, A; Ostrowski, R; Rolland, WB; Tang, J; Zhang, JH | 1 |
| Brinkman, V; Cojean, C; Li, L; Matsumoto, M; Pachner, AR; Seabrook, TJ | 1 |
| Comi, G; de Vera, A; Eckert, B; Gold, S; Kappos, L; Montalban, X; O'Connor, P | 1 |
| Baker, D; Giovannoni, G; Jackson, SJ | 1 |
| Huang, Q; Huang, SA; Li, XQ; Yang, Y | 1 |
| Bernardi, G; Centonze, D; De Chiara, V; Furlan, R; Lo Giudice, T; Martino, G; Martorana, A; Motta, C; Musella, A; Rossi, S; Studer, V | 1 |
| Apicco, D; Guckian, K; Hu, Y; Ji, B; Lee, X; Mi, S; Miller, RH; Pepinsky, RB | 1 |
| Hohlfeld, R | 1 |
| Aliaga, C; Amin, S; Baab, KT; Broeg, K; Desai, D; Dewey, A; Fox, T; Hirsch, L; Jarbadan, NR; Kester, M; Li, Y; Liao, A; Liao, J; Liu, X; Loughran, K; Loughran, TP; Rogers, A; Ryland, L; Shah, MV; Tan, SF; Wang, HG; Watters, R; Yang, J; Zhang, LQ | 1 |
| Agarwal, S; Franklin, M; Meyer, K; Miller, RM; O'Day, K | 1 |
| Bankovich, AJ; Cyster, JG; Kim, P; Lin, CP; Pitsillides, C; Thompson, BD; Wu, MX; Yun, SH; Zhi, L | 1 |
| Derfuss, T; Kappos, L; Mehling, M | 1 |
| Scott, LJ | 1 |
| Hla, T; Obinata, H | 1 |
| Gillingwater, TH | 1 |
| Casanova, B; Díaz-Llopis, M; España-Gregori, E; Gallego-Pinazo, R; Pardo-López, D | 1 |
| Cohen, D | 1 |
| Jia, X; Liu, X; Ma, J; Mu, S; Sui, M; Wu, H; Xie, R; Zhou, J | 1 |
| Braun, R; Conzett, KB; Dummer, R; French, LE; Hofbauer, GF; Jelcic, I; Kamarachev, J; Kolm, I; Linnebank, M | 1 |
| Löbermann, M; Reisinger, EC; Winkelmann, A; Zettl, UK | 1 |
| Frohman, T; Hardeman, P; O'Donoghue, DL; Orchard, M | 1 |
| Barker, D; Botchwey, E; Cui, Q; Das, A; Huang, C; Ogle, R; Tholpady, S; Wang, T | 1 |
| Constantinescu, CS; Gran, B; Sanvito, L | 1 |
| Czech-Zechmeister, B; Foerch, C; Huwiler, A; Koch, A; Mirceska, A; Pfeilschifter, J; Pfeilschifter, W; Rami, A; Steinmetz, H; Sujak, M | 1 |
| Abramowicz, D; Hoitsma, AJ; Proot, P; Vanrenterghem, Y; Woodle, ES | 1 |
| Böhler, T; Pchejetski, D; Stebbing, J; Waxman, J | 1 |
| Popova, NF | 1 |
| Konoeda, F; Shichita, T; Yoshimura, A | 1 |
| Bittman, R; Pyne, NJ; Pyne, S | 1 |
| Birod, K; Ferreiròs, N; Fuchs, S; Geisslinger, G; Grösch, S; Hartmann, D; Schiffmann, S; Schreiber, Y; Stark, H; Zivkovic, A | 1 |
| Huggins, A; Sergott, RC | 2 |
| Brinkmann, V; Chun, J | 1 |
| Graham, SL; Gupta, VK; Klistorner, A; You, Y | 1 |
| Killestein, J; Polman, CH; Rudick, RA | 1 |
| Deglave, F; Emotte, C; Heudi, O; Kretz, O; Picard, F | 1 |
| Cahalan, SM; Cameron, MD; Gonzalez-Cabrera, PJ; Kago, T; Leaf, NB; Nguyen, N; Rosen, H; Sarkisyan, G | 1 |
| Alinari, L; Baiocchi, RA; Blum, KA; Byrd, JC; Chen, CS; Earl, CT; Goldenberg, DM; Huynh, L; Mahoney, E; Mani, R; Mao, Y; Muthusamy, N; Patton, J; Praetorius-Ibba, M; Quinion, C; Towns, WH; Yu, B; Zhang, X | 1 |
| Del Santo, F; Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| David, OJ; Hariry, S; Schmouder, R | 1 |
| Cartwright, EJ; Gui, J; Jin, J; Ke, Y; Lei, M; Liu, W; Naumann, R; Neyses, L; Prehar, S; Solaro, RJ; Taglieri, DM; Tsui, H; Ulm, S; Wang, X; Xiao, RP; Zi, M | 1 |
| Botchwey, EA; Bowers, DT; Brayman, KL; Chhabra, P; Langman, L | 1 |
| Domínguez, J; Giacaman, A; Lira, F; Mendez, G | 1 |
| Dev, KK; Sheridan, GK | 2 |
| Huang, Q; Huang, S; Li, X; Lu, Y; Yang, Y | 1 |
| David, OJ; Looby, M; Mercier, F; Schmouder, RL; Wu, K | 1 |
| Matsushita, T | 1 |
| He, X; Li, S; Wang, L; Xiao, J; Zheng, Z; Zhong, W | 1 |
| Anderson, K; Brinkmann, V; Copland, DA; Dick, AD; Liu, J; Nicholson, LB; Schewitz-Bowers, LP | 1 |
| Bissel, P; Kharel, Y; Knott, K; Lynch, KR; Raje, MR; Santos, WL | 1 |
| Kim, BJ; Lee, KH; Min, JH | 1 |
| David, OJ; Kovarik, JM; Schmouder, RL | 1 |
| Cyster, JG; Schwab, SR | 1 |
| Angerer, H; Fuerst, FC; Graninger, WB; Hermann, J; Kremser, ML; Ortner, T; Setznagl, D; Stradner, MH | 1 |
| Baaj, Y; Cook-Moreau, J; Faucher-Durand, K; Fourcade, L; Funalot, B; Mollard, S; Mousseau, Y; Nizou, A; Plainard, X; Qiu, H; Richard, L; Sturtz, FG | 1 |
| Do, JS; Foucras, G; Kamada, N; Min, B; Nuñez, G; Paul, WE; Schenk, AF; Shaw, M | 1 |
| Bedoui, S; Carbone, FR; Eidsmo, L; Heath, WR; Stock, AT | 1 |
| Boulton, C; David, OJ; Meiser, K; Schmouder, R | 1 |
| Choi, J; Ma, ZA; Zhao, C; Zhao, Z | 1 |
| Sørensen, PS | 1 |
| Hagiya, H; Ito, T; Kurata, H; Mizuno, H; Song, J | 1 |
| Campbell, C; Cryan, J; Deeks, N; Demont, E; Dowell, S; Garden, H; Gaskin, P; Gray, JR; Haynes, A; Leavens, K; Morse, M; Patel, A; Taylor, S; Willis, R; Witherington, J | 1 |
| Bryan, JS; Turaka, K | 1 |
| Alewijnse, AE; Peters, SL; Spijkers, LJ | 1 |
| Ruediger, R; Walter, G | 1 |
| Hafler, DA; Pelletier, D | 1 |
| Hu, R; Li, J; Li, Y; Liao, A; Liu, Z; Wang, H; Yang, W; Yao, K; Zhang, R; Zhao, Q | 1 |
| Hassan, M; Karmouty-Quintana, H; Marti-Solano, M; Martin, JG; Risse, PA; Siddiqui, S; Tsuchiya, K; Xicota-Vila, L | 1 |
| Buja, LM; Haden-Pinneri, K; Lindsey, JW; Memon, NB | 1 |
| Chabwine, JN; Démonet, JF; du Pasquier, RA; Hirt, L; Kuntzer, T; Michel, P; Rossetti, AR; Schluep, M; Vingerhoets, FG | 1 |
| Kharel, Y; Knott, K; Lynch, KR; Raje, MR; Santos, WL | 1 |
| Abeynaike, LD; Bonder, CS; Escarbe, S; Hickey, MJ; Pitson, SM; Smith, CD; Sun, WY | 1 |
| Gerdes, LA; Havla, JB; Hohlfeld, R; Kümpfel, T; Meinl, I; Pellkofer, HL | 1 |
| Hu, R; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yao, K; Zhang, R | 1 |
| Ferreirós, N; Geisslinger, G; Labocha, S; Radeke, HH; Schröder, M | 1 |
| Estrada-Bernal, A; Palanichamy, K; Ray Chaudhury, A; Van Brocklyn, JR | 1 |
| Hao, Q; Itoyama, Y; Kikuchi, S; Kira, J; Kurosawa, T; Nagato, K; Saida, T; Tang, D; Zhang-Auberson, L | 1 |
| Wise, J | 1 |
| Bhatti, MT; Jain, N | 1 |
| Feng, XJ; Li, X; Lu, W; Luo, Y; Tang, W; Yang, XY; Zuo, JP | 1 |
| Alinari, L; Baiocchi, RA; Praetorius-Ibba, M | 1 |
| Amor, S; Kipp, M | 1 |
| Bogen, B; Corthay, A; Lorvik, KB | 1 |
| Fan, ST; Geng, W; Li, CX; Ling, CC; Liu, XB; Lo, CM; Ma, YY; Man, K; Ng, KT; Shao, Y | 1 |
| Albrecht, H; Berthele, A; Castrop, F; Haslinger, B; Hemmer, B; Kowarik, MC; Krause, M; Zimmer, C | 1 |
| Lai, X; Song, B; Wang, T; Ye, Y; Zeng, X; Zeng, Y; Zhu, C | 1 |
| Hoshino, Y; Kimura, A; Madoiwa, S; Mimuro, J; Norimatsu, Y; Ohmori, T; Sakata, Y; Seichi, A; Yatomi, Y | 1 |
| Doxani, C; Hadjigeorgiou, GM; Mprotsis, T; Schmid, CH; Zintzaras, E | 1 |
| Hogan, EL; Krotkiewski, H; Podbielska, M | 1 |
| Deng, AP; Huang, XD; Jiang, JY; Wang, Y; Zhou, JH | 1 |
| Bergonzini, V; Costa, S; Galletti, M; Nofer, JR; Pignatti, E; Poti, F; Simoni, M; Weber, C | 1 |
| Eckert, BJ; Roskell, NS; Rycroft, CE; Tyas, DA; Zimovetz, EA | 1 |
| Belyaev, O; Bergmann, U; Burr, W; McArthur, N; Müller, CA; Munding, J; Tannapfel, A; Uhl, W; Werner, J | 1 |
| Blake, CR; Hahm, B; McClain, ME; Pritzl, CJ; Seo, YJ; Vijayan, M | 1 |
| Jin, J; Tian, YL; Wang, XJ | 1 |
| Rudick, RA | 1 |
| Agoropoulou, C; Devonshire, V; Francis, G; Häring, DA; Havrdova, E; Kappos, L; O'Connor, P; Radue, EW; Zhang-Auberson, L | 1 |
| Boockvar, J; Gursel, DB; Kulidzhanov, FG; Nori, D; Parashar, B; Sabbas, AM; Schwartz, A; Stessin, AM; Wernicke, AG | 1 |
| Gong, Y; Huang, Y; Jiang, J; Li, Y; Liu, Y; Wang, D; Wang, X; Xiao, H | 1 |
| Graham-Rowe, D | 1 |
| Chen, X; Chen, Y; Cheng, Q; Gao, D; Lei, D; Li, D; Liang, H; Long, X; Yang, H; Zhu, P | 1 |
| Cocco, G | 1 |
| Adachi, K; Chiba, K | 1 |
| Nakamura, S; Okada, T | 1 |
| Brown, TS; Davis, TA; Elster, EA; Graybill, JC; Hawksworth, JS; Tadaki, DK; Wallace, SM | 1 |
| Buttmann, M; Weise, G | 1 |
| Fozard, JR; Trifilieff, A | 1 |
| Bendall, LJ; Bradstock, KF; Don, AS; Hewson, J; Lock, RB; Papa, RA; Qiao, Q; Wallington-Beddoe, CT | 1 |
| Gong, Y; Huang, Y; Jiang, J; Li, Y; Liu, Y; Wang, X; Xiao, H | 1 |
| Charlton, SJ; Dowling, MR; Riddy, DM; Stamp, C; Sykes, DA | 1 |
| Deng, A; Huang, X; Jiang, J; Wang, Y; Zhou, J | 1 |
| Baxter, DC; Coleman, CI; Lee, S; Limone, B; Roberts, MS | 1 |
| Ayala-Perez, R; Fynch, S; Graham, KL; Kay, TW; Krishnamurthy, B; Santamaria, P; Slattery, RM; Thomas, HE | 1 |
| Lei, T; Liu, G; Peng, J; Sun, C; Wang, R; Wu, T; Xu, K; Zhang, L; Zhao, Y | 1 |
| Hall, LJ; Hurley, G; MacSharry, J; Melgar, S; Murphy, CT; Nally, K; Quinlan, A; Shanahan, F | 1 |
| Davletov, B; Kreft, M; Parpura, V; Potokar, M; Stenovec, M; Trkov, S; Zorec, R | 1 |
| Johnston, J; So, TY | 1 |
| Iwasaki, T; Kitano, S; Sano, H; Sato, C; Tsunemi, S | 1 |
| Don, AS; Kim, HJ; Morris, JC; Qiao, Q; Toop, HD | 1 |
| Du Pasquier, R; Schluep, M | 1 |
| Danilycheva, IV; Kryzhanovskiĭ, SM; Shmyrev, VI | 1 |
| Lai, X; Song, B; Wang, T; Xing, X; Ye, Y; Zeng, X; Zeng, Y; Zhu, C | 1 |
| Graves, D; Vernino, S | 1 |
| García-Merino, JA; Sánchez, AJ | 1 |
| Jakab, G | 1 |
| Bade, ND; Blazar, BR; Kelly, RM; Smith, MJ; Stefanski, HE; Taylor, PA | 1 |
| Chiba, K; Yoshii, N | 1 |
| Faber, H; Fischer, HJ; Weber, F | 1 |
| David, OJ; den Daas, I; Emotte, C; Jakab, A; Meiser, K; Ocwieja, M; Schmouder, R; Wemer, J | 1 |
| Frequin, ST; Groot, MT; Heisen, M; Treur, MJ; van der Hel, WS; Verheggen, BG | 1 |
| Aguilera, C; Tintoré, M; Tur, C | 1 |
| Armstrong, B; Deng, J; Forman, S; Kowolik, C; Lee, H; Liu, Y; Scuto, A; Wang, L; Weiss, LM; Yu, H | 1 |
| Agashivala, N; Kim, E | 1 |
| Agoropoulou, C; Burtin, P; Calabresi, P; de Vera, A; Francis, G; Hohlfeld, R; Holdbrook, F; Kappos, L; Mueller-Lenke, N; O'Connor, P; Polman, CH; Radue, EW; Selmaj, K; Zhang-Auberson, L | 1 |
| Dehmel, T; Hartung, HP; Jangouk, P; Kieseier, BC; Köhne, A; Lehmann, HC; Stettner, M | 1 |
| Chen, X; Li, J; Lu, Y; Wan, H; Ye, S; Zhang, S; Zheng, G; Zhu, H | 1 |
| Bourdette, D; Yadav, V | 1 |
| Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG | 1 |
| Hopkins, CR | 1 |
| Katz, KD; King, AM; Menke, NB; Pizon, AF | 1 |
| Lassmann, H | 1 |
| Chen, XG; Jin, J; Li, C; Li, Y; Zhang, HJ; Zhou, WQ | 1 |
| de Vries, HE; Dekker, N; Dijkstra, C; Kooij, G; Lopes-Pinheiro, MA; Nijland, PG; Reijerkerk, A; van Doorn, R; van het Hof, B; van Horssen, J; van van der Valk, P; Witte, ME | 1 |
| Baaj, Y; Cook-Moreau, J; Faucher-Durand, K; Fourcade, L; Funalot, B; Mollard, S; Mousseau, Y; Nizou, A; Qiu, H; Richard, L; Sturtz, FG | 1 |
| Cervera, C | 1 |
| Amato, MP; Giannini, M; Hakiki, B; Pastò, L; Portaccio, E; Razzolini, L | 1 |
| Lopez, AF; Pitman, MR; Pitson, SM; Woodcock, JM | 1 |
| Jeong, JK; Lee, JH; Lee, YJ; Moon, MH; Park, SY; Park, YG; Seol, JW | 1 |
| Fujita, T; Inoue, M; Iwatsuki, R; Kohno, T; Tsuji, T; Yoshida, Y | 1 |
| Barde, YA; Dekkers, MP; Deogracias, R; Guy, J; Ionescu, MC; Vogt, KE; Yazdani, M | 1 |
| Brandão, W; Bueno, V; Commodaro, AG; Pedregosa, JF; Peron, JP; Rizzo, LV | 1 |
| Berger, T; Fabjan, TH; Fazekas, F; Havrdová, E; Jakab, G; Jazbec, SS; Komoly, S; Kraus, J; Kurča, E; Kyriakides, T; Ledinek, AH; Lisý, L; Milanov, I; Panayiotou, P; Taláb, R; Traykov, L; Turčáni, P; Vass, K; Vella, N | 1 |
| Beppu, M; Kato, T; Masuko, K; Murata, M; Nakamura, H; Yudoh, K | 1 |
| Chaunu, MP; Daelman, L; Maarouf, A; Maitrot, A; Papeix, C; Tourbah, A | 1 |
| Cao, F; Fan, L; Gao, H; Tao, L; Wang, H; Wei, L; Yin, Z; Zhang, R | 1 |
| Choi, J; Chon, J; In, J; Joo, J; Kim, D; Lee, H; Moon, H; Park, J | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Campos, CR; Cannon, RE; Hawkins, BT; Miller, DS; Peart, JC | 1 |
| Gao, F; Jiang, W; Li, X; Liu, Y; Wang, Y; Wei, D | 1 |
| Gardner, NM; Gelineau-van Waes, J; Maddox, JR; Rainey, MA; Riley, RT; Sachs, AJ; Voss, KA; Wilberding, JD | 1 |
| Bourdette, D; Gilden, D | 1 |
| Centonze, D; Gallo, P; Rinaldi, F; Rossi, S | 1 |
| Linssen, WH; Pouwels, PJ; van Oosten, BW; Visser, F; Wattjes, MP | 1 |
| Calabresi, PA; Costello, K; Ratchford, JN; Reich, DS | 1 |
| Baumgartner, A; Gross, CM; Rauer, S; Stich, O | 1 |
| Bermel, RA; Cohen, JA; Hara-Cleaver, C; Ontaneda, D; Rudick, RA | 1 |
| Baune, BT; Clark, SR; Davis, A; Fitzpatrick, A; Newcombe, R | 1 |
| Battaglia, G; Bruno, V; Caraci, F; Copani, A; Di Menna, L; Di Nuzzo, L; Molinaro, G; Nicoletti, F; Pozzilli, C; Riozzi, B; Turrini, R; Zappulla, C | 1 |
| Hemmer, B; Stüve, O | 1 |
| Calabrese, M; Gallo, P; Perini, P; Rinaldi, F; Seppi, D | 1 |
| Hartung, HP; Jander, S; Kieseier, BC; Turowski, B | 1 |
| Alossaimi, M; Bittman, R; Chan, E; Pyne, NJ; Pyne, S; Tate, RJ; Tonelli, F; Watson, DG; Williamson, L | 1 |
| Adachi, K; Hamada, M; Hikawa, H; Yokoyama, Y | 1 |
| Baer, K; Frevert, U; Kappe, SH; Mikolajczak, SA; Movila, A; Nacer, A | 1 |
| Tar, L; Vécsei, L | 1 |
| Feng, Y; Mahmood, R; Ni, E; Qin, X; Sun, B; Xie, J; Yang, W; Yue, L; Yue, Z; Zhang, Y | 1 |
| Annovazzi, P; Baroncini, D; Comi, G; Filippi, M; Ghezzi, A; Minonzio, G; Rocca, MA; Zaffaroni, M | 1 |
| Bianco, R; Carlomagno, C; D'Amato, C; D'Amato, V; Damiano, V; De Placido, S; De Stefano, A; Del Vecchio, S; Formisano, L; Greco, A; Malapelle, U; Marciano, R; Marfè, G; Nappi, L; Rosa, R; Troncone, G; Veneziani, BM; Zannetti, A | 1 |
| Liu, J; Liu, M; Tao, W; Zhang, C | 1 |
| Campos, CR; Cannon, RE; Cartwright, TA; Miller, DS | 1 |
| Baum, K; Björnsson, ES; Chen, EY; Collins, W; Lee, WM; Löve, A; Merz, M; Olafsson, S | 1 |
| Bielawski, J; De Palma, RM; Fedarovich, D; Garrett-Mayer, E; Gencer, S; Habib, AA; Liu, A; Mukhopadhyay, A; Oaks, J; Ogretmen, B; Perrotti, D; Peterson, YK; Saddoughi, SA; Selvam, SP; Senkal, CE; Stahelin, RV; Szulc, ZM; Thomas, RJ; Ward, KE | 1 |
| Babb, JR; Bruce, CR; Febbraio, MA; Henstridge, DC; Lee-Young, RS; Risis, S; Yang, C | 1 |
| Abate, L; Brogi, D; Laroni, A; Mancardi, G; Milesi, V; Uccelli, A | 1 |
| Rohacs, T | 1 |
| Haas, J; Hartung, HP; Linker, RA; Meergans, M; Ortler, S; Tracik, F | 1 |
| Niino, M | 1 |
| Basmadjian, C; Buzard, D; Gharbaoui, T; Johnson, BR; Jones, RM; Kasem, M; Lopez, L; Schrader, TO; Sengupta, D | 1 |
| Bergvall, N; Fredrikson, S; Henriksson, F; Tambour, M | 1 |
| Dinkin, M; Paul, F | 1 |
| Gelfand, JM; Green, AJ; Nolan, R | 1 |
| Chenevier, F; Confavreux, C; Roggerone, S; Vukusic, S | 1 |
| Filippi, M; Rocca, MA | 1 |
| Engel, D; Kalff, JC; Koscielny, A; Kurts, C; Maurer, J; Wehner, S | 1 |
| Hoogsteden, HC; Kleinjan, A; Lambrecht, BN; Leman, K; van Nimwegen, M | 1 |
| Altay, O; Hartman, R; Hasegawa, Y; Krafft, PR; Lekic, T; Manaenko, A; Ostrowski, R; Rolland, WB; Tang, J; Zhang, JH | 1 |
| Arnon, TI; Cyster, JG; Grigorova, IL; Horton, RM | 1 |
| Eienbröker, C; Gold, R; Havla, J; Hellwig, K; Hohlfeld, R; Kleiter, I; Krumbholz, M; Kümpfel, T; Meinl, I; Seitz, F; Tackenberg, B | 1 |
| Allegood, JC; Avni, D; Hait, NC; Harikumar, KB; Huang, WC; Kim, EY; Kordula, T; Liang, J; Milstien, S; Nagahashi, M; Price, MM; Spiegel, S; Takabe, K; Yamada, A | 1 |
| Bhattaram, A; Huang, SM; Mehrotra, N; Wang, Y | 1 |
| Chen, RR; Dinallo, RM; Fryer, RM; Harrington, KE; Harrison, PC; Horan, JC; Modis, LK; Muthukumarana, A; Nodop Mazurek, S; Patnaude, L; Reinhart, GA | 1 |
| Arai, K; Campos, F; Castillo, J; Lo, EH; Qin, T; Seo, JH; Waeber, C | 1 |
| Merkely, B; Széplaki, G | 1 |
| Komoly, S | 1 |
| Mizuno, T; Noda, H; Suzumura, A; Takeuchi, H | 1 |
| Bandichhor, R; Iqbal, J; Mulakayala, N; Oruganti, S; Rao, P | 1 |
| Bosworth, BP; Dannenberg, AJ; Hla, T; Jung, B; Montrose, DC; Scherl, EJ; Zhou, XK | 1 |
| Fox, RJ | 1 |
| Afshar, AR; Fernandes, JK; Hariprasad, SM; Ksiazek, SM; Patel, RD; Reder, AT; Sheth, VS | 1 |
| Adams, D; Bachman, S; Dinh, C; Hendry, M; Henning, T; Kersh, E; Luo, W; McNicholl, J; Mitchell, J; Powell, N; Sharma, P; Sweeney, E; Tsuiki, A; Vishwanathan, S | 1 |
| Park, K; Tanaka, K; Tanaka, M | 1 |
| Berenguer-Ruiz, L; Feliu-Rey, E; Martín-Medina, P; Pérez-Carmona, N; Polache-Vengud, J; Sanchez-Perez, R; Sempere, AP | 1 |
| Akhade, AS; Qadri, A; Sharma, N | 1 |
| Baek, DJ; Bittman, R; MacRitchie, N; Pyne, NJ; Pyne, S | 1 |
| Betensky, RA; Chin, P; Eckert, B; Mandel, M; Mercier, F | 1 |
| Isaka, Y; Li, XK; Liu, C; Nagahara, Y; Saito, T; Zhu, P; Zhuang, J | 1 |
| Brinkmann, V; Burgener, AV; Gubser, P; Hess, C; Kappos, L; Luster, AD; Mehling, M | 1 |
| Ahmadiani, A; Asle-Rousta, M; Dargahi, L; Kolahdooz, Z; Oryan, S | 1 |
| Adusumalli, P; Anderson, SM; Brown, ML; Desai, SN; Fogal, SE; Haxhinasto, SA; Lewis, ND; Lukas, SM; Modis, LK; Patnaude, LA; Ryan, KR; Slavin, AJ; Stefanopoulos, DE | 1 |
| Abassi, T; Berdyshev, E; Bittman, R; Dudek, SM; Garcia, JG; Huang, LS; Jacobson, JR; Mathew, B; Moreno-Vinasco, L; Natarajan, V; Wang, L; Weichselbaum, R; Zhao, Y | 1 |
| Brush, RS; Chen, H; Eckerd, A; Elliott, MH; Huynh, TP; Mandal, NA; Tran, JA | 1 |
| Li, S; Niu, X; Wang, J; Wang, P; Zhang, M; Zhou, H | 1 |
| Hirt, SW; Lehle, K; Puehler, T; Schmid, C; von Suesskind-Schwendi, M | 1 |
| Fujimoto, M; Hamaguchi, Y; Hasegawa, M; Huu, DL; Jin, G; Matsushita, T; Takehara, K | 1 |
| Antel, JP; Bar-Or, A; Bernier, LP; Cui, QL; Gris, P; Johnson, TA; Kennedy, TE; Leong, SY; Moore, CS; Séguéla, P; Wu, C | 1 |
| Itokazu, T; Takahashi, R; Yamashita, T | 1 |
| Abouzeid, N; Al-Jumah, M; Alroughani, R; Alsaadi, T; Alsharoqi, I; Bohlega, S; Dahdaleh, M; ElKallab, K; Hashem, S; Inshasi, J; Khoury, S; Tawfeek, T; Yamout, B; Zakaria, M | 1 |
| Chun, J; Groves, A; Kihara, Y | 1 |
| Arakawa, M; Hokari, M; Ishiguro, T; Ishihara, T; Kawachi, I; Nishizawa, M; Okamoto, K; Saji, E; Yanagimura, F; Yokoseki, A | 1 |
| Andriukhina, OM; Iakushina, TI; Kotov, SV; Lizhdvoĭ, VIu; Vasilenko, IA | 1 |
| Fedorova, SI; Iakushina, TI; Kotov, SV; Lizhdvoĭ, VIu | 1 |
| Eadie, M; Hollingworth, S; Page, A; Walker, K | 1 |
| Collins, W; Francis, G; Jager, RD; Jampol, LM; Reder, AT; Tang, D; Zarbin, MA; Zhang, X | 1 |
| Chang, A; Chui, J; Herkes, GK | 1 |
| Guerrero, M; Roberts, E; Rosen, H; Urbano, M | 1 |
| Honbo, N; Imhof, I; Karliner, JS; Li, L; Vessey, DA | 1 |
| Cha, SS; Chen, CS; Choi, CK; Galie, PA; Nguyen, DH; Stapleton, SC; Yang, MT | 1 |
| Ihlefeld, K; Pfeilschifter, J; Zu Heringdorf, DM | 1 |
| Griffith, JW; Luster, AD | 1 |
| Dev, KK; Healy, LM; Mullershausen, F; Pritchard, AJ; Rutkowska, A; Sheridan, GK | 1 |
| Dai, L; Di, W; Qi, Y; Xia, P; Zhang, N | 1 |
| Almeida, DR; Belliveau, MJ; Dorrepaal, SJ; Gale, JS; Minuk, A | 1 |
| An, X; Goto, H; Kezuka, T; Matsuda, R; Matsunaga, Y; Usui, Y; Yamakawa, N | 1 |
| Barkhof, F; Cohen, JA; Comi, G; Eckert, B; Francis, G; Häring, DA; Izquierdo, G; Khatri, B; Montalban, X; Pelletier, J | 1 |
| Georgakopoulos, CD; Georgalas, I; Makri, OE | 1 |
| Barker, DA; Botchwey, EA; Das, A; Green, D; Tanner, S | 1 |
| Bäumer, W; Dickhaut, J; Japtok, L; Kietzmann, M; Kleuser, B; Mischke, R; Schaper, K | 1 |
| Amato, MP; Hakiki, B; Pastò, L; Piscolla, E; Portaccio, E; Razzolini, L | 1 |
| Barbato, LM; Cascione, M; McCague, K; Pestreich, L; Schofield, L; Wynn, D | 1 |
| Battaglia, F; Brogi, D; Fenoglio, D; Filaci, G; Kalli, F; Mancardi, GL; Parodi, A; Serpero, LD; Uccelli, A | 1 |
| Ebinuma, I; Isshiki, H; Iwatsubo, T; Osawa, S; Sasaki, T; Takasugi, N; Takeo, K; Tomita, T | 1 |
| Inaba, S; Kubota, K; Sakurai, H; Shinagawa, A; Takanaka, K | 1 |
| Axelberg, H; Grände, PO; Lundblad, C | 1 |
| Derfuss, T; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Lindberg, RL; Lorscheider, J; Mehta, SK; Paroz, C; Pierson, DL; Ricklin, ME; Sprenger, T; Waschbisch, A | 1 |
| Ferrer, F; Hla, T; Li, MH | 1 |
| Cohen, JA; Willis, MA | 1 |
| Benoilid, A; Blanc, F; Chanson, JB; Collongues, N; Courtois, S; de Seze, J; Fleury, M; Ongagna, JC; Zaenker, C | 1 |
| Leiner, P | 1 |
| Campbell, JD; Corboy, JR; McQueen, RB; Miravalle, A; Nair, K; Vollmer, TL | 1 |
| Byrd, JC; Jarjoura, D; Lee, LJ; Lee, RJ; Mao, Y; Mo, X; Muthusamy, N; Paulaitis, ME; Wang, X; Yu, B; Yuan, Y; Yue, C | 1 |
| Singer, BA | 1 |
| Berry, A; Cartwright, EJ; Chowdhury, SK; Hanley, NA; Ke, Y; Lei, M; Liu, W; Meng, QJ; Neyses, L; Oceandy, D; Prehar, S; Solaro, RJ; Travis, M; Tsui, H; Wang, X; Xiao, RP; Zeef, L; Zi, M | 1 |
| Ahmadiani, A; Chik, Z; Dargahi, L; Hemmati, F; Mohamed, Z; Naidu, M; Nasoohi, S; Omidbakhsh, R | 1 |
| Huwiler, A; Pfeilschifter, J; Schwalm, S | 1 |
| Hu, R; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yao, K | 1 |
| Benghiat, F; Lysandropoulos, AP | 1 |
| Amling, M; Bindl, R; Haffner-Luntzer, M; Heilmann, A; Ignatius, A; Liedert, A; Rapp, A; Schinke, T; Wehner, T | 1 |
| Berenguer-Ruiz, L; Feliu-Rey, E; Sempere, AP | 1 |
| Bhatti, MT; Freedman, SM; Mahmoud, TH | 1 |
| Chen, JF; Liu, BC; Liu, H; Ma, KL; Ni, HF; Pan, MM; Tang, RN; Zhang, JD; Zhang, MH | 1 |
| Chinen, Y; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Sakamoto, N; Sasaki, N; Shimura, Y; Taniwaki, M; Yamamoto-Sugitani, M | 1 |
| Fukaura, H; Izaki, S; Kubota, A; Mitsui, T; Narukawa, S; Nomura, K | 1 |
| Huys, AC; Lalive, PH; Sekoranja, L | 1 |
| Chen, J; Chen, P; Liu, B; Ni, H; Pan, M; Zhang, J; Zhang, M | 1 |
| Kim, BJ; Kim, WK; Nam, JH | 1 |
| Arruda, DC; Bueno, V; Figueiredo, CR; Massaoka, MH; Matsuo, AL; Pereira, FV; Rodrigues, EG | 1 |
| Awojoodu, AO; Botchwey, E; Bowers, DT; Brayman, KL; Lynch, KR; Martin, K; Ogle, ME; Peirce-Cottler, SM; Sefcik, LS | 1 |
| Abdel-Wahab, O; Apperley, J; Arlinghaus, RB; Bittman, R; Briesewitz, R; Caligiuri, MA; Eisfeld, AK; Ferenchak, G; Goldman, JM; Harb, JG; Levine, R; Marcucci, G; Milojkovic, D; Nagata, K; Neviani, P; Oaks, JJ; Ogretmen, B; Perrotti, D; Quintas-Cardama, A; Reid, A; Roof, S; Saddoughi, SA; Santhanam, R; Van Brocklyn, JR; Walker, CJ; Ziolo, MT | 1 |
| Brunkhorst, R; Derouiche, A; Ferreirós, N; Foerch, C; Kanaan, N; Koch, A; Mirceska, A; Mittelbronn, M; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H; Zeiner, P | 1 |
| Brieland, JK; Chen, YJ; Kim, JH; O'Neal, J; O'Neil, SP; Song, SK; Trinkaus, K; Tu, TW; Wang, X | 1 |
| Garland, SL | 1 |
| Cohen, JA; Collins, W; Francis, G; Kappos, L; Mercier, F; O'Connor, P; Tang, D | 1 |
| Brane, L; Cheong, C; Choi, JH; Do, Y; Lavelle, EC; Mayer, L; Mehandru, S; Mucida, D; Poles, J; Reis, BS; Ruane, D; Steinman, RM; Studt, N; Velinzon, K; Zhu, H | 1 |
| Airas, L; Malm, H; Ruuskanen, J | 1 |
| Byrd, JC; Chen, CS; Kwak, KJ; Lee, LJ; Lee, RJ; Mao, Y; Muthusamy, N; Phelps, MA; Wang, J; Wu, Y; Zhao, Y | 1 |
| Banno, R; Fujita, T; Kohno, T; Matsushima, A; Matsushima, Y; Tsuji, T; Watanabe, S; Yoshida, Y | 1 |
| Apperley, J; Arlinghaus, RB; Bhatia, R; Bielawski, J; Bittman, R; Blum, W; Byrd, JC; Caligiuri, MA; Chen, CS; Cortes, J; Croce, CM; Devine, S; Dorrance, AM; Eiring, AM; Ellis, JJ; Ferenchak, G; Garzon, R; Goldman, JM; Harb, JG; Hokland, P; Holyoake, TL; Huettner, CS; Klisovic, RB; Koschmieder, S; Ma, Y; Mao, HC; Marcucci, G; May, PC; Milojkovic, D; Mulloy, JC; Neviani, P; Oaks, JJ; Ogretmen, B; Paisie, CA; Perrotti, D; Reid, A; Roy, DC; Saddoughi, SA; Santhanam, R; Solt, JA; Sun, C; Volinia, S; Walker, CJ; Wunderlich, M; Zhang, B | 1 |
| Dunk, CE; Lye, SJ; Zhang, J | 1 |
| Bergmann, A; Braune, S; Lang, M | 1 |
| Dalrymple, NA; Gavrilovskaya, IN; Gorbunova, EE; Mackow, ER | 1 |
| Brede, M; Deppermann, C; Göb, E; Göbel, K; Herrmann, AM; Kleinschnitz, C; Kraft, P; Lorenz, K; Meuth, SG; Nieswandt, B; Pfeilschifter, W; Schuhmann, MK; Stoll, G; Thielmann, I | 1 |
| Afazel, S; Harrer, A; Haschke-Becher, E; Kraus, J; Oppermann, K; Pilz, G; Sellner, J; Trinka, E; Wipfler, P | 1 |
| Chen, Y; Huang, H; Jiang, J; Ouyang, Y; Wang, L; Xu, J; Ying, Y | 1 |
| Aidhen, IS; Borkar, SR; Mishra, AK; Mohapatra, M; Swain, J | 1 |
| Balcer, LJ; Calabresi, PA; Cello, KE; Durbin, MK; Harvey, DJ; Keltner, JL; Werner, JS; Winges, KM | 1 |
| Agashivala, N; Balderston McGuiness, C; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; Petrilla, A; Pradhan, A | 1 |
| Ouyang, YL; Wang, JF; Wang, L; Xu, J; Ying, YF | 1 |
| Botchwey, EA; Bowers, DT; Das, A; Hughley, BB; Segar, CE | 1 |
| Abouzaid, S; Agashivala, N; Boulanger, L; Brandes, DW; Kim, E; Wu, N; Wu, Y | 1 |
| Bourdette, D; Paul, F | 1 |
| Fazekas, F; Harrer, A; Kraus, J; Oppermann, K; Pilz, G; Sellner, J; Trinka, E; Wipfler, P | 1 |
| Cong, ZX; Ji, XJ; Wang, HD; Zhang, L; Zhou, Y; Zhu, JH | 1 |
| Ahmad, I; Deshmukh, VA; Gage, FH; Green, CC; Kerman, B; Kim, HJ; Kondo, T; Lairson, LL; Lawson, BR; Lyssiotis, CA; Padmanabhan, K; Schultz, PG; Swoboda, JG; Tardif, V; Theofilopoulos, AN | 1 |
| Antel, J; Bar-Or, A; Galleguillos, L; Henault, D; Johnson, T; Moore, C | 1 |
| Jeong, JK; Lee, YJ; Moon, MH; Park, SY | 1 |
| Brosa, M; Crespo, C; García-Ruiz, A; Granell, M; Izquierdo, G | 1 |
| Borghi, V; Cossarizza, A; De Biasi, S; Federzoni, L; Ferraro, D; Nichelli, PF; Simone, AM; Sola, P; Vitetta, F | 1 |
| Tanaka, K; Tanaka, M | 1 |
| Al-Jaderi, Z; Maghazachi, AA | 1 |
| Crump, N; Greene, SL; Kerr, F; Rotella, JA; Stephenson, M; Wong, A | 1 |
| Altay, O; Hasegawa, Y; Rolland, W; Suzuki, H; Zhang, JH | 1 |
| Agarwal, S; Deniz, B; Fox, RJ; Havrdova, E; Hutchinson, M; Kurukulasuriya, NC; Sarda, SP; Siddiqui, MK; Taneja, A | 1 |
| Bijarnia, M; Comi, G; Gold, R; Gottschalk, R; Kappos, L; Palace, J; Siever, A; Tomic, D; von Rosenstiel, P | 1 |
| Freedman, MS | 1 |
| Bassilana, F; Bigaud, M; Billich, A; Brinkmann, V; Guerini, D | 1 |
| Asensio-Sánchez, VM; Ramoa-Osorio, R; Trujillo-Guzmán, L | 1 |
| Amico, E; Castrataro, R; Di Pardo, A; Favellato, M; Fucile, S; Maglione, V; Squitieri, F | 1 |
| Keane, D; O'Kelly, S; Saiva, L; Voon, V | 1 |
| Chiba, K; Hagihara, K; Kita, A; Kitai, Y; Kunoh, T; Masuko, T; Matzno, S; Mizukura, A; Sugiura, R; Yao, M | 1 |
| Francis, CE | 1 |
| Thomas, K; Ziemssen, T | 1 |
| Blasczyk, R; Buddaseth, S; Göttmann, W; Huyton, T | 1 |
| Bittman, R; Camp, SM; Dudek, SM; Garcia, JG; Letsiou, E; Moreno-Vinasco, L; Sammani, S; Wang, L; Wang, T | 1 |
| Alwan, S; Dahlgren, L; Lu, E; Sadovnick, AD; Synnes, A; Tremlett, H; Wang, BW | 1 |
| Chiba, K; Fukunari, A; Maeda, Y; Masuko, T; Sugahara, K; Takemoto, K; Utsumi, H; Yagi, H | 1 |
| Louapre, C; Lubetzki, C; Maillart, E; Papeix, C | 1 |
| Fernández, Ó; Garcia-Garcia, M; Montalban, X; Oreja-Guevara, C; Rodríguez-Antigüedad, A | 1 |
| Anthony, DC; Leppert, D; Losey, P; Meier, DP; Sibson, NR | 1 |
| Aguilera, O; Borrero, A; Caramés, C; Cristóbal, I; García-Foncillas, J; Madoz-Gúrpide, J; Manso, R; Martínez-Useros, J; Rincón, R; Rodriguez, M; Rojo, F; Senin, C; Zazo, S | 1 |
| Fujii, K; Hirafuji, M; Iizuka, K; Machida, T | 1 |
| Langer-Gould, AM | 1 |
| Cohen, JA; Collins, W; Francis, G; Heining, P; Kappos, L; Karlsson, G; Koren, G; Zhang, X | 1 |
| Montalban, X; Tur, C | 1 |
| Hao, Q; Itoyama, Y; Kikuchi, S; Kira, J; Kurosawa, T; Nagato, K; Saida, T; Tsumiyama, I; von Rosenstiel, P; Zhang-Auberson, L | 1 |
| Bittman, R; Ohotski, J; Pyne, NJ; Pyne, S; Rosen, H | 1 |
| Weinstock-Guttman, B | 1 |
| Ayata, C; Barfejani, AH; Dong, Q; Lu, L; Qin, T; Waeber, C | 1 |
| Chiba, K; Hagihara, K; Ishida, K; Kita, A; Kitai, Y; Kunoh, T; Masuko, T; Matzno, S; Mizukura, A; Sugiura, R; Yao, M | 1 |
| Aoki, M; Bar-Or, A; Fujihara, K; Kuroda, H; Misu, T; Nakashima, I; Nishiyama, S; Sato, DK; Suzuki, C | 1 |
| Ching, D; Eberlé, D; Honbo, N; Imhof, I; Karliner, JS; Kim, RY; Kumar, N; Li, K; Luk, FS; Raffai, RL; Wang, G; Zhu, BQ | 1 |
| Alroughani, R | 1 |
| Agashivala, N; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; McGuiness, CB; Petrilla, AA; Pradhan, A | 2 |
| Damoiseaux, J; Hupperts, R; Muris, AH; Rolf, L; van Daele, M | 1 |
| Araki, M; Aranami, T; Chihara, N; Lin, Y; Matsuoka, T; Miyake, S; Murata, M; Nakamura, M; Ogawa, M; Okamoto, T; Sato, W; Yamamura, T | 1 |
| Kuboyama, T; Tohda, C | 1 |
| Al Khedr, A; Anne, O; Berger, E; Bourre, B; Brassat, D; Brochet, B; Camdessanche, JP; Camu, W; Casez, O; Castelnovo, G; Clavelou, P; Cohen, M; Courtois, S; De Sèze, J; Debouverie, M; Defer, G; Fromont, A; Heinzlef, O; Le Page, E; Lebrun, C; Maillart, E; Papeix, C; Pelletier, J; Rico, A; Ruet, A; Stankoff, B; Tourbah, A; Vukusic, S; Wiertlewski, S; Zephir, H | 1 |
| Bi, Y; Chen, W; Chu, Y; Liu, G; Liu, H; Lu, Y; Wang, R; Wang, X; Yang, H; Yang, R; Zhang, Y; Zhang, Z | 1 |
| Breit, SN; Brown, DA; Hart, PH; Hassanpour, M; Li, H; Mohammad, MG; Ruitenberg, MJ; Sawchenko, PE; Tsai, VW | 1 |
| Huang, Y; Jia, L; Liu, Y; Wang, L; Zhu, J | 1 |
| Constantinescu, CS; Tanasescu, R | 1 |
| Murayama, T; Nakamura, H | 1 |
| Akin, M; Arndt, T; Hedrich, HJ; Jörns, A; Lenzen, S; Terbish, T; Wedekind, D; Zu Vilsendorf, AM | 1 |
| Beggiato, E; Broganelli, P; Cavalla, P; Chiavazza, C; Crosasso, P; Masera, S; Mattioda, A; Pinessi, L; Superti, G | 1 |
| Amino, I; Doi, S; Fujiki, N; Fukazawa, T; Kikuchi, S; Minami, N; Miyazaki, Y; Niino, M; Nonaka, T; Takahashi, E; Tashiro, J | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Duquette, P; Girard, M; Giuliani, G; Grand'Maison, F; Haartsen, J; Hodgkinson, S; Izquierdo, G; Jokubaitis, VG; Kalincik, T; Lechner-Scott, J; Li, V; Liew, D; Lugaresi, A; Shaw, C; Slee, M; Spitaleri, DL; Trojano, M; Verheul, F | 1 |
| Giovannoni, G; Naismith, RT | 1 |
| Kawai, A; Kondo, T; Kubota, D; Yoshida, A | 1 |
| Alexander, CE; Amante, FH; Best, SE; Bunn, PT; de Labastida Rivera, F; Engwerda, CR; Faleiro, RJ; Haque, A; James, KR; Kaye, PM; Montes De Oca, M; Mulherin, A; Sheel, M; Stanley, AC | 1 |
| Ahmed, SF; Al-Hashel, J; Alroughani, R; Behbehani, R | 2 |
| Agosti, V; Altomare, E; Amodio, N; Barone, A; Bianco, C; Bianco, R; Caraglia, M; Lombardi, A; Marvaso, G; Raimondi, L; Scotti, V; Tagliaferri, P; Tassone, P | 1 |
| Ferrer, FA; Hla, T; Shapiro, LH; Silva, C; Thangada, S; Yamase, H | 1 |
| Calabresi, PA; Gocke, AR; Grishkan, IV; Hall, O; Klein, SL; Ntranos, A; Robinson, DP; Schott, JT; Tosi, DM | 1 |
| Kong, Y; Tang, N; Wang, H; Wang, S | 1 |
| Agius, M; Chin, P; Grinspan, A; Hashmonay, R; Meng, X | 1 |
| Agius, MA; Calabresi, PA; Cappiello, L; Goodin, D; Jeffery, D; Kappos, L; Li, B; Lublin, FD; Radue, EW; Rammohan, KW; Reder, AT; Stites, T; Vollmer, T; von Rosenstiel, P | 1 |
| Sorensen, PS | 2 |
| Brogi, D; Comi, G; Guidi, L; Laroni, A; Lugaresi, A; Mancardi, GL; Morra, VB; Pozzilli, C; Raimondi, D; Turrini, R; Uccelli, A | 1 |
| Fukumoto, K; Horiuchi, H; Jin, S; Kawanokuchi, J; Mizoguchi, H; Mizuno, T; Suzumura, A; Takeuchi, H | 1 |
| Nikitin, AV | 1 |
| Al-Adawy, N; Graham, SL; Gupta, VK; Klistorner, A; Li, JC; You, Y | 1 |
| Bergvall, N; Korn, JR; Lahoz, R; Reynolds, T | 1 |
| Erminio, C; La Mantia, L; Marazzi, MR; Prone, V; Protti, A | 1 |
| Blanco-Prieto, MJ; Christensen, DJ; Dominguez, A; Moreno-Miralles, I; Odero, MD; Pippa, R; Vitek, MP | 1 |
| Almazan, G; Antel, JP; Cui, QL; Fang, J; Kennedy, TE | 1 |
| Barkhof, F; Cohen, J; de Jong, R; de Vera, A; Francis, G; Sfikas, N | 1 |
| Absalom, AR; Bouma, HR; Buikema, H; Epema, AH; Henning, RH; Houwertjes, MC; Mungroop, HE; Samarska, IV | 1 |
| Kreft, M; Stenovec, M; Trkov, S; Zorec, R | 1 |
| Baldi, E; Caniatti, L; Curti, E; Ferraro, D; Granella, F; Guareschi, A; Immovilli, P; Montanari, E; Montepietra, S; Motti, L; Pesci, I; Senesi, C; Simone, AM; Sola, P; Tola, MR; Vitetta, F | 1 |
| Botto, G; Pentimalli, F; Vanoli, E | 1 |
| Eienbröker, C; Gold, R; Havla, J; Hellwig, K; Hoepner, R; Hohlfeld, R; Kleiter, I; Kümpfel, T; Meinl, I; Tackenberg, B | 1 |
| Khatri, M; Rajasagi, NK; Reddy, PB; Rouse, BT; Sehrawat, S; Suryawanshi, A | 1 |
| Buckle, GJ; Carruthers, RL; Chitnis, T; Healy, BC; Rotstein, DL; Weiner, HL | 1 |
| Andreeff, M; Burks, JK; Calin, G; Coombes, KR; Duvvuri, SR; Hail, N; Jacamo, R; Konopleva, M; Kornblau, SM; Pan, R; Qiu, Y; Ruvolo, PP; Ruvolo, VR; Yoo, SY; Zeng, Z; Zhang, N; Zhou, L | 1 |
| Allegood, JC; Avni, D; Hait, NC; Knapp, PE; Lichtman, AH; Lu, J; Luo, C; Miles, MF; Milstien, S; O'Brien, M; Reeves, TM; Spiegel, S; Wise, LE | 1 |
| Blankenbach, K; Engelhardt, B; Enzmann, G; Fallegger, D; Homann, T; Huwiler, A; Imeri, F; Kleuser, B; Meyer zu Heringdorf, D; Pfeilschifter, J; Schwalm, S; Stark, H; Zivkovic, A | 1 |
| Daniels, JM; Killestein, J; Looysen, EE; van Rossum, JA | 1 |
| Han, Y; Ma, DH; Wang, ZH; Xing, Y | 1 |
| Bieberich, E; Bryant, L; Chen, C; Chen, Z; Cuzzocrea, S; Doyle, T; Esposito, E; Janes, K; Kamocki, K; Li, C; Little, JW; Neumann, WL; Nicol, G; Obeid, L; Petrache, I; Salvemini, D; Snider, A | 1 |
| di Nuzzo, L; Nasca, C; Nicoletti, F; Orlando, R | 1 |
| Lv, L; Qian, J; Ye, S; Ye, Y; Zhu, C | 1 |
| Halank, M; Schrötter, H; Thomas, K; Ziemssen, T | 1 |
| Erdem-Özdamar, S; Erdener, ŞE; Göçmen, R; Kurne, A; Nurlu, G | 1 |
| Dev, KK; Mir, AK; Pritchard, AJ | 1 |
| Francolini, M; Joshi, P; Mastrangelo, R; Matteoli, M; Ruiz, A; Verderio, C | 1 |
| Byrd, JC; Chen, CS; Lee, LJ; Lee, RJ; Li, H; Mao, Y; Muthusamy, N; Phelps, MA; Wang, J; Yan, R; Zhao, Y | 1 |
| Goldman, MD; Jones, DE; Ward, MD | 1 |
| Höjer, J; Olsson, E | 1 |
| Andritsos, L; Baskar, S; Byrd, JC; Chen, CS; Chiang, CL; Flynn, J; Frissora, FW; Jones, J; Lee, LJ; Lee, RJ; Mani, R; Mao, Y; Mo, X; Muthusamy, N; Phelps, MA; Rader, C; Wang, J; Wu, Y; Yan, R; Yu, B; Yu, L; Zhao, Y | 1 |
| Davletov, B | 1 |
| Matheos, DP; Wood, MA | 1 |
| Danhof, M; Luttringer, O; Ploeger, BA; Snelder, N; Stanski, DR | 1 |
| David, OJ; Meiser, K; Ocwieja, M; Pleyer, U; Schmouder, R; Schreiber, SJ; Valencia, J; Wagner, F; Ziemer, S | 1 |
| Faßbender, K; Halmer, R; Walter, S | 1 |
| Lovera, J; Villemarette-Pittman, N | 1 |
| Fichman-Horn, S; Hellmann, MA; Inbar, E; Lev, N; Lotan, I; Luckman, J; Mosberg-Galili, R; Steiner, I; Yakimov, M | 1 |
| Fu, Y; Hao, J; Huang, D; Li, YJ; Ren, L; Shi, FD; Sun, N; Yan, Y; Yu, C; Zhang, N | 1 |
| Bonitz, JA; Chandler, B; Deitch, EA; Feketeova, E; Prescott, LM; Qin, Y; Son, JY; Tomaio, JN | 1 |
| Rosand, J; Sheth, KN | 1 |
| Ding, Z; Heyman, B; Xu, H; Zhang, L | 1 |
| Crespo, MI; García, IA; Gorlino, CV; Harman, MF; Maletto, BA; Morón, G; Pistoresi-Palencia, MC; Ranocchia, RP | 1 |
| Falato, E; Filippi, MM; Ghazaryan, A; Landi, D; Mulas, D; Pasqualetti, P; Pellegrino, G; Rossini, PM; Vollaro, S | 1 |
| Cruz, VT; Fonseca, J | 1 |
| Gu, G; Liu, Y; Lu, L; Tao, R; Wang, M | 1 |
| Alessandri, G; Bornati, A; Campanella, R; de Rezende, G; Di Vito, C; Giussani, P; Hadi, LA; Marfia, G; Navone, SE; Parati, E; Rampini, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P | 1 |
| Capitolo, E; Chaabane, L; Colombo, E; Di Dario, M; Farina, C; Martino, G; Newcombe, J | 1 |
| Chen, L; Chen, SJ; Jiang, H; Li, KK; Li, L; Liu, H; Liu, YF; Lu, J; Luo, C; Luo, LF; Song, H; Wang, J | 1 |
| Dillman, R; Franklin, MA; Happe, LE; Marshall, LZ | 1 |
| Sanford, M | 1 |
| Ding, K; Wang, H; Xu, J; Zhang, L; Zhu, J | 1 |
| Barker, DA; Botchwey, EA; Das, A; Lau, CM; Lin, Y; Wang, T | 1 |
| Albert-Weissenberger, C; Hennig, N; Hopp, S; Kleinschnitz, C; Mencl, S; Schuhmann, MK; Sirén, AL | 1 |
| Lovett-Racke, AE; Racke, MK; Yang, Y | 1 |
| Becker, KA; Edwards, MJ; Futerman, AH; Grassmé, H; Gulbins, E; Japtok, L; Joseph, T; Kleuser, B; Lang, S; Lentsch, AB; Pewzner-Jung, Y; Schuchman, EH; Steinmann, J; Tavakoli Tabazavareh, S; Tuemmler, B | 1 |
| Ahmadiani, A; Dargahi, L; Khallaghi, B; Mohamed, Z; Naidu, M; Nasoohi, S; Omidbakhsh, R; Rajabli, B | 1 |
| Banno, Y; Fujine, E; Ishitsuka, A; Kanoh, H; Mizutani, Y; Seishima, M; Tawada, C | 1 |
| Awojoodu, AO; Botchwey, EA; Chiappa, NF; Lynch, K; Ogle, ME; Peirce-Cottler, S; Sefcik, LS | 1 |
| Blanc, CA; Lane, TE; Rosen, H | 1 |
| Damoiseaux, J; Hupperts, R; Koeman, E; Muris, AH; Rolf, L | 1 |
| Bajwa, A; Chroscicki, P; Dondeti, K; Hoehn, KL; Jobin, K; Kenwood, BM; Kinsey, GR; Lee, S; Lynch, KR; Okusa, MD; Rosin, DL; Stevens, BK; Ye, H | 1 |
| Chen, XG; Jin, J; Wang, XJ; Yin, DL; Zhang, HJ; Zhou, WQ | 1 |
| Al-Jarallah, A; Chen, X; González, L; Trigatti, BL | 1 |
| Eder, C; Miralles, F; Schilling, T | 1 |
| Ottenlinger, F; Pfeilschifter, JM; Radeke, HH; Rüger, K; Schröder, M; Stark, H; Zivković, A | 1 |
| Gao, M; Han, G; Huang, Y; Jia, L; Lei, T; Liu, Y; Wang, L; Xiao, Y | 1 |
| Amor, S; Beyer, C; Clarner, T; Kipp, M; Schmidt, T; Slowik, A | 1 |
| Beak, DJ; Bertaina, A; Bittman, R; Chiarini, F; Evangelisti, C; Falconi, M; Locatelli, F; Martelli, AM; McCubrey, JA; Melchionda, F; Pession, A; Pyne, NJ; Pyne, S; Teti, G | 1 |
| Benedetti, MD; Bianchi, MR; Deotto, L; Gajofatto, A | 1 |
| Arellano, B; Castro-Rojas, C; Cravens, PC; Deason, K; Eagar, TN; Hayardeny, L; Hussain, RZ; Stüve, O; Yarovinsky, F | 1 |
| Abraham, SN; Ang, WXG; Chan, EW; Gunn, MD; Huang, MN; Kunder, CA; St John, AL | 1 |
| Ahmadiani, A; Asle-Rousta, M; Dargahi, L; Kolahdooz, Z; Nasoohi, S | 2 |
| Bridel, C; Lalive, PH | 1 |
| Callegaro, D; Sato, DK | 1 |
| Arruda, CC; Arruda, WO; Brooks, JB; Damasceno, A; Damasceno, CA; de Morais, MM; Finkelsztejn, A; Finkelsztejn, J; Fragoso, YD; Gama, PD; Giacomo, MC; Gomes, S; Goncalves, MV; Matta, AP; Oliveira, EM; Ribeiro, Y; Sato, HK; Tauil, CB | 1 |
| Azumaya, I; Hamada, M; Hikawa, H; Kikkawa, S; Uchida, Y; Yokoyama, Y | 1 |
| Gutkind, S; Hla, T; Hwa, J; Obinata, H; Okuno, T; Stitham, J; Yokomizo, T | 1 |
| McDonald, EA; Sedal, L; Wilson, IB | 1 |
| Shoenfeld, Y; Steinman, L | 1 |
| Hu, S; Jin, Y; Ni, H; Xu, H; Zhang, Q | 1 |
| Almulla, A; Alroughani, R; Lamdhade, S; Thussu, A | 1 |
| Hay, JW; Niu, X; Zhang, X | 1 |
| Jiang, H; Liang, Y; Liu, L; Lu, Z; Pan, S; Pei, T; Song, R; Wang, J; Yin, D; Zheng, T | 1 |
| Harada, H; Hattori, K; Hirose, J; Kawato, Y; Koshika, T; Maeda, M; Morokata, T; Nagasaka, Y; Okada, Y; Saito, R; Yamamoto, R | 1 |
| Chi, M; Guo, ST; Jiang, CC; Jin, L; Liu, X; Tay, KH; Tseng, HY; Verrills, NM; Zhang, XD | 1 |
| Broux, B; Claes, N; Dhaeze, T; Fraussen, J; Hellings, N; Hupperts, R; Somers, V; Stinissen, P; Van Wijmeersch, B | 1 |
| Dehmel, T; Hartung, HP; Holmen, C; Kieseier, BC; Leussink, VI; Nordin, N; Olsson, T; Ramanujam, R; Warnke, C; Wolfram, K | 1 |
| Moses, H | 1 |
| Aubert, RD; Butler, K; Garber, D; Henning, T; Jenkins, L; Kersh, EN; McNicholl, J; Mitchell, J; Morris, M | 1 |
| Ding, LH; Liu, BC; Liu, D; Liu, H; Lv, LL; Ma, KL; Tang, RN; Wen, Y; Wu, M; Xu, M | 1 |
| Hentati, A; Issa, NP | 1 |
| Arvin, AM; Bezuidenhoudt, M; Gershon, A; Gershon, M; Kappos, L; Levin, MJ; Morris, MI; Putzki, N; Reder, AT; Tornatore, C; Wolinsky, JS | 1 |
| Tyler, KL | 1 |
| Bae, DS; Cho, YJ; Choi, CH; Choi, JJ; Do, IG; Jeon, HK; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Ryu, JY; Song, SY; Yoon, G | 1 |
| Bakshi, R; Brinkmann, V; Camm, J; Hla, T | 1 |
| Baumann, JM; Bhaumik, SK; Chougnet, CA; Dunn, RS; Kallapur, SG; Kuan, CY; Lee, YH; Lewkowich, IP; Li, Y; Lin, SH; Lin, X; Lindquist, DM; Liu, CY; Murali-Krishna, K; Shie, FS; Sun, YY; Wills-Karp, M; Yang, D; Zhang, Y | 1 |
| Daneman, R; Frevert, U; Girgis, NM; Gundra, UM; Loke, P; Movila, A; Nacer, A; Sohet, F | 1 |
| Fu, Y; Han, W; Hao, J; Li, YJ; Liu, Q; Ren, L; Shi, FD; Sun, N; Xue, R; Yan, Y; Yu, C; Zhang, N | 1 |
| Bencsik, K; Karácsony, M; Vécsei, L | 1 |
| Thomas, RH; Wakefield, RA | 1 |
| Bankó, N; Bencsik, K; Csete, G; Faragó, P; Kincses, ZT; Király, A; Szabó, N; Tóth, E; Vécsei, L; Veréb, D | 1 |
| Tanaka, M | 1 |
| Alroughani, R; Barnett, M; Bergamaschi, R; Boz, C; Butzkueven, H; Csepany, T; Duquette, P; Fernandez-Bolanos, R; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Izquierdo, G; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Lugaresi, A; McCombe, P; Oreja-Guevara, C; Pucci, E; Rozsa, C; Rum, G; Sanchez-Menoyo, J; Simo, M; Slee, M; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Verheul, F | 1 |
| Airas, L; Anthony, DC; Dickens, AM; Elo, P; Eskola, O; Haaparanta-Solin, M; Johansson, J; Jones, PA; Marjamäki, P; Rinne, J; Solin, O; Trigg, W | 1 |
| Sellebjerg, F; Sørensen, PS | 1 |
| Fratta, M; Lus, G; Sagliocchi, A; Signoriello, E | 1 |
| Barkhof, F; Bright, JR; Cohen, JA; de Vera, A; Francis, G; Häring, DA; Kappos, L; Radue, EW; Sprenger, T; von Rosenstiel, P | 1 |
| Arroyo, R; Bijarnia, M; Curovic-Perisic, V; Izquierdo, G; Kappos, L; Keil, A; Mehling, M; Selmaj, K; Singh, A; von Rosenstiel, P | 1 |
| Goldman, MD; Naismith, RT | 1 |
| Alroughani, R; Butzkueven, H; Duquette, P; Fernandez-Bolaños, R; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Havrdova, E; He, A; Hodgkinson, S; Horakova, D; Hupperts, R; Iuliano, G; Izquierdo, G; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Lugaresi, A; Oreja-Guevara, C; Pucci, E; Rozsa, C; Sánchez-Menoyo, JL; Sola, P; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Van Pesch, V; Verheul, F | 1 |
| Fellows, SE; Nomura, JT; Rajasimhan, S; Rosini, JM | 1 |
| Angioni, C; Arlt, O; Huwiler, A; Pfeilschifter, JM; Radeke, HH; Schmidt, H; Schröder, M; Schwiebs, A | 1 |
| Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE | 1 |
| Abe, M; Kanda, T; Koga, M; Maeda, T; Nishihara, H; Sano, Y; Shimizu, F; Takeshita, Y | 1 |
| Francis, G; Hohlfeld, R; Kappos, L; O'Connor, P; Polman, C; Radue, EW; Ritter, S; Schlosshauer, R; Selmaj, K; von Rosenstiel, P; Zhang-Auberson, L | 1 |
| Chen, Y; Dahlke, F; Disanto, G; Francis, G; Giovannoni, G; Kappos, L; Kuhle, J; Lorscheider, J; Radue, EW; Shrinivasan, A; Stites, T | 1 |
| Haufe, G; Hermann, S; Keul, P; Levkau, B; Schäfers, M; Schilson, SS; Shaikh, RS; Wagner, S | 1 |
| Anstadt, EJ; Clark, RB; Fujiwara, M; Khanna, KM | 1 |
| Hla, T; Proia, RL | 1 |
| Alarcón-Duque, JA; Castillo-Trivino, T; Lopetegui, I; López de Munain, A; Olascoaga, J | 1 |
| Bittman, R; Dudek, SM; Garcia, JG; Wang, L | 1 |
| Chiu, AW; Chow, YC; Huang, CJ; Pan, WH; Shih, HJ; Wang, TY; Yen, JC | 1 |
| Egom, EE; Kruzliak, P; Lei, M; Rotrekl, V | 1 |
| Barkley, A; Silber, E; Tully, T | 1 |
| Guerrero, M; Kays, J; Li, C; Li, JN; Nicol, GD | 1 |
| Baumgartner, A; Berger, B; Farenkopf, U; Luetzen, N; Mader, I; Rauer, S; Stich, O | 1 |
| Charles, EJ; Huerter, ME; Johnston, WF; Kron, IL; Laubach, VE; Lynch, KR; Sharma, AK; Stone, ML; Zhao, Y | 1 |
| Bordin, L; Brunati, AM; Facco, M; Frezzato, F; Pagano, MA; Pavan, V; Ribaudo, G; Semenzato, G; Tibaldi, E; Trentin, L; Trimarco, V; Zagotto, G; Zonta, F | 1 |
| Baiocchi, R; Baskar, S; Byrd, JC; Chen, CS; Chiang, CL; Frissora, FW; Klisovic, R; Lee, LJ; Lee, RJ; Mani, R; Mo, X; Muthusamy, N; Phelps, MA; Rader, C; Yan, R | 1 |
| Prager, B; Ransohoff, RM; Spampinato, SF | 1 |
| Ding, K; Wang, H; Xu, J; Zhang, L | 1 |
| Jelcic, I; Linnebank, M; Martin, R; Pfender, N; Schwarz, U | 1 |
| Butzkueven, H; Comi, G; Dahlke, F; Derfuss, T; Giovannoni, G; Gottschalk, R; Griffiths, S; Hartung, HP; Kappos, L; Montalban, X; Mueller-Lenke, N; Naegelin, Y; Radue, EW; Sprenger, T; Tomic, D; von Rosenstiel, P; Wiendl, H; Zhang, Y | 1 |
| Cai, Y; Heng, BC; Hong, L; Liu, H; Lu, P; Ouyang, H; Ren, H; Wang, J; Wang, Y; Zhou, J | 1 |
| Blaho, VA; Engelbrecht, E; Galvani, S; Han, MH; Hla, T; Kono, M; Liu, C; Proia, RL; Steinman, L; Swendeman, SL | 1 |
| Gábor, L | 1 |
| Cotleur, A; Kanda, T; Love, A; Obermeier, B; Ransohoff, RM; Sano, Y; Spampinato, SF; Takeshita, Y | 1 |
| Khoury, SJ; Sawaya, RA; Yamout, BI; Zeineddine, MM | 1 |
| Alme, MN; Bø, L; Myhr, KM; Nystad, AE; Torkildsen, Ø; Vedeler, CA; Wergeland, S | 1 |
| Bittman, R; Camp, SM; Chiang, ET; Dudek, SM; Garcia, JG; Natarajan, V; Sun, C; Usatyuk, PV | 1 |
| Blanco-Prieto, MJ; Castello-Cros, R; Cirauqui, C; Estella-Hermoso de Mendoza, A; Imbuluzqueta, E; Odero, MD; Pippa, R | 1 |
| Bakshi, R; Häring, DA | 1 |
| Cavarretta, R; Di Rienzo, M; Ferratini, M; Racca, V; Rovaris, M; Toccafondi, A; Vaini, E | 1 |
| Dev, KK; O'Sullivan, C | 1 |
| Faber, H; Hofereiter, J; Hoffmann, FS; Hohlfeld, R; Krumbholz, M; Loleit, V; Meinl, E; Melms, J; Pütz, B; Rübsamen, H; Schwarz, S; Weber, F; Weber, P | 1 |
| Bendix, I; Felderhoff-Müser, U; Hadamitzky, M; Hansen, W; Herrmann, R; Herz, J; Heumann, R; Hou, X; Kempe, K; Lumpe, K; Reinboth, BS; Serdar, M; Sifringer, M; Sizonenko, SV; van de Looij, Y | 1 |
| Choi, JW; Chun, J; Han, JE; Jeon, S; Moon, E; Ryu, JH | 1 |
| Rana, A; Sharma, S | 1 |
| Gao, E; He, Y; Lee, Y; Tao, L; Wang, W; Xia, Y; Xin, C; Yan, W; Zhang, F; Zhang, H; Zhang, L; Zhao, S; Zhou, F; Zhu, D | 1 |
| Delgado, A; Martínez-Cartro, M | 1 |
| Grüner, S; Mayer, CA; Ottenlinger, F; Pfarr, K; Pfeilschifter, JM; Radeke, HH; Schwiebs, A; Wagner, A | 1 |
| Barnawi, J; Davies, LT; Haberberger, R; Hamon, R; Hodge, G; Hodge, S; Pitson, SM; Reynolds, PN; Roscioli, E; Tran, HB; Ween, M | 1 |
| Bock, S; Pfalzgraff, A; Weindl, G | 1 |
| Chae, MK; Kim, SE; Lee, EJ; Lee, JH; Yoon, JS | 1 |
| Byun, HJ; Kang, GJ; Kim, EJ; Kim, HJ; Kim, SH; Kim, SY; Lee, CH; Lee, H; Park, MK; Park, S | 1 |
| Asghar, MY; Kalhori, V; Magnusson, M; Pulli, I; Törnquist, K | 1 |
| Guerrero, M; Roberts, E; Urbano, M | 1 |
| Herr, DR; Ibrahim, MH; Johnson, SP; Lai, SL; Lopes, V; Murray, PG; Narayanaswamy, P; Panja Bernam, S; Paterson, IC; Patmanathan, SN; Torta, F; Wei, W; Wenk, MR; Yap, LF | 1 |
| Adams, BJ; Allegood, JC; Aoyagi, T; Huang, WC; Milstien, S; Miyazaki, H; Nagahashi, M; Rashid, OM; Spiegel, S; Takabe, K; Terracina, KP; Tsuchida, J; Wakai, T; Yamada, A | 1 |
| Beretta, M; Berno, V; Campanella, R; Fassina, L; Geginat, J; Gualtierotti, R; Hadi, LA; Ingegnoli, F; Levi, V; Marfia, G; Miozzo, M; Navone, SE; Paroni, M; Rampini, P; Riboni, L; Tremolada, C | 1 |
| Bauer, M; Benetti, E; Coldewey, SM; Collino, M; Huwiler, A; Pfeilschifter, J; Sponholz, C; Thiemermann, C | 1 |
| Han, MH; Tsai, HC | 1 |
| East, JE; Subrahmanyam, PB; Tiper, IV; Webb, TJ | 1 |
| Ader, I; Cuvillier, O; Gstalder, C | 1 |
| Sadik, CD; Thieme, M; Zillikens, D | 1 |
| Bidadkosh, A; Buikema, H; Deelman, LE; Hamidi Shishavan, M; Henning, RH; Lambooy, S; van den Born, J; Yazdani, S | 1 |
| Hartikainen, JE; Hartikainen, P; Laitinen, TM; Laitinen, TP; Simula, S | 1 |
| Angerer, IC; Fitzner, B; Flechtner, K; Friess, J; Hecker, M; Koczan, D; Meister, S; Roch, L; Schröder, I; Thiesen, HJ; Winkelmann, A; Zettl, UK | 1 |
| Chew, WS; Herr, DR; Wang, W | 1 |
| Gräler, MH; Hemdan, NY; Reimann, CM; Weigel, C | 1 |
| Adachi, T; Fujii, C; Hashi, Y; Kondo, T; Matsumoto, S; Mizuno, T; Nakagawa, M; Ochi, H; Okada, Y; Shin-Ya, M; Takahashi, R | 1 |
| Huo, Z; Li, C; Wang, R; Wang, Z; Zhao, Z | 1 |
| Citraro, R; Constanti, A; De Sarro, G; Leo, A; Marra, R; Palma, E; Paola, EDD; Russo, E | 1 |
| Brait, VH; Gavaldà, A; Godessart, N; Planas, AM; Tarrasón, G | 1 |
| Jiménez-Altayó, F; Jurado, A; Meissner, A; Miro, F; Planas, AM; Vila, E | 1 |
| Antel, J; Blain, M; Borucki, DM; Chao, CC; de Lima, KA; Healy, L; Kenison, JE; Quintana, FJ; Rothhammer, V; Takenaka, MC; Tjon, E; Wilz, A | 1 |
| Allegood, J; Chalfant, CE; Karamichos, D; Mandal, NA; Nicholas, SE; Priyadarsini, S; Qi, H; Sarker-Nag, A | 1 |
| Chen, C; Han, Q; Liang, W; Luo, Z; Lv, X; Su, K; Wang, Y; Yan, M; Zeng, P | 1 |
| Dyckman, AJ | 1 |
| Gusman, DH; Shoemake, C | 1 |
| Adams, DH; Frampton, J; Haldar, D; Henderson, NC; Houlihan, DD; Kalia, N; Kavanagh, D; King, A; Luu, N; Newsome, PN; Owen, A; Penny, J; Ramachandran, P; Reynolds, G; Sumption, H; Suresh, S; Than, NN | 1 |
| Banik, NL; Dasgupta, S; Miller, LG; Purohit, S; Ray, SK; Wang, G; Young, JA | 1 |
| Huang, Z; Kumar T, P; Ma, S; Santhosh, D | 1 |
| Bal, M; Darios, FD; Davletov, B; Flašker, A; García-Martinez, V; Gutiérrez, LM; Jorgacevski, J; Kavalali, ET; Leese, C; Nosyreva, E; Villanueva, J; Zorec, R | 1 |
| Bertlich, M; Canis, M; Freytag, S; Ihler, F; Jakob, M; Pellkofer, H; Strupp, M; Weiss, BG | 1 |
| Danese, S; Furfaro, F; Vetrano, S | 1 |
| Hait, NC; Katsuta, E; Lyon, DE; Nagahashi, M; Rashid, OM; Raza, A; Sturgill, JL; Takabe, K; Yan, L | 1 |
| Feng, R; Fu, S; Sun, F; Xiao, W; Xu, K; Ye, W | 1 |
| Chen, X; Germain, RN; Huang, Y; Kawabe, T; Li, W; Mao, K; Paul, WE; Sun, MA; Urban, JF; Usher, N; Zhu, J | 1 |
| Abe, M; Allegood, JC; Aoyagi, T; Hait, NC; Huang, WC; Katsuta, E; Milstien, S; Nagahashi, M; Nakajima, M; Sakimura, K; Spiegel, S; Takabe, K; Terracina, KP; Tsuchida, J; Wakai, T; Yamada, A; Yuza, K | 1 |
| Fu, J; Gao, F; Gao, Y; Li, Y; Meng, F; Yang, C | 1 |
| Panés, J; Salas, A | 1 |
| Edinger, AL; Garsi, JB; Hanessian, S; McCracken, AN; Sernissi, L; Simitian, G; Vece, V | 1 |
| Han, Y; Kuai, F; Su, J; Wang, L; Wang, Y; Zhou, S | 1 |
| Cuda, CM; Der, E; Gadhvi, GT; Gulinello, M; Makinde, HM; Mike, EV; Putterman, C; Stock, A; Winter, DR | 1 |
| Bieberich, E; Dinkins, MB; Elsherbini, A; Jiang, X; Kong, JN; Leanhart, S; Qin, H; Wang, G; Wang, R; Zhao, Y; Zhong, L; Zhu, Z | 1 |
| Hartung, HP; Heinen, A; Küry, P; Poschmann, G; Schira, J; Stühler, K; Ziegler, B | 1 |
| Azedi, F; Ebrahimi-Barough, S; Hoveizi, E; Joghataei, MT; Keyhanvar, P; Tavakol, B; Tavakol, S | 1 |
| Hu, JP; Li, Y; Yang, S | 1 |
| Boraldi, F; Fernandez, O; Garcia-Fernandez, M; Hurtado-Guerrero, I; Lara, E; Martín-Montañez, E; Oliver, B; Pavia, J; Valverde, N | 1 |
| Asgharpour, A; Bedossa, P; Cowart, LA; Maczis, MA; Montefusco, D; Rohrbach, TD; Sanyal, AJ; Spiegel, S | 1 |
| Brait, VH; Chamorro, A; Gallizioli, M; Justicia, C; Meissner, A; Miró-Mur, F; Planas, AM; Salas-Perdomo, A; Urra, X | 1 |
| Huang, JJ; Ji, J; Sun, XL; Wang, J; Wang, XP; Xue, TF; Yang, J | 1 |
| Cooper, BE; Ezzyat, Y; Fielding, RA; McDonald, DJ; Rice, NP; Rivas, DA | 1 |
| Akgün, K; Bucki, R; Proschmann, U; Sehr, T; Zendzian-Piotrowska, M; Ziemssen, T | 1 |
| Maeda, S; Matsuki, N; Nakagawa, T; Nakazawa, M; Ohno, K; Yokoyama, N; Yonezawa, T | 1 |
| Blanchard, F; Bougault, C; Briolay, A; Brizuela, L; El Jamal, A; Le Goff, B; Magne, D; Mebarek, S | 1 |
| Dasgupta, S; Ray, SK | 1 |
| Singh, SK; Spiegel, S | 1 |
| Brettle, M; Couttas, TA; Don, AS; Fath, T; Guillemin, GJ; Heng, B; Humphrey, SJ; Qi, Y; Stefen, H; Teo, JD; Tran, C | 1 |
| Higashikawa, K; Houkin, K; Kawabori, M; Kihara, A; Kuge, Y; Midori, YA; Ohno, Y; Wang, Z; Yasui, H | 1 |
| Chen, H; Han, M; Sun, T; Wang, D | 1 |
| Aoki, M; Honda, A; Kondo, A; Matsunaga, N; Ogawa, R; Okubo, Y; Takabe, K | 1 |
| Abdelshafy, AAA; Chu, X; Elsaid, KMK; Elshawwaf, M; Ghobrial, RM; Kloc, M; Uosef, A; Vaughn, N | 1 |
| Abouhany, R; Caroli, A; Grasso, G; Lanzillotta, M; Li, Q; Pan, G; Rurack, K; Sellergren, B; Shinde, S; Wan, W | 1 |
| Bennett, C; Byrd, JC; Chen, M; Coss, CC; Cui, F; Freed, C; Goswami, S; Jennings, RN; Kisseberth, WC; Kulp, SK; Lewis, S; Malbrue, R; Mani, R; Muthusamy, N; Phelps, MA; Schaaf, LJ; Schober, KK; Wang, D; Xie, Z | 1 |
| Bosque, A; Bukrinsky, M; Chomont, N; Dubrovsky, L; Fromentin, R; Newman, D; Resop, RS; Rigsby, H | 1 |
| Breier, A; Francis, MM; Hummer, TA; Kovacs, RJ; Liffick, E; Mehdiyoun, NF; Visco, AC; Vohs, JL; Yang, Z; Zhang, Y | 1 |
| Engelhardt, B; Enzmann, G; Homann, T; Huwiler, A; Kleuser, B; Stark, H; Stepanovska, B; Tietz, S; Zivkovic, A | 1 |
| Choi, JW; Gaire, BP | 1 |
| Avasarala, J | 1 |
| Adams, DR; Pyne, NJ; Pyne, S | 1 |
| Chen, S; Chen, W; Ghobrial, RM; Kloc, M; Uosef, A | 1 |
| Tasat, DR; Yakisich, JS | 1 |
| Chen, CP; Chew, WS; Chua, XY; Herr, DR; Ho, LTY; Lai, MKP; Lam, BWS; Ong, WY; Xiang, P | 1 |
| Amargant, F; Duncan, FE; Johnson, BW; Larmore, MJ; Lawson, M; Manuel, SL; Pritchard, MT; Zelinski, MB | 1 |
| Filippi, M; Gelibter, S; Moiola, L; Nozzolillo, A; Orrico, M; Preziosa, P; Sangalli, F | 1 |
| Bayat, M; Haghani, M; Naseh, M; Rafati, A; Vatanparast, J | 1 |
| Kang, DL; Li, TT; Shi, ZA; Su, H; Tu, FP | 1 |
| Colombo, E; Farina, C | 1 |
| Homann, T; Huwiler, A; Imeri, F; Kleuser, B; Stark, H; Stepanovska Tanturovska, B; Zivkovic, A | 1 |
| Ali, S; Aziz, A; Egom, EE; Elfaki, MY; Memon, D; Shiwani, HA | 1 |
| Klein, K; Mann, JFS; McKay, PF; Pankrac, J; Shattock, RJ; Tregoning, JS | 1 |
| Abe, S; Hait, NC; Ichikawa, H; Ikarashi, M; Koyama, Y; Ling, Y; Moro, K; Nagahashi, M; Okuda, S; Sakata, J; Sato, N; Shimada, Y; Takabe, K; Takeuchi, S; Toshikawa, C; Tsuchida, J; Wakai, T | 1 |
| Busra Azizoglu, Z; Canatan, H; Eken, A; Zehra Okus, F | 1 |
| Choi, JW; Kim, B; Kim, HJ; Kim, J; Kim, R; Kim, S; Kim, Y; Lee, EH; Park, JH; Park, KD; Park, SJ | 1 |
| Bravo, GÁ; Casadevall, MP; Cedeño, RR; Ramió-Torrentà, L | 1 |
| Hu, WJ; Wu, YP; Xiong, MC; Yi, Y; Zeng, H; Zeng, N; Zhang, Q; Zhao, CR | 1 |
| Arnatt, CK; Cuzzocrea, S; Doyle, TM; Esposito, E; Farr, SA; Green, M; Niehoff, ML; Salvemini, D; Spiegel, S; Squillace, S | 1 |
| Hazarosova, R; Krastev, N; Krastev, P; Momchilova, A; Nikolova, B; Pankov, R; Pankov, S; Pinkas, A; Robev, B; Staneva, G; Vassileva, E | 1 |
| Arai, K; Esposito, E; Lee, J; Li, W; Lizasoain, I; Lo, EH; Mandeville, ET; Mandeville, JB; Moro, MÁ; Nakano, T; Park, JH; Quinto-Alemany, D; Waeber, C; Zhang, F | 1 |
| Akgün, K; Constantinescu, V; Ziemssen, T | 1 |
| Carreras, I; Dedeoglu, A; Jung, Y; Lopez-Benitez, J; Tognoni, CM | 1 |
| Krastev, D; Krastev, N; Momchilova, A; Nikolaev, G; Pankov, R; Pankov, S; Pinkas, A; Robev, B; Vassileva, E | 1 |
| Bigaud, M; Brinkmann, V; Dahlke, F; de Micco, M; Graham, G; Hach, T; Nicoletti, F; Petricoul, O; Piani-Meier, D; Shakeri-Nejad, K; Turrini, R | 1 |
| Baker, D; Forte, E; Giovannoni, G; James, LK; Kang, AS; Pryce, G; Schmierer, K | 1 |
| Ansarin, K; Ardalan, M; Hejazian, SM; Hejazian, SS; Pourbayram Kaleybar, S; Teymouri, S; Zununi Vahed, S | 1 |
| van Echten-Deckert, G | 1 |
| Fernandes, V; Khatri, DK; Preeti, K; Singh, SB; Sood, A | 1 |
| Blanco-Vaca, F; Diarte-Añazco, EMG; Julve, J; Muñoz, JP; Sànchez-Fernàndez-de-Landa, P; Zorzano, A | 1 |
| Cheng, X; Huang, W; Huang, Y; Nie, G; Qiu, W; Shen, S; Wang, H; Wu, S; Zhang, J; Zhao, Y | 1 |
| Cha, E; Gotina, L; Hwang, H; Joo, J; Kang, M; Kim, HJ; Kim, J; Lee, J; Lim, SM; Pae, AN; Park, JE; Park, JH; Park, KD; Seo, SH | 1 |
| Berg, AJ; Cai, Y; Cui, T; Lok, C; Morency, DT; Paganelli, PM; Vicini, S; Wang, T; Xue, Y; Yin, P | 1 |
231 review(s) available for fingolimod hydrochloride and sphingosine
| Article | Year |
|---|---|
["Sphingosine pathway": a novel apoptosis inducing pathway].
Topics: Animals; Apoptosis; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Immunosuppressive Agents; Propylene Glycols; Signal Transduction; Sphingosine | 1996 |
Preclinical evaluation of a new immunosuppressive agent, FTY720.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Activation; Propylene Glycols; Sphingosine; Transplantation Immunology | 1998 |
FTY720: a new immunosuppressive agent with novel mechanism(s) of action.
Topics: Animals; Dogs; Fingolimod Hydrochloride; Graft Survival; Haplorhini; Immunosuppressive Agents; Mice; Molecular Structure; Organ Transplantation; Propylene Glycols; Rats; Sphingosine | 1998 |
The potential role of rapamycin in pediatric transplantation as observed from adult studies.
Topics: Acute Disease; Adult; Age Factors; Antibodies, Monoclonal; Basiliximab; Child; Cohort Studies; Cyclosporine; Drug Monitoring; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Sirolimus; Sphingosine; Time Factors; Tyrphostins | 1999 |
FTY720: mechanisms of action and its effect on organ transplantation (review).
Topics: Animals; Apoptosis; Dogs; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver Transplantation; Propylene Glycols; Rats; Sphingosine; Transplantation Immunology | 1999 |
The FTY720 story.
Topics: Animals; Clinical Trials as Topic; Drug Combinations; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunity, Cellular; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2000 |
[Immunomodulation after organ grafting by novel immunosuppressive drug and gene transfection].
Topics: Animals; Antigens, Surface; Apoptosis; Fas Ligand Protein; fas Receptor; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Ligands; Membrane Glycoproteins; Organ Transplantation; Propylene Glycols; Sphingosine; Transfection | 1999 |
[Immunosuppressive agent FTY720].
Topics: Acute Disease; Animals; Autoimmune Diseases; Cyclosporine; Drug Design; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine; Transplantation, Homologous | 2000 |
Immunosuppressive drugs in paediatric liver transplantation.
Topics: Animals; Child; Child, Preschool; Cyclosporine; Drug Interactions; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Liver Transplantation; Mycophenolic Acid; Propylene Glycols; Sirolimus; Sphingosine; Tacrolimus | 2001 |
New immunosuppressive drugs: an update.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Calcineurin Inhibitors; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Purines; Pyrimidines; Sirolimus; Sphingosine; Vitamin D | 2001 |
FTY720: altered lymphocyte traffic results in allograft protection.
Topics: Animals; Autoimmune Diseases; Cell Movement; Chemokines; Clinical Trials as Topic; Cyclosporine; Diabetes Mellitus, Type 1; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Humans; Immunologic Memory; Immunosuppressive Agents; Inflammation; Islets of Langerhans Transplantation; Lymphocyte Activation; Lymphocytes; Models, Animal; Propylene Glycols; Safety; Sphingosine; Transplantation, Homologous | 2001 |
Treatment of transplant rejection: are the traditional immunosuppressants good enough?
Topics: Antibodies, Monoclonal; Antimetabolites; Calcineurin Inhibitors; Cyclosporine; Cytokines; Drug Design; Fingolimod Hydrochloride; Graft Rejection; Guanidines; Humans; Immunosuppressive Agents; Lymphocyte Activation; Molecular Structure; Organ Transplantation; Propylene Glycols; Signal Transduction; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; Triterpenes | 2001 |
FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity.
Topics: Animals; Autoimmune Diseases; Bone Marrow Transplantation; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymph Nodes; Peyer's Patches; Propylene Glycols; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2002 |
Linking Chinese medicine and G-protein-coupled receptors.
Topics: Adjuvants, Immunologic; Animals; Fingolimod Hydrochloride; GTP-Binding Proteins; Humans; Medicine, Chinese Traditional; Propylene Glycols; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2003 |
FTY720: A new kid on the block for transplant immunosuppression.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dogs; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Infections; Mice; Primates; Propylene Glycols; Rats; Reperfusion Injury; Sphingosine; Transplantation Immunology; Transplantation, Heterologous | 2003 |
Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm.
Topics: Animals; Binding, Competitive; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ligands; Lymphocytes; Lysophospholipids; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingolipids; Sphingosine | 2003 |
Egress: a receptor-regulated step in lymphocyte trafficking.
Topics: Animals; Cell Movement; Fingolimod Hydrochloride; Humans; Lymph Nodes; Lymphocytes; Lymphoid Tissue; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2003 |
Renal transplantation: basic concepts and evolution of therapy.
Topics: Antibodies, Monoclonal; Azathioprine; Calcineurin Inhibitors; Cyclosporine; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Propylene Glycols; Receptors, Interleukin-2; Sirolimus; Sphingosine; Tacrolimus | 2003 |
Current immunosuppressive agents: efficacy, side effects, and utilization.
Topics: Abatacept; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Area Under Curve; Basiliximab; Cyclosporine; Daclizumab; Drug Therapy, Combination; Drug Utilization; Everolimus; Fingolimod Hydrochloride; Graft Survival; Humans; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Muromonab-CD3; Mycophenolic Acid; Propylene Glycols; Recombinant Fusion Proteins; Sirolimus; Sphingosine; Tacrolimus | 2003 |
Pharmacologic immunosuppression.
Topics: Adrenal Cortex Hormones; Animals; Antimetabolites; Calcineurin Inhibitors; Cyclosporine; Fingolimod Hydrochloride; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Immunotherapy; Muromonab-CD3; Propylene Glycols; Sphingosine | 2004 |
FTY720: from bench to bedside.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Models, Molecular; Molecular Conformation; Propylene Glycols; Sphingosine; Transplantation Immunology | 2004 |
FTY720: early clinical experience.
Topics: Animals; Drug Therapy, Combination; Fingolimod Hydrochloride; Half-Life; Heart Rate; Humans; Immunosuppressive Agents; Models, Animal; Propylene Glycols; Sphingosine; Transplantation Immunology | 2004 |
FTY720 immunomodulation: optimism for improved transplant regimens.
Topics: Clinical Trials as Topic; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Propylene Glycols; Sphingosine; Transplantation Immunology | 2004 |
Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy.
Topics: Animals; Cell Movement; Fingolimod Hydrochloride; GTP-Binding Proteins; Immunosuppressive Agents; Lysophospholipids; Mice; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2004 |
FTY: not just a homely drug.
Topics: Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine; Transplants | 2004 |
FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.
Topics: Animals; Cell Proliferation; Clinical Trials as Topic; Endothelium, Vascular; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Inflammation; Lymphocytes; Lysophospholipids; Models, Biological; Models, Chemical; Phosphorylation; Propylene Glycols; Protein Binding; Rats; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Sphingosine; Thymus Gland | 2004 |
FTY720--the first compound of a new promising class of immunosuppressive drugs.
Topics: Animals; Clinical Trials as Topic; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Sphingosine; T-Lymphocytes | 2004 |
Future immunosuppressive agents in solid-organ transplantation.
Topics: Drug Approval; Drug Interactions; Drug Monitoring; Everolimus; Fingolimod Hydrochloride; Forecasting; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Mycophenolic Acid; Organ Transplantation; Propylene Glycols; Safety; Sirolimus; Sphingosine; Transplantation Immunology; Treatment Outcome | 2004 |
Modulation of adaptive immune responses by sphingosine-1-phosphate.
Topics: Animals; Cytokines; Fingolimod Hydrochloride; Humans; Immune System; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2004 |
Overview of FTY720 clinical pharmacokinetics and pharmacology.
Topics: Animals; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Propylene Glycols; Sphingosine | 2004 |
Editorial overview: Tie me up, tie me down: immunosuppressive therapies for the 21st century.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Propylene Glycols; Sphingosine | 2004 |
Novel immunosuppressants.
Topics: Abatacept; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; CD40 Ligand; Child; Fingolimod Hydrochloride; Guanidines; Humans; Immunoconjugates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Depletion; Propylene Glycols; Sphingosine; T-Lymphocytes | 2004 |
FTY720: mechanism of action and potential benefit in organ transplantation.
Topics: Animals; Autoimmune Diseases; Clinical Trials as Topic; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Organ Transplantation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Transplantation Immunology | 2004 |
[Immunossupresive drugs in renal transplantation].
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Azathioprine; Cyclosporine; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Propylene Glycols; Risk Factors; Rituximab; Sirolimus; Sphingosine; Tacrolimus | 2004 |
On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Half-Life; Humans; Immunoglobulin E; Macaca fascicularis; Male; Models, Biological; Omalizumab; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Tumor Necrosis Factor-alpha | 2005 |
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs.
Topics: Adaptation, Physiological; Animals; Antigen-Presenting Cells; Cell Movement; Chemokines; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Activation; Lymphocytes; Lymphoid Tissue; Lysophospholipids; Models, Immunological; Plasma Cells; Propylene Glycols; Receptors, Chemokine; Sphingosine | 2005 |
Fingolimod. Mitsubishi Pharma/Novartis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Meta-Analysis as Topic; Propylene Glycols; Sphingosine | 2005 |
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Topics: Animals; Autoimmune Diseases; Calcineurin Inhibitors; Clinical Trials as Topic; Disease Models, Animal; Drug Synergism; Fingolimod Hydrochloride; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymph Nodes; Lymphocytes; Peyer's Patches; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Spleen; T-Lymphocytes; Thymus Gland | 2005 |
[Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants].
Topics: Antibodies, Monoclonal; Azathioprine; Basiliximab; Cyclophosphamide; Cyclosporine; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Mycophenolic Acid; Propylene Glycols; Recombinant Fusion Proteins; Ribonucleosides; Sphingosine | 2006 |
Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Topics: Animals; Cell Movement; Chemokines; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymph; Lymphocytes; Molecular Structure; Propylene Glycols; Receptors, Chemokine; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism; Structure-Activity Relationship; Thymus Gland | 2006 |
Pulmonary and vascular pharmacology of sphingosine 1-phosphate.
Topics: Animals; Asthma; Capillary Permeability; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lung; Lysophospholipids; Mast Cells; Muscle, Smooth, Vascular; Propylene Glycols; Receptors, Lysosphingolipid; Respiratory Mucosa; Signal Transduction; Sphingosine; T-Lymphocytes; Vasoconstriction | 2006 |
Bioactive sphingolipids in the modulation of the inflammatory response.
Topics: Animals; Cyclooxygenase 2; Cytokines; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lipopolysaccharides; Phospholipases A; Propylene Glycols; Prostaglandins; Sphingolipids; Sphingosine | 2006 |
[Multifunctional sphingolipid, sphingosine (long-chain base) 1-phosphate: physiological role, metabolism, and intracellular dynamics].
Topics: Animals; Biological Transport; Cell Membrane; Drug Design; Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lysophospholipids; Membrane Proteins; Neovascularization, Physiologic; Phosphoric Monoester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Saccharomyces cerevisiae Proteins; Signal Transduction; Sphingosine | 2006 |
FTY720 (fingolimod) in renal transplantation.
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2006 |
Tipping the gatekeeper: S1P regulation of endothelial barrier function.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Cell Movement; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Lectins, C-Type; Lymphocytes; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2007 |
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Topics: Animals; Central Nervous System; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Endothelium, Lymphatic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2007 |
Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.
Topics: Anti-Inflammatory Agents; Apoptosis; Atherosclerosis; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
Current perspectives on FTY720.
Topics: Animals; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Chemokines and chemokine receptors in renal transplantation--from bench to bedside.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; CCR5 Receptor Antagonists; Chemokines; Chemotaxis; Clinical Trials as Topic; Duffy Blood-Group System; Fingolimod Hydrochloride; Graft Rejection; Humans; Kidney Transplantation; Models, Animal; Propylene Glycols; Receptors, CCR1; Receptors, Cell Surface; Receptors, Chemokine; Sirolimus; Sphingosine | 2007 |
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Topics: Antibodies, Monoclonal; Cladribine; Cyclophosphamide; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoxazoles; Ligands; Mitoxantrone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Topics: Animals; Disease; Fingolimod Hydrochloride; Gene Deletion; Graft Rejection; Health; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
Topics: Administration, Oral; Animals; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
FTY720: a most promising immunosuppressant modulating immune cell functions.
Topics: Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lymphocytes; Propylene Glycols; Sphingosine | 2007 |
Fingolimod: a novel immunosuppressant for multiple sclerosis.
Topics: Animals; Drugs, Investigational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Topics: Animals; Brain; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2008 |
Sphingosine-1-phosphate signaling and the skin.
Topics: Acne Vulgaris; Animals; Cell Transformation, Neoplastic; Connective Tissue; Epidermis; Fingolimod Hydrochloride; Humans; Immunity; Immunosuppressive Agents; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Skin; Sphingosine; T-Lymphocytes | 2007 |
[Regulation of immunity by sphingosine 1-phosphate and its G protein-coupled receptors--review].
Topics: Fingolimod Hydrochloride; Humans; Immunomodulation; Lysophospholipids; Propylene Glycols; Receptors, G-Protein-Coupled; Sphingosine | 2007 |
[Cordyceps sinensis, a fungi used in the Chinese traditional medicine].
Topics: Animals; Cordyceps; Cyclosporine; Didanosine; Drug Costs; Drugs, Chinese Herbal; Fingolimod Hydrochloride; History, 19th Century; History, 20th Century; History, Ancient; Humans; Kidney Diseases; Larva; Medicine, Chinese Traditional; Moths; Mycology; Oxygen Consumption; Propylene Glycols; Sphingosine | 2007 |
Therapeutic targeting of leukocyte trafficking across the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Cell Movement; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Leukocytes; Propylene Glycols; Sphingosine | 2007 |
New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.
Topics: Animals; Fingolimod Hydrochloride; Humans; Lysophospholipids; Oxadiazoles; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Pyrazoles; Pyridines; Receptors, Lysosphingolipid; Sphingosine; Sulfhydryl Compounds; Thiazolidines; Thiophenes | 2008 |
Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Topics: Administration, Oral; Animals; Ascomycota; Biological Products; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Molecular Structure; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Treatment Outcome | 2008 |
[Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
Topics: Animals; Autoimmune Diseases; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2008 |
FTY720 (fingolimod) for relapsing multiple sclerosis.
Topics: Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine; Treatment Outcome | 2008 |
Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immune System Diseases; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2008 |
Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
Topics: Animals; Antineoplastic Agents; Central Nervous System; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon Type I; Multiple Sclerosis; Peptides; Propylene Glycols; Recombinant Proteins; Sphingosine | 2008 |
"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Enzyme Activation; Fingolimod Hydrochloride; Humans; Hypersensitivity; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sulfhydryl Compounds | 2008 |
Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Topics: Animals; Biological Transport; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2008 |
Sphingosine 1-phosphate chemical biology.
Topics: Animals; Biochemical Phenomena; Biochemistry; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2008 |
Central nervous system-directed effects of FTY720 (fingolimod).
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2008 |
Azathioprine in multiple sclerosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Chemistry, Pharmaceutical; Cyclophosphamide; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Methotrexate; Methyltransferases; Mitoxantrone; Models, Chemical; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2008 |
Emerging oral drugs for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2008 |
The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an "immature" vascular maturation factor to a "mature" mediator of lymphocyte behavior and function.
Topics: Animals; B-Lymphocytes; Cell Movement; Endothelium; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymph Nodes; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes | 2009 |
[Lysophospholipid mediators].
Topics: Animals; Cell Physiological Phenomena; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Insulin; Insulin Secretion; Lysophospholipids; Neurotransmitter Agents; Propylene Glycols; Receptors, G-Protein-Coupled; Sphingosine | 2009 |
Thymic emigration: sphingosine-1-phosphate receptor-1-dependent models and beyond.
Topics: Animals; Cell Movement; Fingolimod Hydrochloride; Humans; Kruppel-Like Transcription Factors; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets; Thymus Gland | 2009 |
[A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Topics: Animals; Autoimmune Diseases; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2009 |
Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer.
Topics: Fingolimod Hydrochloride; Humans; Lysophospholipids; Neoplasms; Propylene Glycols; Receptors, Lysophosphatidic Acid; Receptors, Lysosphingolipid; Sphingosine | 2009 |
[New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Topics: Animals; Autoimmune Diseases; Clinical Trials as Topic; Encephalomyelitis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2009 |
[Molecular target drug development for curing multiple sclerosis].
Topics: Abatacept; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmunity; Clinical Trials as Topic; Daclizumab; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunoconjugates; Immunoglobulin G; Integrin alpha4beta1; JC Virus; Leukoencephalopathy, Progressive Multifocal; Ligands; Lysophospholipids; Multiple Sclerosis; Natalizumab; Opportunistic Infections; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; Ustekinumab | 2009 |
[Fingolimod - a new immunomodulator].
Topics: Biological Availability; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2009 |
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Topics: Animals; Astrocytes; Brain; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gap Junctions; Humans; Immune System; Inflammation; Lymph Nodes; Lysophospholipids; Multiple Sclerosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2009 |
New oral drugs for multiple sclerosis.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
Systemically circulating colitogenic memory CD4+T cells may be an ideal target for the treatment of inflammatory bowel diseases.
Topics: CD4-Positive T-Lymphocytes; Colon; Fingolimod Hydrochloride; Humans; Immunologic Memory; Immunosuppressive Agents; Inflammatory Bowel Diseases; Leukapheresis; Propylene Glycols; Sphingosine | 2009 |
Fingolimod for relapsing multiple sclerosis: an update.
Topics: Administration, Oral; Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Sphingosine | 2010 |
[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Topics: Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
Emerging therapies in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.
Topics: Apoptosis; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Membrane Potential, Mitochondrial; Organophosphates; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Lysosphingolipid; Sphingosine; TOR Serine-Threonine Kinases | 2010 |
Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions.
Topics: Autoimmune Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2010 |
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Interactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ketoconazole; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2010 |
Fingolimod is a potential novel therapy for multiple sclerosis.
Topics: Animals; Cell Movement; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Mice; Multiple Sclerosis; Nerve Regeneration; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2010 |
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Topics: Administration, Oral; Animals; Cladribine; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2010 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
Topics: Administration, Oral; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Prevalence; Propylene Glycols; Receptors, Lysosphingolipid; Risk Assessment; Risk Factors; Sphingosine; Treatment Outcome | 2011 |
Emerging oral agents for multiple sclerosis.
Topics: 4-Aminopyridine; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Quinolones; Sphingosine | 2010 |
Emerging disease-modifying oral therapies for multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2011 |
Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunomodulation; Inflammation Mediators; Propylene Glycols; Sphingosine; Uveitis | 2011 |
Roles for lysophospholipid S1P receptors in multiple sclerosis.
Topics: Animals; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Inflammation; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Phosphorylation; Propylene Glycols; Receptors, Lysophospholipid; Signal Transduction; Sphingosine | 2011 |
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
Topics: Administration, Oral; Animals; Drug Discovery; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Research; Sphingosine | 2010 |
Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Topics: Animals; Drugs, Investigational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Neuroglia; Phosphorylation; Prodrugs; Propylene Glycols; Protein Isoforms; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2010 |
Sphingosine kinase and sphingosine 1-phosphate in asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Cytokines; Disease Models, Animal; Epithelial Cells; Fingolimod Hydrochloride; Humans; Inflammation; Lung; Lysophospholipids; Mast Cells; Mice; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingolipids; Sphingosine | 2011 |
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Fingolimod for the treatment of relapsing multiple sclerosis.
Topics: Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Lymphocytes; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Therapeutic approach to multiple sclerosis by novel oral drug.
Topics: Administration, Oral; Cladribine; Crotonates; Diterpenes; Epoxy Compounds; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Patents as Topic; Phenanthrenes; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls.
Topics: Animals; Fingolimod Hydrochloride; Humans; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2011 |
Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
Topics: Biomarkers; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2011 |
Impact of sphingosine 1-phosphate modulation on immune outcomes.
Topics: Animals; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Immune System; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Virus Diseases | 2011 |
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Topics: Animals; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Topics: Animals; Autoimmune Diseases; Cardiovascular System; Central Nervous System; Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lymph Nodes; Lysophospholipids; Models, Biological; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Oral fingolimod (gilenya) for multiple sclerosis.
Topics: Administration, Oral; Animals; Fingolimod Hydrochloride; Headache; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2010 |
[Immunosuppressive agents in kidney transplantation].
Topics: Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Pyrazines; Rituximab; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; TOR Serine-Threonine Kinases | 2011 |
Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Topics: Activities of Daily Living; Administration, Oral; Bradycardia; Central Nervous System; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Macular Edema; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroimmunomodulation; Neurologic Examination; Propylene Glycols; Receptors, Lysosphingolipid; Recurrence; Sphingosine; Treatment Outcome; Young Adult | 2011 |
Managing MS in a changing treatment landscape.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2011 |
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Topics: Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Hypocreales; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Structure-Activity Relationship; United States; United States Food and Drug Administration | 2011 |
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Topics: Animals; Central Nervous System; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Heart Diseases; Humans; Immunosuppressive Agents; Infections; Liver Diseases; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Respiration Disorders; Sphingosine | 2011 |
Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Topics: Animals; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Chronic Progressive; Propylene Glycols; Sphingosine | 2012 |
Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Topics: Administration, Oral; Adult; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Risk Factors; Secondary Prevention; Sphingosine; Treatment Outcome; Young Adult | 2011 |
Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B.
Topics: Biological Products; Drug Discovery; Ethers, Cyclic; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Furans; Ketones; Macrolides; Molecular Structure; Propylene Glycols; Sphingosine; Structure-Activity Relationship | 2011 |
Targeting sphingosine-1-phosphate in hematologic malignancies.
Topics: Animals; Fingolimod Hydrochloride; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lysophospholipids; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
[Current treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome | 2011 |
Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
Topics: Central Nervous System; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2011 |
Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Animals; Drug Delivery Systems; Drug Interactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Sphingosine 1-phosphate in coagulation and inflammation.
Topics: Animals; Atherosclerosis; Blood Coagulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lymph Nodes; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Tumor Necrosis Factor-alpha | 2012 |
Novel therapeutic approaches to autoimmune demyelinating disorders.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2011 |
Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Male; Mice; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostatic Neoplasms; Signal Transduction; Sphingosine | 2011 |
[Role of T lymphocytes in ischemic brain injury].
Topics: Animals; Antibodies, Neutralizing; Brain Ischemia; Corynebacterium; Cytokines; Disease Progression; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Interleukin-17; Interleukin-23; Mice; Molecular Targeted Therapy; Propylene Glycols; Sphingosine; T-Lymphocytes; Time Factors | 2010 |
Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Cell Division; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Organophosphonates; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sphingosine; Vinyl Compounds | 2011 |
Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Topics: Administration, Oral; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2011 |
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Topics: Administration, Oral; Animals; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Oral treatment for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Sphingosine | 2012 |
Population pharmacokinetics of fingolimod phosphate in healthy participants.
Topics: Administration, Oral; Adult; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Biological; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Time Factors; Tissue Distribution; Young Adult | 2012 |
[Multiple sclerosis: current therapies and future perspectives].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Peptides; Propylene Glycols; Sphingosine | 2011 |
Clinical pharmacokinetics of fingolimod.
Topics: Animals; Blood Proteins; Drug Interactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Diseases; Liver Diseases; Multiple Sclerosis; Propylene Glycols; Protein Binding; Sphingosine | 2012 |
Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.
Topics: Animals; Bone Marrow; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymph Nodes; Lymphocytes; Lymphoid Tissue; Lysophospholipids; Models, Biological; Propylene Glycols; Sphingosine; Thymus Gland | 2012 |
Fingolimod for multiple sclerosis.
Topics: Adult; Algorithms; Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Fingolimod-associated macular edema: incidence, detection, and management.
Topics: Fingolimod Hydrochloride; Humans; Macular Edema; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2012 |
FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Topics: Animals; Astrocytes; Axons; Central Nervous System; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mice; Microglia; Multiple Sclerosis; Myelin Sheath; Neurons; Oligodendroglia; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Network analysis of randomized controlled trials in multiple sclerosis.
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; Placebos; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2012 |
Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis.
Topics: Apoptosis; Ceramides; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Humans; Lysophospholipids; Metabolic Networks and Pathways; Multiple Sclerosis; Myelin Sheath; Propylene Glycols; Receptors, G-Protein-Coupled; Serine C-Palmitoyltransferase; Signal Transduction; Sphingolipids; Sphingosine | 2012 |
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Peptides; Poisson Distribution; Propylene Glycols; Recurrence; Sphingosine; Time Factors | 2012 |
[2012: Update on diagnosis and treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Immunosuppressive Agents; Infusions, Intravenous; Interferon-beta; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Plasmapheresis; Propylene Glycols; Pulse Therapy, Drug; Sphingosine; Spinal Cord | 2012 |
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2012 |
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Topics: Animals; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocytes; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
[Role of S1P acting both inside and outside the cells].
Topics: Adaptive Immunity; Animals; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immunity, Innate; Immunosuppressive Agents; Lysophospholipids; Membrane Microdomains; Nervous System Physiological Phenomena; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Second Messenger Systems; Sphingolipids; Sphingosine | 2012 |
[New disease-modifying and symptomatic therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Cannabinoids; Cooperative Behavior; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interdisciplinary Communication; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Infant; Injections, Intramuscular; Injections, Subcutaneous; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis; Peptides; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine; Time Factors | 2012 |
[Multiple sclerosis: beyong first line therapies].
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal, Humanized; Choice Behavior; Combined Modality Therapy; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Immunotherapy; Multiple Sclerosis; Natalizumab; Patient Education as Topic; Propylene Glycols; Sphingosine; Therapies, Investigational | 2012 |
[Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2012 |
Immunotherapies in neurologic disorders.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Cyclosporine; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Mitoxantrone; Mycophenolic Acid; Natalizumab; Nervous System Diseases; Peptides; Plasma Exchange; Propylene Glycols; Rituximab; Sphingosine; Tacrolimus | 2012 |
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Secondary Prevention; Sphingosine; Th17 Cells | 2012 |
[Emerging therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult | 2013 |
ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neurosciences; Propylene Glycols; Randomized Controlled Trials as Topic; Societies, Scientific; Sphingosine | 2011 |
4-aminopyridine toxicity: a case report and review of the literature.
Topics: 4-Aminopyridine; Adult; Benzodiazepines; Drug Overdose; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Paroxetine; Propylene Glycols; Sphingosine | 2012 |
[Infections and fingolimod].
Topics: Community-Acquired Infections; Contraindications; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunocompromised Host; Immunologic Memory; Immunologic Surveillance; Immunosuppressive Agents; Kidney Transplantation; Leukoencephalopathy, Progressive Multifocal; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Opportunistic Infections; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Vaccination | 2012 |
Molecular targets of FTY720 (fingolimod).
Topics: Antineoplastic Agents; Apoptosis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Lysophospholipids; Multiple Sclerosis; Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Topics: Administration, Oral; Animals; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Topics: Administration, Oral; Algorithms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunologic Memory; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Lymphocyte Count; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes; Treatment Outcome | 2012 |
[Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Cardiovascular System; Central Nervous System; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Lysophospholipids; Multiple Sclerosis; Organophosphates; Propylene Glycols; Sphingosine; Th17 Cells; Treatment Outcome | 2012 |
Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Propylene Glycols; Receptors, Lysosphingolipid; Recovery of Function; Sphingosine; Stroke; Treatment Outcome | 2013 |
[An update on the treatment options for multiple sclerosis].
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferons; Japan; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
Multiple sclerosis: new measures to monitor the disease.
Topics: Brain; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Neuromyelitis Optica; Propylene Glycols; Sphingosine | 2013 |
[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Topics: Atrioventricular Block; Bradycardia; Cardiovascular System; Clinical Trials as Topic; Drug Administration Schedule; Fingolimod Hydrochloride; Heart Conduction System; Humans; Hypertension; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Secondary Prevention; Sphingosine; Treatment Outcome | 2012 |
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
Topics: Cladribine; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Molecular Structure; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Small Molecule Libraries; Sphingosine; Toluidines | 2013 |
Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Biomarkers; Capillary Permeability; Fingolimod Hydrochloride; Humans; Lung; Lysophospholipids; Membrane Proteins; Nerve Tissue Proteins; Phosphotransferases (Alcohol Group Acceptor); Pneumonia; Propylene Glycols; Receptors, Lysosphingolipid; Sepsis; Sphingosine; Transferases (Other Substituted Phosphate Groups); Translational Research, Biomedical | 2013 |
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Topics: Animals; Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2013 |
[Update on current care guidelines: multiple sclerosis].
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Practice Guidelines as Topic; Propylene Glycols; Sphingosine | 2013 |
Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012).
Topics: Animals; Bradycardia; Cognition Disorders; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Patents as Topic; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2013 |
Pharmacology of the sphingosine-1-phosphate signalling system.
Topics: Aldehyde-Lyases; Animals; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Lysophospholipids; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2013 |
Targeting cells in motion: migrating toward improved therapies.
Topics: Antibodies, Monoclonal, Humanized; Cell Adhesion; Cell Migration Inhibition; Fingolimod Hydrochloride; Humans; Immunosuppression Therapy; Immunotherapy; Integrin alpha4; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Signal Transduction; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2013 |
Drug-induced macular edema.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Fingolimod Hydrochloride; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Interferons; Macular Edema; Niacin; Ophthalmic Solutions; Propylene Glycols; Sphingosine; Tamoxifen; Taxoids; Thiazolidinediones; Timolol | 2013 |
Fingolimod therapy for multiple sclerosis.
Topics: Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2013 |
Fingolimod for the treatment of relapsing multiple sclerosis.
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2013 |
Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Fibrosis; Fingolimod Hydrochloride; Glomerulonephritis; Humans; Inflammation; Kidney Failure, Chronic; Lysophospholipids; Molecular Targeted Therapy; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2014 |
Are GPCRs still a source of new targets?
Topics: Anilides; Antineoplastic Agents; Binding Sites; Crystallography, X-Ray; Databases, Chemical; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ligands; Propylene Glycols; Protein Binding; Pyridines; Receptors, G-Protein-Coupled; Sphingosine | 2013 |
[Multiple sclerosis and pregnancy].
Topics: Female; Fetus; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Maternal-Fetal Exchange; Multiple Sclerosis; Peptides; Pregnancy; Propylene Glycols; Recurrence; Sphingosine | 2013 |
Tumefactive MS lesions under fingolimod: a case report and literature review.
Topics: Adolescent; Brain; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Oligoclonal Bands; Plasma Exchange; Propylene Glycols; Sphingosine | 2013 |
FTY720 for cancer therapy (Review).
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; United States; United States Food and Drug Administration | 2013 |
[New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 9. Therapeutic progress in multiple sclerosis and neuromyelitis optica].
Topics: Antibodies, Monoclonal; Autoantibodies; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuromyelitis Optica; Propylene Glycols; Secondary Prevention; Sphingosine | 2013 |
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Topics: Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Randomized Controlled Trials as Topic; Recurrence; Sphingosine; Toluidines | 2014 |
Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
Topics: Antibodies, Monoclonal, Humanized; Databases, Bibliographic; Decision Making; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
Second generation S1P pathway modulators: research strategies and clinical developments.
Topics: Biomedical Research; Clinical Medicine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Research Design; Signal Transduction; Sphingosine | 2014 |
Visual issues in multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Neuromyelitis Optica; Nystagmus, Pathologic; Ocular Motility Disorders; Optic Neuritis; Prognosis; Propylene Glycols; Sphingosine; Uveitis | 2013 |
Management of fingolimod in clinical practice.
Topics: Administration, Oral; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine | 2013 |
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis; Nitriles; Pregnancy; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Toluidines | 2014 |
An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Crotonates; Daclizumab; Drug Approval; Female; Fingolimod Hydrochloride; Forecasting; Humans; Hydroxybutyrates; Immunoglobulin G; Injections, Intramuscular; Injections, Subcutaneous; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Patient Safety; Prognosis; Propylene Glycols; Severity of Illness Index; Sphingosine; Toluidines; Treatment Outcome | 2013 |
[New perspective in pharmacology brought by studying traditional medicine].
Topics: Animals; Curcumin; Diosgenin; Drug Discovery; Drugs, Chinese Herbal; Fingolimod Hydrochloride; Glycyrrhizic Acid; Humans; Medicine, Traditional; Molecular Targeted Therapy; Pharmacology; Phytotherapy; Plant Preparations; Plants, Medicinal; Propylene Glycols; Sphingosine | 2014 |
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
Topics: Administration, Oral; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Treatment Outcome | 2014 |
Role of sphingolipids in arachidonic acid metabolism.
Topics: Active Transport, Cell Nucleus; Animals; Arachidonic Acid; Cells, Cultured; Ceramides; Cyclooxygenase 2; Fingolimod Hydrochloride; Golgi Apparatus; Group IV Phospholipases A2; Humans; Inflammation; Lactosylceramides; Lysophospholipids; Propylene Glycols; Sphingolipids; Sphingomyelins; Sphingosine | 2014 |
[Molecular and cellular mechanisms of fingolimod action].
Topics: Animals; Antineoplastic Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Phospholipids; Propylene Glycols; Signal Transduction; Sphingosine | 2013 |
New management algorithms in multiple sclerosis.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Clinical Protocols; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Vagomimetic effects of fingolimod: physiology and clinical implications.
Topics: Animals; Atrioventricular Block; Bradycardia; Electrocardiography; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2014 |
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immune System; Multiple Sclerosis; NF-E2-Related Factor 2; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
Sphingolipids: important players in multiple sclerosis.
Topics: Ceramides; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Sphingolipids; Sphingomyelin Phosphodiesterase; Sphingomyelins; Sphingosine | 2014 |
Central effects of fingolimod.
Topics: Animals; Blood-Brain Barrier; Chemotaxis, Leukocyte; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunologic Memory; Mice; Mice, Knockout; Mice, Neurologic Mutants; Multicenter Studies as Topic; Multiple Sclerosis, Relapsing-Remitting; Neurogenesis; Neuroglia; Neuroprotective Agents; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets | 2014 |
Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
Is T-bet a potential therapeutic target in multiple sclerosis?
Topics: Animals; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Immunotherapy; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine; T-Box Domain Proteins; Th17 Cells | 2014 |
Update on multiple sclerosis treatments.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Current management of relapsing-remitting multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Risk Assessment; Sphingosine; Toluidines | 2014 |
Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
Topics: Atrioventricular Node; Cardiovascular System; Down-Regulation; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2014 |
[[Natalizumab therapy, 2013].
Topics: Adult; Antibodies, Monoclonal, Humanized; Disease Progression; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Approval; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2015 |
Grey matter atrophy in patients suffering from multiple sclerosis.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal, Humanized; Atrophy; Fingolimod Hydrochloride; Glatiramer Acetate; Gray Matter; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis; Muscle, Skeletal; Natalizumab; Peptides; Predictive Value of Tests; Propylene Glycols; Sphingosine; Treatment Outcome | 2014 |
Therapeutic interference with leukocyte recirculation in multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2015 |
[Oral treatments in multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
Topics: Acute Lung Injury; Anemia, Sickle Cell; Animals; Autoimmune Diseases; Cardiovascular Diseases; Cell Physiological Phenomena; Disease Models, Animal; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Influenza, Human; Lysophospholipids; Membrane Lipids; Mice; Multiple Sclerosis; Neoplasms; Neovascularization, Physiologic; Neurogenesis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2015 |
Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).
Topics: Animals; Autoimmune Diseases; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lysophospholipids; Multiple Sclerosis, Relapsing-Remitting; Patents as Topic; Receptors, Lysosphingolipid; Sphingosine | 2016 |
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
Topics: Animals; Autoimmune Diseases; Fingolimod Hydrochloride; Humans; Inflammation; Lymphocytes; Lysophospholipids; Molecular Targeted Therapy; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2016 |
Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.
Topics: Animals; Chemotaxis, Leukocyte; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Hematologic Neoplasms; Host-Pathogen Interactions; Humans; Immune System; Immunosuppressive Agents; Infections; Inflammation; Lymphocytes; Lysophospholipids; Signal Transduction; Sphingosine; Transcription Factors | 2016 |
Sphingosine-1-phosphate modulators in inflammatory skin diseases - lining up for clinical translation.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Receptors, Lymphocyte Homing; Receptors, Lysophospholipid; Skin Diseases; Sphingosine; Thiazoles | 2017 |
To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Signal Transduction; Sphingosine | 2016 |
The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
Topics: Animals; Epilepsy; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lysophospholipids; Signal Transduction; Sphingosine | 2017 |
Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P
Topics: Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Ligands; Lysophospholipids; Molecular Structure; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2017 |
Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Cell Communication; Chemotaxis, Leukocyte; Endothelial Cells; Fingolimod Hydrochloride; Gastrointestinal Agents; Gastrointestinal Tract; Humans; Immunoglobulins; Immunosuppressive Agents; Indans; Inflammatory Bowel Diseases; Integrins; Intercellular Adhesion Molecule-1; Leukocytes; Lysophospholipids; Mucoproteins; Natalizumab; Oxadiazoles; Phosphorothioate Oligonucleotides; Receptors, Lysosphingolipid; Sphingosine | 2018 |
Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis.
Topics: Animals; Brain; Ceramides; Fingolimod Hydrochloride; Humans; MicroRNAs; Molecular Targeted Therapy; Multiple Sclerosis; Myelin Sheath; Rats; Serine C-Palmitoyltransferase; Sphingosine | 2019 |
Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain.
Topics: Bortezomib; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fingolimod Hydrochloride; Humans; Lysophospholipids; Neuralgia; Signal Transduction; Sphingosine; Triple Negative Breast Neoplasms | 2020 |
Potential sphingosine-1-phosphate-related therapeutic targets in the treatment of cerebral ischemia reperfusion injury.
Topics: Animals; Brain; Fingolimod Hydrochloride; Humans; Lysophospholipids; Reperfusion Injury; Sphingosine; Sphingosine-1-Phosphate Receptors | 2020 |
Sphingosine 1-Phosphate Receptors in Cerebral Ischemia.
Topics: Animals; Brain Damage, Chronic; Brain Ischemia; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Humans; Infarction, Middle Cerebral Artery; Inflammation; Ischemic Stroke; Lysophospholipids; Neovascularization, Physiologic; Nerve Tissue Proteins; Neuroprotective Agents; Phosphotransferases (Alcohol Group Acceptor); Rats; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2021 |
Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases.
Topics: Animals; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Ligands; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
Rationale for the use of sphingosine analogues in COVID-19 patients.
Topics: COVID-19; COVID-19 Drug Treatment; Cytokines; Fingolimod Hydrochloride; Humans; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2021 |
Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment.
Topics: Aldehyde-Lyases; Alzheimer Disease; Animals; Cerebrovascular Disorders; Clinical Trials as Topic; Dementia, Vascular; Drug Delivery Systems; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Humans; Infarction, Middle Cerebral Artery; Inflammation; Ischemic Stroke; Lysophospholipids; Mice; Mice, Knockout; Neurodegenerative Diseases; Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2021 |
The emerging role of FTY720 as a sphingosine 1-phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms.
Topics: Animals; Brain Ischemia; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ischemic Stroke; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stroke | 2021 |
Lessons from S1P receptor targeting in multiple sclerosis.
Topics: Animals; Central Nervous System; Fingolimod Hydrochloride; Humans; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2022 |
Updates on sphingolipids: Spotlight on retinopathy.
Topics: Animals; Ceramides; Fingolimod Hydrochloride; Humans; Lysophospholipids; Molecular Targeted Therapy; Photoreceptor Cells, Vertebrate; Retina; Retinal Diseases; Retinal Ganglion Cells; Retinal Pigment Epithelium; Signal Transduction; Sphingolipids; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2021 |
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Topics: Autoimmune Diseases; Fingolimod Hydrochloride; Humans; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2022 |
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2022 |
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2023 |
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Vaccination | 2023 |
The role of sphingosine 1-phosphate metabolism in brain health and disease.
Topics: Animals; Brain; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mammals; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2023 |
80 trial(s) available for fingolimod hydrochloride and sphingosine
| Article | Year |
|---|---|
The potential role of rapamycin in pediatric transplantation as observed from adult studies.
Topics: Acute Disease; Adult; Age Factors; Antibodies, Monoclonal; Basiliximab; Child; Cohort Studies; Cyclosporine; Drug Monitoring; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Sirolimus; Sphingosine; Time Factors; Tyrphostins | 1999 |
FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism.
Topics: Apoptosis; Dose-Response Relationship, Drug; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Lymphocytes; Placebos; Propylene Glycols; Sphingosine | 2000 |
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
Topics: Adult; Amylases; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Kidney; Kidney Function Tests; Kidney Transplantation; Lipase; Lung; Lymphocyte Count; Male; Middle Aged; Propylene Glycols; Respiratory Function Tests; Sphingosine | 2002 |
FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients.
Topics: Antigens, CD; Dose-Response Relationship, Drug; Double-Blind Method; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2002 |
Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.
Topics: Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Subsets; Lymphopenia; Propylene Glycols; Sphingosine | 2003 |
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Topics: Adult; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Middle Aged; Placebos; Prednisone; Propylene Glycols; Sphingosine | 2003 |
Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine.
Topics: Apoptosis; Cells, Cultured; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocytes; Propylene Glycols; Sphingosine | 2003 |
FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.
Topics: Cell Culture Techniques; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Propylene Glycols; Receptors, Chemokine; Receptors, Leukocyte-Adhesion; Sphingosine; T-Lymphocytes | 2004 |
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Circadian Rhythm; Cross-Over Studies; Dietary Fats; Fasting; Fingolimod Hydrochloride; Food; Heart Rate; Humans; Immunosuppressive Agents; Intestinal Absorption; Lymphocyte Count; Male; Propylene Glycols; Sphingosine | 2004 |
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Capsules; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Half-Life; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Male; Propylene Glycols; Sphingosine; Time Factors | 2004 |
FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes.
Topics: Apoptosis; Biomarkers; CD11a Antigen; CD3 Complex; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Integrin alpha4; Kidney Transplantation; L-Selectin; Lymphopenia; Propylene Glycols; Receptors, CCR5; Sphingosine; T-Lymphocytes | 2004 |
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Topics: Adolescent; Adult; Aged; Cadaver; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Propylene Glycols; Safety; Sphingosine; Tissue Donors; Treatment Outcome | 2004 |
Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Cyclosporine; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Middle Aged; Mycophenolic Acid; Propylene Glycols; Sphingosine; Time Factors | 2005 |
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Topics: Adolescent; Adult; Aged; Biopsy; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Infections; Kidney Transplantation; Middle Aged; Mycophenolic Acid; Postoperative Complications; Propylene Glycols; Safety; Sphingosine; Time Factors; Treatment Outcome | 2005 |
FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
Topics: Adult; Aged; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Models, Biological; Propylene Glycols; Sphingosine | 2005 |
Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.
Topics: Adult; Area Under Curve; Bilirubin; Biomarkers; Female; Fingolimod Hydrochloride; Half-Life; Heart Rate; Humans; Immunologic Factors; Liver Diseases, Alcoholic; Liver Function Tests; Lymphocyte Count; Male; Middle Aged; Propylene Glycols; Protein Binding; Prothrombin Time; Sphingosine | 2006 |
FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells.
Topics: B-Lymphocytes; Fingolimod Hydrochloride; Granulocytes; Humans; Immunosuppressive Agents; Kidney Transplantation; Killer Cells, Natural; Leukocytes, Mononuclear; Monocytes; Mycophenolic Acid; Propylene Glycols; Receptors, CCR5; Receptors, CCR7; Receptors, Chemokine; Receptors, CXCR3; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2006 |
FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.
Topics: Adult; Biopsy; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lung; Male; Middle Aged; Propylene Glycols; Sphingosine; Time Factors | 2006 |
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Exercise Test; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Rate; Humans; Immunosuppressive Agents; Male; Propylene Glycols; Reference Values; Sphingosine | 2006 |
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Topics: Adolescent; Adult; Brain; Brain Diseases; Double-Blind Method; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Respiratory Tract Infections; Sphingosine; Statistics, Nonparametric | 2006 |
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia.
Topics: Adult; Australasia; Creatinine; Cyclosporine; Drug Therapy, Combination; Europe; Fingolimod Hydrochloride; Graft Survival; Histocompatibility Testing; Humans; Kidney Transplantation; Liver Function Tests; Mycophenolic Acid; Propylene Glycols; Safety; Sphingosine | 2006 |
Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.
Topics: B-Lymphocytes; CD11a Antigen; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Integrin alpha4; Kidney Transplantation; L-Selectin; Propylene Glycols; Receptors, CXCR4; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2007 |
Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function.
Topics: Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Function Tests; Kidney Transplantation; Lymphocyte Count; Postoperative Complications; Propylene Glycols; Sirolimus; Sphingosine | 2006 |
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
Topics: Adult; Creatinine; Cyclosporine; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Propylene Glycols; Sphingosine | 2006 |
Oral pharmacokinetic and pharmacodynamic effects of FTY720 in cats.
Topics: Administration, Oral; Animals; Blood Cell Count; Cats; Fingolimod Hydrochloride; Flow Cytometry; Immunologic Factors; Lymphocyte Subsets; Male; Propylene Glycols; Sphingosine | 2007 |
Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Injections, Intravenous; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Propylene Glycols; Sphingosine | 2007 |
Ethnic sensitivity study of fingolimod in white and Asian subjects.
Topics: Area Under Curve; Asian People; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Inactivation, Metabolic; Lymphocyte Count; Lymphocytes; Male; Metabolic Clearance Rate; Propylene Glycols; Sphingosine; White People | 2007 |
The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.
Topics: Adult; Animals; Arteries; Cyclosporine; Elasticity; Endothelium, Vascular; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mice; Middle Aged; Propylene Glycols; Sphingosine; Vasodilation | 2007 |
FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.
Topics: Adult; Biopsy; Bradycardia; Cohort Studies; Cyclosporine; Double-Blind Method; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mycophenolic Acid; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient.
Topics: Cyclosporine; Drug Therapy, Combination; Fingolimod Hydrochloride; Fluorescein Angiography; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Macular Edema; Prednisone; Propylene Glycols; Sphingosine; Tomography, Optical Coherence; Transplantation, Homologous | 2008 |
The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
Topics: Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diltiazem; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Propylene Glycols; Receptors, Lysosphingolipid; Single-Blind Method; Sphingosine | 2008 |
A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Area Under Curve; Atrial Fibrillation; Bradycardia; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Infusions, Intravenous; Isoproterenol; Male; Patient Dropouts; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Tachycardia; Time Factors | 2008 |
The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.
Topics: Adult; Anti-Arrhythmia Agents; Area Under Curve; Atropine; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Propylene Glycols; Sphingosine; Telemetry; Time Factors; Treatment Outcome | 2008 |
Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
Topics: Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Half-Life; Humans; Immunosuppressive Agents; Ketoconazole; Male; Middle Aged; Propylene Glycols; Sphingosine; Young Adult | 2009 |
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
Topics: Administration, Oral; Adolescent; Adult; Disability Evaluation; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Respiratory Function Tests; Severity of Illness Index; Sphingosine; Time Factors; Young Adult | 2009 |
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Topics: Administration, Oral; Adolescent; Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome; Young Adult | 2010 |
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Liver Function Tests; Macular Edema; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2010 |
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Intention to Treat Analysis; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Statistics, Nonparametric; Young Adult | 2010 |
Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
Topics: Adult; CD8-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Count; Lymphocytes; Lymphopenia; Mediastinum; Middle Aged; Multiple Sclerosis; Patient Dropouts; Propylene Glycols; Receptors, CCR7; Sphingosine; Withholding Treatment | 2010 |
Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Topics: Absorption; Administration, Oral; Adult; Biotransformation; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Feces; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Molecular Structure; Oxidation-Reduction; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Tandem Mass Spectrometry; Time Factors; Tissue Distribution; Xenobiotics | 2011 |
Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
Topics: CD8-Positive T-Lymphocytes; Cell Count; Cell Movement; Chemokine CCL2; Chemokine CXCL12; Cytokines; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Interferon-gamma; Multiple Sclerosis; Propylene Glycols; Receptors, CCR2; Sphingosine; Tumor Necrosis Factor-alpha | 2010 |
Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
Topics: Adaptive Immunity; Adult; Enzyme-Linked Immunospot Assay; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Influenza Vaccines; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; T-Lymphocytes | 2011 |
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Topics: Adult; Aged; Aged, 80 and over; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes; Young Adult | 2011 |
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult | 2011 |
Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Follow-Up Studies; Graft Survival; Heart Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Monitoring, Physiologic; Postoperative Care; Propylene Glycols; Prospective Studies; Risk Assessment; Sphingosine; T-Lymphocyte Subsets | 2011 |
Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
Topics: CD56 Antigen; Cells, Cultured; Chemotaxis, Leukocyte; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunophenotyping; Immunosuppressive Agents; Killer Cells, Natural; Lymphocyte Count; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2011 |
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Topics: Administration, Oral; Adult; Canada; Chi-Square Distribution; Depression; Double-Blind Method; Europe; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Psychiatric Status Rating Scales; Quality of Life; Sphingosine; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2011 |
FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.
Topics: Adolescent; Adult; Aged; Cyclosporine; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prognosis; Propylene Glycols; Sphingosine; Survival Rate; Tacrolimus; Young Adult | 2011 |
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.
Topics: Adult; Cardiac Output; Double-Blind Method; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Propylene Glycols; Respiratory Function Tests; Sphingosine; Stroke Volume; Vascular Resistance | 2012 |
Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.
Topics: Administration, Oral; Adult; Antigens; Antigens, Fungal; Candida albicans; Double-Blind Method; Female; Fingolimod Hydrochloride; Hemocyanins; Humans; Hypersensitivity, Delayed; Immunoglobulin G; Immunoglobulin M; Immunosuppressive Agents; Male; Pneumococcal Vaccines; Propylene Glycols; Sphingosine; T-Lymphocytes; Tetanus Toxoid; Young Adult | 2012 |
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
Topics: Adolescent; Adult; Asian People; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Japan; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Odds Ratio; Propylene Glycols; Recurrence; Sphingosine; Time Factors; Treatment Outcome; Young Adult | 2012 |
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Topics: Administration, Oral; Adult; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Proportional Hazards Models; Propylene Glycols; Secondary Prevention; Sex Factors; Sphingosine | 2012 |
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome; Young Adult | 2012 |
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Brain; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Encephalitis; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; International Cooperation; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Outcome Assessment, Health Care; Propylene Glycols; Sphingosine; Time Factors; Young Adult | 2012 |
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Topics: Adolescent; Adult; Double-Blind Method; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Multiple Sclerosis; Ophthalmoscopy; Propylene Glycols; Sphingosine; Tomography, Optical Coherence; Treatment Outcome; Uveitis; Visual Acuity; Young Adult | 2013 |
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Topics: Adult; Aging; Analysis of Variance; Brain; Data Interpretation, Statistical; Female; Fingolimod Hydrochloride; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2013 |
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Topics: Canada; Drug Tolerance; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient-Centered Care; Propylene Glycols; Quality of Life; Sphingosine; Standard of Care; Treatment Outcome; United States | 2013 |
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infections; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2014 |
Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macula Lutea; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers; North America; Propylene Glycols; Retina; Retrospective Studies; Sphingosine; Tomography, Optical Coherence; Young Adult | 2013 |
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Topics: Adolescent; Adult; Age Factors; Aged; Bradycardia; Disability Evaluation; Electrocardiography; Endpoint Determination; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Diseases; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Safety; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult | 2014 |
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
Topics: Adolescent; Adult; Asian People; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult | 2014 |
Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
Topics: Cell Separation; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes, Regulatory; Th17 Cells | 2014 |
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Drug Substitution; Female; Fingolimod Hydrochloride; France; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propylene Glycols; Prospective Studies; Risk Factors; Sphingosine; Tertiary Care Centers; Young Adult | 2014 |
Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Outcome | 2014 |
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Secondary Prevention; Sphingosine; Treatment Outcome; Young Adult | 2014 |
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
Topics: Adolescent; Adult; Atrioventricular Block; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2014 |
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Topics: Adult; Brain; Double-Blind Method; Drug Combinations; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers.
Topics: Adult; Blood Flow Velocity; Blood Platelets; Cerebrovascular Circulation; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Macula Lutea; Male; Middle Aged; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2014 |
Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study.
Topics: Aged; Cerebral Hemorrhage; Female; Fingolimod Hydrochloride; Glasgow Coma Scale; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Propylene Glycols; Recovery of Function; Severity of Illness Index; Single-Blind Method; Sphingosine; Treatment Outcome | 2014 |
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphopenia; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Consensus; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Incidence; Male; Medication Reconciliation; Middle Aged; Product Surveillance, Postmarketing; Propylene Glycols; Risk Assessment; Risk Factors; Severity of Illness Index; Sphingosine; Young Adult | 2015 |
Impact of an immune modulator fingolimod on acute ischemic stroke.
Topics: Adult; Aged; Brain Ischemia; Case-Control Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Subsets; Male; Middle Aged; Propylene Glycols; Single-Blind Method; Sphingosine; Stroke | 2014 |
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Registries; Severity of Illness Index; Sphingosine; Treatment Outcome | 2015 |
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
Topics: Brain; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Organ Size; Propylene Glycols; Sphingosine; Treatment Outcome | 2015 |
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
Topics: Adolescent; Adult; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Influenza Vaccines; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome; Vaccination; Young Adult | 2015 |
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Topics: Adolescent; Adult; Brain; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Single-Blind Method; Sphingosine; Treatment Outcome; Young Adult | 2015 |
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Topics: Adult; Axons; Biomarkers; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intermediate Filaments; Male; Multiple Sclerosis, Relapsing-Remitting; Neurofibrils; Placebos; Propylene Glycols; Sphingosine; Treatment Outcome | 2015 |
Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia.
Topics: Anisotropy; Brain; Cognition; Diffusion Tensor Imaging; Fingolimod Hydrochloride; Humans; Lysophospholipids; Magnetic Resonance Imaging; Pilot Projects; Schizophrenia; Sphingosine; White Matter | 2021 |
The protective role of FTY720 in promoting survival of allograft fat in mice.
Topics: Allografts; Animals; Cytokines; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine | 2022 |
The effect of Fingolimod on patients with moderate to severe COVID-19.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; SARS-CoV-2; Sphingosine | 2023 |
1042 other study(ies) available for fingolimod hydrochloride and sphingosine
| Article | Year |
|---|---|
A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation.
Topics: Animals; Cell Death; Cells, Cultured; Dogs; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Liver Transplantation; Male; Propylene Glycols; Rats; Sphingosine; Spleen; Transplantation, Homologous | 1996 |
FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats.
Topics: Animals; Cyclosporine; Drug Synergism; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Interleukin-2; Major Histocompatibility Complex; Male; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Inbred Strains; Skin Transplantation; Sphingosine; Spleen; T-Lymphocytes; Transplantation, Homologous | 1996 |
FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A.
Topics: Animals; Cyclosporine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Fingolimod Hydrochloride; Flow Cytometry; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred ACI; Rats, Inbred Strains; Sphingosine; Time Factors; Transplantation, Heterotopic; Transplantation, Homologous | 1996 |
FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Cyclosporine; Dogs; Drug Synergism; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Sphingosine; Time Factors; Transplantation, Homologous | 1996 |
Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720.
Topics: Animals; Cyclosporine; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Liver Transplantation; Propylene Glycols; Rats; Rats, Inbred ACI; Rats, Inbred Strains; Sphingosine; Transplantation, Homologous | 1996 |
Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720.
Topics: Animals; Apoptosis; Cell Line; Creatinine; Cyclosporine; Dogs; Fingolimod Hydrochloride; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocytes; Lymphoma; Male; Mice; Mice, Mutant Strains; Neoplasm Transplantation; Propylene Glycols; Sphingosine; Time Factors; Transplantation, Homologous; Tumor Cells, Cultured | 1996 |
Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720.
Topics: Animals; Apoptosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Subsets; Male; Propylene Glycols; Rats; Rats, Inbred ACI; Sphingosine; T-Lymphocytes | 1996 |
Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in rats.
Topics: Animals; Dose-Response Relationship, Immunologic; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Lymphocyte Activation; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred ACI; Rats, Inbred Strains; Sphingosine; Transplantation, Homologous | 1996 |
The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Apoptosis; CD3 Complex; fas Receptor; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Leukocyte Common Antigens; Male; Mice; Mice, Inbred MRL lpr; Propylene Glycols; Sphingosine; T-Lymphocytes; Thymus Gland | 1997 |
A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes.
Topics: Apoptosis; bcl-2-Associated X Protein; Fingolimod Hydrochloride; Gene Expression; Genes, bcl-2; Humans; Immunosuppressive Agents; Intracellular Fluid; Jurkat Cells; Leukocytes, Mononuclear; Propylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Transfection | 1996 |
Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation.
Topics: Animals; Cyclosporine; Fingolimod Hydrochloride; Graft Rejection; Graft vs Host Reaction; Immunosuppressive Agents; Intestine, Small; Lymphocyte Count; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 1997 |
Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation.
Topics: Abdomen; Animals; Drug Administration Schedule; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Intraoperative Period; Kidney Function Tests; Liver Function Tests; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Regression Analysis; Sphingosine; Tacrolimus; Transplantation, Heterotopic; Transplantation, Homologous; Weight Gain | 1997 |
An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60.
Topics: Apoptosis; Calcium; DNA Fragmentation; Estrenes; Fingolimod Hydrochloride; HL-60 Cells; Humans; Immunosuppressive Agents; Lymphocytes; Pertussis Toxin; Phosphodiesterase Inhibitors; Propylene Glycols; Pyrrolidinones; Sphingosine; Type C Phospholipases; Virulence Factors, Bordetella | 1997 |
Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720.
Topics: Animals; Epitopes; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Histocompatibility Antigens Class I; Immune Tolerance; Immunization, Passive; Immunosuppressive Agents; Interleukin-2; Male; Propylene Glycols; Rats; Rats, Inbred ACI; Rats, Inbred BN; Rats, Inbred WF; Sphingosine; Transplantation, Homologous | 1997 |
A new immunosuppressant, FTY720, prolongs limb allograft survival in rats.
Topics: Animals; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Survival; Hindlimb; Immunosuppressive Agents; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Transplantation, Homologous | 1998 |
An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation.
Topics: Animals; Cyclosporine; Dogs; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Graft vs Host Disease; Immunosuppressive Agents; Kidney Transplantation; Leukocyte Count; Propylene Glycols; Sphingosine | 1998 |
Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus.
Topics: Animals; Antibodies, Monoclonal; Cyclosporine; Drug Synergism; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Activation; Lymphocytes; Male; Phytohemagglutinins; Polyenes; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred BUF; Rats, Inbred WF; Sirolimus; Sphingosine; Stimulation, Chemical | 1998 |
FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.
Topics: Animals; CD11 Antigens; Cell Line; Cell Movement; Cyclosporine; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Interleukin-2; Lymphocyte Count; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred F344; Skin Transplantation; Sphingosine; Tacrolimus | 1998 |
FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production
Topics: Animals; CD3 Complex; Cell Movement; Cyclosporine; Cytokines; Fingolimod Hydrochloride; Graft Survival; Histocompatibility; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Lymphocyte Culture Test, Mixed; Major Histocompatibility Complex; Male; Polymerase Chain Reaction; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Strains; RNA, Messenger; Skin Transplantation; Sphingosine; T-Lymphocytes; Time Factors; Transplantation, Homologous | 1998 |
Cytotoxic actions of FTY720, a novel immunosuppressant, on thymocytes and brain neurons dissociated from the rat.
Topics: Animals; Brain; Digitoxin; Fingolimod Hydrochloride; Flow Cytometry; Fluorescent Dyes; Immunosuppressive Agents; In Vitro Techniques; Neurons; Propylene Glycols; Rats; Rats, Wistar; Spectrometry, Fluorescence; Sphingosine; Thymus Gland | 1998 |
Donor-specific blood transfusion does not enhance the effect of FTY720 in rat cardiac allotransplantation.
Topics: Animals; Blood Transfusion; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppression Therapy; Immunosuppressive Agents; Myocardial Contraction; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Transplantation, Homologous | 1998 |
Prevention of experimentally induced autoimmune type I diabetes in rats by the new immunosuppressive reagent FTY720.
Topics: Animals; Diabetes Mellitus, Type 1; Fingolimod Hydrochloride; Immunosuppressive Agents; Islets of Langerhans; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Thymectomy | 1998 |
An effect of FTY720 on acute rejection in canine renal transplantation.
Topics: Acute Disease; Animals; Blood Cell Count; Cyclosporine; Dogs; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Propylene Glycols; Sphingosine; Transplantation, Homologous | 1998 |
Beneficial immunosuppressive effect of FTY720 combined with intrathymic injection of splenic cells on rat pancreaticoduodenal allograft.
Topics: Animals; Combined Modality Therapy; Duodenum; Fingolimod Hydrochloride; Graft Survival; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Pancreas Transplantation; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Spleen; Thymus Gland; Transplantation, Homologous | 1998 |
Effect of FTY720 on immunoregulation in concordant xenotransplantation.
Topics: Animals; Apoptosis; B-Lymphocytes; Cricetinae; Fingolimod Hydrochloride; Graft Survival; Humans; Immunosuppressive Agents; Propylene Glycols; Rats; Rats, Inbred Lew; Skin Transplantation; Sphingosine; T-Lymphocytes; Transplantation Immunology; Transplantation, Heterologous | 1998 |
Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation.
Topics: Animals; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Kidney; Leukocyte Count; Liver; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Tacrolimus; Transplantation, Homologous | 1998 |
Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival.
Topics: Animals; Cyclosporine; Drug Synergism; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Male; Polyenes; Propylene Glycols; Rats; Rats, Inbred BUF; Rats, Inbred WF; Sirolimus; Sphingosine; Transplantation, Homologous | 1998 |
FTY720 inhibits the mRNA expression of intragraft cytotoxic molecules, leading to cardiac allograft survival.
Topics: Animals; DNA Primers; Fingolimod Hydrochloride; Graft Survival; Granzymes; Heart Transplantation; Immunosuppressive Agents; Membrane Glycoproteins; Perforin; Polymerase Chain Reaction; Pore Forming Cytotoxic Proteins; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred Lew; RNA, Messenger; Serine Endopeptidases; Sphingosine; T-Lymphocytes, Cytotoxic; Transcription, Genetic; Transplantation, Homologous | 1998 |
FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation.
Topics: Animals; Drug Administration Schedule; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Tacrolimus; Time Factors; Transplantation, Heterotopic | 1998 |
Caspase requirement for the apoptotic death of WR19L-induced by FTY720.
Topics: Animals; Apoptosis; Caspase 1; Caspase 2; Caspases; Cell Nucleus; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Enzyme Activation; Fingolimod Hydrochloride; Immunosuppressive Agents; Kinetics; Lymphoma; Mice; Propylene Glycols; Proteins; Sphingosine; Tumor Cells, Cultured | 1998 |
A novel immunosuppressant, FTY720, increases the efficiency of a superantigen-induced peripheral T-cell deletion whilst inhibiting negative selection in the thymus.
Topics: Animals; Apoptosis; Enterotoxins; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Receptors, Antigen, T-Cell; Skin Transplantation; Sphingosine; Staphylococcus aureus; Superantigens; T-Lymphocytes; Thymus Gland | 1998 |
Immunosuppressive effect of FTY 720 on rat pancreas allograft.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Duodenum; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Male; Pancreas Transplantation; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Transplantation, Homologous | 1998 |
Immunosuppressive effect of FTY 720 on autoimmune diabetes models.
Topics: Animals; Diabetes Mellitus, Type 1; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Islets of Langerhans; Lymphopenia; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Thymectomy | 1998 |
Prolongation of concordant xenograft survival by treatment with FTY720.
Topics: Administration, Oral; Animals; B-Lymphocytes; Cricetinae; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Humans; Immunosuppressive Agents; Liver Transplantation; Lymphocyte Depletion; Mesocricetus; Propylene Glycols; Rats; Rats, Inbred Lew; Skin Transplantation; Sphingosine; T-Lymphocytes; Transplantation, Heterologous | 1998 |
FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.
Topics: Animals; Antigens, CD; Cell Movement; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Integrin alpha1; L-Selectin; Lymph Nodes; Lymphocyte Count; Lymphocyte Function-Associated Antigen-1; Male; Peyer's Patches; Propylene Glycols; Rats; Rats, Inbred F344; Receptors, Lymphocyte Homing; Sphingosine; Stimulation, Chemical; T-Lymphocytes | 1998 |
Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine.
Topics: Acute Disease; Animals; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Macaca fascicularis; Propylene Glycols; Sphingosine; Transplantation, Homologous | 1999 |
Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720.
Topics: Animals; Ethanolamines; Fingolimod Hydrochloride; Host vs Graft Reaction; Immunosuppressive Agents; Propylene Glycols; Rats; Sphingosine; Structure-Activity Relationship; T-Lymphocytes | 1998 |
Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway.
Topics: Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Enzyme Activation; Fingolimod Hydrochloride; Glycogen Synthase Kinase 3; Humans; Immunosuppressive Agents; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Mitogen-Activated Protein Kinases; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Propylene Glycols; Signal Transduction; Sphingosine; T-Lymphocytes | 1999 |
Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation.
Topics: Androgens; Apoptosis; Caspase 3; Caspases; Fingolimod Hydrochloride; Humans; Male; Propylene Glycols; Prostatic Neoplasms; Sphingosine; Tumor Cells, Cultured | 1999 |
Effect of a new immunosuppressant, FTY720, on joint allografts.
Topics: Anastomosis, Surgical; Animals; Disease Models, Animal; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Knee Joint; Male; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred F344; Sphingosine; Statistics, Nonparametric; Transplantation, Homologous; Treatment Outcome | 1999 |
Analysis of the mode of action of a novel immunosuppressant FTY720 in mice.
Topics: Animals; Cell Movement; Female; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Propylene Glycols; Skin Transplantation; Sphingosine; T-Lymphocytes | 1999 |
FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.
Topics: Animals; Coronary Artery Disease; Cyclosporine; Disease Progression; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Postoperative Complications; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 1999 |
FTY 720.
Topics: Animals; Drugs, Investigational; Fingolimod Hydrochloride; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 1999 |
Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720.
Topics: Animals; Body Weight; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver; Organ Size; Propylene Glycols; Rats; Sphingosine; Spleen; Thyroid Gland; Thyroiditis, Autoimmune; Thyrotropin | 1999 |
A short-course therapy with FTY720 prolongs allograft survival after canine kidney transplantation.
Topics: Animals; Dogs; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Propylene Glycols; Sphingosine; Time Factors | 1999 |
Combination effect of tacrolimus and FTY720 in liver transplantation in rats.
Topics: Animals; Apoptosis; Cytokines; Fingolimod Hydrochloride; Gene Expression Regulation; Graft Rejection; Graft Survival; Immunosuppressive Agents; In Situ Nick-End Labeling; Liver Transplantation; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; RNA, Messenger; Sphingosine; Tacrolimus; Transcription, Genetic; Transplantation, Homologous | 1999 |
Prolonged graft survival induced by CTLA4IG-gene transfection combined with FTY720 administration in rat heart grafting.
Topics: Abatacept; Animals; Antigens, CD; Antigens, Differentiation; Combined Modality Therapy; CTLA-4 Antigen; Fingolimod Hydrochloride; Genetic Therapy; Graft Survival; Heart Transplantation; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Recombinant Fusion Proteins; Sphingosine; Transfection; Transplantation, Homologous | 1999 |
Prolongation of concordant xenograft survival by a newly developed drug, FTY720.
Topics: Animals; Antibodies, Heterophile; Combined Modality Therapy; Cricetinae; Fingolimod Hydrochloride; Graft Survival; Guanidines; Heart Transplantation; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Culture Test, Mixed; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Spleen; Splenectomy; Transplantation, Heterologous | 1999 |
A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons.
Topics: Animals; B-Lymphocytes; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Immunosuppressive Agents; In Vitro Techniques; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Depletion; Macaca fascicularis; Papio; Propylene Glycols; Species Specificity; Sphingosine; T-Lymphocytes; Transplantation Immunology; Transplantation, Heterologous; Transplantation, Homologous | 1999 |
Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.
Topics: Animals; Antibodies; Arrestin; Autoimmune Diseases; Blood Cell Count; Body Weight; Chi-Square Distribution; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Retinitis; Sphingosine; Statistics, Nonparametric; T-Lymphocytes; Uveitis | 2000 |
Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation.
Topics: Animals; Apoptosis; CD2 Antigens; Drug Combinations; Fingolimod Hydrochloride; Graft Survival; Granzymes; Immunosuppressive Agents; In Situ Nick-End Labeling; Interferon-gamma; Interleukin-2; Liver; Liver Transplantation; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; RNA, Messenger; Serine Endopeptidases; Sphingosine; Tacrolimus | 2000 |
FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation.
Topics: Cell Movement; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Activation; Lymphocyte Subsets; Organ Transplantation; Propylene Glycols; Protective Agents; Sphingosine; Transplantation, Homologous | 2000 |
Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs.
Topics: Animals; Bilirubin; Cyclosporine; Dogs; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Liver Transplantation; Propylene Glycols; Sphingosine; Survival Rate; Tacrolimus; Time Factors | 2000 |
Effect of pretreatment with FTY720 and cyclosporin on ischaemia-reperfusion injury of the liver in rats.
Topics: Animals; Cyclosporine; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Leukocytes, Mononuclear; Liver; Male; Neutrophil Activation; Peroxidase; Propylene Glycols; Rats; Rats, Wistar; Reperfusion Injury; Sphingosine; Transaminases; Tumor Necrosis Factor-alpha | 1999 |
Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats.
Topics: Animals; Arthritis, Experimental; Collagen; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Prednisolone; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Ribonucleosides; Sphingosine | 2000 |
FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes.
Topics: Analysis of Variance; Animals; Autoimmune Diseases; Body Weight; Fingolimod Hydrochloride; Immunosuppressive Agents; Injections, Intraperitoneal; Lymphocyte Count; Lymphocytes; Male; Myocarditis; Organ Size; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Tacrolimus | 2000 |
Antibody against a novel, myriocin (ISP-I)-based immunosuppressant, FTY720.
Topics: Animals; Antibodies; Antibody Formation; Antibody Specificity; Cross Reactions; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Immunosuppressive Agents; Propanolamines; Propylene Glycols; Rabbits; Sphingosine | 2000 |
FTY720 blocks allograft rejection by homing of lymphocytes in vivo.
Topics: Animals; Fingolimod Hydrochloride; Graft Rejection; Heart Transplantation; Immunosuppressive Agents; Propylene Glycols; Rats; Rats, Inbred BUF; Rats, Inbred WF; Sphingosine; T-Lymphocytes, Cytotoxic; Transplantation, Homologous | 2000 |
Apoptotic cells actively inhibit the expression of CD69 on Con A activated T lymphocytes.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Apoptosis; Concanavalin A; Cycloheximide; Dose-Response Relationship, Immunologic; Fingolimod Hydrochloride; HL-60 Cells; Humans; Immunosuppressive Agents; K562 Cells; Lectins, C-Type; Leukocyte Count; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Propylene Glycols; Protein Synthesis Inhibitors; Sphingosine; T-Lymphocyte Subsets | 2000 |
New immunosuppressive agents.
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Propylene Glycols; Sirolimus; Sphingosine; Transplantation | 2000 |
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.
Topics: Animals; Antibodies, Viral; Autoimmune Diseases; Cell Movement; Cytotoxicity, Immunologic; Diabetes Mellitus, Experimental; Edema; Fingolimod Hydrochloride; Hypersensitivity, Delayed; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Lymphocyte Count; Lymphocytic choriomeningitis virus; Lymphopenia; Mice; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 2000 |
Immunosuppressant FTY720 inhibits thymocyte emigration.
Topics: Animals; Cell Movement; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; Thymus Gland | 2000 |
Evidence that FTY720 induces T cell apoptosis in vivo.
Topics: Administration, Oral; Animals; Annexin A5; Apoptosis; B-Lymphocytes; Cell Separation; Dose-Response Relationship, Drug; Down-Regulation; Fingolimod Hydrochloride; Fluorescein-5-isothiocyanate; Granulocytes; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Monocytes; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; T-Lymphocytes | 2000 |
Prevention of graft vessel disease by combined FTY720/cyclosporine. A treatment in a rat carotid artery transplantation model.
Topics: Animals; Carotid Arteries; Carotid Artery Diseases; Cyclosporine; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Count; Magnetic Resonance Imaging; Male; Muscle, Smooth, Vascular; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 2000 |
FTY720 in combination with CsA inhibits islet xenograft rejection: a study in the pig-to-rat model.
Topics: Animals; Cyclosporine; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Islets of Langerhans Transplantation; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Swine; Transplantation, Heterologous | 2000 |
Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
Topics: Animals; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Inhibitory Concentration 50; Lymph Nodes; Organ Size; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Skin Transplantation; Sphingosine; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes | 2000 |
Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria.
Topics: Apoptosis; Caspase 3; Caspases; Cell Nucleus; Cytochrome c Group; Cytosol; Enzyme Activation; Fingolimod Hydrochloride; HL-60 Cells; Humans; Immunosuppressive Agents; Intracellular Membranes; Jurkat Cells; Membrane Potentials; Mitochondria; Permeability; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Sphingosine | 2000 |
The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival.
Topics: Animals; CD8-Positive T-Lymphocytes; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Lymphocyte Count; Male; Propylene Glycols; Rats; Rats, Inbred F344; Skin Transplantation; Sphingosine; Time Factors; Transplantation, Homologous | 2000 |
Tolerance induction with FTY720 and donor-specific blood transfusion: discrepancy between heart transplantation and intestinal transplantation.
Topics: Animals; Blood Transfusion; Combined Modality Therapy; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppression Therapy; Immunosuppressive Agents; Intestine, Small; Male; Propylene Glycols; Rats; Rats, Inbred Strains; Sphingosine; Survival Rate; T-Lymphocytes; Time Factors; Transplantation, Homologous | 2000 |
The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD.
Topics: Animals; Body Weight; Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Lymphocyte Count; Male; Myocardium; Propylene Glycols; Rats; Rats, Inbred Lew; Sirolimus; Sphingosine; Transplantation, Heterotopic | 2000 |
Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats.
Topics: Animals; Arthritis, Experimental; Cyclosporine; Edema; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Lymphocytes; Male; Monocytes; Mycobacterium tuberculosis; Neutrophils; Osteolysis; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Tacrolimus | 2000 |
Effect of a novel immunosuppressant, FTY720, on allograft survival after renal transplant in rats.
Topics: Animals; Blood Cell Count; Blood Cells; CD4-CD8 Ratio; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Flow Cytometry; Graft Rejection; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Monocytes; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Wistar; Receptors, Interleukin-2; Sphingosine; Spleen; Transplantation, Homologous | 2000 |
New immunosuppressive reagent, FTY 720, spares immunologic memory.
Topics: Animals; Bone Marrow Cells; Dendritic Cells; Female; Fingolimod Hydrochloride; H-Y Antigen; Immunization; Immunologic Memory; Immunosuppressive Agents; Isoantibodies; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Recombination, Genetic; Skin Transplantation; Sphingosine; Transplantation, Isogeneic | 2000 |
Rescuing acute rejection of rat cardiac allografts with FTY720.
Topics: Animals; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred WKY; Sphingosine; Survival Rate; Time Factors; Transplantation, Homologous | 2000 |
Perioperative administration of FTY720 and CTLA4IG in rat heart transplantation.
Topics: Abatacept; Animals; Antigens, CD; Antigens, Differentiation; CTLA-4 Antigen; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunoconjugates; Immunosuppressive Agents; Intraoperative Period; Lymphocyte Culture Test, Mixed; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Time Factors | 2000 |
The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD.
Topics: Administration, Oral; Animals; B-Lymphocytes; Cyclosporine; Dose-Response Relationship, Drug; Drug Tolerance; Everolimus; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Depletion; Macaca fascicularis; Propylene Glycols; Sirolimus; Sphingosine; T-Lymphocytes; Transplantation Immunology | 2000 |
FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 6; Caspases; Cell Death; Cell Survival; Cysteine Proteinase Inhibitors; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Etoposide; Fingolimod Hydrochloride; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Glioma; Humans; Immunosuppressive Agents; Oligopeptides; Phosphatidylinositol 3-Kinases; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Sphingosine; Time Factors; Tumor Cells, Cultured; Tyrosine; Vanadates | 2001 |
Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720.
Topics: Animals; Apoptosis; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Liver; Liver Transplantation; Lymphocytes; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Transplantation, Homologous | 2001 |
Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to lewis heart and skin transplantation models.
Topics: Adjuvants, Immunologic; Animals; Body Weight; Cyclosporine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Histocompatibility Antigens; Immunosuppressive Agents; Lymphocyte Count; Male; Models, Animal; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Skin Transplantation; Sphingosine | 2001 |
Long-term graft acceptance in rat heart transplantation by CTLA4Ig gene transfection combined with FTY720 treatment.
Topics: Abatacept; Animals; Antigens, CD; Antigens, Differentiation; CTLA-4 Antigen; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunoconjugates; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Recombinant Fusion Proteins; Sphingosine; Transfection | 2001 |
Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis.
Topics: Acute Disease; Animals; Cardiovirus Infections; Disease Models, Animal; Drug Evaluation, Preclinical; Encephalomyocarditis virus; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-12; Interleukin-2; Male; Mice; Mice, Inbred DBA; Myocarditis; Nitric Oxide; Proportional Hazards Models; Propylene Glycols; Severity of Illness Index; Sphingosine; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2001 |
A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor.
Topics: Animals; Cyclosporine; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Fibrosarcoma; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Histocompatibility; Immunity, Cellular; Immunosuppression Therapy; Immunosuppressive Agents; Mice; Mice, Inbred Strains; Mice, Nude; Models, Immunological; Neoplasm Transplantation; Propylene Glycols; Sirolimus; Sphingosine; T-Lymphocytes; Transplantation, Homologous; Tumor Cells, Cultured | 2001 |
Neointima suppression in rat carotid allografts by FTY720 combined with a small fixed cyclosporine dose is related to a diminution of the peripheral lymphocyte count.
Topics: Animals; Carotid Arteries; Cyclosporine; Drug Therapy, Combination; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Lymphocyte Count; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Time Factors; Transplantation, Homologous; Tunica Intima | 2001 |
FTY-720 is efficacious in monkey kidney transplantation.
Topics: ABO Blood-Group System; Animals; B-Lymphocytes; Cyclosporine; Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Graft Survival; Histocompatibility Testing; Immunophenotyping; Immunosuppressive Agents; Kidney Transplantation; Macaca fascicularis; Major Histocompatibility Complex; Propylene Glycols; Sirolimus; Sphingosine; T-Lymphocytes; Time Factors | 2001 |
Coexpression of CD4 and CD8alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs.
Topics: Animals; Biomarkers; CD4 Antigens; CD4-Positive T-Lymphocytes; CD8 Antigens; Concanavalin A; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Flow Cytometry; Guanidines; Immunosuppressive Agents; Mitogens; Propylene Glycols; Rats; Rats, Inbred Lew; Sirolimus; Sphingosine; Tacrolimus | 2001 |
Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Division; DNA Fragmentation; Down-Regulation; Enzyme Activation; Fingolimod Hydrochloride; HL-60 Cells; Humans; Immunosuppressive Agents; Jurkat Cells; Okadaic Acid; Phosphoprotein Phosphatases; Phosphorylation; Precipitin Tests; Propylene Glycols; Retinoblastoma Protein; Signal Transduction; Sphingosine; Time Factors | 2001 |
Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model.
Topics: Animals; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Female; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Lymphocyte Count; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Propylene Glycols; Sphingosine; Transplantation, Heterotopic; Transplantation, Homologous | 2001 |
Proteasome inhibitors and immunosuppressive drugs promote the cleavage of eIF4GI and eIF4GII by caspase-8-independent mechanisms in Jurkat T cell lines.
Topics: Acetylcysteine; Apoptosis; Calpain; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cyclosporine; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Eukaryotic Initiation Factor-4G; fas Receptor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Jurkat Cells; Leupeptins; Multienzyme Complexes; Peptide Fragments; Peptide Initiation Factors; Propylene Glycols; Proteasome Endopeptidase Complex; Sphingosine; T-Lymphocytes | 2001 |
[mTOR and FTY 720 inhibitors].
Topics: Cyclosporine; Drug Interactions; Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Hyperlipidemias; Immunosuppressive Agents; Kidney; Neoplasms; Propylene Glycols; Sirolimus; Sphingosine | 2001 |
[What is new on transplantation in 2001?].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Chicago; Fingolimod Hydrochloride; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Organ Transplantation; Propylene Glycols; Review Literature as Topic; Sphingosine | 2001 |
Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat.
Topics: Apoptosis; Caspase Inhibitors; Caspases; Chromatin; DNA Fragmentation; Enzyme Activation; Enzyme Inhibitors; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunohistochemistry; Immunosuppressive Agents; Indicators and Reagents; Jurkat Cells; Mitochondria; Propylene Glycols; Proteins; Sphingosine | 2001 |
CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720.
Topics: Animals; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Movement; Chemokine CCL19; Chemokine CCL21; Chemokines, CC; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Receptors, CCR7; Receptors, Chemokine; Sphingosine | 2001 |
Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus.
Topics: Animals; Drug Interactions; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Organ Transplantation; Propylene Glycols; Rats; Sirolimus; Sphingosine | 2002 |
What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation?
Topics: Animals; Dogs; Fingolimod Hydrochloride; Graft Rejection; Hematopoietic Stem Cell Transplantation; Immunosuppressive Agents; Propylene Glycols; Sphingosine; T-Lymphocytes; Whole-Body Irradiation | 2002 |
L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance.
Topics: Animals; Antibodies, Monoclonal; Cell Movement; Cells, Cultured; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Isoantigens; Kinetics; L-Selectin; Lymph Nodes; Lymphocyte Activation; Lymphoid Tissue; Mice; Mice, Knockout; Propylene Glycols; Sphingosine; Spleen; T-Lymphocytes; Transplantation Tolerance | 2002 |
Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis.
Topics: Adenocarcinoma; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Cell Cycle Proteins; Cysteine Proteinase Inhibitors; Enzyme Inhibitors; Fingolimod Hydrochloride; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Kinetics; Male; MAP Kinase Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Mitogens; p38 Mitogen-Activated Protein Kinases; Propylene Glycols; Prostatic Neoplasms; Protein-Tyrosine Kinases; Signal Transduction; Sphingosine; Tumor Cells, Cultured | 2002 |
Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells).
Topics: Antibodies; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspases; DNA Fragmentation; Enzyme Activation; Enzyme Activators; Etoposide; fas Receptor; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Immunosuppressive Agents; Indicators and Reagents; Jurkat Cells; Propylene Glycols; Sphingosine | 2002 |
Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.
Topics: Actins; Animals; Apoptosis; Cell Adhesion; Cell Movement; Cytoskeleton; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Integrins; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron; Neoplasm Metastasis; Propylene Glycols; Sphingosine; Tumor Cells, Cultured | 2002 |
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.
Topics: Animals; B-Lymphocytes; Binding, Competitive; Calcium; CHO Cells; Cricetinae; Cyclic AMP; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Ligands; Lymph Nodes; Lymphocyte Count; Lymphopenia; Lysophospholipids; Mice; Organophosphates; Organophosphonates; Phosphorylation; Propylene Glycols; Rats; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; Spleen; Stereoisomerism; T-Lymphocytes | 2002 |
Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Apoptosis; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; DNA; Female; Fingolimod Hydrochloride; Flow Cytometry; Immunoglobulin G; Immunosuppressive Agents; Interleukin-2; Kidney Glomerulus; Longevity; Lupus Erythematosus, Systemic; Lymphoid Tissue; Methylprednisolone; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Propylene Glycols; Sphingosine; T-Lymphocytes | 2002 |
Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.
Topics: Administration, Oral; Animals; Biological Transport; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Injections, Intravenous; Macaca fascicularis; Male; Models, Animal; Propylene Glycols; Sex Factors; Sphingosine | 2002 |
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Topics: Animals; Apoptosis; Cell Line; Cell Membrane; Chemotaxis; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Insecta; Kidney; Lipid Metabolism; Lymphocytes; Lymphopenia; Mice; Models, Chemical; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Wistar; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recombinant Proteins; Signal Transduction; Sphingosine; Time Factors | 2002 |
Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Topics: Animals; Autoimmune Diseases; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Mice, Inbred NOD; Propylene Glycols; Sphingosine; Time Factors | 2002 |
Combined use of FTY720 and cyclosporine A prevents chronic allograft vasculopathy.
Topics: Animals; Blood Transfusion; Cyclosporine; Fingolimod Hydrochloride; Graft Rejection; Heart Transplantation; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Inbred Strains; Sphingosine; Transplantation, Homologous | 2002 |
Donor pretreatment with FTY720 increases graft lymphocytes but does not affect graft survival following rat small bowel transplantation.
Topics: Animals; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Intestine, Small; Lymphocytes; Propylene Glycols; Rats; Rats, Inbred BN; Sphingosine; Time Factors; Transplantation, Homologous | 2002 |
Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model.
Topics: Abatacept; Animals; Antigens, CD; Antigens, Differentiation; Bronchiolitis Obliterans; CTLA-4 Antigen; Disease Models, Animal; Fingolimod Hydrochloride; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Lung Transplantation; Mice; Postoperative Complications; Propylene Glycols; Respiratory Mucosa; Sphingosine; Trachea | 2002 |
A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine.
Topics: Apoptosis; Cell Movement; Cyclosporine; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine; Transforming Growth Factor beta; Tumor Cells, Cultured | 2002 |
Combined therapy of CTLA4Ig-gene transfection with FTY720 administration in rat lung allografts.
Topics: Adenoviridae; Animals; Fingolimod Hydrochloride; Genetic Vectors; Graft Survival; Immunosuppression Therapy; Immunosuppressive Agents; Lung Transplantation; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Transfection; Transplantation, Homologous | 2002 |
FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury.
Topics: Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver; Liver Circulation; Lymphocyte Count; Peroxidase; Propylene Glycols; Rats; Rats, Inbred Lew; Reperfusion Injury; Sphingosine | 2002 |
Transplantation.
Topics: Animals; Chemokines; Fingolimod Hydrochloride; Humans; Immune Tolerance; Propylene Glycols; Sphingosine; Stem Cell Transplantation; T-Lymphocytes; Transplantation Immunology | 2002 |
Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat.
Topics: Administration, Oral; Animals; Blood Pressure; Creatinine; Fingolimod Hydrochloride; Heart Rate; Hemodynamics; Immunosuppressive Agents; Kidney; Liver; Liver Circulation; Portal System; Propylene Glycols; Rats; Renal Circulation; Sodium; Sphingosine; Urea; Vascular Resistance | 2002 |
FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration.
Topics: Animals; Cell Movement; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Liver; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Reperfusion Injury; Sphingosine; T-Lymphocytes | 2002 |
Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD.
Topics: Administration, Oral; Animals; B-Lymphocytes; Cyclosporine; Drug Combinations; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Macaca fascicularis; Male; Phenotype; Propylene Glycols; Sirolimus; Sphingosine; T-Lymphocytes; Transplantation, Homologous | 2002 |
T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Survival; Cytochrome c Group; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Jurkat Cells; Mitochondria; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Rats; Sphingosine; T-Lymphocytes; Transfection; Tumor Cells, Cultured | 2002 |
Sirolimus and FTY720: new approaches to transplant immunosuppression.
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Multicenter Studies as Topic; Propylene Glycols; Sirolimus; Sphingosine; Transplantation Immunology | 2002 |
Effects of mycophenolate sodium with or without FTY720 in a DA-to-Lewis rat heart transplantation model.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Mycophenolic Acid; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Time Factors; Transplantation, Homologous | 2002 |
Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model.
Topics: Animals; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Leukocyte Count; Male; Mycophenolic Acid; Myocardium; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Transplantation, Homologous | 2002 |
Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice.
Topics: Animals; Body Weight; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Islets of Langerhans Transplantation; Mice; Mice, Inbred NOD; Propylene Glycols; Sphingosine | 2002 |
Different mechanisms for membrane and nuclear damages in apoptosis induced by an immunosuppressant, FTY720.
Topics: Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Membrane; Cell Nucleus; Dose-Response Relationship, Drug; Enzyme Inhibitors; fas Receptor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoma; Mice; Propylene Glycols; Sphingolipids; Sphingosine; Tumor Cells, Cultured | 2002 |
[Effects of three different immunosuppressive drugs on SD rat islet cell viability].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Survival; Cells, Cultured; Daclizumab; Fingolimod Hydrochloride; Immunoglobulin G; Immunosuppressive Agents; Islets of Langerhans; Propylene Glycols; Rats; Sirolimus; Sphingosine | 2003 |
CTLA4Ig-gene transfection with FTY720 administration markedly inhibits the obliterative airway disease in heterotopically transplanted rat tracheas.
Topics: Abatacept; Animals; Combined Modality Therapy; Fingolimod Hydrochloride; Immunoconjugates; Immunosuppressive Agents; Male; Models, Animal; Postoperative Period; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Recombinant Proteins; Sphingosine; Time Factors; Trachea; Transfection; Transplantation, Heterotopic; Transplantation, Homologous | 2003 |
Pretreatment with FTY720 alone induced long-term survival of mouse heart allograft.
Topics: Animals; Drug Administration Schedule; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microsurgery; Propylene Glycols; Sphingosine; Time Factors; Transplantation, Homologous | 2003 |
FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemokine CCL19; Chemokines, CC; Chemotaxis, Leukocyte; Cysteine; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukotrienes; Lymph Nodes; Lysophospholipids; Mice; Mice, Inbred C57BL; Multidrug Resistance-Associated Proteins; Phosphorylation; Propylene Glycols; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; T-Lymphocytes | 2003 |
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.
Topics: Animals; Bone Marrow Transplantation; Cell Movement; Female; Fingolimod Hydrochloride; Graft vs Host Disease; Graft vs Tumor Effect; Immunosuppressive Agents; Lymphocyte Activation; Lymphocytes; Male; Mice; Mice, Inbred Strains; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 2003 |
Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells.
Topics: Animals; Antigens; Bromodeoxyuridine; CD4-Positive T-Lymphocytes; Cell Division; Cell Movement; Epitopes, T-Lymphocyte; Fingolimod Hydrochloride; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Growth Inhibitors; Immunosuppressive Agents; Injections, Subcutaneous; Interphase; Lymph Nodes; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Ovalbumin; Propylene Glycols; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; Succinimides; Th1 Cells | 2003 |
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
Topics: Animals; Apoptosis; Central Nervous System; Central Nervous System Diseases; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; T-Lymphocytes | 2003 |
FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.
Topics: Animals; Chronic Disease; Complement C3; Coronary Vessels; Cyclosporine; Drug Therapy, Combination; Endothelium, Vascular; Fingolimod Hydrochloride; Graft Rejection; Heart Transplantation; Immunoglobulin G; Immunohistochemistry; Immunosuppressive Agents; Lymphocyte Subsets; Lymphocytes; Male; Monocytes; Myocardium; Propylene Glycols; Rats; Sphingosine | 2003 |
Ubiquitin pathway proteins influence the mechanism of action of the novel immunosuppressive drug FTY720 in Saccharomyces cerevisiae.
Topics: Amino Acid Transport Systems; Base Sequence; DNA, Fungal; Fingolimod Hydrochloride; Gene Expression; Genes, Fungal; Genes, Regulator; Humans; Immunosuppressive Agents; Models, Biological; Mutation; Plasmids; Propylene Glycols; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Sphingosine; T-Lymphocytes; Ubiquitin | 2003 |
A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells.
Topics: Blood Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; In Vitro Techniques; Leukemia; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Sphingosine; U937 Cells | 2003 |
Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats.
Topics: Animals; Blood Cell Count; Cyclosporine; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Immunosuppression Therapy; Immunosuppressive Agents; Islets of Langerhans Transplantation; Isoantibodies; Mice; Mice, Nude; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Swine; Transplantation, Heterologous | 2003 |
Elimination of cell-cycle regulators during caspase-3-dependent apoptosis caused by an immunosuppressant, FTY720.
Topics: Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Line; Enzyme Activation; fas Receptor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoenzymes; Lymphoma; Mice; Oligopeptides; Proliferating Cell Nuclear Antigen; Propylene Glycols; Retinoblastoma Protein; Sphingosine; T-Lymphocytes; Transcription Factors; Transfection | 2003 |
The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 1; Female; Fingolimod Hydrochloride; Glucose; Immunohistochemistry; Immunosuppressive Agents; Insulin; Islets of Langerhans; Lymphocyte Count; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Propylene Glycols; Random Allocation; Sphingosine | 2003 |
Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment.
Topics: Animals; Apoptosis; Blotting, Western; Cell Division; Cell Line; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Fibroblasts; Fingolimod Hydrochloride; Hepatocyte Growth Factor; Humans; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Phosphorylation; Propylene Glycols; Sphingosine; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells.
Topics: Animals; Cell Movement; Fingolimod Hydrochloride; Immunosuppressive Agents; Intestine, Small; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation, Homologous | 2003 |
The effect of FTY 720 on engraftment in a model of spontaneous allograft acceptance.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibody Formation; Blood Transfusion; Fingolimod Hydrochloride; Heart Transplantation; Histocompatibility; Immunoglobulin G; Immunoglobulin M; Immunosuppressive Agents; Intestines; Lymphocyte Culture Test, Mixed; Lymphocyte Subsets; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred Strains; Sphingosine; Tissue Donors; Transplantation Conditioning; Transplantation Tolerance; Transplantation, Heterotopic; Transplantation, Homologous | 2003 |
Prevention of renal ischemic reperfusion injury using FTY 720 and ICAM-1 antisense oligonucleotides.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Kidney Transplantation; Male; Oligonucleotides, Antisense; Propylene Glycols; Rats; Rats, Sprague-Dawley; Renal Circulation; Reperfusion Injury; Sphingosine; Thionucleotides; Transplantation, Isogeneic | 2003 |
Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.
Topics: Adherens Junctions; Animals; Capillary Permeability; Cell Survival; Cells, Cultured; Drug Antagonism; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; Umbilical Veins; Vascular Endothelial Growth Factor A | 2003 |
FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation.
Topics: Animals; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Lymphocyte Count; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myocardium; Propylene Glycols; Sphingosine; Transplantation, Homologous | 2003 |
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.
Topics: Animals; Blotting, Northern; Cell Line; Cloning, Molecular; DNA, Complementary; Endothelial Cells; Fingolimod Hydrochloride; Genetic Variation; Genome, Human; Humans; Immunosuppressive Agents; Kinetics; Mice; Mice, Inbred BALB C; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Isoforms; Protein Structure, Tertiary; Rats; Rats, Wistar; Sphingosine; Tissue Distribution | 2003 |
FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model.
Topics: Acute Disease; Animals; Dogs; Fingolimod Hydrochloride; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Immunosuppressive Agents; Lymphocyte Count; Propylene Glycols; Recurrence; Severity of Illness Index; Sphingosine | 2003 |
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
Topics: Animals; Biotransformation; Cell Line; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Octoxynol; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Sphingosine; Transfection | 2003 |
Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchial Hyperreactivity; Bystander Effect; Cell Movement; Disease Models, Animal; Epitopes, T-Lymphocyte; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Lung; Mice; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; Th1 Cells; Th2 Cells | 2003 |
Significant prolongation of orthotopic corneal-graft survival in FTY720-treated mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Corneal Transplantation; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Propylene Glycols; Sphingosine; Transplantation, Homologous | 2003 |
CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential.
Topics: Animals; CD4 Antigens; CD4-Positive T-Lymphocytes; Cell Division; Cell Movement; Cell Separation; Chemokine CCL19; Chemokine CCL2; Chemokines, CC; Chemotaxis; Colitis; Cytokines; Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Flow Cytometry; Gastritis; L-Selectin; Lymphocyte Subsets; Lymphocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Phenotype; Propylene Glycols; Receptors, CCR2; Receptors, CCR7; Receptors, Chemokine; Receptors, Interleukin-2; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; T-Lymphocytes; Time Factors | 2004 |
The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors.
Topics: Animals; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Drug Design; Endocytosis; Fingolimod Hydrochloride; Gene Targeting; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphocyte Subsets; Lymphopenia; Lysophospholipids; Mice; Propylene Glycols; Protein Isoforms; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recombinant Fusion Proteins; Signal Transduction; Sphingosine; Transduction, Genetic; Transfection | 2004 |
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
Topics: Animals; Calcium; Cell Movement; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Heart Rate; Immunosuppressive Agents; Lymphatic System; Lymphocytes; Lymphopenia; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phosphorylation; Propylene Glycols; Protein Kinases; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Signal Transduction; Sphingosine | 2004 |
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
Topics: Adoptive Transfer; Animals; Cell Movement; Chemotaxis; Chimera; Down-Regulation; Fingolimod Hydrochloride; Gene Deletion; Lymphocyte Activation; Lymphocytes; Lymphoid Tissue; Lysophospholipids; Mice; Mice, Knockout; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; Thymus Gland | 2004 |
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
Topics: Anesthesia; Animals; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Humans; Lysophospholipids; Male; Mice; Myocardium; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2004 |
[Study the mechanisms and inducing transplantation immune tolerance of FTY720].
Topics: Adjuvants, Immunologic; Animals; Apoptosis; Fingolimod Hydrochloride; Heart Transplantation; Immune Tolerance; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myocardium; Propylene Glycols; Sphingosine; Transplantation Immunology | 2003 |
FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury.
Topics: Animals; Cell Movement; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Kidney Tubular Necrosis, Acute; Lymphocyte Subsets; Male; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Reperfusion Injury; Sphingosine | 2004 |
The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells.
Topics: Antigens, CD; Antigens, CD34; Bone Marrow Cells; Cell Separation; Cells, Cultured; Chemokines; Endothelial Cells; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Integrin alpha4beta1; Integrin alpha5beta1; Propylene Glycols; Receptors, CXCR4; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine | 2004 |
Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury.
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Disease Models, Animal; Endothelial Cells; Endotoxins; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney; Kidney Diseases; Lipopolysaccharides; Lung; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Neutrophils; Organ Size; Perfusion; Peroxidase; Pneumonia; Propylene Glycols; Respiratory Distress Syndrome; Sphingosine; Time Factors | 2004 |
The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat.
Topics: Adjuvants, Immunologic; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Fingolimod Hydrochloride; Immunity, Innate; Immunosuppressive Agents; Propylene Glycols; Rats; Rats, Inbred BB; Sphingosine; Survival Analysis | 2004 |
Immunoregulatory lysophospholipids: new stars in the mast cell constellation.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Mast Cells; Mice; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophosphatidic Acid; Receptors, Lysophospholipid; Sphingosine; T-Lymphocytes | 2004 |
Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720.
Topics: Animals; Antibodies, Monoclonal; Basiliximab; Diabetes Mellitus, Experimental; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Islets of Langerhans; Islets of Langerhans Transplantation; Macaca fascicularis; Propylene Glycols; Recombinant Fusion Proteins; Sirolimus; Sphingosine | 2004 |
FTY720 prevents anti-CD4 mAb-induced tolerance but cannot reverse established tolerance in a rat kidney transplantation model.
Topics: Animals; Antibodies, Monoclonal; Biopsy; CD4 Antigens; Creatinine; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Male; Models, Animal; Polymerase Chain Reaction; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; T-Lymphocytes; Transplantation Tolerance; Uremia | 2004 |
Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720.
Topics: Animals; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Injections, Intravenous; Male; Mice; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine | 2004 |
Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720.
Topics: Catalysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Iron; Molecular Structure; Propylene Glycols; Sphingosine | 2004 |
Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Topics: Calcium Signaling; Cells, Cultured; Endothelium, Vascular; Fingolimod Hydrochloride; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Immunosuppressive Agents; Isomerism; Lysophospholipids; Mitogen-Activated Protein Kinases; Molecular Structure; Organogenesis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship; Umbilical Veins | 2004 |
Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937.
Topics: Apoptosis; Cell Division; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; HL-60 Cells; Humans; Immunosuppressive Agents; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Propylene Glycols; Signal Transduction; Sphingosine; U937 Cells | 2004 |
Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone.
Topics: Animals; Antigens; B-Lymphocytes; Cell Movement; Chemokine CXCL13; Chemokines, CXC; Chimera; Down-Regulation; Fingolimod Hydrochloride; Flow Cytometry; Immunohistochemistry; Lipopolysaccharides; Liver; Mice; Mice, Transgenic; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; Spleen | 2004 |
Genetic, biochemical, and transcriptional responses of Saccharomyces cerevisiae to the novel immunomodulator FTY720 largely mimic those of the natural sphingolipid phytosphingosine.
Topics: Amino Acids; Biological Transport; Cell Division; Cell Membrane; Cytoskeleton; DNA, Complementary; Down-Regulation; Escherichia coli; Fingolimod Hydrochloride; Genotype; Immunoblotting; Immunosuppressive Agents; Mutation; Oligonucleotide Array Sequence Analysis; Phosphotransferases (Alcohol Group Acceptor); Plasmids; Polymerase Chain Reaction; Propylene Glycols; Reverse Transcriptase Polymerase Chain Reaction; RNA; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Sphingolipids; Sphingosine; Transcription, Genetic; Up-Regulation | 2004 |
FTY720 impairs necrosis development after ischemia-reperfusion injury.
Topics: Analysis of Variance; Animals; Creatinine; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver; Mice; Necrosis; Propylene Glycols; Reperfusion Injury; Sphingosine; Urea | 2004 |
FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination.
Topics: Animals; Fingolimod Hydrochloride; Graft Survival; Histocompatibility Testing; Immunosuppression Therapy; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Skin Transplantation; Sphingosine; Time Factors; Transplantation, Homologous | 2004 |
FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations.
Topics: Animals; Antigens, CD; Corneal Transplantation; Female; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Mycophenolic Acid; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sphingosine; Weight Loss | 2004 |
The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor.
Topics: 1-Methyl-3-isobutylxanthine; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Androstadienes; Bombesin; Calcitonin Gene-Related Peptide; Cell Movement; Chemotaxis, Leukocyte; Cholera Toxin; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fingolimod Hydrochloride; Gene Expression Regulation; Heterotrimeric GTP-Binding Proteins; Humans; Immunologic Factors; Indoles; Leukocytes, Mononuclear; Maleimides; N-Formylmethionine Leucyl-Phenylalanine; Neuropeptides; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Receptors, Lysosphingolipid; RNA, Messenger; Secretogranin II; Sphingosine; Staurosporine; Tyrphostins; Vasoactive Intestinal Peptide; Wortmannin | 2004 |
Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Topics: Acute Disease; Animals; Blood-Brain Barrier; Brain; Contrast Media; Dextrans; Encephalomyelitis, Autoimmune, Experimental; Female; Ferrosoferric Oxide; Fingolimod Hydrochloride; Heterocyclic Compounds; Immunohistochemistry; Immunosuppressive Agents; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organometallic Compounds; Oxides; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recurrence; Sphingosine | 2004 |
Effect of FTY720 on rat small bowel transplantation.
Topics: Animals; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Intestine, Small; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred Lew; Sphingosine; Survival Analysis; Time Factors; Transplantation, Homologous | 2004 |
Should we B-leavin' now?
Topics: Animals; B-Lymphocytes; Chemokine CXCL13; Chemokines, CXC; Chemotaxis; Fingolimod Hydrochloride; Mice; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2004 |
FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Movement; Fingolimod Hydrochloride; Immunosuppressive Agents; Ligands; Mice; Propylene Glycols; Receptors, CCR2; Receptors, CCR5; Receptors, CCR7; Receptors, Chemokine; Receptors, CXCR4; Receptors, G-Protein-Coupled; Receptors, Leukotriene; Receptors, Lysophospholipid; Sphingosine; T-Lymphocytes | 2004 |
['Vegetable wasps and plant worms' and G-protein-coupled receptors].
Topics: Cordyceps; Depression, Chemical; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation Mediators; Ligands; Lymphocyte Count; Lymphocytes; Lysophospholipids; Phosphorylation; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine | 2004 |
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Immunosuppressive Agents; Interferon-gamma; Lymphocytes; Lymphopenia; Mice; Mice, Inbred Strains; Mitoxantrone; Molecular Sequence Data; Myelin Proteins; Myelin Proteolipid Protein; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peptide Fragments; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine; Time Factors | 2004 |
Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis.
Topics: Animals; Apoptosis; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colitis; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Interferon-gamma; Interleukin-10; Lymphocytes; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Tissue Distribution | 2004 |
FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Enzyme Inhibitors; Fingolimod Hydrochloride; G1 Phase; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunosuppressive Agents; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Sphingosine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2004 |
Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Liver; Liver Transplantation; Male; MAP Kinase Signaling System; Propylene Glycols; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Lew; Signal Transduction; Sphingosine; Transcription Factors; Transplantation, Homologous | 2004 |
FTY720 suppresses humoral immunity by inhibiting germinal center reaction.
Topics: Animals; Antibodies; Antibody Formation; B-Lymphocytes; Fingolimod Hydrochloride; Flow Cytometry; Germinal Center; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; T-Lymphocytes | 2004 |
Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration.
Topics: Animals; Chronic Disease; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; In Situ Nick-End Labeling; Kidney Transplantation; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred F344; Sphingosine; Transplantation, Homologous | 2004 |
Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720.
Topics: Animals; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Molecular Conformation; Organophosphates; Propylene Glycols; Sphingosine | 2004 |
A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice.
Topics: Animals; Dermatitis, Atopic; Disease Models, Animal; Epidermis; Fingolimod Hydrochloride; Immunoglobulin E; Immunosuppressive Agents; Male; Mice; Mice, Inbred Strains; Propylene Glycols; Specific Pathogen-Free Organisms; Sphingosine; Time Factors | 2004 |
Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.
Topics: Adjuvants, Immunologic; Animals; Cell Movement; Cyclosporine; Drug Synergism; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Intestine, Small; Lymph Nodes; Lymphocyte Count; Lymphocytes; Male; Premedication; Preoperative Care; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred Lew; Sphingosine; Tissue Donors | 2004 |
Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
Topics: Animals; Blood Pressure; Blood Urea Nitrogen; Body Weight; Creatinine; Extracellular Matrix; Fibrosis; Fingolimod Hydrochloride; Glomerulosclerosis, Focal Segmental; Heart Rate; Immunosuppressive Agents; Isoantibodies; Lymphocyte Count; Lymphocytes; Male; Propylene Glycols; Proteinuria; Rats; Rats, Wistar; Sphingosine | 2004 |
Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.
Topics: Animals; Base Sequence; DNA; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocytes; Lymphopenia; Lysophospholipids; Mice; Mice, Knockout; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2004 |
Sphingosine mediates FTY720-induced apoptosis in LLC-PK1 cells.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Cell Line; DNA Fragmentation; Endothelial Cells; Enzyme Inhibitors; Fingolimod Hydrochloride; Kidney; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Sphingosine; Swine; Up-Regulation | 2004 |
Effects of FTY720 on rat lymphoid organs.
Topics: Animals; Antigens, CD; Atrophy; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocytes; Lymphoid Tissue; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Spleen; Thymus Gland | 2004 |
Sphingosine 1-phosphate analogs as receptor antagonists.
Topics: Calcium; Cell Line; Cell Membrane; Cell Movement; Dose-Response Relationship, Drug; Drug Design; Fingolimod Hydrochloride; Guanosine Triphosphate; Humans; Inhibitory Concentration 50; Kinetics; Ligands; Lipids; Lymphocytes; Lysophospholipids; Models, Chemical; Phosphoserine; Propylene Glycols; Protein Binding; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Structure-Activity Relationship; Transfection | 2005 |
A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
Topics: Animals; Blood Cell Count; Coronary Vessels; Cyclosporine; Dogs; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Intestines; Kidney; Liver Transplantation; Lung; Propylene Glycols; Sphingosine; Survival Analysis; Tacrolimus | 2004 |
Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate.
Topics: Animals; Cell Line; Cell Movement; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Mice; Models, Chemical; Molecular Structure; Propylene Glycols; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism | 2005 |
Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Fingolimod Hydrochloride; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propylene Glycols; rac GTP-Binding Proteins; Signal Transduction; Sphingosine | 2005 |
A convenient synthesis of immunosuppressive agent FTY720 using the petasis reaction.
Topics: Benzylamines; Catalysis; Dihydroxyacetone; Fingolimod Hydrochloride; Hydrogenation; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2005 |
FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers.
Topics: Animals; Apoptosis; Blotting, Western; Chemokine CXCL2; Chemokines, CXC; DNA Primers; Down-Regulation; Endothelin-1; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Fingolimod Hydrochloride; Gene Expression Regulation; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Hepatocytes; HSP70 Heat-Shock Proteins; Immunosuppressive Agents; In Situ Nick-End Labeling; Inflammation; Intercellular Signaling Peptides and Proteins; Interleukin-10; Liver; Male; MAP Kinase Signaling System; Microscopy, Electron; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Propylene Glycols; Proteins; raf Kinases; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sphingosine; Time Factors; Up-Regulation | 2005 |
Effect of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice.
Topics: Acute Disease; Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Cell Division; Concanavalin A; Fingolimod Hydrochloride; Hepatocytes; Immunosuppressive Agents; Interferon-gamma; Interleukin-4; Lipopolysaccharides; Liver Diseases; Male; Mice; Mycobacterium bovis; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Spleen | 2005 |
KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.
Topics: Animals; Bradycardia; Chemotaxis, Leukocyte; Chronic Disease; Cyclosporine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Guinea Pigs; Heart Rate; Heart Transplantation; Immunosuppressive Agents; Male; Molecular Structure; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Inbred Strains; Rats, Wistar; Skin Transplantation; Sphingosine; Sulfhydryl Compounds; Transplantation, Heterotopic; Transplantation, Homologous | 2005 |
The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.
Topics: Actins; CD18 Antigens; CD40 Antigens; Chemokines; Chemotaxis; Dendritic Cells; Fingolimod Hydrochloride; Gene Expression; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-10; Interleukin-4; Propylene Glycols; Sphingosine; T-Lymphocytes; Time Factors | 2005 |
A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis.
Topics: Adrenomedullin; Animals; Autoimmune Diseases; Blood Chemical Analysis; Fingolimod Hydrochloride; Glomerulonephritis; Humans; Immunosuppressive Agents; Kidney; Male; Mercuric Chloride; Peptides; Propylene Glycols; Proteinuria; Radioimmunoassay; Random Allocation; Rats; Sphingosine; Statistics as Topic; Urine | 2005 |
FTY720 in corneal concordant xenotransplantation.
Topics: Animals; Corneal Transplantation; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Lymph Nodes; Mice; Mice, Inbred BALB C; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine; Transplantation, Heterologous | 2005 |
The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.
Topics: Animals; Depression, Chemical; Fingolimod Hydrochloride; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Heart Atria; Heart Rate; Immunosuppressive Agents; Mice; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Propylene Glycols; Sphingosine | 2005 |
Novel mediators of FTY720 in human lymphocytes.
Topics: Cell Adhesion; Cell Movement; Cytoskeleton; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Phosphatidylinositol 3-Kinases; Propylene Glycols; Proteomics; Sphingosine; Ubiquitin-Conjugating Enzymes | 2005 |
FTY720 pharmacokinetics in mild to moderate hepatic impairment.
Topics: Case-Control Studies; Female; Fingolimod Hydrochloride; Humans; Liver Diseases; Male; Middle Aged; Propylene Glycols; Sphingosine | 2005 |
FTY720, an immunosuppressant, attenuates chronic pancreatitis in rats by suppressing T-cell infiltration.
Topics: Animals; Body Weight; Fingolimod Hydrochloride; Hydroxyproline; Immunosuppressive Agents; Interferon-gamma; Male; Organ Size; Pancreas; Pancreatitis, Chronic; Peroxidase; Propylene Glycols; Rats; Rats, Wistar; RNA, Messenger; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.
Topics: Cells, Cultured; Enzyme Activation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Lysosphingolipid; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sphingosine; Vasodilation | 2005 |
A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice.
Topics: Animals; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Myasthenia Gravis, Autoimmune, Experimental; Propylene Glycols; Specific Pathogen-Free Organisms; Sphingosine; Time Factors | 2005 |
Preoperative administration of FTY720 prolonged renal allograft survival.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Fingolimod Hydrochloride; Graft Survival; Granulocytes; Immunosuppressive Agents; Kidney Transplantation; Leukocytes; Male; Preoperative Care; Propylene Glycols; Rats; Receptors, Interleukin-2; Sphingosine; Transplantation, Homologous | 2005 |
The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches.
Topics: Adoptive Transfer; Animals; Chemotaxis, Leukocyte; Fingolimod Hydrochloride; Immunosuppressive Agents; Integrins; Lymph Nodes; Lymphatic Vessels; Lymphocyte Count; Lymphocytes; Lysophospholipids; Mice; Mice, Knockout; Microscopy, Video; Peyer's Patches; Propylene Glycols; Sphingosine; T-Lymphocytes | 2005 |
Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred NOD; Propylene Glycols; Sphingosine | 2005 |
Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement.
Topics: Animals; Antigens, CD; B-Lymphocytes; Cell Movement; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Germinal Center; Immunosuppressive Agents; Injections, Intraperitoneal; Lipopolysaccharides; Lymphocyte Activation; Lymphoid Tissue; Macrophages; Mice; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2005 |
Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in experimental autoimmune encephalitis.
Topics: Animals; Blood-Brain Barrier; Brain; Contrast Media; Dextrans; Encephalomyelitis, Autoimmune, Experimental; Ferrosoferric Oxide; Fingolimod Hydrochloride; Heterocyclic Compounds; Immunohistochemistry; Immunosuppressive Agents; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organometallic Compounds; Oxides; Propylene Glycols; Rats; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recurrence; Sphingosine | 2005 |
[Study of the effects of immunosuppressive agents on human islet cells in vitro].
Topics: Cell Separation; Cell Survival; Cells, Cultured; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Islets of Langerhans; Propylene Glycols; Sirolimus; Sphingosine; Tacrolimus | 2005 |
Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates.
Topics: Animals; Cyclophosphamide; Cyclosporine; Drug Synergism; Everolimus; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Macaca fascicularis; Male; Methotrexate; Mycophenolic Acid; Organ Transplantation; Papio; Propylene Glycols; Sirolimus; Sphingosine | 2005 |
Protection of mouse small bowel allografts by FTY720 and costimulation blockade.
Topics: Animals; Antibodies, Monoclonal; Fingolimod Hydrochloride; Flow Cytometry; Graft Rejection; Graft Survival; Immunosuppressive Agents; Intestine, Small; Lymphocytes; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Transplantation, Homologous | 2005 |
Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
Topics: Animals; Benzimidazoles; Binding Sites; Bradycardia; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Immunosuppressive Agents; Lethal Dose 50; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2005 |
FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
Topics: Androgens; Animals; Apoptosis; beta Catenin; Body Weight; Cadherins; Caspase 3; Caspases; Cell Division; Fingolimod Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Orchiectomy; Platelet Endothelial Cell Adhesion Molecule-1; Propylene Glycols; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Vascular Endothelial Growth Factor A | 2005 |
The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs.
Topics: Animals; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Lymphatic Diseases; Lymphocyte Count; Lymphocytes; Lymphoid Tissue; Lymphopenia; Male; Mice; Propylene Glycols; Skin Transplantation; Sphingosine; Splenectomy; T-Lymphocytopenia, Idiopathic CD4-Positive | 2005 |
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
Topics: Adjuvants, Immunologic; Animals; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Cricetulus; Crystallography, X-Ray; Fingolimod Hydrochloride; Humans; Male; Organophosphates; Phosphorylation; Propylene Glycols; Radioligand Assay; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism; Structure-Activity Relationship | 2005 |
Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.
Topics: Animals; Fingolimod Hydrochloride; Flow Cytometry; Homozygote; Immunosuppressive Agents; Lymphocytes; Lymphopenia; Lysophospholipids; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Propylene Glycols; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine | 2005 |
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bone Marrow Cells; Caspases; Cell Growth Processes; Coculture Techniques; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Immunosuppressive Agents; Insulin-Like Growth Factor I; Interleukin-6; Membrane Potentials; Mitochondria; Multiple Myeloma; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sphingosine; Stromal Cells | 2005 |
Sphingosine 1-phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells.
Topics: Animals; Cell Communication; Cell Movement; Chemokine CCL19; Chemokine CXCL12; Chemokines; Chemokines, CC; Chemokines, CXC; Endothelial Cells; Fingolimod Hydrochloride; Lymph Nodes; Lysophospholipids; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Spleen; T-Lymphocytes | 2005 |
Sphingosine-1-phosphate mediates migration of mature dendritic cells.
Topics: Animals; Cell Differentiation; Cell Movement; Dendritic Cells; Fingolimod Hydrochloride; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2005 |
The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity.
Topics: Aldehyde-Lyases; Animals; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Mice; Propylene Glycols; Sphingosine; Tissue Distribution | 2005 |
[Effects of sphingosine 1-phosphate on functions of T cell - review].
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes | 2005 |
Immunology. Dietary factors and immunological consequences.
Topics: Aldehyde-Lyases; Animals; Cell Movement; Chemotaxis, Leukocyte; Diet; Enzyme Inhibitors; Fingolimod Hydrochloride; Food Coloring Agents; Imidazoles; Immunosuppressive Agents; Lymphoid Tissue; Lysophospholipids; Mice; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2005 |
Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Endothelium, Vascular; Fingolimod Hydrochloride; Flow Cytometry; G1 Phase; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Propylene Glycols; Sphingosine; Transplantation, Heterologous; Umbilical Veins; Wounds and Injuries | 2005 |
The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Adhesion Molecules; Cell Differentiation; Dendritic Cells; DNA Primers; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Depletion; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Oxadiazoles; Polymerase Chain Reaction; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes; Thiophenes | 2005 |
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
Topics: Animals; Cell Movement; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Kinetics; Lymphocytes; Mice; Mice, Knockout; Phosphates; Phosphotransferases (Alcohol Group Acceptor); Polymerase Chain Reaction; Propylene Glycols; RNA, Messenger; Sphingosine | 2006 |
NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.
Topics: Calcium; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Lysophospholipids; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Chemical; Oxadiazoles; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Binding; Receptors, Lysosphingolipid; Recombinant Proteins; Sphingosine; Substrate Specificity; Time Factors | 2006 |
[Multiple sclerosis. A new oral immunomodulator].
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocytes | 2005 |
Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Topics: Animals; Cell Movement; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymph Nodes; Lymphoid Tissue; Lymphopenia; Male; Mice; Mice, Inbred C57BL; Models, Biological; Propylene Glycols; Sphingosine; T-Lymphocytes | 2005 |
The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.
Topics: Animals; Cells, Cultured; Collagen Type IV; Connective Tissue Growth Factor; Fibrosis; Fingolimod Hydrochloride; Glomerular Mesangium; Immediate-Early Proteins; Immunosuppressive Agents; Intercellular Signaling Peptides and Proteins; Male; MAP Kinase Signaling System; Phosphorylation; Propylene Glycols; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Smad1 Protein; Smad2 Protein; Smad3 Protein; Sphingosine; Transforming Growth Factor beta; Up-Regulation | 2006 |
Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes.
Topics: Animals; Cell Communication; Endothelial Cells; Endothelium, Lymphatic; Endothelium, Vascular; Female; Fingolimod Hydrochloride; Fluorescent Antibody Technique; Immunosuppressive Agents; Lymph Nodes; Lymphocytes; Macrophages; Mesentery; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Microscopy, Immunoelectron; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Tight Junctions | 2005 |
Effect of FTY720 on chronic cyclosporine nephropathy in rats.
Topics: Angiotensin II; Animals; Chronic Disease; Cyclosporine; Extracellular Matrix Proteins; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney; Kidney Diseases; Lymphocytes; Macrophages; Male; Osteopontin; Propylene Glycols; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.
Topics: Animals; Antigens, CD34; Carcinoma, Hepatocellular; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Propylene Glycols; rac GTP-Binding Proteins; Sphingosine; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Wound Healing | 2005 |
The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.
Topics: Animals; Cell Proliferation; Chemotaxis, Leukocyte; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Lymph Nodes; Lymphocyte Activation; Lymphocyte Count; Mice; Mice, Inbred C57BL; Organ Specificity; Ovalbumin; Propylene Glycols; Receptors, Interleukin-2; Receptors, Lysosphingolipid; Respiratory System; Sphingosine; T-Lymphocytes, Regulatory | 2005 |
Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection.
Topics: Adoptive Transfer; Animals; Apoptosis; CD4-Positive T-Lymphocytes; Chemotaxis, Leukocyte; Chronic Disease; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Graft Rejection; Heart Transplantation; Immunohistochemistry; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Transgenic; Propylene Glycols; Receptors, Antigen, T-Cell; Skin Transplantation; Sphingosine; Transplantation, Homologous | 2006 |
Multiple sclerosis poses tough drug development challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Integrin alpha2; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2005 |
FTY720 inhibits TH1-mediated allogeneic humoral immune response.
Topics: Animals; Antibody Formation; Female; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Animal; Propylene Glycols; Skin Transplantation; Sphingosine; Thymectomy; Time Factors; Transplantation, Homologous | 2005 |
Use of FTY 720 and ICAM-1 antisense oligonucleotides for attenuating chronic renal damage secondary to ischemia-reperfusion injury.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Intercellular Adhesion Molecule-1; Inulin; Kidney; Kidney Function Tests; Male; Oligonucleotides, Antisense; Propylene Glycols; Rats; Rats, Inbred Lew; Reperfusion Injury; Sphingosine | 2005 |
Effect of FTY720 in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1.
Topics: Animals; Fingolimod Hydrochloride; Gene Expression Regulation; Graft Survival; Immunoglobulins; Immunosuppressive Agents; Intestinal Mucosa; Jejunum; Mucoproteins; Propylene Glycols; Rats; Rats, Inbred BN; Sphingosine; Transplantation, Homologous; Transplantation, Isogeneic | 2005 |
Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunologic Memory; Immunosuppressive Agents; Isoantibodies; Lymphoid Tissue; Male; Mice; Mice, Congenic; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Propylene Glycols; Sphingosine; Transplantation, Homologous | 2006 |
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
Topics: Animals; Calcium; Cell Growth Processes; Cell Movement; Cornea; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Melanoma, Experimental; Mice; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Phthalazines; Propylene Glycols; Pyridines; Receptors, Lysosphingolipid; Sphingosine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney.
Topics: Animals; Capillary Permeability; Creatinine; Fingolimod Hydrochloride; Kidney; Leukocytes; Lymphocyte Count; Mice; Mice, Inbred C57BL; Oxadiazoles; Peroxidase; Propylene Glycols; Receptors, Lysosphingolipid; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine; T-Lymphocytes; Thiophenes | 2006 |
Enhanced FTY720-mediated lymphocyte homing requires G alpha i signaling and depends on beta 2 and beta 7 integrin.
Topics: Adjuvants, Immunologic; Animals; CD18 Antigens; Cell Adhesion; Cell Adhesion Molecules; Cell Movement; Endothelium, Lymphatic; Fingolimod Hydrochloride; GTP-Binding Protein alpha Subunits, Gi-Go; Homeostasis; Immunotherapy, Adoptive; Integrin beta Chains; Intercellular Adhesion Molecule-1; Lymph Nodes; Lymphocyte Transfusion; Mice; Mice, Inbred C57BL; Mice, Knockout; Mucoproteins; Propylene Glycols; Signal Transduction; Sphingosine; Spleen; Time Factors; Vascular Cell Adhesion Molecule-1 | 2006 |
FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glycoproteins; Male; Mice; Myelin Basic Protein; Myelin Proteolipid Protein; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2005 |
Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival.
Topics: Adiponectin; Animals; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Fingolimod Hydrochloride; Follow-Up Studies; Graft Rejection; Graft Survival; Immunosuppressive Agents; Liver Transplantation; Male; Propylene Glycols; Rats; Rats, Zucker; Sphingosine; Treatment Outcome | 2006 |
FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cytoskeleton; Fingolimod Hydrochloride; Humans; Male; Neoplasm Invasiveness; Propylene Glycols; Prostatic Neoplasms; rhoA GTP-Binding Protein; Sphingosine | 2006 |
A photoreactive analogue of the immunosuppressant FTY720.
Topics: Azides; Fingolimod Hydrochloride; Immunosuppressive Agents; Photochemistry; Propanolamines; Propylene Glycols; Sphingosine | 2006 |
Preparation of antibodies against a novel immunosuppressant, FTY720, and development of an enzyme immunoassay for FTY720.
Topics: Administration, Oral; Animals; Antibodies; Antigen-Antibody Reactions; Female; Fingolimod Hydrochloride; Haptens; Immunoenzyme Techniques; Molecular Structure; Ovalbumin; Propylene Glycols; Rabbits; Sphingosine; Stereoisomerism; Structure-Activity Relationship | 2006 |
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Topics: Animals; Benzoxazines; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Cyclohexanols; Endocytosis; Enzyme Activation; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Naphthalenes; Phenols; Piperidines; Propylene Glycols; Proto-Oncogene Proteins c-akt; Pyrazoles; Radioligand Assay; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Sphingosine | 2006 |
FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.
Topics: Animals; CD4 Antigens; Colitis; Female; Fingolimod Hydrochloride; Hyaluronan Receptors; Immunologic Memory; Immunosuppressive Agents; Inflammation Mediators; L-Selectin; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Sphingosine | 2006 |
In vitro evaluation of the effect of a novel immunosuppressive agent, FTY720, on the function of feline neutrophils.
Topics: Animals; Cats; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Neutrophils; Phosphorylation; Propylene Glycols; Reactive Oxygen Species; Sphingosine | 2006 |
Evidence that FTY720 induces rat thymocyte apoptosis.
Topics: Animals; Apoptosis; Atrophy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; DNA Fragmentation; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; In Situ Nick-End Labeling; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, Antigen, T-Cell, alpha-beta; Sphingosine; T-Lymphocyte Subsets; Thymus Gland | 2006 |
FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia in C57/BL6 mice.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Injections, Intraperitoneal; Ischemia; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Renal Circulation; Reperfusion Injury; Sphingosine | 2006 |
Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice.
Topics: Animals; Chemical and Drug Induced Liver Injury; Concanavalin A; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Liver; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sulfhydryl Compounds; Treatment Outcome | 2006 |
Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway.
Topics: Animals; Brain; CD11a Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Movement; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Pertussis Toxin; Propylene Glycols; Receptors, CCR7; Receptors, Chemokine; Skin; Specific Pathogen-Free Organisms; Sphingosine | 2006 |
Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
Topics: Administration, Oral; Animals; Computer Simulation; Dogs; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Models, Biological; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Tissue Distribution | 2006 |
Measurement and stability of FTY720 in human whole blood by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Fingolimod Hydrochloride; Humans; Propylene Glycols; Sphingosine; Tandem Mass Spectrometry | 2006 |
Inhibition of donor-derived T cells trafficking into target organs by FTY720 during acute graft-versus-host disease in small bowel transplantation.
Topics: Acute Disease; Animals; Body Weight; Cytokines; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Intestine, Small; Liver; Lymphocyte Count; Male; Propylene Glycols; Rats; Rats, Inbred WF; Skin; Sphingosine; T-Lymphocyte Subsets; Transplantation Chimera | 2006 |
The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Transplantation; Colitis; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammatory Bowel Diseases; L-Selectin; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Spleen | 2006 |
Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Topics: Animals; Autoantigens; Cell Movement; Central Nervous System; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymph Nodes; Lysophospholipids; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes | 2006 |
The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
Topics: Animals; Cell Degranulation; Cell Line; Cysteine; Cytosol; Eicosanoids; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukotrienes; Mast Cells; Phospholipases A; Phospholipases A2; Propylene Glycols; Prostaglandin D2; Rats; Receptors, Lysosphingolipid; Sphingosine | 2007 |
Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.
Topics: Animals; Aza Compounds; Calcium; Cell Line; CHO Cells; Chromatography, Thin Layer; Cricetinae; Cricetulus; Cytoplasm; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Indicators and Reagents; Magnetic Resonance Spectroscopy; Molecular Probes; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function.
Topics: Administration, Inhalation; Allergens; Animals; Asthma; Cell Differentiation; Cell Movement; Cell Polarity; Dendritic Cells; Disease Models, Animal; Fingolimod Hydrochloride; Gene Expression Regulation; Heart; Lymph Nodes; Lymphocytes; Lysophospholipids; Mice; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2006 |
Effect of FTY720 in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes in gut-associated lymphoid tissues.
Topics: Animals; Apoptosis; Fas Ligand Protein; Fingolimod Hydrochloride; Immunosuppressive Agents; Intestinal Mucosa; Intestine, Small; Models, Animal; Peyer's Patches; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred Lew; Sphingosine; Transplantation, Homologous; Transplantation, Isogeneic | 2006 |
The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Practice Patterns, Physicians'; Propylene Glycols; Sphingosine | 2006 |
FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
Topics: Adjuvants, Immunologic; Administration, Oral; Adoptive Transfer; Animals; Apoptosis; Bone Marrow Transplantation; Cells, Cultured; Female; Fingolimod Hydrochloride; Graft vs Host Disease; Lymphocyte Activation; Lymphocyte Depletion; Lymphopenia; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; T-Lymphocytes | 2007 |
The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Movement; Cells, Cultured; Cholesterol, Dietary; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Gene Expression Regulation; Immunohistochemistry; Lysophospholipids; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Probability; Propylene Glycols; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine; Statistics, Nonparametric | 2007 |
Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.
Topics: Animals; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Enzyme Activation; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Lysophospholipids; Mice; Mice, Transgenic; Propylene Glycols; Receptors, CXCR4; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; src-Family Kinases; Stem Cells | 2007 |
FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
Topics: Animals; Antigens, CD; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Movement; Female; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Kidney; Liver; Lung; Lymph Nodes; Lymphocyte Depletion; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Spleen; T-Lymphocyte Subsets; T-Lymphocytes | 2006 |
FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
Topics: Animals; Body Weight; Cell Count; Creatinine; Cyclosporine; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Histocompatibility Antigens Class II; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Kidney; Lymph Nodes; Lymphocyte Count; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Potassium; Propylene Glycols; Skin Transplantation; Sodium; Sphingosine; Spleen; Transplantation, Homologous | 2006 |
Multiple sclerosis: new insights and therapeutic progress.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain; Canada; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interleukin-18; Multiple Sclerosis; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sex Factors; Sphingosine | 2007 |
Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.
Topics: Amidohydrolases; Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Ceramidases; Ceramides; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Lipid Metabolism; Lysophospholipids; Neoplasms; Neovascularization, Pathologic; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2006 |
Regulation of donor T cells in the tolerant rats to graft-versus-host disease by FTY720 following small bowel transplantation.
Topics: Animals; Cytokines; Fingolimod Hydrochloride; Graft vs Host Disease; Immune Tolerance; Immunosuppressive Agents; Intestine, Small; Male; Propylene Glycols; Rats; Rats, Inbred ACI; Rats, Inbred WF; Sphingosine; T-Lymphocytes; Transplantation, Homologous; Transplantation, Isogeneic | 2006 |
Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.
Topics: Animals; Cell Differentiation; Cells, Cultured; Extracellular Matrix Proteins; Fibroblasts; Fingolimod Hydrochloride; Immunologic Factors; Mice; Mice, Knockout; Muscle, Smooth; Phosphorylation; Propylene Glycols; Receptor Cross-Talk; Receptors, Lysosphingolipid; Signal Transduction; Smad3 Protein; Sphingosine; Transforming Growth Factor beta | 2007 |
Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Down-Regulation; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Immunosuppressive Agents; Liver Neoplasms; Lymphocytes; Neoplasm Transplantation; Propylene Glycols; Proto-Oncogene Proteins c-akt; Rats; Sphingosine; Up-Regulation | 2007 |
The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Cell Division; Cells, Cultured; Coculture Techniques; Collagen; Drug Combinations; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Laminin; Mice; Mice, Inbred C57BL; Muscle, Smooth; Neoplasm Transplantation; Neovascularization, Pathologic; Neutralization Tests; Oxadiazoles; Propylene Glycols; Proteoglycans; Receptors, CXCR4; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Transcriptional Activation; Transplantation, Isogeneic; Umbilical Veins; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics.
Topics: Cells, Cultured; Chloroquine; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Lysophospholipids; Oxadiazoles; Propylene Glycols; Protein Transport; Proteomics; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Ubiquitin | 2007 |
Tacrolimus in combination with FTY720--an analysis of renal and blood parameters.
Topics: Animals; Biomarkers; Blood Glucose; Creatinine; Diabetes Mellitus; Diuresis; Drug Synergism; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney; Lymphocyte Count; Lymphopenia; Male; Mice; Mice, Inbred C57BL; Potassium; Propylene Glycols; Sodium; Sphingosine; Tacrolimus | 2006 |
Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production.
Topics: Animals; Antibodies, Antiphospholipid; Antibodies, Bacterial; B-Lymphocytes; Bacterial Vaccines; Cell Movement; Female; Fingolimod Hydrochloride; Immunoglobulin A; Immunoglobulin J-Chains; Immunosuppressive Agents; Intestine, Small; Lymphoid Tissue; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, SCID; Peritoneal Cavity; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Streptococcus pneumoniae; Vaccination | 2007 |
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Topics: Angiogenesis Inhibitors; Cell Line; Enzyme Inhibitors; Fingolimod Hydrochloride; Green Fluorescent Proteins; Humans; Immunosuppressive Agents; Leupeptins; Ligands; Microscopy, Confocal; Propylene Glycols; Proteasome Endopeptidase Complex; Protein Binding; Receptors, Lysosphingolipid; Sphingosine; Ubiquitin | 2007 |
FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Topics: Animals; Atherosclerosis; Cell Division; Cholesterol, HDL; Cytokines; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Lysophospholipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Propylene Glycols; Receptors, LDL; Signal Transduction; Sphingosine; Triglycerides | 2007 |
FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.
Topics: Animals; Antigens, CD; Antigens, Differentiation; Aziridines; Cell Differentiation; Choline; Colitis; CTLA-4 Antigen; Cytokines; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Forkhead Transcription Factors; Immunosuppressive Agents; Inflammation; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; Mice; Mice, Inbred BALB C; Neuromuscular Blocking Agents; Propylene Glycols; Sphingosine; T-Lymphocytes, Regulatory; Th1 Cells | 2007 |
New immunosuppresor strategies in the treatment of murine lupus nephritis.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Apoptosis; Autoantigens; Cell Movement; Chromatin; Complement C3; Complement C3 Nephritic Factor; Cyclophosphamide; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Glomerular Mesangium; Immunoglobulin G; Immunosuppressive Agents; Injections, Intraperitoneal; Kidney Glomerulus; Lupus Nephritis; Lymphocytes; Mice; Mice, Inbred NZB; Nucleosomes; Propylene Glycols; Proteinuria; Receptors, Lysosphingolipid; Sirolimus; Sphingosine | 2007 |
Mechanism of mitochondrial 7A6 antigen exposure triggered by distinct apoptotic pathways: involvement of caspases.
Topics: Apoptosis; Caspases; Cytochrome c Group; DNA Fragmentation; Enzyme Inhibitors; Fingolimod Hydrochloride; Flow Cytometry; Humans; Jurkat Cells; Ligands; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondrial Proteins; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Time Factors; Transfection | 2007 |
FTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Cells, Cultured; Fingolimod Hydrochloride; Group II Phospholipases A2; Histone Deacetylase Inhibitors; Hydroxamic Acids; Immunosuppressive Agents; Interleukin-1beta; Mesangial Cells; Phospholipases A; Phospholipases A2; Propylene Glycols; Protein Synthesis Inhibitors; Rats; RNA, Messenger; Sphingosine; Transcription, Genetic | 2007 |
Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Movement; Cells, Cultured; Dendritic Cells; Dose-Response Relationship, Drug; Down-Regulation; Endocytosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Knockout; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiophenes | 2007 |
[Effect of mono and combination therapy with FTY720 and ICAM-1 mAb for mouse-to-rat cardiac xenotransplantation].
Topics: Animals; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Immunoglobulin M; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukin-2; Interleukin-4; Mice; Mice, Inbred BALB C; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Time Factors; Transplantation, Heterologous | 2007 |
Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients.
Topics: Adrenergic Antagonists; Adult; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Propylene Glycols; Sphingosine | 2007 |
S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
Topics: Animals; Antibodies, Blocking; Blood Pressure; Body Weight; Collagen Type III; Extracellular Matrix; Fibronectins; Fingolimod Hydrochloride; Glomerulonephritis, Membranoproliferative; Heart Rate; Immunohistochemistry; Kidney Glomerulus; Leukocyte Count; Lipopolysaccharides; Male; Nitric Oxide Synthase Type II; Plasminogen Activator Inhibitor 1; Propylene Glycols; Proteinuria; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Thy-1 Antigens; Transforming Growth Factor beta | 2007 |
FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model.
Topics: Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver; Male; Mice; Mice, Inbred C57BL; Models, Animal; Propylene Glycols; Reperfusion Injury; Sphingosine; Survival Analysis; Time Factors | 2007 |
FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Renal Circulation; Reperfusion Injury; Sphingosine; Survival Analysis; T-Lymphocytes | 2007 |
Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors.
Topics: Animals; Astrocytes; Blotting, Western; Cells, Cultured; Cerebral Cortex; Extracellular Signal-Regulated MAP Kinases; Female; Fingolimod Hydrochloride; GTP-Binding Protein alpha Subunits, Gi-Go; Immunohistochemistry; Pertussis Toxin; Phosphorylation; Pregnancy; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine | 2007 |
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Topics: Animals; Apoptosis; Autoimmune Diseases; bcl-2-Associated X Protein; Calcium Signaling; Caspases; Cell Membrane Permeability; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Fingolimod Hydrochloride; HeLa Cells; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoproliferative Disorders; Mice; Mice, Knockout; Mitochondria; Mutagenesis; Organ Specificity; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Transport; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine; Spleen; Thymus Gland | 2007 |
Immunology. The sources of a lipid conundrum.
Topics: Animals; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Mice; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate.
Topics: Animals; CD4 Antigens; Cells, Cultured; Cytokines; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-23; Lymphocyte Activation; Lysophospholipids; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Spleen; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer | 2007 |
Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone.
Topics: Animals; Calcium; Calcium Signaling; Cells, Cultured; Female; Fingolimod Hydrochloride; Immunoblotting; Immunosuppressive Agents; Lysophospholipids; Muscle Contraction; Muscle Tonus; Muscle, Smooth; Propylene Glycols; Rabbits; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; Type C Phospholipases | 2007 |
FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Ascomycota; Cell Division; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Pancreatic Neoplasms; Propylene Glycols; Sphingosine; Wound Healing | 2007 |
FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions.
Topics: Adjuvants, Immunologic; Animals; Cells, Cultured; Colitis, Ulcerative; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Oxazolone; Propylene Glycols; Sphingosine; Th2 Cells | 2007 |
Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Topics: Adenoviridae; Capillary Permeability; Cells, Cultured; Cytoskeleton; Electric Impedance; Endothelial Cells; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lung; Models, Biological; Phosphorylation; Propylene Glycols; Pulmonary Artery; rac1 GTP-Binding Protein; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Sphingosine; Threonine | 2007 |
Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice.
Topics: Animals; Blood Glucose; Cell Movement; Diabetes Mellitus, Experimental; Disease Models, Animal; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymphocyte Count; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Random Allocation; Sphingosine; Time Factors | 2007 |
Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Astrocytes; beta-Alanine; Calcium Signaling; Cell Movement; Cell Proliferation; Cells, Cultured; Cerebral Cortex; Cyclic AMP; Dose-Response Relationship, Drug; Embryo, Mammalian; Fingolimod Hydrochloride; Glial Fibrillary Acidic Protein; Glutamic Acid; Hippocampus; Immunosuppressive Agents; Inositol Phosphates; Organ Culture Techniques; Oxadiazoles; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Thiophenes | 2007 |
The perivascular space as a path of hematopoietic progenitor cells and mature T cells between the blood circulation and the thymic parenchyma.
Topics: Animals; Basement Membrane; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Movement; Collagen; DNA-Binding Proteins; Endothelial Cells; Fibronectins; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Immunosuppressive Agents; Interleukin-7 Receptor alpha Subunit; Laminin; Mice; Mice, Inbred C57BL; Mice, Knockout; Pericytes; Propylene Glycols; Proto-Oncogene Proteins c-kit; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes; Thymus Gland | 2007 |
The immunomodulator FTY720 is phosphorylated and released from platelets.
Topics: Animals; Blood Platelets; Cell Line; Erythrocytes; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Male; Phosphorylation; Plasma; Prodrugs; Propylene Glycols; Rats; Rats, Wistar; Sphingosine | 2007 |
FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3.
Topics: Cells, Cultured; Fingolimod Hydrochloride; Humans; Phosphates; Phosphatidate Phosphatase; Propylene Glycols; Sphingosine; Transfection | 2007 |
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).
Topics: Animals; Cells, Cultured; Chemotaxis, Leukocyte; Combined Modality Therapy; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Immunotherapy, Adoptive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Sphingosine; Spleen; Survival Analysis; T-Lymphocytes, Regulatory; Transplantation Conditioning | 2007 |
Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720.
Topics: Animals; Apoptosis; Blood Glucose; C-Peptide; Cells, Cultured; Fingolimod Hydrochloride; Follow-Up Studies; Glucose Tolerance Test; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; In Situ Nick-End Labeling; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Tissue and Organ Procurement | 2007 |
Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Migration Inhibition; Cells, Cultured; Chemotaxis, Leukocyte; Diarrhea; Epitopes, T-Lymphocyte; Female; Fingolimod Hydrochloride; Food Hypersensitivity; Immunosuppressive Agents; Intestine, Large; Lysophospholipids; Mast Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Propylene Glycols; Sphingosine; Spleen; Th2 Cells | 2007 |
Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine.
Topics: Animals; Apoptosis; Cell Proliferation; Creatinine; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Follow-Up Studies; Immunohistochemistry; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Proliferating Cell Nuclear Antigen; Propylene Glycols; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sphingosine; Treatment Outcome | 2007 |
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Topics: Administration, Oral; Animals; Autoradiography; Brain; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Count; Multiple Sclerosis; Phosphorylation; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 2007 |
FTY720 improves survival after transient ischemia and reperfusion of the hind limbs.
Topics: Analysis of Variance; Animals; Biomarkers; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Hindlimb; Immunosuppressive Agents; Interleukin-1; Ischemia; Male; Mice; Mice, Inbred C57BL; Peroxidase; Probability; Propylene Glycols; Random Allocation; Reference Values; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sphingosine; Survival Rate | 2007 |
Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Bone Density; CD4 Antigens; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8 Antigens; CD8-Positive T-Lymphocytes; Chickens; Collagen Type II; Female; Fingolimod Hydrochloride; Flow Cytometry; Forelimb; Immunohistochemistry; Immunosuppressive Agents; Inflammation; Prednisone; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss | 2007 |
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Topics: Animals; Benzamides; Blast Crisis; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Propylene Glycols; Protein Phosphatase 2; Pyrimidines; Signal Transduction; Sphingosine; Thiazoles; Time Factors; Tumor Cells, Cultured | 2007 |
The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors.
Topics: Animals; Apoptosis; Cell Differentiation; Cells, Cultured; Cytoprotection; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Immunosuppressive Agents; Microglia; Neurotrophin 3; Oligodendroglia; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Sphingosine; Stem Cells | 2007 |
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Topics: Animals; Apoptosis; B-Lymphocytes; Caspases; Cell Line; Cysteine Endopeptidases; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lysophospholipids; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propylene Glycols; Protein Phosphatase 2; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sphingosine; Xenograft Model Antitumor Assays | 2008 |
Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Fingolimod Hydrochloride; Hypercholesterolemia; Immunosuppressive Agents; Lipid Metabolism; Lymphocyte Subsets; Lymphocytes; Lymphopenia; Lysophospholipids; Male; Mice; Mice, Knockout; Propylene Glycols; Sphingosine; Spleen | 2007 |
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.
Topics: Analysis of Variance; Animals; Body Weight; Disease Models, Animal; Electric Stimulation; Encephalomyelitis, Autoimmune, Experimental; Evoked Potentials, Somatosensory; Evoked Potentials, Visual; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Longitudinal Studies; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Neural Conduction; Propylene Glycols; Rats; Reaction Time; Sphingosine; Spinal Cord; Time Factors | 2007 |
The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers.
Topics: Animals; Disease Models, Animal; Female; Fingolimod Hydrochloride; Flow Cytometry; Graft Rejection; Graft Survival; Immunosuppressive Agents; Major Histocompatibility Complex; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Skin Transplantation; Sphingosine; Thymus Gland; Transplantation, Homologous; Treatment Outcome | 2007 |
Sphingosine 1-phosphate dependence in the regulation of lymphocyte trafficking to the gut epithelium.
Topics: Animals; CD4 Antigens; CD8 Antigens; Cell Adhesion Molecules; Cell Differentiation; Cell Movement; Epithelium; Female; Fingolimod Hydrochloride; Intestines; Lymphocyte Activation; Lymphocytes; Lysophospholipids; Mice; Mice, Inbred BALB C; Propylene Glycols; Sensitivity and Specificity; Sphingosine; Thymus Gland | 2007 |
Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart.
Topics: Animals; Antibodies; Blotting, Western; Chromatography, Gel; Enzyme Activation; Fingolimod Hydrochloride; Isoenzymes; Mice; Myocardium; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Sphingosine | 2007 |
Synthesis and spectral properties of cholesterol- and FTY720-containing boron dipyrromethene dyes.
Topics: Boron Compounds; Cholesterol; Fingolimod Hydrochloride; Fluorescent Dyes; Molecular Structure; Porphobilinogen; Propylene Glycols; Spectrophotometry, Ultraviolet; Sphingosine; Stereoisomerism | 2007 |
FTY720 modulates human oligodendrocyte progenitor process extension and survival.
Topics: Cell Differentiation; Cell Line; Cell Movement; Cell Surface Extensions; Cell Survival; Cytoskeleton; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Oligodendroglia; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; rho-Associated Kinases; RNA, Messenger; Signal Transduction; Sphingosine; Stem Cells; Suramin | 2008 |
Sphingosine-1 phosphate signaling regulates positioning of dendritic cells within the spleen.
Topics: Animals; Cell Line; Dendritic Cells; Fingolimod Hydrochloride; Integrins; Ligands; Lysophospholipids; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, CCR7; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Spleen | 2007 |
Effect of FTY720 on apoptosis of smooth muscle cells.
Topics: Animals; Apoptosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Models, Animal; Muscle, Smooth, Vascular; Propylene Glycols; Rabbits; Sphingosine | 2007 |
Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Injuries; Dexamethasone; Fingolimod Hydrochloride; Functional Laterality; Immunohistochemistry; Interleukin-16; Macrophages; Propylene Glycols; Rats; Sphingosine; Up-Regulation | 2008 |
Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.
Topics: Animals; Calcium; Cell Line; Cricetinae; Cricetulus; Fingolimod Hydrochloride; Humans; Immunologic Factors; Mice; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Propylene Glycols; Radioligand Assay; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism; Structure-Activity Relationship | 2007 |
Evaluation of stem cell administration in a model of kidney ischemia-reperfusion injury.
Topics: Animals; Creatinine; Disease Models, Animal; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Kidney; Male; Mice; Mice, Inbred C57BL; Necrosis; Propylene Glycols; Reperfusion Injury; Sphingosine | 2007 |
Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools.
Topics: Animals; Cerebral Arteries; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; In Vitro Techniques; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Oxadiazoles; Propylene Glycols; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Vasoconstriction | 2008 |
Follicular shuttling of marginal zone B cells facilitates antigen transport.
Topics: Animals; Antigens; B-Lymphocytes; Biological Transport; Dendritic Cells, Follicular; Fingolimod Hydrochloride; Mice; Mice, Knockout; Propylene Glycols; Receptors, CXCR5; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Spleen | 2008 |
The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics.
Topics: Animals; Cell Movement; Endothelium, Lymphatic; Fingolimod Hydrochloride; Homeostasis; Inflammation; Integrin alpha4beta1; Intercellular Adhesion Molecule-1; Lymph Nodes; Lymphatic Vessels; Lymphocyte Function-Associated Antigen-1; Lysophospholipids; Mice; Mice, Inbred C57BL; Models, Immunological; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes; Vascular Cell Adhesion Molecule-1 | 2008 |
Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1.
Topics: Animals; Cell Adhesion Molecules; Disease Models, Animal; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Intestinal Mucosa; Intestine, Small; Mucoproteins; Organ Transplantation; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred Lew; Sphingosine; Transplantation, Homologous | 2008 |
FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury.
Topics: Animals; Creatinine; Cyclosporine; Disease Models, Animal; Extracellular Matrix; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney Transplantation; Male; Propylene Glycols; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sphingosine; Transplantation, Homologous | 2007 |
Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes.
Topics: Animals; Apoptosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Intestine, Small; Lymphocytes; Propylene Glycols; Rats; Rats, Inbred BN; Rats, Inbred Lew; Sphingosine; Survival Analysis; Transplantation, Homologous | 2007 |
Antibody-mediated rejection with a striking interstitial monocyte/macrophage infiltration in a renal allograft under FTY720 treatment.
Topics: Antibodies; Cell Movement; Extracellular Fluid; Fingolimod Hydrochloride; Graft Rejection; HLA-B27 Antigen; HLA-DR Antigens; HLA-DR Serological Subtypes; HLA-DR4 Antigen; Humans; Immunosuppressive Agents; Kidney Transplantation; Macrophages; Male; Middle Aged; Monocytes; Propylene Glycols; Sphingosine; Transplantation, Homologous | 2008 |
Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Fingolimod Hydrochloride; Immunologic Factors; Liver; Liver Cirrhosis; Lysophospholipids; Male; Platelet-Derived Growth Factor; Propylene Glycols; Protein Transport; Rats; Rats, Wistar; Receptor Cross-Talk; Signal Transduction; Sphingosine | 2008 |
Sphingosine 1-phosphate restrains insulin-mediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype.
Topics: Cell Proliferation; Cells, Cultured; Fingolimod Hydrochloride; Humans; Insulin; Insulin-Like Growth Factor I; Keratinocytes; Lysophospholipids; Phosphorylation; Propylene Glycols; Protein Kinase C-delta; Proto-Oncogene Proteins c-akt; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2008 |
FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves.
Topics: Animals; Body Weight; CD3 Complex; Disease Models, Animal; Ectodysplasins; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Lymphocytes; Macrophages; Male; Neuritis, Autoimmune, Experimental; Propylene Glycols; Rats; Rats, Inbred Lew; Sciatic Nerve; Sphingosine; Sulfonamides | 2008 |
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; Humans; Liver Neoplasms; Propylene Glycols; Protein Kinase C-delta; Reactive Oxygen Species; Signal Transduction; Sphingosine | 2008 |
[Effect of FTY720 on glomerulosclerosis and expression of cell cycle regulatory proteins in subtotally nephrectomized rats].
Topics: Animals; Cell Cycle Proteins; Disease Models, Animal; Fingolimod Hydrochloride; Glomerulosclerosis, Focal Segmental; Immunosuppressive Agents; Kidney; Male; Nephrectomy; Postoperative Period; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine | 2007 |
Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Female; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Homeostasis; Immunologic Memory; Immunosuppressive Agents; Interferon-gamma; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Sphingosine; Spleen | 2008 |
Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis.
Topics: Amylases; Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Cytokines; Fingolimod Hydrochloride; Lipase; Lung; Lung Injury; Lysophospholipids; Macrophages, Alveolar; Male; NF-kappa B; Pancreatitis, Acute Necrotizing; Peroxidase; Propylene Glycols; Pulmonary Edema; Rats; Rats, Wistar; Sphingosine | 2008 |
Non-specific anti-proliferative effect of FTY720, a derivative of fungal metabolite from Iscaria sinclarii.
Topics: Aniline Compounds; Animals; Antibiotics, Antineoplastic; Cell Proliferation; Crotonates; Cyclosporine; Fingolimod Hydrochloride; Fungi; Hydroxybutyrates; Immunity, Cellular; Immunosuppressive Agents; Interleukin-2; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nitric Oxide; Nitriles; Propylene Glycols; Sphingosine; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Toluidines; Tumor Necrosis Factor-alpha | 2008 |
Synthesis of the key intermediate, diethyl 2-acetylamino-2-(2-(4-octanoylphenyl)ethyl)propane-1,3-dioate, of the immunomodulatory agent FTY720 (fingolimod).
Topics: Fingolimod Hydrochloride; Immunologic Factors; Indicators and Reagents; Magnetic Resonance Spectroscopy; Propylene Glycols; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Sphingosine | 2008 |
Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues.
Topics: Catalysis; Fingolimod Hydrochloride; Immunosuppressive Agents; Models, Chemical; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Sphingosine | 2008 |
The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen.
Topics: Animals; Antigen Presentation; Apoptosis; Apoptosis Regulatory Proteins; Autoantigens; CD8-Positive T-Lymphocytes; Clonal Deletion; fas Receptor; Fingolimod Hydrochloride; Glucose; Immunosuppressive Agents; Insulin-Secreting Cells; Mice; Mice, Inbred BALB C; Mice, Transgenic; Propylene Glycols; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Self Tolerance; Sphingosine | 2008 |
Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses.
Topics: Animals; B-Lymphocytes; Female; Fingolimod Hydrochloride; Immunoglobulin A; Immunosuppressive Agents; Intestinal Mucosa; Intestines; Lysophospholipids; Mice; Mice, Inbred BALB C; Ovalbumin; Peyer's Patches; Plasma Cells; Propylene Glycols; Sphingosine | 2008 |
FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression.
Topics: Actins; Cell Adhesion Molecules; Cell Membrane; Cell Movement; Cells, Cultured; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Neovascularization, Physiologic; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Wound Healing | 2008 |
Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice.
Topics: Animals; Fingolimod Hydrochloride; Flow Cytometry; Graft Survival; Immunosuppressive Agents; Kidney; Kidney Function Tests; Mice; Propylene Glycols; Skin Transplantation; Sphingosine; Tacrolimus; Transplantation, Homologous | 2008 |
FTY720 treatment in experimentally urethane-induced lung tumors.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Anticarcinogenic Agents; Carcinogens; Disease Models, Animal; Fingolimod Hydrochloride; Leukocytes, Mononuclear; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Propylene Glycols; Sphingosine; Spleen; Urethane | 2008 |
Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators.
Topics: Animals; CD4-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Forkhead Transcription Factors; Herpesvirus 1, Human; Immunosuppressive Agents; Keratitis, Herpetic; Lymphocyte Count; Mice; Mice, Mutant Strains; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2008 |
FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fingolimod Hydrochloride; Glucose Tolerance Test; Immunosuppressive Agents; Insulin; Insulin Resistance; Lymphopenia; Male; Mice; Mice, Inbred C57BL; Panniculitis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Weight Gain | 2008 |
Antinociceptive activity of the S1P-receptor agonist FTY720.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Gabapentin; gamma-Aminobutyric Acid; Injections, Intraperitoneal; Injections, Spinal; Pain; Pain Measurement; Propylene Glycols; Prostaglandins; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine | 2008 |
Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
Topics: Amino Acid Sequence; Animals; Cell Movement; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Ligands; Lysophospholipids; Mice; Molecular Sequence Data; NIH 3T3 Cells; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; RGS Proteins; Sphingosine | 2008 |
Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indicators and Reagents; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Spectrophotometry, Infrared; Sphingosine | 2008 |
FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
Topics: Animals; Antigens; Blood-Brain Barrier; Blotting, Western; Brain; Capillary Permeability; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunization; Immunosuppressive Agents; Myelin Proteins; Phospholipases A2, Cytosolic; Polymerase Chain Reaction; Propylene Glycols; Random Allocation; Rats; Sphingosine; Spinal Cord | 2009 |
Cell cycle arrest effects of large-dose FTY720 on lymphocytes in mouse skin transplantation models.
Topics: Animals; Cell Cycle; Cyclin D; Cyclin-Dependent Kinase Inhibitor p16; Cyclins; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Gene Expression Regulation; Graft Survival; Immunosuppressive Agents; Lymphocytes; Mice; Mice, Inbred BALB C; Models, Biological; Propylene Glycols; Skin Transplantation; Sphingosine; Transplantation, Homologous | 2008 |
Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients.
Topics: Cyclosporine; Fingolimod Hydrochloride; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Kidney Transplantation; Lymphocyte Activation; Lymphopenia; Methylprednisolone; NFATC Transcription Factors; Propylene Glycols; RNA, Messenger; Sphingosine; T-Lymphocytes | 2008 |
Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro.
Topics: Cell Division; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Pancreatic Neoplasms; Propylene Glycols; Sirolimus; Sphingosine | 2008 |
Impaired initiation of contact hypersensitivity by FTY720.
Topics: Animals; Chemotaxis; Dermatitis, Contact; Female; Fingolimod Hydrochloride; Hyaluronan Receptors; Immunologic Memory; L-Selectin; Lymph Nodes; Lymphocytes; Major Histocompatibility Complex; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2008 |
TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity.
Topics: Alkynes; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membrane; Fingolimod Hydrochloride; Magnetic Resonance Spectroscopy; Mass Spectrometry; Propylene Glycols; Quantum Theory; Spectrophotometry, Infrared; Sphingosine | 2008 |
Infections cast cloud over Novartis' MS therapy.
Topics: Drug Industry; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Propylene Glycols; Sphingosine; Virus Diseases | 2008 |
Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Topics: Animals; B7-2 Antigen; Cell Movement; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Histocompatibility Antigens Class II; Immunosuppressive Agents; Langerhans Cells; Lymph Nodes; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Organophosphates; Propylene Glycols; Receptors, CCR7; Receptors, Lysosphingolipid; Skin Transplantation; Sphingosine; Transplantation, Homologous | 2008 |
Immunology: Surprising side effects.
Topics: Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymph Nodes; Lymphocytes; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Mice; Propylene Glycols; Sphingosine | 2008 |
Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection.
Topics: Animals; Chronic Disease; Fingolimod Hydrochloride; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Lymphopenia; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; T-Lymphocytes; Time Factors | 2008 |
A splicing isoform of LPP1, LPP1a, exhibits high phosphatase activity toward FTY720 phosphate.
Topics: Alternative Splicing; Animals; CHO Cells; Cricetinae; Cricetulus; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Phosphatidate Phosphatase; Propylene Glycols; Protein Isoforms; Sphingosine | 2008 |
Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.
Topics: Adult; Apoptosis; Cell Differentiation; Cell Survival; Cytoskeleton; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Gene Expression Regulation; Glucose; Humans; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Messenger; Serum; Sphingosine; Time Factors | 2008 |
The suppressive effect that myriocin has on hepatitis C virus RNA replication is independent of inhibition of serine palmitoyl transferase.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Hepacivirus; Propylene Glycols; RNA, Viral; Serine C-Palmitoyltransferase; Sphingosine; Virus Replication | 2008 |
Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease.
Topics: Administration, Oral; Animals; Autoimmune Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Treatment; Female; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Propylene Glycols; Random Allocation; Reference Values; Retinitis; Sensitivity and Specificity; Sphingosine; Treatment Outcome; Uveitis | 2008 |
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Topics: Animals; Antigens, CD; Cell Proliferation; Cytokines; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Lymphocyte Subsets; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocytes | 2008 |
Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury.
Topics: Animals; Fingolimod Hydrochloride; Gene Expression Regulation, Enzymologic; Kidney; Kidney Diseases; Lysophospholipids; Mice; Mice, Knockout; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Reperfusion Injury; RNA, Messenger; Sphingosine | 2009 |
Immunosuppressive therapy and post-transplant malignancy.
Topics: Azathioprine; Calcineurin Inhibitors; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mycophenolic Acid; Neoplasms; Organ Transplantation; Propylene Glycols; Protein Kinases; Sphingosine; TOR Serine-Threonine Kinases | 2009 |
FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow.
Topics: Animals; Apoptosis; Bone Marrow; CD4-Positive T-Lymphocytes; Cell Movement; Colitis; Cytokines; Fingolimod Hydrochloride; Lymph Node Excision; Lymphoid Tissue; Lymphotoxin-alpha; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Splenectomy | 2008 |
Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Topics: Animals; Calcium; Chemotaxis; Chromatography, Liquid; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Lymphoid Tissue; Mass Spectrometry; Organophosphates; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Spleen | 2009 |
An investigation of the impact of the location and timing of antigen-specific T cell division on airways inflammation.
Topics: Adoptive Transfer; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Division; Cell Movement; Cytokines; Eosinophilia; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Lung; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Transgenic; Microscopy, Confocal; Models, Animal; Ovalbumin; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; Th2 Cells; Time Factors | 2009 |
Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Topics: Animals; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sirolimus; Sphingosine; Transplantation, Homologous | 2008 |
Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Forkhead Transcription Factors; Immunity, Cellular; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Activation; Lymphocyte Count; Lymphoid Tissue; Male; Neuritis, Autoimmune, Experimental; Polyradiculoneuropathy; Propylene Glycols; Rats; Rats, Inbred Lew; Sciatic Nerve; Sphingosine; Spleen; T-Lymphocytes, Regulatory | 2009 |
FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
Topics: Cells, Cultured; Ceramides; Chromatography, Liquid; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lung; Lysophospholipids; Oxidoreductases; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Pulmonary Artery; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Serine C-Palmitoyltransferase; Sphingosine; Tandem Mass Spectrometry; Up-Regulation | 2009 |
FTY720 and lung tumor development.
Topics: Adenoma; Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Proliferating Cell Nuclear Antigen; Propylene Glycols; Sphingosine; Urethane; Vascular Endothelial Growth Factor A | 2009 |
Trial watch: Phase III promise for oral multiple sclerosis therapy.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2009 |
Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration.
Topics: Administration, Topical; Animals; Cell Movement; Dendritic Cells; Dermatitis, Allergic Contact; Female; Fingolimod Hydrochloride; Histocompatibility Antigens Class II; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Inbred BALB C; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Skin; Sphingosine; Thiophenes; Toluene 2,4-Diisocyanate | 2009 |
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis.
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Cell Line; Cell Lineage; Chemotaxis; Female; Fingolimod Hydrochloride; Homeostasis; Lysophospholipids; Mice; Mice, Inbred C57BL; Monocytes; Osteoclasts; Osteoporosis; Ovariectomy; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2009 |
FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis.
Topics: Animals; Chemotaxis, Leukocyte; Fingolimod Hydrochloride; Flow Cytometry; Immunohistochemistry; Immunosuppressive Agents; Interleukin-17; Lymph Nodes; Lysophospholipids; Male; Neuritis, Autoimmune, Experimental; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; Sciatic Nerve; Signal Transduction; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2009 |
Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.
Topics: Adenoma; Animals; Apoptosis; Caspase 3; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Lung; Lung Neoplasms; Lysophospholipids; Male; Mice; Mice, Inbred BALB C; Proliferating Cell Nuclear Antigen; Propylene Glycols; Sphingosine; Urethane | 2009 |
Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques.
Topics: Animals; DNA, Viral; Fingolimod Hydrochloride; Immunologic Factors; Injections, Intraventricular; Lymphocyte Count; Lymphocytes; Macaca mulatta; Male; Propylene Glycols; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Sphingosine; Viral Load | 2009 |
B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis.
Topics: Animals; B-Lymphocytes; Cell Movement; Chemotaxis; Endothelium; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Lymph Nodes; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2009 |
Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice.
Topics: Allergens; Ambrosia; Animals; Conjunctivitis, Allergic; Disease Models, Animal; Eosinophils; Fingolimod Hydrochloride; Immunosuppressive Agents; Macrophages; Mice; Mice, Inbred BALB C; Propylene Glycols; Sphingosine; T-Lymphocytes | 2009 |
[An additional role of FTY720 in chronic colitis].
Topics: Animals; CD4-Positive T-Lymphocytes; Chronic Disease; Colitis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, SCID; Propylene Glycols; Sphingosine; T-Lymphocytes | 2009 |
Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists.
Topics: Amides; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Imidazoles; Mice; Propylene Glycols; Protein Subunits; Receptors, Lysosphingolipid; Sphingosine | 2009 |
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
Topics: Adult; Brain; Cerebral Hemorrhage; Contrast Media; Encephalitis; Epilepsy, Complex Partial; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Necrosis; Propylene Glycols; Sphingosine | 2009 |
Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720.
Topics: Animals; Cells, Cultured; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intestinal Mucosa; Molecular Structure; Organophosphonates; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism; Vinyl Compounds | 2009 |
FTY720 Inhibits Tumor Necrosis Factor-alpha-Induced Proliferation and Extracellular Signal-Regulated Kinase Phosphorylation of Human Smooth Muscle Cells.
Topics: Cell Division; Cell Survival; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Muscle, Smooth; Phosphorylation; Propylene Glycols; Signal Transduction; Sphingosine; Transplantation, Homologous; Tumor Necrosis Factor-alpha | 2009 |
Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner.
Topics: Acyl Coenzyme A; Binding, Competitive; Carcinoma, Hepatocellular; Cell Line, Tumor; Ceramides; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney; Liver Neoplasms; Mast Cells; Oxidoreductases; Propylene Glycols; Sphingosine; Tritium | 2009 |
Pig embryonic pancreatic tissue as a source for transplantation in diabetes: transient treatment with anti-LFA1, anti-CD48, and FTY720 enables long-term graft maintenance in mice with only mild ongoing immunosuppression.
Topics: Animals; Antigens, CD; CD48 Antigen; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppression Therapy; Lymphocyte Function-Associated Antigen-1; Mice; Mice, Inbred C57BL; Pancreas; Pancreas Transplantation; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Swine; Transplantation, Heterologous | 2009 |
Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cell Death; Cells, Cultured; ErbB Receptors; Fingolimod Hydrochloride; Humans; Lysophospholipids; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxadiazoles; Perfusion; Propylene Glycols; Proto-Oncogene Proteins c-akt; Rats; Receptors, Lysosphingolipid; Recovery of Function; Signal Transduction; Sphingosine; Thiophenes; Time Factors; Ventricular Function, Left; Ventricular Pressure | 2009 |
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.
Topics: Animals; Calcium; Cell Movement; CHO Cells; Cricetinae; Cricetulus; Endocytosis; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2009 |
The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.
Topics: Animals; Blood Pressure; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Matrix; Fibrosis; Fingolimod Hydrochloride; Hypertension; Immunosuppressive Agents; Kidney; Kidney Diseases; Lymphocytes; Macrophages; Male; Nephrectomy; Propylene Glycols; Proteinuria; Rats; Rats, Wistar; Sphingosine; Transforming Growth Factor beta | 2009 |
Expression of sphingosine kinase 2 in synovial fibroblasts of rheumatoid arthritis contributing to apoptosis by a sphingosine analogue, FTY720.
Topics: Apoptosis; Arthritis, Rheumatoid; Blotting, Western; Cells, Cultured; Fibroblasts; Fingolimod Hydrochloride; Fluorescent Antibody Technique; Humans; Immunosuppressive Agents; In Situ Nick-End Labeling; Microscopy, Confocal; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; Synovial Membrane | 2009 |
Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Case-Control Studies; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Propylene Glycols; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Sphingosine; Tumor Cells, Cultured | 2009 |
Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.
Topics: Administration, Oral; Albuminuria; Animals; Blood Pressure; Body Weight; Chemokine CCL2; Chemokine CCL5; Chemokines; Creatinine; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Fibronectins; Fibrosis; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Inflammation Mediators; Kidney; Kidney Failure, Chronic; Lymphocytes; Macrophages; Male; Nephrectomy; Nephritis; Phenotype; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, CCR1; Receptors, CCR2; Receptors, CCR5; Sphingosine; Time Factors; Transforming Growth Factor beta1 | 2009 |
Fragile maintenance of allograft tolerance induced by lymphocyte sequestration and co-stimulation blockade.
Topics: Animals; Antibodies, Blocking; Antibodies, Monoclonal; CD40 Ligand; Cell Proliferation; Drug Therapy, Combination; Fingolimod Hydrochloride; Forkhead Transcription Factors; Graft Rejection; Graft Survival; Interleukin-4; Isoantigens; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Skin Transplantation; Sphingosine; T-Lymphocytes, Regulatory; Transplantation Tolerance | 2009 |
Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro.
Topics: Animals; Capillary Permeability; Cell Line; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Lung; Mice; Mice, Inbred C57BL; Organophosphonates; Propylene Glycols; Pulmonary Artery; Sphingosine | 2009 |
Langerhans cell migration: not necessarily always at the center of the skin sensitization universe.
Topics: Animals; Cell Movement; Dermatitis, Allergic Contact; Fingolimod Hydrochloride; Humans; Langerhans Cells; Lysophospholipids; Propylene Glycols; Sphingosine | 2009 |
FTY720 reduces inflammation and promotes functional recovery after spinal cord injury.
Topics: Animals; Autoimmunity; Chemotaxis, Leukocyte; Demyelinating Autoimmune Diseases, CNS; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Lymphocyte Activation; Myelitis; Nerve Fibers, Myelinated; Nerve Regeneration; Paralysis; Propylene Glycols; Rats; Rats, Long-Evans; Recovery of Function; Sphingosine; Spinal Cord Injuries; T-Lymphocytes; Treatment Outcome; Urinary Bladder, Neurogenic; Wallerian Degeneration | 2009 |
Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Mice; Prodrugs; Propanols; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2009 |
Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2.
Topics: Animals; Arterioles; Brain Edema; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Fingolimod Hydrochloride; Hypoxia-Ischemia, Brain; Immunosuppressive Agents; Infarction, Middle Cerebral Artery; Ischemic Preconditioning; Lysophospholipids; Male; Mice; Microcirculation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Reperfusion Injury; RNA, Messenger; Sphingosine | 2009 |
Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy.
Topics: Animals; Autoimmunity; Blood-Nerve Barrier; Blotting, Western; Cell Culture Techniques; Cell Proliferation; Cell Survival; Cytokines; Electrophysiology; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred NOD; Mice, Transgenic; Oxadiazoles; Polymerase Chain Reaction; Polyneuropathies; Propylene Glycols; Schwann Cells; Severity of Illness Index; Sphingosine; Spleen; Thiophenes | 2009 |
Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins.
Topics: Actins; Adherens Junctions; Cadherins; Cell Adhesion Molecules; Cells, Cultured; Electric Impedance; Endothelial Cells; Endothelium, Vascular; Fingolimod Hydrochloride; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hyperglycemia; Immunosuppressive Agents; Lysophospholipids; Microvessels; Monomeric GTP-Binding Proteins; Phosphorylation; Propylene Glycols; rac GTP-Binding Proteins; Receptors, Lysosphingolipid; rho GTP-Binding Proteins; Sphingosine | 2009 |
FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
Topics: Animals; Autoantibodies; Axons; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Propylene Glycols; Rats; Rats, Inbred Strains; Recombinant Proteins; Severity of Illness Index; Sphingosine; Spinal Cord; Time Factors | 2010 |
Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro.
Topics: Animals; Biomarkers; Cells, Cultured; Drug Administration Schedule; Fingolimod Hydrochloride; Flow Cytometry; Forkhead Transcription Factors; Immunologic Factors; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Culture Test, Mixed; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Propylene Glycols; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine; T-Lymphocytes, Regulatory | 2009 |
The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.
Topics: Adoptive Transfer; Animals; Cell Proliferation; Fingolimod Hydrochloride; Immunosuppression Therapy; Immunosuppressive Agents; Interleukin-2; Mice; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes, Regulatory | 2009 |
The future of multiple sclerosis therapy.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Injections, Intravenous; Injections, Subcutaneous; Interferon-beta; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Apoptosis Inducing Factor; Blood-Brain Barrier; Brain; Brain Ischemia; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Neutrophils; Propylene Glycols; Sphingosine | 2009 |
Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Movement; Cell Proliferation; Epitopes, T-Lymphocyte; Female; Fingolimod Hydrochloride; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Propylene Glycols; Sphingosine | 2009 |
[Role of sphingosine 1-phosphate receptor signaling in hematopoietic stem/progenitor cell transmigration].
Topics: Antigens, CD34; Cell Movement; Cells, Cultured; Chemokine CXCL12; Fetal Blood; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2009 |
A functional role for CCR6 on proallergic T cells in the gastrointestinal tract.
Topics: Adoptive Transfer; Animals; Antibodies; CD3 Complex; Cells, Cultured; Chemokine CCL20; Cholera Toxin; Diarrhea; Female; Fingolimod Hydrochloride; Food Hypersensitivity; Immunoglobulin E; Immunosuppressive Agents; Jejunum; Lymph Nodes; Mast Cells; Mice; Mice, Inbred BALB C; Mice, Mutant Strains; Ovalbumin; Propylene Glycols; Receptors, CCR6; Sphingosine; Th2 Cells | 2010 |
Activation of the lung S1P(1) receptor reduces allergen-induced plasma leakage in mice.
Topics: Administration, Intranasal; Allergens; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; beta-Alanine; Budesonide; Capillary Permeability; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Immunologic Factors; Lung; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Knockout; Pneumonia; Propylene Glycols; Pulmonary Edema; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiophenes | 2009 |
T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow.
Topics: Animals; Bone Marrow Cells; Cell Count; Cell Movement; Ethylnitrosourea; Fingolimod Hydrochloride; Killer Cells, Natural; Lymph Nodes; Lymphocyte Activation; Lysophospholipids; Mice; Mice, Mutant Strains; Mutation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Box Domain Proteins | 2009 |
FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration.
Topics: Animals; Antibodies; Antigens, CD1d; Arthritis, Experimental; Cell Movement; Cytokines; Fingolimod Hydrochloride; GATA3 Transcription Factor; Immunosuppressive Agents; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, Transgenic; Natural Killer T-Cells; Propylene Glycols; Receptors, Antigen, T-Cell; Receptors, GABA-A; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2010 |
FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release.
Topics: Chemokines; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunoblotting; Immunosuppressive Agents; K562 Cells; Killer Cells, Natural; Lysophospholipids; Oxadiazoles; Propylene Glycols; Sphingosine; Thiophenes; Up-Regulation | 2010 |
FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling.
Topics: Animals; Animals, Newborn; Arrhythmias, Cardiac; Disease Models, Animal; Enzyme Activation; Fingolimod Hydrochloride; Gene Expression Regulation; In Vitro Techniques; Intracellular Space; Male; p21-Activated Kinases; Pertussis Toxin; Phosphorylation; Propylene Glycols; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Reperfusion Injury; RNA, Messenger; Signal Transduction; Sinoatrial Node; Sphingosine; Time Factors; Ultrasonography | 2010 |
Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog.
Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Movement; Culture Media; Down-Regulation; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Propylene Glycols; Rats; Rats, Inbred BUF; Receptors, Lysosphingolipid; Recurrence; Sphingosine | 2009 |
T-cell activation in ischemic stroke: a new therapeutic target for delayed infarct expansion?
Topics: Animals; Brain Infarction; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Infarction, Middle Cerebral Artery; Interleukin-17; Interleukin-23; Mice; Mice, Knockout; Propylene Glycols; Sphingosine; T-Lymphocytes | 2009 |
Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Fingolimod Hydrochloride; Immunosuppressive Agents; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; MAP Kinase Signaling System; Nerve Degeneration; Neuroprotective Agents; Oxadiazoles; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Stroke; Thiophenes; Treatment Outcome | 2010 |
[FTY720 reduces peritubular micrangium loss in renal interstitial fibrotic rats].
Topics: Animals; Apoptosis; Capillaries; Fibrosis; Fingolimod Hydrochloride; Kidney Diseases; Kidney Tubules; Male; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine; Vascular Diseases | 2009 |
Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.
Topics: Animals; Antiviral Agents; beta-Alanine; Fingolimod Hydrochloride; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Lymphopenia; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Thiophenes; Treatment Outcome | 2010 |
Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema.
Topics: Animals; Apoptosis; Blotting, Western; Cells, Cultured; Ceramides; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Indoles; Lysophospholipids; Mice; Mice, Inbred C57BL; Phosphotransferases (Alcohol Group Acceptor); Polymerase Chain Reaction; Propylene Glycols; Pulmonary Alveoli; Pulmonary Emphysema; Pyrroles; Receptors, Lysosphingolipid; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sphingosine | 2010 |
Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats.
Topics: Animals; Axons; Evoked Potentials, Somatosensory; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Myelin Sheath; Propylene Glycols; Rats; Rats, Sprague-Dawley; Recovery of Function; Sphingosine; Spinal Cord Injuries; Tacrolimus | 2009 |
United airways: circulating Th2 effector cells in an allergic rhinitis model are responsible for promoting lower airways inflammation.
Topics: Animals; Asthma; Disease Models, Animal; Female; Fingolimod Hydrochloride; Inflammation; Mice; Mice, Inbred BALB C; Ovalbumin; Propylene Glycols; Rhinitis, Allergic, Perennial; Sphingosine; Th2 Cells | 2010 |
Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.
Topics: Animals; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Fingolimod Hydrochloride; Heart Transplantation; Immunosuppressive Agents; Male; Propylene Glycols; Protein Kinase C; Pyrroles; Quinazolines; Rats; Rats, Inbred Lew; Rats, Wistar; Sirolimus; Sphingosine | 2010 |
[Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Causality; Cladribine; Disabled Persons; Fingolimod Hydrochloride; Forecasting; France; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Research; Sphingosine; Vaccination; Vaccines, DNA | 2009 |
Evaluation of experimental autoimmune uveitis in mice treated with FTY720.
Topics: Animals; Autoimmune Diseases; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Movement; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Eye Proteins; Fingolimod Hydrochloride; Flow Cytometry; Immunoglobulin G; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Intubation, Gastrointestinal; Lymph Nodes; Mice; Peptide Fragments; Propylene Glycols; Retinol-Binding Proteins; Sphingosine; T-Lymphocytes, Regulatory; Uveitis, Posterior | 2010 |
FTY720 promotes local microvascular network formation and regeneration of cranial bone defects.
Topics: Animals; Bone Diseases; Bone Regeneration; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Microvessels; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Skull; Sphingosine; Tissue Scaffolds; X-Ray Microtomography | 2010 |
FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages.
Topics: Apolipoprotein A-I; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Carrier Proteins; Cell Culture Techniques; Cell Death; Cell Survival; Cells, Cultured; Cholesterol; Cholesterol Esters; Endoplasmic Reticulum; Endosomes; Fingolimod Hydrochloride; Humans; Hydroxycholesterols; Intracellular Signaling Peptides and Proteins; Lipoproteins, LDL; Liver X Receptors; Macrophages; Membrane Glycoproteins; Niemann-Pick C1 Protein; Orphan Nuclear Receptors; Propylene Glycols; Receptors, Scavenger; Signal Transduction; Sphingosine; Time Factors | 2010 |
Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.
Topics: Animals; beta-Alanine; Bleomycin; Blood Coagulation; Endothelial Cells; Fibrosis; Fingolimod Hydrochloride; Humans; Lung Injury; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Oxadiazoles; Pneumonia; Propylene Glycols; Pulmonary Alveoli; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Survival Analysis; Thiophenes; Vascular Diseases | 2010 |
Oral therapy for multiple sclerosis--sea change or incremental step?
Topics: Administration, Oral; Arrhythmias, Cardiac; Cladribine; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2010 |
Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
Topics: Animals; Calcium; Cerebral Arteries; CHO Cells; Coronary Circulation; Cricetinae; Cricetulus; Dogs; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Heart Rate; Hydrazones; Lysophospholipids; Male; Phosphorylation; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; rho-Associated Kinases; Sphingosine; Vasoconstriction | 2010 |
[FTY720-induced lymphocyte apoptosis inhibits acute graft versus host disease in rat small bowel transplantation].
Topics: Animals; Apoptosis; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Intestine, Small; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred WF; Sphingosine; Transplantation, Heterotopic | 2010 |
Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells.
Topics: Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Myxoma virus; Neoplasms; Okadaic Acid; Phosphoric Monoester Hydrolases; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Sphingosine; TOR Serine-Threonine Kinases; Viral Proteins; Viral Tropism; Virus Replication | 2010 |
Discovery of a novel series of potent S1P1 agonists.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Discovery; Fingolimod Hydrochloride; High-Throughput Screening Assays; Humans; Mice; Microsomes, Liver; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2010 |
S1P receptor mediated activity of FTY720 phosphate mimics.
Topics: Administration, Oral; Amino Acids; Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Isoleucine; Lymphocytes; Phosphates; Phosphorylation; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2010 |
A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow.
Topics: Animals; B-Lymphocytes; Bone Marrow; Bromodeoxyuridine; Cell Movement; Chemotaxis, Leukocyte; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Transgenic; Precursor Cells, B-Lymphoid; Propylene Glycols; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sphingosine | 2010 |
Cytoprotective Actions of FTY720 Modulate Severe Preservation Reperfusion Injury in Rat Renal Transplants.
Topics: Adenosine; Allopurinol; Animals; Cell Culture Techniques; Cell Division; Cell Survival; Fingolimod Hydrochloride; Flow Cytometry; Glutathione; Immunohistochemistry; Immunosuppressive Agents; Inflammation; Insulin; Kidney Transplantation; Male; Organ Preservation Solutions; Propylene Glycols; Raffinose; Rats; Rats, Inbred Lew; Reperfusion Injury; Sphingosine | 2010 |
Targeting the sphingolipid signaling pathway in stroke.
Topics: Animals; Blood-Brain Barrier; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Neuroprotective Agents; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Signal Transduction; Sphingolipids; Sphingosine; Stroke | 2010 |
Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats.
Topics: Animals; Blood; Cell Cycle; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Interphase; Lymph Nodes; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Propylene Glycols; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sphingosine; Thymus Gland | 2010 |
New drugs may improve, complicate treatment for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
Effect of combined treatment with FK506, FTY720, and ex vivo graft irradiation in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1.
Topics: Animals; Combined Modality Therapy; Fingolimod Hydrochloride; Immunoglobulins; Immunosuppressive Agents; Intestine, Small; Mucoproteins; Propylene Glycols; Rats; Sphingosine; Tacrolimus; Transplants | 2010 |
FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice.
Topics: Animals; Antibodies, Antinuclear; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphocytes; Mesangial Cells; Mice; Monocytes; Propylene Glycols; Sphingosine; Spleen | 2010 |
Multiple sclerosis: closing in on an oral treatment.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2010 |
Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints.
Topics: Adoptive Transfer; Animals; Antigen-Presenting Cells; Arthritis, Experimental; Arthritis, Rheumatoid; Autoantibodies; Cell Movement; Female; Fingolimod Hydrochloride; Gene Knock-In Techniques; Humans; Immunosuppressive Agents; Joints; Lymph Nodes; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Proteoglycans; Sphingosine; T-Lymphocytes | 2010 |
Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.
Topics: Adolescent; Animals; CD4-Positive T-Lymphocytes; Child; Diabetes Mellitus; Diabetes Mellitus, Type 1; DNA-Binding Proteins; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Islets of Langerhans; Lymphocytes; Mice; Mice, Inbred NOD; Mice, Knockout; Propylene Glycols; Sphingosine; T-Lymphocytes; Young Adult | 2010 |
Cell phenotype evaluation at various sites after skin transplantation and FTY720 plus sirolimus therapy.
Topics: Animals; Cell Count; Fingolimod Hydrochloride; Flow Cytometry; Graft Survival; Immunosuppressive Agents; Leukocyte Count; Leukocytes; Male; Mice; Mice, Inbred BALB C; Models, Animal; Phenotype; Propylene Glycols; Sirolimus; Skin; Skin Transplantation; Sphingosine; Transplantation, Homologous | 2010 |
Leishmania (Leishmania) amazonensis infection in mice treated with FTY720.
Topics: Animals; CD4-Positive T-Lymphocytes; Fingolimod Hydrochloride; Flow Cytometry; Hindlimb; Immunosuppressive Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Lymphocyte Count; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Spleen | 2010 |
Sirolimus in combination with FTY720: analysis of urinary and serum parameters.
Topics: Animals; Creatinine; Diuresis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Proteinuria; Sirolimus; Sphingosine | 2010 |
Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury.
Topics: Acute Kidney Injury; Animals; Apoptosis; Cell Movement; Disease Models, Animal; Epithelial Cells; Fingolimod Hydrochloride; Homeodomain Proteins; Kidney Tubules, Proximal; Leukocytes; Lipopolysaccharides; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase Kinases; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Reperfusion Injury; RNA, Messenger; Signal Transduction; Sphingosine; Thiophenes | 2010 |
[Progress of therapy in patients with multiple sclerosis].
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Brain; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Rituximab; Sphingosine | 2010 |
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Topics: Fingolimod Hydrochloride; Humans; Immunomodulation; Immunosuppressive Agents; Multiple Sclerosis; Neurons; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2010 |
Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function.
Topics: 14-3-3 Proteins; Animals; Apoptosis; Caspases; Cell Survival; Chlorocebus aethiops; COS Cells; Fingolimod Hydrochloride; Humans; Jurkat Cells; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Isoforms; Protein Kinase C-delta; Sphingosine | 2010 |
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
Topics: Animals; Animals, Newborn; Astrocytes; Cerebellum; Demyelinating Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Mice; Microglia; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stem Cells; Tissue Culture Techniques | 2010 |
Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model.
Topics: Administration, Oral; Animals; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cell Line; Cytokines; Dinoprostone; Disease Models, Animal; Female; Fingolimod Hydrochloride; Glucans; Humans; Immunosuppressive Agents; Interleukin-4; Mice; Mice, Inbred Strains; Polysaccharides; Propylene Glycols; Specific Pathogen-Free Organisms; Sphingosine; Spleen; Thymus Gland | 2010 |
[How rare is tuberculosis?].
Topics: Antitubercular Agents; Europe; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Orphan Drug Production; Propylene Glycols; Sphingosine; Tuberculosis | 2010 |
Regulation of learning and memory by meningeal immunity: a key role for IL-4.
Topics: Animals; Bone Marrow Transplantation; Cognition Disorders; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-4; Learning; Lymphocyte Depletion; Meninges; Mice; Mice, Inbred BALB C; Mice, Knockout; Propylene Glycols; Sphingosine; T-Lymphocytes | 2010 |
Oral cladribine and fingolimod for relapsing multiple sclerosis.
Topics: Cladribine; Ethics, Research; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Informed Consent; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Research Design; Sphingosine | 2010 |
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin D1; Female; Fingolimod Hydrochloride; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Propylene Glycols; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sphingosine; Xenograft Model Antitumor Assays | 2010 |
Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Topics: Adoptive Transfer; Animals; Bone Marrow; Cell Count; Cell Movement; Fingolimod Hydrochloride; Hypersensitivity, Delayed; Immunization; Lymphoid Tissue; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Ovalbumin; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes; Thiophenes | 2010 |
Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation.
Topics: Animals; CD8 Antigens; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immune System; Immunomodulation; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Activation; Male; Pancreas; Propylene Glycols; Rats; Sphingosine | 2010 |
PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Fingolimod Hydrochloride; G1 Phase; Humans; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Propylene Glycols; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction; Sphingosine; Stomach Neoplasms; Tumor Suppressor Protein p53 | 2010 |
Naïve T cells re-distribute to the lungs of selectin ligand deficient mice.
Topics: Animals; Fingolimod Hydrochloride; Immunologic Memory; Ligands; Lung; Mice; Mice, Knockout; Propylene Glycols; Selectins; Sphingosine; T-Lymphocytes | 2010 |
Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival.
Topics: Adoptive Transfer; Animals; Bone Marrow Cells; Cells, Cultured; Dendritic Cells; Female; Fingolimod Hydrochloride; Forkhead Transcription Factors; Graft Survival; Heart Transplantation; Interferon-gamma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phagocytosis; Propylene Glycols; Sphingosine; T-Lymphocytes, Regulatory | 2010 |
Arthritis: where are the T cells?
Topics: Animals; Antigens; Arthritis; Arthritis, Experimental; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Joints; Lysophospholipids; Mice; Propylene Glycols; Sphingosine; T-Lymphocytes, Helper-Inducer | 2010 |
Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis.
Topics: Adult; Arm; Blood Flow Velocity; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Vascular Diseases | 2010 |
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
Topics: Aged; Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Enzyme Activation; Female; Fingolimod Hydrochloride; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred DBA; Phosphorylation; Propylene Glycols; Protein Phosphatase 2; Protein Subunits; Proto-Oncogene Proteins c-kit; Signal Transduction; Sphingosine | 2010 |
FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
Topics: Androgens; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Humans; Male; Muscle, Smooth, Vascular; Organophosphonates; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pulmonary Artery; Sphingosine; Stereoisomerism; Vinyl Compounds | 2010 |
[Emerging treatments for multiple sclerosis].
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Prognosis; Propylene Glycols; Sphingosine | 2010 |
Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics.
Topics: Amino Acid Substitution; Animals; Base Sequence; Cell Membrane; Chemotaxis, Leukocyte; Endocytosis; Fingolimod Hydrochloride; Kinetics; Lymphopenia; Lysophospholipids; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Mutant Proteins; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2010 |
Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Ischemic Preconditioning, Myocardial; Lymphocyte Count; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Tumor Necrosis Factor-alpha | 2010 |
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Topics: Adult; Case-Control Studies; CD3 Complex; CD4 Antigens; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunologic Memory; Immunosuppressive Agents; Interferon-beta; Interleukin-17; Male; Multiple Sclerosis; Propylene Glycols; Prospective Studies; Receptors, CCR4; Receptors, CCR6; Sphingosine; T-Lymphocytes | 2010 |
FTY720 mediates cytochrome c release from mitochondria during rat thymocyte apoptosis.
Topics: Animals; Apoptosis; Caspases; CD4 Antigens; Cell Count; Cells, Cultured; Cytochromes c; Enzyme Activation; Fingolimod Hydrochloride; Injections, Intramuscular; Male; Mitochondria; Propylene Glycols; Rats; Rats, Inbred Strains; Receptors, Antigen, T-Cell; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes; Thymus Gland | 2010 |
A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination.
Topics: Animals; BCG Vaccine; CD4-Positive T-Lymphocytes; Cell Count; Cell Movement; Fingolimod Hydrochloride; Histocompatibility Antigens Class II; Immunologic Memory; Interferon-gamma; Lung; Lymphocyte Activation; Macrophages, Alveolar; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Propylene Glycols; Sphingosine; Tuberculosis, Pulmonary; Vaccination | 2010 |
Elimination of a hydroxyl group in FTY720 dramatically improves the phosphorylation rate.
Topics: Animals; Cell Line; Cells, Cultured; Chemistry, Pharmaceutical; Fingolimod Hydrochloride; HeLa Cells; Humans; Hydroxyl Radical; Jurkat Cells; Mice; Mice, Inbred C57BL; Phosphorylation; Propylene Glycols; Rats; Sphingosine | 2010 |
FTY720 and central memory: out of sight, out of mind.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2010 |
The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY720.
Topics: Animals; Bone and Bones; Bone Remodeling; Bone Transplantation; Coated Materials, Biocompatible; Compressive Strength; Elastic Modulus; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Neovascularization, Physiologic; Osseointegration; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Tissue Engineering; Transplantation, Homologous | 2010 |
News & views in ... Immunotherapy.
Topics: Animals; Antibodies, Blocking; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Fingolimod Hydrochloride; HIV Envelope Protein gp120; HIV Infections; Humans; Maximum Tolerated Dose; Multiple Sclerosis; Ovarian Neoplasms; Propylene Glycols; Sphingosine; Thymidylate Synthase; Virus Internalization | 2009 |
Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Brain; Cells, Cultured; Chemokines; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; T-Lymphocytes; Up-Regulation | 2010 |
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.
Topics: Adoptive Transfer; Animals; Antigen Presentation; Antigen-Presenting Cells; beta 2-Microglobulin; Carcinoma, Lewis Lung; CD11a Antigen; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Fingolimod Hydrochloride; Granzymes; Hyaluronan Receptors; Immunosuppressive Agents; Integrin alpha4; Interferon-gamma; Lymph Nodes; Lymphocyte Activation; Lysosomal Membrane Proteins; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Monophenol Monooxygenase; Neoplasms; Ovalbumin; Peptide Fragments; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; T-Lymphocyte Subsets | 2010 |
Update on emerging therapies for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Multiple Sclerosis; Neurology; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells.
Topics: Adoptive Transfer; Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Fingolimod Hydrochloride; Immunomodulation; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Propylene Glycols; Sphingosine; T-Lymphocytes | 2011 |
CD4+ CD25+ regulatory T cells partially mediate the beneficial effects of FTY720, a sphingosine-1-phosphate analogue, during ischaemia/reperfusion-induced acute kidney injury.
Topics: Acute Kidney Injury; Animals; CD4-Positive T-Lymphocytes; Dendritic Cells; Fingolimod Hydrochloride; Flow Cytometry; Forkhead Transcription Factors; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Kidney; Lymphocyte Culture Test, Mixed; Lymphopenia; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine; Spleen; T-Lymphocytes, Regulatory | 2011 |
FTY720 regulates bone marrow egress of eosinophils and modulates late-phase skin reaction in mice.
Topics: Animals; Blotting, Western; Bone Marrow; Cell Movement; Chemotaxis; Disease Models, Animal; Eosinophils; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Inflammation; Interleukin-5; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Skin Diseases; Sphingosine | 2010 |
Characterization of sphingosine-1-phosphate lyase activity by electrospray ionization-liquid chromatography/tandem mass spectrometry quantitation of (2E)-hexadecenal.
Topics: Aldehyde-Lyases; Aldehydes; Animals; Chromatography, High Pressure Liquid; Fingolimod Hydrochloride; Hydrogenation; Kinetics; Lysophospholipids; Mice; Microsomes, Liver; Propylene Glycols; Rats; Semicarbazones; Spectrometry, Mass, Electrospray Ionization; Sphingosine; Stereoisomerism; Tandem Mass Spectrometry | 2011 |
Design and synthesis of selective and potent orally active S1P5 agonists.
Topics: Administration, Oral; Amino Acid Sequence; Animals; Binding Sites; Computer Simulation; Drug Design; Fingolimod Hydrochloride; Molecular Sequence Data; Myelin Basic Protein; Oligodendroglia; Phthalazines; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2010 |
[Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].
Topics: Activities of Daily Living; Administration, Oral; Disability Evaluation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Recovery of Function; Sphingosine; Treatment Outcome | 2010 |
Avoiding infusion therapy prime benefit of new MS drug.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infusions, Parenteral; Managed Care Programs; Multiple Sclerosis; Propylene Glycols; Sphingosine; United States; United States Food and Drug Administration; Young Adult | 2010 |
Differential responses of human microglia and blood-derived myeloid cells to FTY720.
Topics: Blotting, Western; Cytokines; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Gene Expression; Humans; Immunosuppressive Agents; Lysophospholipids; Macrophages; Microglia; Myeloid Cells; Propylene Glycols; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine | 2011 |
Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Epidermal Growth Factor; Female; Fingolimod Hydrochloride; HEK293 Cells; Humans; Lysophospholipids; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Propylene Glycols; Pyrazoles; Pyridines; Receptor, ErbB-2; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sphingosine | 2010 |
Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth.
Topics: Actins; Animals; Delayed-Action Preparations; Fingolimod Hydrochloride; Male; Mice; Mice, Inbred C57BL; Microvessels; Models, Animal; Muscles; Neovascularization, Physiologic; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2011 |
FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy.
Topics: Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Cisplatin; Cytoprotection; Drug Screening Assays, Antitumor; Female; Fingolimod Hydrochloride; Humans; Inhibitory Concentration 50; Lysophospholipids; Necrosis; Ovarian Neoplasms; Propylene Glycols; Signal Transduction; Sphingosine | 2010 |
Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Topics: Animals; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Mice; Mice, Inbred C57BL; Myelin Proteolipid Protein; Propylene Glycols; Sphingosine | 2011 |
Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Jurkat Cells; Propylene Glycols; RNA, Messenger; Signal Transduction; Sphingosine | 2010 |
FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Fingolimod Hydrochloride; Flow Cytometry; Gamma Rays; Humans; Immunosuppressive Agents; Male; Mice; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostatic Neoplasms; Radiation Tolerance; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sphingosine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Fingolimod Hydrochloride; Humans; In Vitro Techniques; Mass Spectrometry; Microsomes, Liver; Molecular Structure; Multiple Sclerosis, Relapsing-Remitting; Oxidation-Reduction; Propylene Glycols; Sphingosine; Transfection | 2011 |
Novartis eyes oral MS drug as potential blockbuster.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Approval; Drug Industry; Fingolimod Hydrochloride; Humans; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
FTY720-induced suicidal erythrocyte death.
Topics: Annexin A5; Anti-Inflammatory Agents; Apoptosis; Calcium; Erythrocytes; Fingolimod Hydrochloride; Flow Cytometry; Humans; Phosphatidylserines; Propylene Glycols; Sphingosine; Time Factors | 2010 |
FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl.
Topics: Adherens Junctions; Cells, Cultured; Endothelial Cells; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Inflammation; Lung; Lysophospholipids; Permeability; Phosphorylation; Propylene Glycols; Proto-Oncogene Proteins c-abl; Pulmonary Artery; RNA, Small Interfering; Signal Transduction; Sphingosine; Subcellular Fractions; Tight Junctions | 2011 |
The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
Topics: Animals; Biological Transport; Carrier Proteins; CHO Cells; Cricetinae; Cricetulus; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Membrane Proteins; Mice; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
T helper type 1 memory cells disseminate postoperative ileus over the entire intestinal tract.
Topics: Animals; Cell Movement; Dendritic Cells; Fingolimod Hydrochloride; Flow Cytometry; Humans; Ileus; Immunologic Memory; Immunosuppressive Agents; Interferon-gamma; Interleukin-12; Macrophages; Mice; Mice, Inbred C57BL; Postoperative Complications; Propylene Glycols; Sphingosine; Statistics, Nonparametric; Th1 Cells | 2010 |
Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.
Topics: Animals; Antidepressive Agents, Tricyclic; Cathepsins; Cell Line, Tumor; Cells, Cultured; Cysteine Proteinase Inhibitors; Desipramine; Enzyme Inhibitors; Fibroblasts; Fingolimod Hydrochloride; Humans; Hydrolases; Immunosuppressive Agents; Leupeptins; Mice; Neurons; Propylene Glycols; Sphingomyelin Phosphodiesterase; Sphingosine | 2011 |
There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells.
Topics: Animals; Cell Differentiation; Cell Lineage; Cells, Cultured; Ceramides; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Mice; Molecular Structure; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine; Stem Cells | 2011 |
Understanding the effects of FTY720 on leukocyte trafficking.
Topics: Cell Movement; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukocytes; Propylene Glycols; Sphingosine | 2010 |
Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
Topics: Calcium; Fingolimod Hydrochloride; HEK293 Cells; Humans; Lysophospholipids; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism | 2011 |
Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Movement; Cell Proliferation; Disease Models, Animal; Fingolimod Hydrochloride; Inflammation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Peritonitis; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Thioglycolates | 2011 |
The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue.
Topics: Animals; beta Catenin; Cell Line, Transformed; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Indoles; Maleimides; Melanins; Melanocytes; Mice; Microphthalmia-Associated Transcription Factor; Monophenol Monooxygenase; Phosphorylation; Propylene Glycols; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sphingosine | 2011 |
Effect of FTY720 treatment on postischemic pancreatic microhemodynamics.
Topics: Animals; Female; Fingolimod Hydrochloride; Hemodynamics; Immunosuppressive Agents; Propylene Glycols; Rats; Rats, Wistar; Reperfusion Injury; Sphingosine | 2010 |
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Topics: Animals; Astrocytes; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple Sclerosis; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2011 |
B cell homeostasis and plasma cell homing controlled by Krüppel-like factor 2.
Topics: Animals; B-Lymphocytes; Bone Marrow Cells; Calcium; Fingolimod Hydrochloride; Gene Deletion; Integrin beta Chains; Kruppel-Like Transcription Factors; L-Selectin; Leukosialin; Mice; Models, Biological; Plasma Cells; Propylene Glycols; Receptors, IgE; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Embryonic pig pancreatic tissue for the treatment of diabetes: potential role of immune suppression with "off-the-shelf" third-party regulatory T cells.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Diabetes Mellitus; Embryo, Mammalian; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Insulin; Mice; Mice, Inbred C57BL; Pancreas Transplantation; Propylene Glycols; Sirolimus; Sphingosine; Swine; T-Lymphocytes, Regulatory; Transplantation Tolerance; Transplantation, Heterologous | 2011 |
Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function.
Topics: Animals; Biological Transport; Cyclosporine; Diarrhea; Everolimus; Fingolimod Hydrochloride; Glucose; Immunosuppressive Agents; Intestinal Absorption; Intestine, Large; Intestine, Small; Male; Mycophenolic Acid; Propylene Glycols; Rats; Rats, Wistar; Sirolimus; Sphingosine; Tacrolimus | 2011 |
Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.
Topics: Animals; Axons; Blotting, Western; Corpus Callosum; Cuprizone; Demyelinating Diseases; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron; Myelin Sheath; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine | 2011 |
FDA approves the first oral drug for reducing multiple sclerosis relapses.
Topics: Administration, Oral; Central Nervous System; Drug Approval; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine; United States; United States Food and Drug Administration | 2010 |
Fingolimod provides long-term protection in rodent models of cerebral ischemia.
Topics: Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; In Vitro Techniques; Inflammation; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Stroke | 2011 |
Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fingolimod Hydrochloride; Kidney; Lymphocytes; Mice; Mice, Inbred C57BL; Oxadiazoles; Phosphotransferases (Alcohol Group Acceptor); Podocytes; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Tumor Necrosis Factor-alpha | 2011 |
Structure-activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-β-alanine moiety.
Topics: Animals; beta-Alanine; Cinnamates; Fingolimod Hydrochloride; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2011 |
In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates.
Topics: Adult; Age Factors; Animals; Drug Delivery Systems; Female; Fingolimod Hydrochloride; Humans; Infertility, Female; Macaca mulatta; Male; Mice; Ovarian Diseases; Ovary; Pregnancy; Pregnancy Outcome; Propylene Glycols; Radiation Injuries, Experimental; Radiation-Protective Agents; Sphingosine; Young Adult | 2011 |
Sphingosine 1-phosphate receptor modulator FTY720 suppresses rat experimental autoimmune prostatitis.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Male; Propylene Glycols; Prostatitis; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Specific Pathogen-Free Organisms; Sphingosine | 2011 |
The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Neurobiology; Neuroglia; Neurons; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2011 |
Modulation of sphingosine 1-phosphate signaling in neurologic disease.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Nervous System Diseases; Propylene Glycols; Signal Transduction; Sphingosine | 2011 |
Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model.
Topics: Animals; Antibodies, Monoclonal; Crohn Disease; Diarrhea; Disease Models, Animal; Female; Fingolimod Hydrochloride; Gastrointestinal Agents; Interleukin-12; Interleukin-23; Mice; Mice, Inbred BALB C; Organ Size; Propylene Glycols; Sphingosine; Sulfasalazine; Trinitrobenzenesulfonic Acid; Weight Loss | 2011 |
Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720.
Topics: Animals; Chromatids; Cyclin B1; Female; Fingolimod Hydrochloride; Gene Expression Regulation, Enzymologic; Genes, Dominant; Metaphase; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Okadaic Acid; Oocytes; Propylene Glycols; Protein Phosphatase 2; Sphingosine; Spindle Apparatus | 2011 |
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Fingolimod Hydrochloride; Hepatocytes; Humans; Liver Neoplasms; Mice; Mice, Nude; Propylene Glycols; Protein Kinase C-delta; Reactive Oxygen Species; Signal Transduction; Sphingosine; Xenograft Model Antitumor Assays | 2011 |
Primary varicella zoster infection associated with fingolimod treatment.
Topics: Acyclovir; Adult; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2011 |
Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Disease Models, Animal; Electrophysiology; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Glycoproteins; Immunosuppressive Agents; Myelin Sheath; Neurons; Oligodendroglia; Optic Neuritis; Propylene Glycols; Rats; Sphingosine | 2011 |
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers -- Letter.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Fingolimod Hydrochloride; Gastrointestinal Stromal Tumors; Humans; Immunosuppressive Agents; Inhibitory Concentration 50; Mice; Mutation; Propylene Glycols; Protein Phosphatase 2; Proto-Oncogene Proteins c-kit; Sphingosine | 2011 |
The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice.
Topics: Animals; Apoptosis; Capillary Permeability; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Lung; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Ventilator-Induced Lung Injury | 2011 |
The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice.
Topics: Animals; Autoantibodies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Female; Fingolimod Hydrochloride; Flow Cytometry; Forkhead Transcription Factors; Iodides; Lymphocyte Count; Male; Mice; Mice, Inbred NOD; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Thyroiditis, Autoimmune | 2011 |
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.
Topics: Animals; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Mice; Nerve Degeneration; Propylene Glycols; Recovery of Function; Sphingosine | 2011 |
FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.
Topics: Adolescent; Aged; Autophagy; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Child, Preschool; Cytoprotection; Enzyme Activation; Female; Fingolimod Hydrochloride; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propylene Glycols; Protein Phosphatase 2; Reactive Oxygen Species; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Young Adult | 2011 |
FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells.
Topics: Actins; Allosteric Regulation; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Models, Chemical; Neoplasm Proteins; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Proteasome Endopeptidase Complex; Sphingosine | 2011 |
A novel lipid natriuretic factor in the renal medulla: sphingosine-1-phosphate.
Topics: Animals; Enzyme Inhibitors; Fingolimod Hydrochloride; Immunohistochemistry; Kidney Cortex; Kidney Medulla; Lipids; Lysophospholipids; Male; Natriuretic Agents; NG-Nitroarginine Methyl Ester; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Renal Circulation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium; Sphingosine | 2011 |
Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival.
Topics: Animals; Antibodies, Monoclonal; Diabetes Mellitus, Experimental; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Immunosuppressive Agents; Indoles; Islets of Langerhans Transplantation; Lymphangiogenesis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Pyrroles; Sphingosine; Sunitinib; T-Lymphocytes; Transplantation Tolerance; Transplantation, Homologous; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Caspase Inhibitors; Cell Line; Fingolimod Hydrochloride; Gene Expression Profiling; Gene Regulatory Networks; Humans; Immunosuppressive Agents; Microarray Analysis; Microglia; Multiple Sclerosis; Pertussis Toxin; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sterol Regulatory Element Binding Protein 2 | 2011 |
New drugs 2011 part 2.
Topics: Benzimidazoles; Contraceptives, Postcoital; Dabigatran; Drug Therapy; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Norpregnadienes; Pharmaceutical Preparations; Propylene Glycols; Pyridines; Sphingosine | 2011 |
Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice.
Topics: Animals; Capillary Leak Syndrome; Dose-Response Relationship, Drug; Endocytosis; Fingolimod Hydrochloride; Gene Knock-In Techniques; Lymphopenia; Lysophospholipids; Mice; Organophosphates; Peptide Hydrolases; Phosphorylation; Propylene Glycols; Protein Processing, Post-Translational; Protein Structure, Tertiary; Pulmonary Edema; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Recombinant Fusion Proteins; Sphingosine; Sphingosine-1-Phosphate Receptors; Ubiquitin-Protein Ligases; Ubiquitination | 2011 |
S1P is associated with protection in human and experimental cerebral malaria.
Topics: Aldehyde-Lyases; Animals; Antimalarials; Artemisinins; Artesunate; Brain; Cell Adhesion Molecules; Child; Child, Preschool; Female; Fingolimod Hydrochloride; Humans; Imidazoles; Immunosuppressive Agents; Infant; Interferon-gamma; Lysophospholipids; Malaria, Cerebral; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Oximes; Plasmodium berghei; Propylene Glycols; Sphingosine; Survival Analysis; T-Lymphocytes; Treatment Outcome | 2011 |
Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants.
Topics: Animals; Apoptosis; Cryopreservation; Female; Fingolimod Hydrochloride; Graft Survival; Humans; Immunohistochemistry; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, SCID; Neovascularization, Physiologic; Ovarian Follicle; Ovary; Oxadiazoles; Propylene Glycols; Sphingosine; Thiophenes; Transplantation, Heterologous | 2011 |
TLR2 and TLR4 expression after kidney ischemia and reperfusion injury in mice treated with FTY720.
Topics: Animals; Creatinine; Fingolimod Hydrochloride; Interleukin-6; Kidney; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Propylene Glycols; Reperfusion Injury; Sphingosine; Spleen; Toll-Like Receptor 2; Toll-Like Receptor 4; Urea | 2011 |
Transforming multiple sclerosis trials into practical reality.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Placebos; Propylene Glycols; Randomized Controlled Trials as Topic; Research Design; Sphingosine | 2011 |
(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells.
Topics: Actins; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Membrane; Enzyme Assays; Female; Fingolimod Hydrochloride; HEK293 Cells; Humans; Lysophospholipids; Microscopy, Fluorescence; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Pseudopodia; Sphingosine | 2011 |
FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Disease Models, Animal; Embryo Loss; Female; Fingolimod Hydrochloride; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Pregnancy; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes, Regulatory | 2011 |
Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
Topics: Animals; Autoantigens; Cyclosporine; Demyelinating Diseases; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Glycoproteins; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Nerve Tissue Proteins; Peptide Fragments; Propylene Glycols; Remission Induction; Secondary Prevention; Specific Pathogen-Free Organisms; Sphingosine; Spinal Cord | 2011 |
Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.
Topics: Animals; Benzene Derivatives; Blotting, Western; Calcium; Capillary Permeability; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Cricetulus; Cyclobutanes; Female; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Lymphocyte Count; Lymphopenia; Mammary Neoplasms, Experimental; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Prodrugs; Propylene Glycols; Protein Conformation; Radioligand Assay; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2011 |
Discovery of S1P agonists with a dihydronaphthalene scaffold.
Topics: Administration, Oral; Animals; CHO Cells; Cricetinae; Cricetulus; Fingolimod Hydrochloride; Humans; Lymphocytes; Mice; Molecular Structure; Naphthalenes; Propanols; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2011 |
Delayed fingolimod-associated asystole.
Topics: Administration, Oral; Antipsychotic Agents; Bradycardia; Electrocardiography; Fingolimod Hydrochloride; Heart Arrest; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Risperidone; Sphingosine; Time Factors; Young Adult | 2011 |
Redirected tumor-specific allogeneic T cells for universal treatment of cancer.
Topics: Animals; Antigens, Neoplasm; Cell Separation; Fingolimod Hydrochloride; Flow Cytometry; Graft vs Host Disease; Immunosuppressive Agents; Immunotherapy, Adoptive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Propylene Glycols; Sphingosine; T-Lymphocytes; Transplantation, Homologous | 2011 |
Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorimetry; Culture Media, Serum-Free; Deoxyuridine; DNA; Drug Design; Estradiol; Estrogens; Fingolimod Hydrochloride; Fluorescent Dyes; Fulvestrant; Humans; Isopropyl Thiogalactoside; Membrane Potential, Mitochondrial; Mitochondria; Propylene Glycols; Reproducibility of Results; Sphingosine; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p14ARF | 2011 |
FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia.
Topics: Animals; Brain Edema; Brain Ischemia; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-6; Leukocytes; Lymphocytes; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Tumor Necrosis Factor-alpha | 2011 |
Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Animals; Arrhythmias, Cardiac; Biotransformation; Blotting, Western; Cardiotonic Agents; Cell Hypoxia; Cell Survival; Coronary Occlusion; Female; Fingolimod Hydrochloride; Humans; In Vitro Techniques; L-Lactate Dehydrogenase; Lysophospholipids; Male; Middle Aged; Myocardial Ischemia; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; p21-Activated Kinases; Pertussis Toxin; Propylene Glycols; Rats; Sphingolipids; Sphingosine | 2011 |
FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.
Topics: Amino Acid Motifs; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fingolimod Hydrochloride; HEK293 Cells; Humans; Immunosuppressive Agents; Ligands; Lipids; Mutagenesis; Propylene Glycols; Protein Structure, Tertiary; Rats; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Recombinant Fusion Proteins; Sphingosine | 2011 |
FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice.
Topics: Analysis of Variance; Animals; Brain Edema; Cerebral Hemorrhage; Collagenases; Disease Models, Animal; Fingolimod Hydrochloride; Functional Laterality; Immunosuppressive Agents; Mice; Nervous System Diseases; Neurologic Examination; Propylene Glycols; Psychomotor Performance; Sphingosine; Time Factors | 2011 |
The effect of FTY720 in the Theiler's virus model of multiple sclerosis.
Topics: Animals; Cardiovirus Infections; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Injections, Intraperitoneal; Mice; Multiple Sclerosis; Propylene Glycols; Sphingosine; Theilovirus; Viral Load | 2011 |
Fingolimod modulates microglial activation to augment markers of remyelination.
Topics: Animals; Biomarkers; Cell Culture Techniques; Cells, Cultured; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Microglia; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Myelin Sheath; Nerve Degeneration; Pregnancy; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Spheroids, Cellular; Sphingosine | 2011 |
[Influence of PP2A activator on proliferation of HL-60 cells and analysis of PP2A activity changes in patients with acute myeloid leukemia].
Topics: Adult; Aged; Apoptosis; Case-Control Studies; Cell Proliferation; Enzyme Activators; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Okadaic Acid; Propylene Glycols; Protein Phosphatase 2; Sphingosine; Young Adult | 2011 |
Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
Topics: Animals; Dendritic Spines; Encephalomyelitis, Autoimmune, Experimental; Excitatory Postsynaptic Potentials; Female; Fingolimod Hydrochloride; Glutamic Acid; Glycoproteins; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Propylene Glycols; Sphingosine; Synapses; Synaptic Transmission | 2012 |
Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Topics: Animals; Chelating Agents; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Myelin Sheath; Nerve Regeneration; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Topics: Cladribine; Clinical Trials as Topic; Device Approval; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2011 |
Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Chronic Disease; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Killer Cells, Natural; Leukemia; Male; Myeloid Cell Leukemia Sequence 1 Protein; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred F344; RNA, Small Interfering; Sphingosine | 2011 |
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; United States | 2011 |
FTY720 blocks egress of T cells in part by abrogation of their adhesion on the lymph node sinus.
Topics: Animals; Cell Adhesion; Cell Separation; Chemotaxis, Leukocyte; Fingolimod Hydrochloride; Flow Cytometry; GTP-Binding Protein alpha Subunit, Gi2; Immunosuppressive Agents; Lymph Nodes; Mice; Mice, Knockout; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2011 |
Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Multiple Sclerosis; Propylene Glycols; Sphingosine; Synapses | 2012 |
Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis.
Topics: Blindness; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Propylene Glycols; Retinal Vein; Retinal Vein Occlusion; Sphingosine | 2011 |
NICE rules out NHS prescription of fingolimod for multiple sclerosis.
Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; National Health Programs; Prescription Drugs; Propylene Glycols; Sphingosine; Treatment Outcome | 2011 |
The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis.
Topics: Analysis of Variance; Animals; Anti-Glomerular Basement Membrane Disease; Apoptosis; CD4-Positive T-Lymphocytes; Creatinine; DNA Primers; Fingolimod Hydrochloride; Freund's Adjuvant; Gene Expression Regulation; Immune Sera; Immunoglobulin G; Immunosuppressive Agents; Interleukin-4; Male; Mice; Mice, Inbred C57BL; Prednisone; Propylene Glycols; Proteinuria; Rabbits; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; Sphingosine; Spleen | 2012 |
Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Multiple Sclerosis; Propylene Glycols; Skin Neoplasms; Sphingosine | 2011 |
[Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
Topics: Fingolimod Hydrochloride; Herpes Simplex; Humans; Immunization, Secondary; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Multiple sclerosis treatment: First oral drug, new antibody therapies.
Topics: Administration, Oral; Antibodies, Monoclonal; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2011 |
Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation.
Topics: Actins; Animals; Blood Vessels; Bone Remodeling; Bone Transplantation; Coated Materials, Biocompatible; Drug Delivery Systems; Female; Fingolimod Hydrochloride; Fluorescence; Lactic Acid; Monocytes; Osteogenesis; Periosteum; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Propylene Glycols; Rats; Rats, Sprague-Dawley; Skull; Sphingosine; Transplantation, Homologous; X-Ray Microtomography | 2012 |
Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia.
Topics: Animals; Brain Ischemia; Enzyme Activation; Fingolimod Hydrochloride; Gene Deletion; Infarction, Middle Cerebral Artery; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Sphingosine | 2011 |
[A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
Topics: Contraindications; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Risk Management; Sphingosine | 2011 |
Inhibitors of specific ceramide synthases.
Topics: Cell Survival; Ceramides; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; HeLa Cells; Humans; Inhibitory Concentration 50; Isoenzymes; Oxidoreductases; Propylene Glycols; Signal Transduction; Sphingosine; Structure-Activity Relationship; Substrate Specificity | 2012 |
Focus on molecules: Sphingosine 1 Phosphate (S1P).
Topics: Animals; Calcium Channels; Cell Proliferation; Cell Survival; Eye Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intermediate Filament Proteins; Lysophospholipids; Membrane Glycoproteins; Nerve Tissue Proteins; Opsins; Peripherins; Propylene Glycols; Receptors, Lysosphingolipid; Retinal Photoreceptor Cell Outer Segment; Rhodopsin; Sphingosine | 2012 |
Fast simultaneous quantitative analysis of FTY720 and its metabolite FTY720-P in human blood by on-line solid phase extraction coupled with liquid chromatography-tandem mass spectrometry.
Topics: Calibration; Chromatography, Liquid; Drug Stability; Fingolimod Hydrochloride; Humans; Organophosphates; Propylene Glycols; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Sphingosine; Tandem Mass Spectrometry | 2012 |
S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
Topics: Animals; Central Nervous System; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Indans; Lymphopenia; Mice; Multiple Sclerosis; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class II; Humans; Immunoblotting; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Lysosomes; Mice; Mice, SCID; Microscopy, Confocal; Microtubule-Associated Proteins; Propylene Glycols; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart.
Topics: Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Female; Fingolimod Hydrochloride; Male; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; NFATC Transcription Factors; p21-Activated Kinases; Propylene Glycols; Rats; Signal Transduction; Sphingosine; Stress, Physiological | 2011 |
FTY720-loaded poly(DL-lactide-co-glycolide) electrospun scaffold significantly increases microvessel density over 7 days in streptozotocin-induced diabetic C57b16/J mice: preliminary results.
Topics: Animals; Automation; Biocompatible Materials; Diabetes Mellitus, Experimental; Drug Delivery Systems; Extracellular Matrix; Fingolimod Hydrochloride; Hypoxia; Image Processing, Computer-Assisted; Immunosuppressive Agents; Lactic Acid; Male; Materials Testing; Mice; Mice, Inbred C57BL; Microvessels; Nanofibers; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Propylene Glycols; Sphingosine; Streptozocin; Tissue Scaffolds | 2011 |
Short-term immunossupressive treatment of the donor does not prevent ischemia-reperfusion kidney damage in the rat.
Topics: Animals; Cadaver; Creatinine; Fingolimod Hydrochloride; Graft Survival; Hypertonic Solutions; Immunosuppressive Agents; Kidney Transplantation; Male; Propylene Glycols; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sirolimus; Sphingosine; Tissue Donors | 2011 |
S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures.
Topics: Animals; Animals, Newborn; Astrocytes; Cell Movement; Cerebellum; Chemokine CCL20; Chemokine CCL3; Chemokines; Demyelinating Diseases; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Lysophosphatidylcholines; Myelin Basic Protein; Neurofilament Proteins; Organ Culture Techniques; Oxadiazoles; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Thiophenes | 2012 |
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Enzyme Reactivators; Fingolimod Hydrochloride; Humans; Leukemia, Myeloid, Acute; Mutation; Propylene Glycols; Protein Phosphatase 2; Proto-Oncogene Proteins c-kit; Sphingosine | 2012 |
Novel immunomodulators based on an oxazolin-2-one-4-carboxamide scaffold.
Topics: Amides; Amino Acids; Benzamides; Catalytic Domain; Chemistry, Pharmaceutical; Drug Design; Fingolimod Hydrochloride; Humans; Hydrogen Bonding; Immunologic Factors; Immunosuppressive Agents; Inhibitory Concentration 50; Models, Chemical; Models, Molecular; Molecular Conformation; Oxazolone; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier.
Topics: Animals; Apoptosis; Autoimmune Diseases; Blood-Retinal Barrier; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Microvessels; Permeability; Propylene Glycols; Retinitis; Sphingosine; Uveitis | 2012 |
Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Enzyme Activation; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Kinetics; Lysophospholipids; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Sphingosine; Structure-Activity Relationship | 2012 |
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.
Topics: Adult; Brain; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Neuromyelitis Optica; Propylene Glycols; Sphingosine | 2012 |
The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage.
Topics: Animals; Cartilage, Articular; Cattle; Cells, Cultured; Chondrocytes; Fingolimod Hydrochloride; Glycosaminoglycans; Immunosuppressive Agents; Interleukin-1beta; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; Nitric Oxide Synthase Type II; Propylene Glycols; Sphingosine; Tumor Necrosis Factor-alpha | 2011 |
Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Carcinoma 256, Walker; Cell Movement; Cells, Cultured; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fingolimod Hydrochloride; Indoles; Male; Mammary Neoplasms, Experimental; Myocytes, Smooth Muscle; Neoplasm Transplantation; Propylene Glycols; Proto-Oncogene Proteins c-sis; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Statistics, Nonparametric; Sunitinib; Tumor Burden; Tyrphostins | 2012 |
Both exogenous commensal and endogenous self antigens stimulate T cell proliferation under lymphopenic conditions.
Topics: Animals; Autoantigens; Cell Proliferation; Fingolimod Hydrochloride; Homeostasis; Immunologic Memory; Lymph Nodes; Lymphocyte Activation; Lymphopenia; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; Spleen; T-Lymphocytes | 2012 |
Reactive murine lymph nodes uniquely permit parenchymal access for T cells that enter via the afferent lymphatics.
Topics: Adoptive Transfer; Animals; Chemotaxis, Leukocyte; Disease Models, Animal; Fingolimod Hydrochloride; Genes, T-Cell Receptor; Herpes Simplex; Herpesvirus 1, Human; Immunosuppressive Agents; Lymph Nodes; Lymphatic Vessels; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Skin; Sphingosine; T-Lymphocytes; Time Factors | 2012 |
FTY720 normalizes hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice through regulation of cyclin D3 and p57(KIP2).
Topics: Administration, Oral; Animals; Cell Count; Cell Proliferation; Cell Survival; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p57; Down-Regulation; Female; Fingolimod Hydrochloride; Hyperglycemia; Insulin-Secreting Cells; Mice; Phosphatidylinositol 3-Kinases; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Up-Regulation | 2012 |
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Pharmacovigilance; Propylene Glycols; Risk Assessment; Sphingosine | 2011 |
Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Cytokines; Disease Models, Animal; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Intestine, Small; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes; Time Factors; Transplantation, Homologous | 2012 |
The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonists.
Topics: Animals; Arrestin; Fingolimod Hydrochloride; GTP-Binding Proteins; Lymphocytes; Lysophospholipids; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Rats; Rats, Inbred Strains; Signal Transduction; Sphingosine | 2012 |
Does fingolimod in multiple sclerosis patients cause macular edema?
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence | 2012 |
FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.
Topics: Animals; Blood Pressure; Carotid Arteries; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; Fingolimod Hydrochloride; Hypertension; Immunosuppressive Agents; Isoenzymes; Male; Muscle, Smooth, Vascular; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sphingosine; Thromboxane A2; Vascular Resistance; Vasoconstrictor Agents | 2012 |
Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
Topics: Animals; Benzopyrenes; Disease Models, Animal; Fingolimod Hydrochloride; Gene Knock-In Techniques; Humans; Immunosuppressive Agents; Lung Neoplasms; Mice; Mice, Knockout; Point Mutation; Propylene Glycols; Protein Phosphatase 2; ras Proteins; Signal Transduction; Sphingosine; Tumor Suppressor Protein p53 | 2012 |
Autophagy induced by FTY720 promotes apoptosis in U266 cells.
Topics: Apoptosis; Autophagy; BH3 Interacting Domain Death Agonist Protein; Caspase 3; Cell Line, Tumor; Cell Survival; Down-Regulation; Fingolimod Hydrochloride; Humans; Inhibitor of Apoptosis Proteins; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sphingosine; Survivin | 2012 |
Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure.
Topics: Airway Remodeling; Allergens; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; CD3 Complex; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Male; Muscle, Smooth; Propylene Glycols; Rats; Severity of Illness Index; Sphingosine; Treatment Outcome | 2012 |
Sudden unexpected death on fingolimod.
Topics: Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Fingolimod Hydrochloride; Humans; Hypertension; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2012 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brain Stimulation; Dopamine Agonists; Epilepsy; Fingolimod Hydrochloride; Genetic Therapy; Humans; Immunosuppressive Agents; Ischemic Attack, Transient; Multiple Sclerosis; Muscular Diseases; Neurology; Parkinson Disease; Phenylenediamines; Polyneuropathies; Propylene Glycols; Sphingosine; Stroke; Treatment Outcome; Valproic Acid | 2012 |
Effect of alkyl chain length on sphingosine kinase 2 selectivity.
Topics: Cyclohexylamines; Enzyme Inhibitors; Fingolimod Hydrochloride; Isoenzymes; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Binding; Sphingosine; Structure-Activity Relationship | 2012 |
Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent.
Topics: Animals; Cells, Cultured; Enzyme Inhibitors; Fingolimod Hydrochloride; Hemodynamics; Histamine; Human Umbilical Vein Endothelial Cells; Humans; Immunosuppressive Agents; Leukocyte Count; Leukocyte Rolling; MAP Kinase Signaling System; Mice; Mice, Knockout; Neutrophil Infiltration; P-Selectin; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Up-Regulation | 2012 |
Fingolimod for multiple sclerosis.
Topics: Administration, Oral; Drug Administration Schedule; Drug Approval; Drug Costs; Drug Information Services; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2012 |
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Topics: Brain; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2012 |
[The study of FTY720 on inducing apoptosis and autophagy in multiple myeloma cell line U266].
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Multiple Myeloma; Propylene Glycols; Sphingosine | 2011 |
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
Topics: Animals; Chromatography, Liquid; Drug Stability; Fingolimod Hydrochloride; Humans; Intracellular Space; Linear Models; Liquid-Liquid Extraction; Mice; Organophosphates; Propylene Glycols; Reproducibility of Results; Sphingosine; Spleen; Tandem Mass Spectrometry | 2012 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Glioblastoma; Humans; Induction Chemotherapy; Membrane Proteins; Mice; Mice, Nude; Neoplastic Stem Cells; Propylene Glycols; Proto-Oncogene Proteins; Receptors, Lysosphingolipid; Sphingosine; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
Topics: Death, Sudden; Disclosure; Drug-Related Side Effects and Adverse Reactions; Europe; Fingolimod Hydrochloride; Government Agencies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Synthesis and immunomodulating activity of new analogues of fingolimod.
Topics: Animals; Female; Fingolimod Hydrochloride; Immunologic Factors; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Ovalbumin; Propylene Glycols; Sphingosine; Structure-Activity Relationship; T-Lymphocytes | 2012 |
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Fingolimod Hydrochloride; Humans; Lymphoma, Mantle-Cell; Mice; Neoplasm Proteins; Phosphorylation; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Immunologic Surveillance; Immunosuppressive Agents; Lymphoma, B-Cell; Mice; Mice, SCID; Mice, Transgenic; Multiple Myeloma; Propylene Glycols; Sphingosine | 2012 |
FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Propylene Glycols; Rats; Reperfusion Injury; Sphingosine; Stem Cells; Time Factors | 2012 |
Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
Topics: Adult; Antibodies, Monoclonal, Humanized; Ataxia; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Plasma Exchange; Propylene Glycols; Recurrence; Sphingosine; Spine | 2012 |
FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Concanavalin A; Down-Regulation; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Lectins, C-Type; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Propylene Glycols; Sphingosine; T-Lymphocytes | 2012 |
FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms.
Topics: Animals; Astrocytes; Capillary Permeability; Cell Movement; Cytokines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Inflammation Mediators; Locomotion; Mice; Mice, Inbred C57BL; Mice, SCID; Microglia; Neutrophils; Propylene Glycols; Receptors, Lysosphingolipid; Recovery of Function; Sphingosine; Spinal Cord Injuries; T-Lymphocytes; Treatment Outcome | 2012 |
[FTY720 attenuates rat anti-Thy-1 mesangial proliferative glomerulonephritis by inhibition of transforming growth factor β1-connective tissue growth factor pathway].
Topics: Animals; Cell Proliferation; Connective Tissue Growth Factor; Down-Regulation; Extracellular Matrix Proteins; Fingolimod Hydrochloride; Gene Expression; Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Immunosuppressive Agents; Isoantibodies; Kidney Glomerulus; Male; Propylene Glycols; Proteinuria; Rats; Rats, Wistar; Signal Transduction; Sphingosine; Thy-1 Antigens; Transforming Growth Factor beta1 | 2012 |
Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Body Weight; CD11b Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Genes, MHC Class II; Indans; Interleukin-2; Interleukin-6; Lymph Nodes; Lymphocyte Activation; Lymphocytes; Macrophages; Mice; Mice, Inbred C57BL; Oxadiazoles; Proprotein Convertases; Propylene Glycols; Receptors, LDL; Receptors, Lysosphingolipid; Serine Endopeptidases; Sphingosine; Spleen | 2012 |
Effects of FTY720 and rapamycin on inflammation in taurocholate-induced acute pancreatitis in the rat.
Topics: Acute Disease; Amylases; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Hydrocortisone; Immunosuppressive Agents; Interleukin-10; Interleukin-6; Pancreas; Pancreatitis; Propylene Glycols; Rats; Rats, Wistar; Sirolimus; Sphingosine; T-Lymphocytes; Taurocholic Acid | 2012 |
Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways.
Topics: Animals; Cells, Cultured; Dendritic Cells; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon Type I; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Propylene Glycols; Signal Transduction; Sphingosine; Toll-Like Receptor 7; Up-Regulation | 2012 |
MS clinical trials: what can subgroup analyses teach us?
Topics: Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2012 |
FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells.
Topics: Cell Differentiation; Cell Line; Cell Survival; Cranial Irradiation; Fingolimod Hydrochloride; Hippocampus; Humans; Immunohistochemistry; Neural Stem Cells; Neuroprotective Agents; Propylene Glycols; Radiation-Protective Agents; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice.
Topics: Administration, Ophthalmic; Animals; Cell Proliferation; Cornea; Corneal Transplantation; Cyclosporine; Cytokines; Fingolimod Hydrochloride; Forkhead Transcription Factors; Gels; Graft Survival; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Ophthalmic Solutions; Propylene Glycols; Sphingosine; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2012 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
Fingolimod: cardiovascular deaths.
Topics: Cardiovascular Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Effects of long-term administration of low-dose FTY720 on survival of murine cardiac allograft.
Topics: Animals; Cytokines; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Longitudinal Studies; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Propylene Glycols; Sphingosine | 2012 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Factor V; Fingolimod Hydrochloride; Heart; Heart Diseases; Heart Failure; Humans; Hypertension; Immunosuppressive Agents; Male; Middle Aged; Mitral Valve Insufficiency; Multiple Sclerosis; Mutation; Myocardium; Propylene Glycols; Pyrazoles; Sjogren's Syndrome; Sphingosine; Sulfonamides | 2012 |
Lymphocyte modulation with FTY720 improves hemorrhagic shock survival in swine.
Topics: Analysis of Variance; Animals; DNA Primers; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunity, Innate; Immunohistochemistry; Immunosuppressive Agents; Liver; Lymph Nodes; Lymphocytes; Male; Neutrophils; Peroxidase; Propylene Glycols; Real-Time Polymerase Chain Reaction; Shock, Hemorrhagic; Sphingosine; Spleen; Swine; Swine Diseases | 2012 |
Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.
Topics: Albuterol; Animals; Asthma; beta-Alanine; Bronchial Hyperreactivity; Bronchoconstriction; Fingolimod Hydrochloride; Lung; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Rats; Rats, Inbred BN; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Tachyphylaxis; Thiophenes; Trachea | 2012 |
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasm Staging; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Propylene Glycols; Protein Phosphatase 2; Sphingosine; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells in vitro.
Topics: Animals; Cell Proliferation; Fingolimod Hydrochloride; Forkhead Transcription Factors; Immunosuppressive Agents; Interleukin-10; Male; Mice; Mice, Inbred BALB C; Organophosphates; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2012 |
Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3 receptor ligands using the DiscoveRx PathHunter™ and Ca2+ release functional assays.
Topics: Animals; Arrestins; beta-Arrestins; Binding, Competitive; Biological Assay; Calcium; CHO Cells; Cricetinae; Cricetulus; Fingolimod Hydrochloride; Humans; Indans; Ligands; Organophosphates; Oxadiazoles; Propylene Glycols; Radioligand Assay; Receptors, Lysosphingolipid; Sphingosine | 2012 |
FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Mesangial Cells; Propylene Glycols; Rats; Sphingosine | 2012 |
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Topics: Adult; Cost-Benefit Analysis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Markov Chains; Models, Econometric; Monte Carlo Method; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Quality-Adjusted Life Years; Sphingosine; United States | 2012 |
Intra-islet proliferation of cytotoxic T lymphocytes contributes to insulitis progression.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Type 1; Disease Progression; Fingolimod Hydrochloride; Flow Cytometry; Histocompatibility Antigens Class I; Immunohistochemistry; Immunosuppressive Agents; Islets of Langerhans; Mice; Mice, Inbred NOD; Mice, Transgenic; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; T-Lymphocytes, Cytotoxic | 2012 |
Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
Topics: Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes; Cell Count; Cyclophosphamide; Cyclosporine; Fingolimod Hydrochloride; Forkhead Transcription Factors; Immune Tolerance; Immunity; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Isoxazoles; Leflunomide; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mycophenolic Acid; Ovalbumin; Propylene Glycols; Sirolimus; Sphingosine; Spleen; T-Lymphocytes, Regulatory | 2012 |
The sphingosine-1-phosphate analogue FTY720 impairs mucosal immunity and clearance of the enteric pathogen Citrobacter rodentium.
Topics: Animals; Citrobacter rodentium; Enterobacteriaceae Infections; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunity, Mucosal; Immunosuppressive Agents; Lymphopenia; Mice; Mice, Inbred Strains; Propylene Glycols; RNA, Messenger; Specific Pathogen-Free Organisms; Sphingosine | 2012 |
Fingolimod--a sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
Topics: Animals; Astrocytes; Calcium; Dose-Response Relationship, Drug; Exocytosis; Fingolimod Hydrochloride; Glutamic Acid; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Transport Vesicles | 2012 |
Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation.
Topics: Animals; Bone Morphogenetic Protein 2; Cell Differentiation; Cell Line; Core Binding Factor Alpha 1 Subunit; Fingolimod Hydrochloride; GTP-Binding Protein alpha Subunits, Gi-Go; Lysophospholipids; Mice; Osteoblasts; Osteocalcin; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Smad Proteins; Sphingosine | 2012 |
A fluorescent assay for ceramide synthase activity.
Topics: Enzyme Assays; Feasibility Studies; Fingolimod Hydrochloride; Fluorescent Dyes; Glycols; HEK293 Cells; Humans; Limit of Detection; Oxidoreductases; Propylene Glycols; Spectrometry, Fluorescence; Sphingosine | 2012 |
Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro.
Topics: Animals; Antigen Presentation; Bone Marrow Cells; Cell Survival; Cytokines; Dendritic Cells; Female; Fingolimod Hydrochloride; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Nitric Oxide; Phagocytosis; Phenotype; Propylene Glycols; Receptors, CCR7; Sphingosine | 2012 |
[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
Topics: Animals; Atrophy; B-Lymphocytes; Brain; Cell Movement; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; L-Selectin; Lysophospholipids; Mice; Molecular Structure; Multiple Sclerosis; Neuroglia; Propylene Glycols; Rats; Receptors, CCR7; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets; Th17 Cells | 2012 |
[Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Congresses as Topic; Contrast Media; European Union; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Posters as Topic; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Failure; Treatment Outcome | 2012 |
FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal.
Topics: Animals; Antibodies, Monoclonal; B-Lymphocytes; Bone Marrow Transplantation; CD40 Ligand; Cell Movement; Drug Synergism; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Graft vs Host Disease; Immunosuppressive Agents; Killer Cells, Natural; Mice; Propylene Glycols; Sphingosine; T-Lymphocytes; Thymocytes; Thymus Gland; Transplantation Chimera; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
Prolonged and symptomatic bradycardia following a single dose of fingolimod.
Topics: Adult; Bradycardia; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
Topics: Adolescent; Adult; Area Under Curve; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Levonorgestrel; Propylene Glycols; Sphingosine | 2012 |
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
Topics: Antibodies, Monoclonal, Humanized; Cost Savings; Costs and Cost Analysis; Fingolimod Hydrochloride; Health Services; Humans; Immunosuppressive Agents; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Netherlands; Propylene Glycols; Sphingosine | 2012 |
[Disease modifying drugs in multiple sclerosis and pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Infant, Newborn; Interferon-beta; Multiple Sclerosis; Natalizumab; Peptides; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Stillbirth | 2012 |
S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Fingolimod Hydrochloride; Gene Silencing; Humans; Lymphocyte Activation; Lymphoma, Large B-Cell, Diffuse; Mice; Neoplasm Invasiveness; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; STAT3 Transcription Factor | 2012 |
Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies?
Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Cell Proliferation; Cells, Cultured; Coculture Techniques; Dose-Response Relationship, Drug; Embryo, Mammalian; Fingolimod Hydrochloride; Ganglia, Spinal; Immunosuppressive Agents; In Situ Nick-End Labeling; Myelin Sheath; Neurons; Phosphorylation; Propylene Glycols; Rats; Reactive Oxygen Species; Receptors, Lysosphingolipid; RNA, Messenger; Schwann Cells; Sphingosine | 2012 |
Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Disease Models, Animal; Female; Fingolimod Hydrochloride; Glutamate Decarboxylase; Immunosuppressive Agents; Kidney; Liver; Mice; Mice, Inbred NOD; Propylene Glycols; Sphingosine; Spleen | 2012 |
New disease-modifying therapies and new challenges for MS.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Propylene Glycols; Risk; Sphingosine | 2012 |
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Topics: Animals; Astrocytes; Blood-Brain Barrier; Ceramides; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; NF-kappa B; Oligodendroglia; Propylene Glycols; Quinolones; Sphingosine | 2012 |
[Immunosuppressive effect of S1P1 receptor agonist FTY720].
Topics: Animals; Cricetinae; Cricetulus; Female; Fingolimod Hydrochloride; Graft Survival; Heart Rate; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microscopy, Confocal; Propylene Glycols; Protein Binding; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Skin Transplantation; Sphingosine; Transplantation, Homologous | 2012 |
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Blood-Brain Barrier; Cell Movement; Cells, Cultured; Ceramides; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Monocytes; Multiple Sclerosis; Propylene Glycols; Sphingomyelins; Sphingosine | 2012 |
Fingolimod inhibits PDGF-B-induced migration of vascular smooth muscle cell by down-regulating the S1PR1/S1PR3 pathway.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Down-Regulation; Fingolimod Hydrochloride; Immunohistochemistry; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Propylene Glycols; Proto-Oncogene Proteins c-sis; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Receptors, Lysosphingolipid; RNA Interference; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2012 |
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.
Topics: Adult; Disability Evaluation; Disease Progression; Drug Administration Schedule; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Antigens, Differentiation; Carrier Proteins; Cell Size; Diet, High-Fat; Disease Models, Animal; Enzyme Activation; Fingolimod Hydrochloride; Gene Expression Regulation, Enzymologic; Glycogen Synthase Kinase 3; Lipase; Lipolysis; Male; Mice; Mice, Inbred C57BL; Obesity; Perilipin-1; Phosphoproteins; Phosphorylation; Propylene Glycols; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Sphingosine; Sterol Esterase | 2012 |
Therapeutic approach to steroid-resistant dermatitis using novel immunomodulator FTY720 (Fingolimod) in combination with betamethasone ointment in NC/Nga mice.
Topics: Animals; Ascomycota; Betamethasone; Biological Products; Dermatitis; Drug Resistance; Epidermis; Fingolimod Hydrochloride; Glucocorticoids; Hypertrophy; Immunologic Factors; Male; Mast Cells; Mice; Mice, Inbred Strains; Phytotherapy; Propylene Glycols; Sphingosine; Steroids; Treatment Outcome | 2012 |
Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.
Topics: Animals; Astrocytes; Brain-Derived Neurotrophic Factor; Cell Death; Cells, Cultured; Disease Models, Animal; Excitatory Amino Acid Agonists; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; MAP Kinase Signaling System; Methyl-CpG-Binding Protein 2; Mice; Motor Activity; N-Methylaspartate; Neurons; Organ Culture Techniques; Pregnancy; Propylene Glycols; Receptors, Lysosphingolipid; Rett Syndrome; Sphingosine | 2012 |
The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection.
Topics: Animals; Cytokines; Female; Fingolimod Hydrochloride; Flow Cytometry; Graft Rejection; Graft Survival; Immunosuppressive Agents; Interleukins; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Real-Time Polymerase Chain Reaction; Skin Transplantation; Sphingosine; T-Lymphocytes, Regulatory; Th17 Cells | 2012 |
Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis.
Topics: Aged; Cartilage, Articular; Cells, Cultured; Chondrocytes; Drug Interactions; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Flavonoids; Gene Expression; Humans; Imidazoles; Immunosuppressive Agents; Lysophospholipids; Male; Mitogen-Activated Protein Kinases; Osteoarthritis; Pertussis Toxin; Propylene Glycols; Pyridines; RNA, Messenger; Sphingosine; Vascular Endothelial Growth Factor A | 2012 |
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.
Topics: Adult; Antibodies, Monoclonal, Humanized; Asthenia; Disease Progression; Drug Administration Schedule; Drug Substitution; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Severity of Illness Index; Sphingosine; Time Factors; Treatment Outcome | 2012 |
FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1/3 in diabetic heart disease.
Topics: Apoptosis; Base Sequence; Blotting, Western; Coronary Vessels; Diabetes Complications; DNA Primers; Fingolimod Hydrochloride; Heart Diseases; Humans; In Situ Nick-End Labeling; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microvessels; Neovascularization, Pathologic; Propylene Glycols; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine | 2012 |
FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cell Survival; Diabetes Mellitus, Type 2; Female; Fingolimod Hydrochloride; Glucose Tolerance Test; Immunosuppressive Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Mice; Propylene Glycols; Sphingosine | 2013 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Blood-Brain Barrier; Calcium Channel Blockers; Capillaries; Drug Delivery Systems; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Nerve Tissue Proteins; Organophosphates; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Sphingolipids; Sphingosine; Tight Junctions; Tumor Necrosis Factor-alpha; Verapamil | 2012 |
Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.
Topics: Animals; Astrocytes; Disease Models, Animal; Encephalitis; Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Hippocampus; Immunohistochemistry; Interleukin-1beta; Lithium Compounds; Male; Pilocarpine; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine; Status Epilepticus; Tumor Necrosis Factor-alpha | 2012 |
Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720.
Topics: Animals; Cells, Cultured; Embryo, Mammalian; Female; Fingolimod Hydrochloride; Fumonisins; Mice; Mice, Inbred Strains; Models, Biological; Neural Tube Defects; Pregnancy; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Up-Regulation | 2012 |
[Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator FTY720 (fingolimod) in combination with betamethasone ointment in NC/Nga mice].
Topics: Animals; Anti-Inflammatory Agents; Betamethasone; Dermatitis, Atopic; Drug Combinations; Female; Fingolimod Hydrochloride; Immunologic Factors; Immunosuppressive Agents; Mice; Mites; Ointments; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
Fingolimod and multiple sclerosis: four cautionary tales.
Topics: Antibodies, Monoclonal, Humanized; Brain; Cerebrovascular Disorders; Encephalitis, Varicella Zoster; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis; Natalizumab; Nerve Fibers, Myelinated; Propylene Glycols; Sphingosine | 2012 |
Severe relapses under fingolimod treatment prescribed after natalizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Natalizumab; Propylene Glycols; Recurrence; Sphingosine | 2012 |
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Topics: Aspartic Acid; Brain; Choline; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inositol; Magnetic Resonance Imaging; Multiple Sclerosis; Nerve Fibers, Myelinated; Propylene Glycols; Sphingosine; Young Adult | 2012 |
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.
Topics: Brain; Cerebrovascular Disorders; Encephalitis, Varicella Zoster; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Propylene Glycols; Sphingosine | 2012 |
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
Topics: Adult; Anti-Inflammatory Agents; Brain; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Early tolerability and safety of fingolimod in clinical practice.
Topics: Adult; Bradycardia; Chest Pain; Drug Substitution; Female; Fingolimod Hydrochloride; Headache; Humans; Hypertension; Lymphopenia; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nausea; Patient Acceptance of Health Care; Product Surveillance, Postmarketing; Propylene Glycols; Retrospective Studies; Sphingosine | 2012 |
Fingolimod exacerbated affective psychosis?
Topics: Adult; Affective Disorders, Psychotic; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2013 |
Gilenya safety update: cardiac and macula.
Topics: Bradycardia; Drug Monitoring; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Fingolimod protects cultured cortical neurons against excitotoxic death.
Topics: Animals; Astrocytes; Cell Death; Cells, Cultured; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Mice; Neurons; Neuroprotective Agents; Organophosphates; Propylene Glycols; Rats; Sphingosine | 2013 |
Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.
Topics: Antibodies, Monoclonal, Humanized; Drug Administration Schedule; Drug Substitution; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Natalizumab; Patient Selection; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Disability Evaluation; Drug Administration Schedule; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; JC Virus; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Topics: Antibodies, Monoclonal, Humanized; Brain; Drug Administration Schedule; Drug Substitution; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; Time Factors; Treatment Outcome | 2012 |
The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Fingolimod Hydrochloride; Free Radical Scavengers; Humans; Isoenzymes; Male; Neoplasm Proteins; Oxidative Stress; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Stability; Receptors, Androgen; RNA, Messenger; Sphingosine; Thiazoles | 2013 |
Synthesis of a key intermediate for the preparation of FTY720 analogs.
Topics: Alkynes; Benzene Derivatives; Catalysis; Fingolimod Hydrochloride; Immunosuppressive Agents; Palladium; Propylene Glycols; Sphingosine; Sulfhydryl Compounds | 2012 |
Neuroimmunological blood brain barrier opening in experimental cerebral malaria.
Topics: Animals; Benzamides; Blood-Brain Barrier; Cerebral Hemorrhage; Disease Models, Animal; Fingolimod Hydrochloride; Imatinib Mesylate; Lipopolysaccharide Receptors; Lymphocyte Function-Associated Antigen-1; Malaria, Cerebral; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neuroimmunomodulation; Parasitemia; Piperazines; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Propylene Glycols; Pyrimidines; Sphingosine | 2012 |
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Topics: Animals; Cells, Cultured; Fingolimod Hydrochloride; HEK293 Cells; Humans; Immunosuppressive Agents; Membrane Potentials; Membrane Transport Modulators; Mice; Myocytes, Cardiac; Organophosphates; Phosphorylation; Propylene Glycols; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Recombinant Proteins; Sphingosine; TRPM Cation Channels | 2013 |
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.
Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Propylene Glycols; Recurrence; Sphingosine; Substance Withdrawal Syndrome | 2013 |
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Gene Expression; Humans; Mice; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Blood-Brain Barrier; Capillaries; Endothelial Cells; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingolipids; Sphingosine; Sphingosine-1-Phosphate Receptors; Spinal Cord; Tumor Necrosis Factor-alpha | 2013 |
Hepatitis E masquerading as drug-induced liver injury.
Topics: Adult; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Fingolimod Hydrochloride; Hepatitis E; Hepatitis E virus; Humans; Male; Multiple Sclerosis; Propylene Glycols; RNA, Viral; Sphingosine | 2012 |
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA-Binding Proteins; Fingolimod Hydrochloride; Gene Knockdown Techniques; Histone Chaperones; Humans; Lung Neoplasms; Mice; Mice, SCID; Models, Molecular; Necrosis; Phosphorylation; Propylene Glycols; Protein Phosphatase 2; Receptor-Interacting Protein Serine-Threonine Kinases; Sphingosine; Transcription Factors; Xenograft Model Antitumor Assays | 2013 |
The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice.
Topics: Animals; Ceramides; Dietary Fats; Fingolimod Hydrochloride; Glucose; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Propylene Glycols; Sphingosine | 2013 |
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.
Topics: Antibodies, Monoclonal, Humanized; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2013 |
Sphingosine and the transient receptor potential channel kinase(s).
Topics: Animals; Fingolimod Hydrochloride; Humans; Membrane Potentials; Membrane Transport Modulators; Myocytes, Cardiac; Propylene Glycols; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sphingosine; TRPM Cation Channels | 2013 |
[Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].
Topics: Adult; Case-Control Studies; Comorbidity; Compassionate Use Trials; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Europe; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Prevalence; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
Complementary asymmetric routes to (R)-2-(7-hydroxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate.
Topics: Acetates; Catalysis; Fingolimod Hydrochloride; Indoles; Molecular Structure; Propylene Glycols; Pyrroles; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism | 2012 |
Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
Topics: Antibodies, Monoclonal, Humanized; Cost of Illness; Costs and Cost Analysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Sweden | 2013 |
Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macula Lutea; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Linear Models; Longitudinal Studies; Macula Lutea; Male; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Retinal Neurons; Sphingosine; Tomography, Optical Coherence | 2013 |
[New therapies in multiple sclerosis].
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2012 |
The role of lymphoid tissue in the attenuation of the postoperative ileus.
Topics: Animals; Cytokines; Enteritis; Fingolimod Hydrochloride; Ileus; Inflammation Mediators; Lymphoid Tissue; Male; Mice; Muscle Contraction; Propylene Glycols; Sphingosine; Up-Regulation | 2013 |
Topical treatment targeting sphingosine-1-phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model.
Topics: Administration, Topical; Animals; Apoptosis; Disease Models, Animal; Drug Delivery Systems; Eosinophils; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Mast Cells; Mice; Mice, Inbred Strains; Ovalbumin; Propylene Glycols; Random Allocation; Rhinitis, Allergic; Rhinitis, Allergic, Perennial; Sensitivity and Specificity; Sphingosine; Th2 Cells | 2013 |
Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage.
Topics: Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Blood Transfusion, Autologous; Brain Edema; CD3 Complex; Cell Count; Cerebral Cortex; Cerebral Hemorrhage; Collagenases; Disease Models, Animal; Fingolimod Hydrochloride; Forelimb; Functional Laterality; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukin-17; Leukocytes; Lymphocytes; Male; Maze Learning; Mice; Nervous System Diseases; Propylene Glycols; Psychomotor Disorders; Rats; Rats, Sprague-Dawley; Space Perception; Sphingosine; Time Factors | 2013 |
Visualization of splenic marginal zone B-cell shuttling and follicular B-cell egress.
Topics: Animals; B-Lymphocytes; Cell Adhesion; Cell Movement; Dendritic Cells, Follicular; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Propylene Glycols; Sphingosine; Spleen | 2013 |
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Time Factors; Young Adult | 2013 |
Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer.
Topics: Animals; Cell Transformation, Neoplastic; Colitis; Colon; Fingolimod Hydrochloride; Gene Deletion; Gene Expression Regulation, Neoplastic; Interleukin-6; Lysophospholipids; Mice; NF-kappa B; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Sphingosine; STAT3 Transcription Factor; Tumor Microenvironment | 2013 |
Is this the dose for you?: the role of modeling.
Topics: Age Factors; Antidepressive Agents; Benzofurans; Citalopram; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indoles; Models, Theoretical; Piperazines; Propylene Glycols; Risk Assessment; Sphingosine; Vilazodone Hydrochloride | 2013 |
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Topics: Animals; Azetidines; Benzyl Compounds; Bradycardia; Cells, Cultured; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Humans; Hypertension; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Substrate Specificity | 2012 |
Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Fingolimod Hydrochloride; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Propylene Glycols; Sphingosine; Thromboembolism; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2013 |
[New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Topics: Cardiovascular System; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Topics: Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Cells, Cultured; Central Nervous System; Cytokines; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Flow Cytometry; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine | 2013 |
S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.
Topics: Animals; beta-Alanine; Capillary Permeability; Colitis, Ulcerative; Colon; Fingolimod Hydrochloride; Humans; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; Sphingosine; Thiophenes | 2013 |
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Multiple Sclerosis; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines | 2013 |
Cystoid macular edema associated with fingolimod use for multiple sclerosis.
Topics: Administration, Oral; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Retrospective Studies; Sphingosine; Tomography, Optical Coherence; Visual Acuity | 2013 |
Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues.
Topics: Administration, Intravaginal; Administration, Intravenous; Animals; Anti-Infective Agents; Cervix Uteri; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; HIV Infections; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Interleukin-8; Lymphocyte Count; Macaca nemestrina; Mucous Membrane; Pilot Projects; Placebos; Propylene Glycols; Sphingosine; Vagina; Vaginal Creams, Foams, and Jellies | 2013 |
Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
Topics: Adult; Aged; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Neutropenia; Propylene Glycols; Sphingosine | 2013 |
Switching from natalizumab to fingolimod: an observational study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; JC Virus; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Observation; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult | 2013 |
Sphingosine-1-phosphate suppresses TLR-induced CXCL8 secretion from human T cells.
Topics: Calcium; Fingolimod Hydrochloride; Flagellin; Gene Expression Regulation; Humans; Interleukin-2; Interleukin-8; Jurkat Cells; Lipopeptides; Lymphocyte Activation; Lysophospholipids; Molecular Mimicry; Oxadiazoles; Propylene Glycols; Receptors, Antigen, T-Cell; Serum; Signal Transduction; Sphingosine; T-Lymphocytes; Thiophenes; Toll-Like Receptors; U937 Cells | 2013 |
Synthesis of selective inhibitors of sphingosine kinase 1.
Topics: Cell Line; Enzyme Inhibitors; Fingolimod Hydrochloride; HEK293 Cells; Humans; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Propylene Glycols; Proteasome Endopeptidase Complex; Sphingosine | 2013 |
Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data.
Topics: Adolescent; Adult; Clinical Trials, Phase III as Topic; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2013 |
Non-myeloablative conditioning is sufficient to induce mixed chimerism and subsequent acceptance of donor specific cardiac and skin grafts.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Count; Fingolimod Hydrochloride; Graft Survival; Green Fluorescent Proteins; Heart Transplantation; HLA-B27 Antigen; Immunosuppressive Agents; Leukocytes; Myeloablative Agonists; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Transgenic; Skin Transplantation; Sphingosine; T-Lymphocytes, Regulatory; Transplantation Chimera; Transplantation Conditioning | 2013 |
Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade.
Topics: Case-Control Studies; Chemotaxis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets | 2013 |
FTY720 (fingolimod) attenuates beta-amyloid peptide (Aβ42)-induced impairment of spatial learning and memory in rats.
Topics: Amyloid beta-Peptides; Animals; Apoptosis; Fingolimod Hydrochloride; Hippocampus; Male; Maze Learning; Memory; Memory Disorders; Peptide Fragments; Propylene Glycols; Rats; Rats, Wistar; Sphingosine | 2013 |
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Topics: Animals; Bone Marrow; Cell Movement; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Killer Cells, Natural; Leukocyte Count; Mice; Monocytes; Neutrophils; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Spleen | 2013 |
Inhibition of de novo ceramide biosynthesis by FTY720 protects rat retina from light-induced degeneration.
Topics: Animals; Ceramides; Fingolimod Hydrochloride; Immunosuppressive Agents; Light; Neuroprotective Agents; Propylene Glycols; Rats; Rats, Sprague-Dawley; Retina; Retinal Degeneration; Sphingosine | 2013 |
Protective effect of FTY720 against sevoflurane-induced developmental neurotoxicity in rats.
Topics: Animals; Apoptosis; Fingolimod Hydrochloride; Methyl Ethers; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurons; Neuroprotective Agents; Neurotoxins; Phosphorylation; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sevoflurane; Sphingosine; Time Factors | 2013 |
Early administration of FTY720 prevents chronic airway as well as vascular destruction in experimental rat lung transplantation.
Topics: Acute Disease; Animals; Bronchiolitis Obliterans; Chronic Disease; Drug Administration Schedule; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Lung; Lung Transplantation; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred WKY; Sclerosis; Sphingosine; Time Factors; Vascular Diseases | 2013 |
FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
Topics: Animals; Bone Marrow Transplantation; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Flow Cytometry; Graft vs Host Disease; Immunohistochemistry; Immunosuppressive Agents; Male; Mice; Propylene Glycols; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Scleroderma, Localized; Skin; Sphingosine; Spleen | 2013 |
Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation.
Topics: Astrocytes; Cells, Cultured; Drug Administration Schedule; Fetus; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; MAP Kinase Signaling System; Propylene Glycols; Sphingosine | 2013 |
[Multiple sclerosis: new drugs and their molecular targets].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2012 |
Consensus guidelines for the diagnosis and treatment of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Middle East; Multiple Sclerosis; Myelitis; Natalizumab; Optic Nerve Diseases; Optic Neuritis; Propylene Glycols; Sphingosine; Spinal Cord Diseases | 2013 |
Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.
Topics: Brain; CD4-Positive T-Lymphocytes; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, CCR7; Sphingosine; Young Adult | 2013 |
[Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
Topics: Brain; Cytokines; Drug Therapy, Combination; Fingolimod Hydrochloride; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; Peptides; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Outcome | 2013 |
[The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
Topics: Administration, Oral; Adult; Blood Pressure; Electrocardiography; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Monitoring, Physiologic; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine; Treatment Outcome | 2013 |
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Australia; Drug Prescriptions; Fingolimod Hydrochloride; Geography; Humans; Immunologic Factors; Interferon-beta; Linear Models; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Pharmacoepidemiology; Prevalence; Propylene Glycols; Pyridostigmine Bromide; Riluzole; Sphingosine | 2013 |
Management of fingolimod-associated macular edema.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dexamethasone; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Glucocorticoids; Humans; Immunosuppressive Agents; Intraocular Pressure; Ketorolac Tromethamine; Macular Edema; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2013 |
FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.
Topics: Adenosine; Algorithms; Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; In Vitro Techniques; Ischemic Postconditioning; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Perfusion; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Reperfusion Injury; Sphingosine | 2013 |
Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro.
Topics: Biomimetics; Cell Polarity; Dimethylpolysiloxanes; Fingolimod Hydrochloride; Fluorescent Antibody Technique; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Lysophospholipids; Microfluidics; Models, Biological; Morphogenesis; Neovascularization, Physiologic; Propylene Glycols; Pseudopodia; Pyrroles; Sphingosine; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes.
Topics: Animals; Astrocytes; Calcium Signaling; Cells, Cultured; Cyclic AMP; Female; Fingolimod Hydrochloride; Humans; Male; MAP Kinase Signaling System; Phosphorylation; Propylene Glycols; Rats, Wistar; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2013 |
Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.
Topics: Adenine; Antineoplastic Agents; Autophagy; Cell Count; Cell Death; Cell Line, Tumor; Cisplatin; Drug Antagonism; Drug Resistance, Neoplasm; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ovarian Neoplasms; Propylene Glycols; RNA, Small Interfering; Sphingosine | 2013 |
Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
Topics: Administration, Oral; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Glucocorticoids; Humans; Immunosuppressive Agents; Injections, Intraocular; Macular Edema; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone | 2013 |
Suppression of experimental autoimmune optic neuritis by the novel agent fingolimod.
Topics: Animals; Disease Models, Animal; Female; Fingolimod Hydrochloride; Freund's Adjuvant; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Neuritis, Autoimmune, Experimental; Optic Nerve; Peptide Fragments; Pertussis Toxin; Propylene Glycols; Sphingosine; Statistics, Nonparametric; Visual Acuity | 2013 |
Delivery of S1P receptor-targeted drugs via biodegradable polymer scaffolds enhances bone regeneration in a critical size cranial defect.
Topics: Animals; Bone Regeneration; Drug Delivery Systems; Fingolimod Hydrochloride; Hydrophobic and Hydrophilic Interactions; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Microspheres; Osteogenesis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Skull; Sphingosine; Time Factors; Tissue Scaffolds | 2014 |
Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Keratinocytes; Local Lymph Node Assay; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Psoriasis; Receptors, Lysosphingolipid; Skin; Skin Transplantation; Sphingosine; Sphingosine-1-Phosphate Receptors; Time Factors | 2013 |
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
Topics: Age of Onset; Brain; Child; Cyclophosphamide; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Plasma Exchange; Propylene Glycols; Sphingosine; Young Adult | 2013 |
Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
Topics: CD8-Positive T-Lymphocytes; Cytokines; Fingolimod Hydrochloride; Humans; Immunophenotyping; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2013 |
FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Brain; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Neurons; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Signal Transduction; Sphingosine; Sulfhydryl Compounds | 2013 |
Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling.
Topics: Alkaline Phosphatase; Amino Alcohols; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoenzymes; Kidney; Propylene Glycols; Proteomics; Pyrroles; Sphingosine | 2013 |
Treatment with the sphingosine-1-phosphate analogue FTY 720 reduces loss of plasma volume during experimental sepsis in the rat.
Topics: Animals; Capillary Leak Syndrome; Capillary Permeability; Cecum; Disease Models, Animal; Diuresis; Drug Evaluation, Preclinical; Edema; Endothelium, Vascular; Fingolimod Hydrochloride; Hematocrit; Hemodynamics; Hemoglobins; Intestinal Perforation; Lysophospholipids; Male; Plasma Volume; Propylene Glycols; Random Allocation; Rats; Rats, Sprague-Dawley; Sepsis; Sphingosine | 2013 |
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Saliva; Sphingosine; T-Lymphocytes; Virus Activation | 2013 |
FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Topics: Animals; Cell Death; Child; Child, Preschool; Drug Synergism; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infant; Male; Mice; Mice, Nude; Neuroblastoma; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Signal Transduction; Sphingolipids; Sphingosine; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2013 |
Reduction of the washout time between natalizumab and fingolimod.
Topics: Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2013 |
[Galenus von Pergamon Prize 2012. Excellent research and innovation].
Topics: Antineoplastic Agents; Awards and Prizes; Drug Approval; Drug Discovery; Drug Industry; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Indoles; Organizational Innovation; Propylene Glycols; Sphingosine; Sulfonamides; Vemurafenib | 2012 |
Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Comparative Effectiveness Research; Cost-Benefit Analysis; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; JC Virus; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quality-Adjusted Life Years; Recurrence; Sphingosine | 2013 |
Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
Topics: Antibodies, Monoclonal; Antigens, CD19; Antigens, CD20; Antigens, Neoplasm; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Propylene Glycols; Sphingosine; Tetraspanins | 2013 |
A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cell Adhesion Molecules; Cells, Cultured; Fibroblasts; Fibrosis; Fingolimod Hydrochloride; Hemodynamics; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Myocardium; NFATC Transcription Factors; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine; Ventricular Pressure | 2013 |
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Gene Expression Profiling; Gene Expression Regulation; Hippocampus; Male; Memantine; Mitogen-Activated Protein Kinases; Nerve Degeneration; Neuroprotective Agents; Peptide Fragments; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sex Factors; Sphingosine | 2013 |
[Mechanisms of ROS in U266 cell death induced by FTY720].
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Apoptosis; Autophagy; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Macrolides; Microtubule-Associated Proteins; Multiple Myeloma; Propylene Glycols; Reactive Oxygen Species; Sphingosine | 2013 |
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Topics: Anemia, Hemolytic, Autoimmune; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2013 |
Systemic treatment with the sphingosine-1-phosphate analog FTY720 does not improve fracture healing in mice.
Topics: Acid Phosphatase; Animals; Biomechanical Phenomena; Bone Regeneration; Female; Fingolimod Hydrochloride; Fracture Healing; Mice; Mice, Inbred C57BL; Osteoclasts; Propylene Glycols; Sphingosine | 2013 |
Rebound of disease activity during pregnancy after withdrawal of fingolimod.
Topics: Adult; Anti-Inflammatory Agents; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine | 2013 |
Fingolimod therapy and macular hemorrhage.
Topics: Blindness; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Hemorrhage; Humans; Immunosuppressive Agents; Macula Lutea; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Tomography, Optical Coherence | 2013 |
FTY720 attenuates tubulointerstitial inflammation and fibrosis in subtotally nephrectomized rats.
Topics: Animals; Cell Movement; Chemokine CCL2; Disease Models, Animal; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-6; Kidney Tubules; Lymphocytes; Male; Nephrectomy; Nephritis, Interstitial; Propylene Glycols; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Sphingosine; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-Associated Death Protein; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; Drug Resistance, Neoplasm; Fas-Associated Death Domain Protein; Fingolimod Hydrochloride; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mutation; Primary Cell Culture; Propylene Glycols; Protein Kinase Inhibitors; Proto-Oncogene Proteins; RNA, Small Interfering; Signal Transduction; Sphingosine | 2013 |
[A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment].
Topics: Aquaporin 4; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Neuromyelitis Optica; Propylene Glycols; Sphingosine | 2013 |
Fingolimod in a patient with Wolff-Parkinson-White syndrome.
Topics: Adult; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Wolff-Parkinson-White Syndrome | 2014 |
FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease.
Topics: Animals; Collagen Type IV; Disease Models, Animal; Disease Progression; Endothelial Cells; Fibronectins; Fibrosis; Fingolimod Hydrochloride; Gene Expression Regulation; Kidney; Kidney Glomerulus; Male; Microvessels; Nitric Oxide; Nitric Oxide Synthase Type III; Propylene Glycols; Rats; Renal Insufficiency, Chronic; Sphingosine; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2013 |
Sphingosine and FTY720 modulate pacemaking activity in interstitial cells of Cajal from mouse small intestine.
Topics: Animals; Biological Clocks; Chloride Channels; Female; Fingolimod Hydrochloride; Gastrointestinal Motility; HEK293 Cells; Humans; Interstitial Cells of Cajal; Intestine, Small; Male; Membrane Potentials; Mice; Mice, Inbred BALB C; Organophosphates; Patch-Clamp Techniques; Propylene Glycols; Sphingosine; TRPM Cation Channels | 2013 |
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Propylene Glycols; Reactive Oxygen Species; Sphingosine; Time Factors | 2013 |
Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis.
Topics: Analysis of Variance; Animals; Blotting, Western; Cells, Cultured; Chemotaxis; Cytokines; DNA Primers; Drug Carriers; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunohistochemistry; Lactic Acid; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Microvessels; Monocytes; Neovascularization, Physiologic; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Propylene Glycols; Prostheses and Implants; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; Sphingosine; Tissue Engineering; Vascular System Injuries | 2013 |
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Topics: Animals; Cell Line, Transformed; Cell Line, Tumor; Cells, Cultured; Class Ib Phosphatidylinositol 3-Kinase; DNA-Binding Proteins; Enzyme Activation; Fingolimod Hydrochloride; Histone Chaperones; Humans; Immunoblotting; Immunosuppressive Agents; Janus Kinase 2; Kaplan-Meier Estimate; Leukemia; Mice; Mice, SCID; Mutation; Oncogene Proteins; Propylene Glycols; Protein Kinase C; Protein Phosphatase 2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sphingosine; Treatment Outcome | 2013 |
FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke.
Topics: Aldehyde-Lyases; Animals; Astrocytes; Cerebral Cortex; Convalescence; Fingolimod Hydrochloride; Gene Expression; Gliosis; Immunosuppressive Agents; Intracranial Thrombosis; Male; Mice; Mice, Inbred C57BL; Post-Synaptic Density; Propylene Glycols; Recovery of Function; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; Stroke; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.
Topics: Animals; Anisotropy; Diffusion Tensor Imaging; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Mice; Mice, Inbred C57BL; Myelin Basic Protein; Propylene Glycols; Sphingosine; Spine | 2013 |
Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract.
Topics: Administration, Intranasal; Adoptive Transfer; Animals; Antigens, CD; Antigens, Surface; Basic-Leucine Zipper Transcription Factors; Cell Movement; Dendritic Cells; Fingolimod Hydrochloride; Gastrointestinal Tract; Immunity, Mucosal; Immunization; Integrins; Intestinal Mucosa; Lectins, C-Type; Lung; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, CCR; Salmonella; Salmonella Infections, Animal; Signal Transduction; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Tretinoin | 2013 |
A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.
Topics: Animals; Antigens, CD19; Antigens, CD20; Antigens, Neoplasm; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Leukemia; Liposomes; Mice; Mice, Inbred ICR; Nanomedicine; Propylene Glycols; Sphingosine; Tetraspanins; Water | 2014 |
Efficacy of combination treatment with fingolimod (FTY720) plus pathogenic autoantigen in a glucose-6-phosphate isomerase peptide (GPI325-339)-induced arthritis mouse model.
Topics: Animals; Arthritis, Rheumatoid; Autoantibodies; Autoantigens; Disease Models, Animal; Drug Therapy, Combination; Fingolimod Hydrochloride; Glucose-6-Phosphate Isomerase; Immunoglobulin G; Immunosuppressive Agents; Joints; Male; Mice; Mice, Inbred DBA; Peptides; Propylene Glycols; Sphingosine; Treatment Outcome | 2013 |
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; Fingolimod Hydrochloride; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplastic Stem Cells; Propylene Glycols; Protein Kinase Inhibitors; Protein Phosphatase 2; Sphingosine; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2013 |
Sphingosine signalling regulates decidual NK cell angiogenic phenotype and trophoblast migration.
Topics: Cell Movement; Cells, Cultured; Decidua; Down-Regulation; Female; Fingolimod Hydrochloride; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Interleukin-8; Killer Cells, Natural; Lysophospholipids; Neovascularization, Physiologic; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Trophoblasts; Vascular Endothelial Growth Factor A | 2013 |
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outpatients; Propylene Glycols; Recurrence; Sphingosine | 2013 |
Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches.
Topics: Animals; Antibodies; Capillary Permeability; Cricetinae; Endothelial Cells; Fingolimod Hydrochloride; Hantavirus Pulmonary Syndrome; Host-Pathogen Interactions; Humans; Immunosuppressive Agents; Mesocricetus; Orthohantavirus; Propylene Glycols; Pulmonary Edema; Signal Transduction; Sirolimus; Sphingosine; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection.
Topics: Animals; Brain Ischemia; Enzyme Inhibitors; Fingolimod Hydrochloride; Homeodomain Proteins; Hypoxia; Immunosuppressive Agents; Inflammation; Lymphocytes; Lymphopenia; Male; Mice; Mice, Transgenic; Middle Cerebral Artery; Neurons; Neuroprotective Agents; Propylene Glycols; Sphingosine; Stroke; Thrombosis | 2013 |
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Time Factors | 2014 |
FTY720 and cyclosporin protect ovarian tissue grafted into rabbits.
Topics: Adolescent; Adult; Animals; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Fingolimod Hydrochloride; Graft Survival; Humans; Interferon-gamma; Interleukin-4; Ki-67 Antigen; Ovary; Propylene Glycols; Rabbits; Sphingosine; Transplantation, Heterologous | 2013 |
Study of aqueous phase aggregation of FTY720 (fingolimod hydrochloride) and its effect on DMPC liposomes using fluorescent molecular probes.
Topics: Anilino Naphthalenesulfonates; Dimyristoylphosphatidylcholine; Diphenylhexatriene; Fingolimod Hydrochloride; Fluorescence Polarization; Fluorescent Dyes; Gels; Lipid Bilayers; Liposomes; Liquid Crystals; Micelles; Naphthols; Phase Transition; Propylene Glycols; Pyrenes; Sphingosine; Transition Temperature; Water | 2013 |
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Topics: Adult; Databases, Factual; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; In Vitro Techniques; Insurance Claim Review; Interferons; Male; Middle Aged; Multiple Sclerosis; Peptides; Propylene Glycols; Recurrence; Retrospective Studies; Sphingosine; United States | 2013 |
VEGF and bFGF increase survival of xenografted human ovarian tissue in an experimental rabbit model.
Topics: Adult; Animals; Apoptosis; Cell Survival; Female; Fibroblast Growth Factor 2; Fingolimod Hydrochloride; Graft Survival; Humans; Immunosuppressive Agents; Ki-67 Antigen; Neovascularization, Physiologic; Ovarian Follicle; Platelet Endothelial Cell Adhesion Molecule-1; Propylene Glycols; Rabbits; Sphingosine; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2013 |
The promotion of mandibular defect healing by the targeting of S1P receptors and the recruitment of alternatively activated macrophages.
Topics: Animals; Fingolimod Hydrochloride; Lysophospholipids; Macrophages; Male; Mandible; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanofibers; Polyesters; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Wound Healing | 2013 |
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Topics: Adult; Aged; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Proportional Hazards Models; Propylene Glycols; Retrospective Studies; Sphingosine; Time Factors | 2013 |
Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Immunotherapy; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
A regenerative approach to the treatment of multiple sclerosis.
Topics: Animals; Antiparkinson Agents; Benztropine; Cell Differentiation; Coculture Techniques; Cuprizone; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immune System; Mice; Mice, Inbred C57BL; Models, Biological; Multiple Sclerosis; Myelin Proteolipid Protein; Myelin Sheath; Oligodendroglia; Optic Nerve; Propylene Glycols; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M3; Recurrence; Regeneration; Sphingosine; Stem Cells | 2013 |
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Topics: Adult; Cell Count; Cytokines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocytes | 2013 |
FTY720 protects neuronal cells from damage induced by human prion protein by inactivating the JNK pathway.
Topics: Cell Death; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitochondria; Neurons; Neuroprotective Agents; Neurotoxins; Peptide Fragments; Phosphorylation; Prions; Propylene Glycols; Sphingosine | 2013 |
Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Cost Control; Drug Costs; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Spain; Sphingosine | 2014 |
Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
Topics: CD8-Positive T-Lymphocytes; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2013 |
Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells.
Topics: Calcitriol; Cell Line, Tumor; Cholecalciferol; Cytotoxicity, Immunologic; Dendritic Cells; Down-Regulation; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Interleukin-2; K562 Cells; Killer Cells, Natural; Membrane Proteins; Multiple Sclerosis; Natural Cytotoxicity Triggering Receptor 2; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily K; Propylene Glycols; Receptors, CCR6; Receptors, CCR7; Sphingosine; Up-Regulation | 2013 |
Deliberate fingolimod overdose presenting with delayed hypotension and bradycardia responsive to atropine.
Topics: Adult; Antidotes; Atropine; Bradycardia; Combined Modality Therapy; Drug Overdose; Female; Fingolimod Hydrochloride; Humans; Hypotension; Immunosuppressive Agents; Muscarinic Antagonists; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2014 |
Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Infarction, Middle Cerebral Artery; Male; Neurons; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine | 2013 |
Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.
Topics: Animals; Brain; Cell Line; Disease Models, Animal; Fingolimod Hydrochloride; Huntington Disease; Immunoblotting; Immunohistochemistry; Male; Mice; Mice, Transgenic; Neurodegenerative Diseases; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Real-Time Polymerase Chain Reaction; Sphingosine | 2014 |
Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Topics: Administration, Oral; Atrioventricular Block; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2014 |
Fingolimod (FTY720) stimulates Ca(2+)/calcineurin signaling in fission yeast.
Topics: Calcineurin; Calcium; Calcium Channels; Cytoplasm; Fingolimod Hydrochloride; Membrane Glycoproteins; Mutation; Propylene Glycols; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Signal Transduction; Sphingosine | 2013 |
Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Genetic Vectors; Humans; Immunosuppressive Agents; Lentivirus; Molecular Docking Simulation; Mutation; Nuclear Proteins; Oncogenes; Phosphoproteins; Propylene Glycols; Protein Structure, Tertiary; Repetitive Sequences, Amino Acid; Sphingosine; Transduction, Genetic | 2014 |
FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury.
Topics: Acute Lung Injury; Animals; Arrestins; beta-Arrestins; Bleomycin; Blotting, Western; Capillary Permeability; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Fingolimod Hydrochloride; Fluorescent Antibody Technique; Humans; Mice; Mice, Inbred C57BL; Propylene Glycols; Random Allocation; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Sensitivity and Specificity; Sphingosine | 2014 |
S1P lyase in thymic perivascular spaces promotes egress of mature thymocytes via up-regulation of S1P receptor 1.
Topics: Aldehyde-Lyases; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Blood Vessels; Blotting, Western; Cell Movement; Extracellular Space; Female; Fingolimod Hydrochloride; Imidazoles; Immunohistochemistry; L-Selectin; Lectins, C-Type; Lysophospholipids; Male; Mice, Inbred C57BL; Microscopy, Confocal; Platelet Endothelial Cell Adhesion Molecule-1; Propylene Glycols; Rats, Inbred F344; Receptors, Lysosphingolipid; Sphingosine; Thymocytes; Thymus Gland; Time Factors; Up-Regulation | 2014 |
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
Topics: Brain; Confidentiality; Drug Prescriptions; Drug Utilization; Electronic Health Records; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Informed Consent; Magnetic Resonance Imaging; Multiple Sclerosis; Patient Dropouts; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Propylene Glycols; Prospective Studies; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Socioeconomic Factors; Spain; Sphingosine; Treatment Outcome | 2014 |
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
Topics: Animals; Blood-Brain Barrier; Brain; Capillary Permeability; Disease Models, Animal; Disease Progression; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocytes; Macrophages; Male; Microglia; Multiple Sclerosis; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 2014 |
PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; DNA-Binding Proteins; Drug Synergism; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Chaperones; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Propylene Glycols; Protein Phosphatase 2; Signal Transduction; Sphingosine; Transcription Factors | 2014 |
Sphingosine 1-phosphate increases an intracellular Ca(2+) concentration via S1P3 receptor in cultured vascular smooth muscle cells.
Topics: Animals; Calcium; Calcium Channels, L-Type; Cells, Cultured; Fingolimod Hydrochloride; Lysophospholipids; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine | 2014 |
The pill times 2: what every woman with multiple sclerosis should know.
Topics: Abnormalities, Drug-Induced; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine | 2014 |
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Propylene Glycols; Sphingosine | 2014 |
Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Topics: Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; CSK Tyrosine-Protein Kinase; Female; Fingolimod Hydrochloride; Humans; Lysophospholipids; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Estrogen; Receptors, Lysosphingolipid; RNA Interference; RNA, Small Interfering; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; src-Family Kinases; Thiazoles; Tyrosine | 2014 |
Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage.
Topics: Animals; Apoptosis; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Fingolimod Hydrochloride; Hematoma; Male; Mice; Neuroprotective Agents; Propylene Glycols; Sphingosine; Weight Loss | 2014 |
FTY720 stimulated ROS generation and the Sty1/Atf1 signaling pathway in the fission yeast Schizosaccharomyces pombe.
Topics: Acetylcysteine; Activating Transcription Factor 1; Calcium; Cell Proliferation; Fingolimod Hydrochloride; Free Radical Scavengers; Immunosuppressive Agents; Mitogen-Activated Protein Kinases; Oxidative Stress; Phosphoproteins; Propylene Glycols; Reactive Oxygen Species; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Signal Transduction; Sphingosine | 2014 |
The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction.
Topics: Animals; Apolipoproteins E; Cardiotonic Agents; Coronary Artery Disease; Diet, High-Fat; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Propylene Glycols; Sphingosine; Survival Rate; T-Lymphocytes, Regulatory; Time Factors; Transforming Growth Factor beta; Ventricular Function, Left | 2014 |
Fingolimod-associated amenorrhea: a report of three cases.
Topics: Adult; Amenorrhea; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2014 |
Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
Topics: Cohort Studies; Databases, Factual; Demography; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Insurance Claim Review; Interferons; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Propylene Glycols; Recurrence; Sphingosine; Time Factors; United States | 2014 |
Fingolimod. Check cardiovascular status again on treatment resumption.
Topics: Cardiovascular Diseases; Death, Sudden; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2014 |
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
Topics: Adult; Atrial Fibrillation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Topics: ADP-ribosyl Cyclase 1; Adult; B-Lymphocyte Subsets; Biomarkers; Case-Control Studies; Cell Proliferation; Drug Resistance; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunologic Memory; Immunosuppressive Agents; Ki-67 Antigen; Lymphocyte Activation; Male; Membrane Glycoproteins; Middle Aged; Multiple Sclerosis; Phenotype; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine; Sphingosine-1-Phosphate Receptors; Syndecan-1; Time Factors; Treatment Outcome | 2014 |
Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells.
Topics: Animals; CD11b Antigen; Cell Differentiation; Cells, Cultured; Chemical and Drug Induced Liver Injury; Female; Fingolimod Hydrochloride; Immunoblotting; Immunosuppressive Agents; Liver; Male; Mice; Mice, Inbred C57BL; Myeloid Cells; Nitric Oxide; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Propylene Glycols; Receptors, Chemokine; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sirolimus; Sphingosine; T-Lymphocytes, Regulatory; Th1 Cells; TOR Serine-Threonine Kinases | 2014 |
Immune cell trafficking from the brain maintains CNS immune tolerance.
Topics: Animals; CD11 Antigens; Cell Movement; Cells, Cultured; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immune Tolerance; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neck; Propylene Glycols; Prosencephalon; Sphingosine; T-Lymphocytes, Regulatory | 2014 |
Effects of topical sphingosine-1-phosphate 1 receptor agonist on corneal allograft in mice.
Topics: Administration, Topical; Allografts; Animals; B7-2 Antigen; Cornea; Corneal Transplantation; CTLA-4 Antigen; Cyclosporine; Dendritic Cells; Fingolimod Hydrochloride; Graft Rejection; Graft Survival; Histocompatibility Antigens Class II; Immune Tolerance; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Animal; Ophthalmic Solutions; Propylene Glycols; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine | 2014 |
Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes.
Topics: Animals; Antibodies; Cell Proliferation; Cytokines; Diabetes Mellitus, Type 1; Disease Models, Animal; Drug Therapy, Combination; Fingolimod Hydrochloride; Hyperglycemia; Immunosuppressive Agents; Insulin-Secreting Cells; Lymph Nodes; Macrophages; Microscopy, Electron, Transmission; Propylene Glycols; Rats; Receptors, Antigen, T-Cell; Sphingosine; T-Lymphocytes | 2014 |
Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod.
Topics: Adult; Angioedema; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Knee; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Receptors, Lysosphingolipid; Skin; Sphingosine; Sphingosine-1-Phosphate Receptors | 2014 |
Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
Topics: Adult; B-Lymphocyte Subsets; B7-1 Antigen; Case-Control Studies; Chemotaxis, Leukocyte; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Interleukin-10; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Receptors, CCR7; Sphingosine; Tumor Necrosis Factor-alpha | 2014 |
Fingolimod after natalizumab and the risk of short-term relapse.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Risk Factors; Secondary Prevention; Sphingosine; Treatment Outcome | 2014 |
Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.
Topics: Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma.
Topics: Adolescent; Adult; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Electrophoresis, Gel, Two-Dimensional; Enzyme Activators; Female; Fingolimod Hydrochloride; Histone Chaperones; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Proteins; Propylene Glycols; Protein Phosphatase 2; Proteome; Proteomics; RNA Interference; Sarcoma, Alveolar Soft Part; Sphingosine; Transcription Factors; Young Adult | 2014 |
Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection.
Topics: Animals; Antigens, Protozoan; CD4-Positive T-Lymphocytes; Dendritic Cells; Epitopes, T-Lymphocyte; Female; Fingolimod Hydrochloride; Immunologic Memory; Immunosuppressive Agents; Leishmania donovani; Leishmaniasis, Visceral; Liver; Lymphocyte Activation; Lymphoid Tissue; Mice; Mice, Knockout; Propylene Glycols; Sphingosine; Spleen | 2014 |
Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
Topics: Adult; Brain; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kuwait; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Retrospective Studies; Sphingosine; Treatment Outcome; Young Adult | 2014 |
Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Fingolimod Hydrochloride; Humans; Propylene Glycols; Radiation Tolerance; Radiation-Sensitizing Agents; Resting Phase, Cell Cycle; Sphingosine | 2014 |
Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction.
Topics: Animals; Blotting, Western; Disease Models, Animal; Female; Fibrosis; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Inflammation; Kidney; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Transforming Growth Factor beta1; Ureteral Obstruction | 2014 |
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Topics: Animals; CD8-Positive T-Lymphocytes; Chemotaxis, Leukocyte; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Flow Cytometry; Granzymes; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Interferon-gamma; Lysophospholipids; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Propylene Glycols; Signal Transduction; Sphingosine | 2014 |
FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells.
Topics: Animals; Bone Marrow Cells; Carbon Tetrachloride; Cell Movement; Disease Models, Animal; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver Cirrhosis; Mesenchymal Stem Cells; Mice; Mice, Inbred ICR; Mice, SCID; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Wound Healing | 2014 |
Effects of fingolimod in relapsing-remitting multiple sclerosis.
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2014 |
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Association Learning; Brain; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Exploratory Behavior; Fingolimod Hydrochloride; Hippocampus; Male; Memory Disorders; Mice, Inbred C57BL; Neuroprotective Agents; Peptide Fragments; Propylene Glycols; Recognition, Psychology; Sphingosine; Up-Regulation | 2014 |
FTY720 protects retinal ganglion cells in experimental glaucoma.
Topics: Animals; Blotting, Western; Disease Models, Animal; Fingolimod Hydrochloride; Glaucoma; Immunohistochemistry; Injections, Intraperitoneal; Male; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Night Vision; Ocular Hypertension; Optic Disk; Phosphatidylinositol 3-Kinase; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Retina; Retinal Ganglion Cells; Sensory Thresholds; Sphingosine | 2014 |
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Health Services; Hospitalization; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propensity Score; Propylene Glycols; Recurrence; Retrospective Studies; Sphingosine; United States; Young Adult | 2014 |
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
Topics: Adult; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Lymphopenia; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
Topics: Cell Line, Tumor; DNA-Binding Proteins; Fingolimod Hydrochloride; Histone Chaperones; Humans; Leukemia, Myeloid, Acute; Peptides; Propylene Glycols; Protein Phosphatase 2; Sphingosine; Transcription Factors | 2014 |
Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors.
Topics: Animals; Cell Count; Cell Survival; Cells, Cultured; Coculture Techniques; Embryonic Stem Cells; Fingolimod Hydrochloride; Ganglia, Spinal; Humans; Immunosuppressive Agents; MAP Kinase Signaling System; Myelin Sheath; Neural Stem Cells; Neurogenesis; Oligodendroglia; p38 Mitogen-Activated Protein Kinases; Propylene Glycols; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2014 |
S1P1 receptor modulation preserves vascular function in mesenteric and coronary arteries after CPB in the rat independent of depletion of lymphocytes.
Topics: Animals; Blood Gas Analysis; Cardiopulmonary Bypass; Cell Count; Coronary Vessels; Fingolimod Hydrochloride; Follow-Up Studies; Interleukin-6; Lymphocytes; Male; Mesenteric Arteries; Oxadiazoles; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Vasoconstriction; Vasodilation | 2014 |
Alterations of calcium homoeostasis in cultured rat astrocytes evoked by bioactive sphingolipids.
Topics: Animals; Astrocytes; Calcium; Calcium Signaling; Cells, Cultured; Cytoplasmic Vesicles; Fingolimod Hydrochloride; Homeostasis; Microscopy, Confocal; Propylene Glycols; Rats; Rats, Wistar; Sphingolipids; Sphingosine | 2014 |
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2014 |
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Retrospective Studies; Risk Factors; Sphingosine | 2014 |
An approach to control relapse of inflammatory lesions after discontinuation of primary therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Cell Differentiation; Disease Models, Animal; Female; Fingolimod Hydrochloride; Herpesvirus 1, Human; Immunosuppressive Agents; Interleukin-6; Keratitis, Herpetic; Mice; Mice, Knockout; Propylene Glycols; Receptors, Lysosphingolipid; Recurrence; Secondary Prevention; Sphingosine; T-Lymphocyte Subsets | 2014 |
Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.
Topics: Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Inbred C57BL; Motor Activity; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Vocalization, Animal | 2014 |
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Biomarkers; Contrast Media; Databases, Factual; Disease-Free Survival; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Predictive Value of Tests; Propylene Glycols; Retrospective Studies; Serologic Tests; Sphingosine; Time Factors; Treatment Outcome | 2014 |
The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
Topics: Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Models, Biological; Phosphorylation; Propylene Glycols; Protein Kinase C-alpha; Protein Phosphatase 2; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; Signal Transduction; Sphingosine; src-Family Kinases | 2014 |
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Topics: Animals; Blotting, Western; Brain; Exploratory Behavior; Extinction, Psychological; Fear; Fingolimod Hydrochloride; Gene Expression; Hippocampus; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Immunosuppressive Agents; Isoenzymes; Learning Disabilities; Lysophospholipids; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Mice, SCID; Models, Molecular; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Spectrometry, Mass, Electrospray Ionization; Sphingosine | 2014 |
Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Topics: Animals; Cell Line; Cell Membrane Permeability; Cells, Cultured; Chemotaxis; CHO Cells; Cricetulus; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Mice; Mice, Inbred C57BL; Oxazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes; U937 Cells | 2014 |
Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.
Topics: Adult; Asthma; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fingolimod Hydrochloride; Gene Expression; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2014 |
The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.
Topics: Anilides; Animals; Antineoplastic Agents, Phytogenic; Cytokines; Enzyme Activation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indans; Lysophospholipids; Male; Neuralgia; Organophosphonates; Oxadiazoles; Paclitaxel; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazoles; Thiophenes | 2014 |
FTY720 attenuates paraquat-induced lung injury in mice.
Topics: Actins; Acute Lung Injury; Animals; Body Weight; Bronchoalveolar Lavage Fluid; Collagen Type I; Collagen Type III; Disease Models, Animal; Fingolimod Hydrochloride; Interleukin-1beta; Interleukin-6; Lung; Lung Injury; Mice; Mice, Inbred C57BL; Paraquat; Propylene Glycols; Pulmonary Edema; Pulmonary Fibrosis; Sphingosine; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2014 |
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
Topics: Coronary Artery Disease; Female; Fingolimod Hydrochloride; Heart Failure; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
Remission with fingolimod in a case of demyelinating polyneuropathy.
Topics: Adolescent; Demyelinating Diseases; Electric Stimulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Neural Conduction; Polyneuropathies; Propylene Glycols; Sphingosine | 2014 |
Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.
Topics: Animals; Cerebellum; Coculture Techniques; Cytokines; Demyelinating Diseases; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation Mediators; Mice; Mice, Transgenic; Myelin-Oligodendrocyte Glycoprotein; Phenotype; Propylene Glycols; Sphingosine; Spleen; T-Lymphocytes; Tissue Culture Techniques | 2014 |
Testing Aβ toxicity on primary CNS cultures using drug-screening microfluidic chips.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Dimethylpolysiloxanes; Embryo, Mammalian; Equipment Design; Fingolimod Hydrochloride; High-Throughput Screening Assays; Hippocampus; Microfluidic Analytical Techniques; Microglia; Neurons; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Printing, Three-Dimensional; Propylene Glycols; Protein Aggregation, Pathological; Rats; Shear Strength; Sphingosine; Surface Properties | 2014 |
Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.
Topics: Animals; Chromatography, Liquid; Female; Fingolimod Hydrochloride; Half-Life; Mice; Mice, Inbred ICR; Plasma; Propylene Glycols; Sphingosine; Tandem Mass Spectrometry | 2014 |
AV block II in a toddler after ingestion of a single tablet fingolimod.
Topics: Atrioventricular Block; Child, Preschool; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Propylene Glycols; Sphingosine | 2014 |
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Lymphoma, Mantle-Cell; Mice; Mice, Transgenic; Nanoparticles; Oligonucleotide Array Sequence Analysis; Phosphorylation; Propylene Glycols; Protein Kinase C; Receptor Tyrosine Kinase-like Orphan Receptors; Sphingosine; Treatment Outcome | 2015 |
A multiple sclerosis drug sheds light on astrocyte biology.
Topics: Animals; Astrocytes; Calcium; Fingolimod Hydrochloride; Propylene Glycols; Sphingolipids; Sphingosine | 2014 |
Unlocking the constraints on memory formation.
Topics: Animals; Extinction, Psychological; Fear; Fingolimod Hydrochloride; Histone Deacetylase Inhibitors; Immunosuppressive Agents; Memory; Propylene Glycols; Sphingosine | 2014 |
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation.
Topics: Administration, Intravenous; Administration, Oral; Animals; Blood Platelets; Double-Blind Method; Fingolimod Hydrochloride; Humans; Lysophospholipids; Male; Phosphates; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Randomized Controlled Trials as Topic; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Sphingosine | 2014 |
Tumefactive multiple sclerosis and fingolimod.
Topics: Brain Injuries; Encephalitis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Occipital Lobe; Propylene Glycols; Sphingosine | 2014 |
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain Injuries; Encephalitis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Magnetic Resonance Imaging; Multiple Sclerosis; Occipital Lobe; Propylene Glycols; Sphingosine | 2014 |
A sphingosine-1 phosphate agonist (FTY720) limits trauma/hemorrhagic shock-induced multiple organ dysfunction syndrome.
Topics: Acute Lung Injury; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Erythrocyte Deformability; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Multiple Organ Failure; Neutrophil Activation; Propylene Glycols; Rats, Sprague-Dawley; Respiratory Burst; Shock, Hemorrhagic; Sphingosine | 2014 |
Targeting the immune system in intracerebral hemorrhage.
Topics: Cerebral Hemorrhage; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Propylene Glycols; Sphingosine | 2014 |
Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kuwait; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Registries; Retrospective Studies; Severity of Illness Index; Sphingosine; Treatment Outcome | 2014 |
Marginal zone B cells transport IgG3-immune complexes to splenic follicles.
Topics: Animals; Antigen-Antibody Complex; Antigens; B-Lymphocytes; Dendritic Cells, Follicular; Female; Fingolimod Hydrochloride; Germinal Center; Immunoglobulin E; Immunoglobulin G; Immunoglobulin M; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Knockout; Ovalbumin; Propylene Glycols; Receptors, Complement 3d; Sphingosine; Spleen; Trinitrobenzenes | 2014 |
Neutrophils exhibit differential requirements for homing molecules in their lymphatic and blood trafficking into draining lymph nodes.
Topics: Adoptive Transfer; Animals; Antigen-Antibody Complex; Cell Movement; Female; Fingolimod Hydrochloride; Immune System Diseases; Immunosuppressive Agents; Inflammation; L-Selectin; Leukocyte Disorders; Lymph Nodes; Lymphatic Vessels; Lymphocyte Function-Associated Antigen-1; Lysophospholipids; Macrophage-1 Antigen; Mice; Mice, Inbred BALB C; Neutrophils; P-Selectin; Propylene Glycols; Receptors, CXCR4; Receptors, Lysosphingolipid; Sphingosine | 2014 |
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Drug Administration Routes; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Insurance Claim Review; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Natalizumab; Peptides; Proportional Hazards Models; Propylene Glycols; Retrospective Studies; Sphingosine; United States; Young Adult | 2014 |
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Animals; Evoked Potentials, Motor; Female; Fingolimod Hydrochloride; Glutamic Acid; Humans; Immunosuppressive Agents; Male; Middle Aged; Motor Cortex; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Prospective Studies; Sphingosine; Transcranial Magnetic Stimulation | 2015 |
FTY720 attenuates hypoxia-reoxygenation-induced apoptosis in cardiomyocytes.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Hypoxia; Cell Line; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-1beta; MAP Kinase Signaling System; Myocytes, Cardiac; Propylene Glycols; Rats; Sphingosine; Tumor Necrosis Factor-alpha | 2014 |
Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Ceramides; Epidermal Growth Factor; Extracellular Fluid; Fibroblast Growth Factor 2; Fingolimod Hydrochloride; Glioblastoma; Humans; Immunosuppressive Agents; Ki-67 Antigen; Lysophospholipids; Mice; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Propylene Glycols; Sphingolipids; Sphingosine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Topics: Aged; Animals; Astrocytes; Cells, Cultured; Cerebrum; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis; Neuroprotective Agents; Nitric Oxide; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-1 Type I; Receptors, Interleukin-17; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Spinal Cord | 2014 |
FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line; Ceramides; Core Binding Factor Alpha 2 Subunit; Fingolimod Hydrochloride; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice, Nude; Models, Molecular; Oncogene Proteins, Fusion; Propylene Glycols; Protein Phosphatase 2; RUNX1 Translocation Partner 1 Protein; Sphingolipids; Sphingosine | 2014 |
Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis.
Topics: Female; Fingolimod Hydrochloride; Health Care Costs; Heart Diseases; Hospitalization; Humans; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Retrospective Studies; Sphingosine | 2014 |
FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway.
Topics: Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Fingolimod Hydrochloride; Glioblastoma; Humans; Immunosuppressive Agents; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propylene Glycols; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sphingosine; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Wound Healing | 2014 |
Delivery of bioactive lipids from composite microgel-microsphere injectable scaffolds enhances stem cell recruitment and skeletal repair.
Topics: Abnormalities, Multiple; Animals; Bone Regeneration; Cataract; Cell Differentiation; Cell Movement; Cornea; Female; Fingolimod Hydrochloride; Gels; Hypogonadism; Intellectual Disability; Lipids; Mice; Mice, Inbred C57BL; Microcephaly; Microspheres; Optic Atrophy; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine; Stem Cells; Tissue Scaffolds | 2014 |
FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Brain Injuries; Disease Models, Animal; Encephalitis; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Lymphopenia; Mice; Mice, Inbred C57BL; Propylene Glycols; Signal Transduction; Sphingosine; T-Lymphocytes; Treatment Outcome | 2014 |
Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa.
Topics: Acid Ceramidase; Administration, Inhalation; Animals; Ceramides; Cystic Fibrosis; Disease Susceptibility; Fingolimod Hydrochloride; Humans; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sphingosine; Trachea | 2014 |
Fingolimod affects gene expression profile associated with LPS-induced memory impairment.
Topics: Animals; Avoidance Learning; Brain; Caspase 3; Dark Adaptation; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Interleukin-1beta; Lipopolysaccharides; Male; Memory Disorders; Nerve Tissue Proteins; Propylene Glycols; Rats; Rats, Wistar; Sphingosine; Transcriptome; Tumor Necrosis Factor-alpha | 2014 |
FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Inhibitory Concentration 50; Lysophospholipids; Melanoma; Phosphatidylinositol 3-Kinases; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Signal Transduction; Sphingosine | 2014 |
Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioning.
Topics: Animals; Fingolimod Hydrochloride; Inflammation; Kinetics; Lactic Acid; Ligands; Lymphocytes; Lysophospholipids; Male; Mice, Inbred C57BL; Microvessels; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Propylene Glycols; Prostheses and Implants; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine; Tissue Engineering; Vascular Remodeling | 2014 |
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Central Nervous System; Demyelinating Diseases; Disease Models, Animal; Encephalitis, Viral; Fingolimod Hydrochloride; Green Fluorescent Proteins; Immunosuppressive Agents; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Murine hepatitis virus; Nerve Tissue Proteins; Propylene Glycols; Severity of Illness Index; Sphingosine; T-Lymphocytes, Cytotoxic; Virus Replication | 2014 |
Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.
Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury.
Topics: Acute Kidney Injury; Animals; Apoptosis; Cell Respiration; Cisplatin; Drug Evaluation, Preclinical; Epithelial Cells; Fingolimod Hydrochloride; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Mitochondria; Mitochondrial Dynamics; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2015 |
[Effect of a novel selective S1P1 agonist, Syl948, on mouse skin transplantation].
Topics: Animals; Fingolimod Hydrochloride; Graft Survival; Immunosuppressive Agents; Lymphocytes; Mice; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Skin Transplantation; Sphingosine; Transplantation, Homologous | 2014 |
High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type I, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists.
Topics: Animals; Cell Line; Cell Movement; Cells, Cultured; Fingolimod Hydrochloride; Intracellular Signaling Peptides and Proteins; Lipoproteins, HDL; Macrophages; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxadiazoles; Pertussis Toxin; Propylene Glycols; Proto-Oncogene Proteins c-akt; Receptors, Lysosphingolipid; Scavenger Receptors, Class B; Sphingosine; Thiophenes | 2014 |
TRPM7 regulates proliferation and polarisation of macrophages.
Topics: 1-Naphthylamine; Animals; Apoptosis; Cell Polarity; Cell Proliferation; Cells, Cultured; Electrophysiology; Fingolimod Hydrochloride; Interleukin-4; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; TRPM Cation Channels; Tumor Necrosis Factor-alpha | 2014 |
Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells.
Topics: Animals; Calcium; Cell Line; Cytokines; Dendritic Cells; Epitopes, T-Lymphocyte; Fingolimod Hydrochloride; Homeostasis; Immunosuppressive Agents; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Interleukins; Lymphocyte Activation; Mice; Propylene Glycols; Receptors, Interleukin; Signal Transduction; Sphingosine; T-Lymphocyte Subsets; Toll-Like Receptors | 2014 |
Prolonging survival of corneal transplantation by selective sphingosine-1-phosphate receptor 1 agonist.
Topics: Animals; Corneal Transplantation; Cytokines; Fingolimod Hydrochloride; Gene Expression Regulation; Graft Survival; Inflammation; Kidney; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Time Factors | 2014 |
The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination.
Topics: Amyloid beta-Protein Precursor; Animals; Corpus Callosum; Cuprizone; Demyelinating Diseases; Fingolimod Hydrochloride; Gene Expression Regulation; Liver; Male; Membrane Proteins; Mice, Inbred C57BL; Neuroprotective Agents; Phosphatidate Phosphatase; Phosphoric Monoester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2015 |
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Microscopy, Electron, Transmission; Phosphotransferases (Alcohol Group Acceptor); Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Propylene Glycols; Sphingosine; Thiazoles; Unfolded Protein Response | 2014 |
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Kaplan-Meier Estimate; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Observation; Propylene Glycols; Retrospective Studies; Severity of Illness Index; Sphingosine; Treatment Outcome | 2014 |
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Topics: Animals; Antigens, CD; Central Nervous System; Disease Models, Animal; Fingolimod Hydrochloride; Glatiramer Acetate; Immunologic Surveillance; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Peptides; Propylene Glycols; Sphingosine; Toxoplasmosis | 2014 |
S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection.
Topics: Animals; CD11 Antigens; CD11b Antigen; Cell Movement; Chemokine CCL21; Dendritic Cells; Female; Fingolimod Hydrochloride; Integrin alpha Chains; Lymph Nodes; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Oxadiazoles; Phagocytes; Plague; Propylene Glycols; Receptors, CCR2; Receptors, CCR7; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Yersinia pestis | 2014 |
Prominence of central sphingosine-1-phosphate receptor-1 in attenuating aβ-induced injury by fingolimod.
Topics: Alzheimer Disease; Animals; Cyclooxygenase 2; Enzyme Inhibitors; Fingolimod Hydrochloride; Male; Maze Learning; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Tumor Necrosis Factor-alpha | 2014 |
Oral fingolimod to treat multiple sclerosis: see your cardiologist first.
Topics: Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
Topics: Adult; Aged; Bradycardia; Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Time Factors; Young Adult | 2014 |
Enantioselective desymmetrization of FTY720.
Topics: Acylation; Benzoates; Catalysis; Coordination Complexes; Copper; Fingolimod Hydrochloride; Oxazoles; Propylene Glycols; Solvents; Sphingosine; Stereoisomerism | 2014 |
Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.
Topics: Aged; Animals; Case-Control Studies; Cell Line; Cells, Cultured; Coronary Artery Disease; Cricetulus; Drug Resistance; Endocytosis; Female; Fingolimod Hydrochloride; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; Lysophospholipids; Male; Middle Aged; Mutant Proteins; Polymorphism, Single Nucleotide; Propylene Glycols; Receptors, Lysosphingolipid; Recombinant Fusion Proteins; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2014 |
From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela.
Topics: Animals; Antibodies, Monoclonal, Humanized; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glatiramer Acetate; History, 20th Century; History, 21st Century; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Peptides; Propylene Glycols; Sphingosine | 2014 |
Sphingosine-1-phosphate receptor agonist, FTY720, restores coronary flow reserve in diabetic rats.
Topics: Ammonia; Animals; Blood Glucose; Capillaries; Cell Adhesion Molecules; Collagen; Coronary Circulation; Coronary Disease; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Gene Expression Regulation; Interleukin-6; Lysophospholipids; Male; Microcirculation; Myocardium; Nitrogen Radioisotopes; Positron-Emission Tomography; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Transforming Growth Factor beta | 2014 |
Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine | 2014 |
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Cohort Studies; Cost-Benefit Analysis; Dimethyl Fumarate; Disability Evaluation; Female; Fingolimod Hydrochloride; Fumarates; Humans; Immunologic Factors; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Male; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine; Young Adult | 2015 |
FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Topics: Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Metastasis; Phosphorylation; Propylene Glycols; Signal Transduction; Sphingosine; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
Topics: Animals; Benzimidazoles; Blood Pressure; Bronchoconstriction; Cell Line; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Heart Rate; Lymphocytes; Male; Mice; Oxadiazoles; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2014 |
Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.
Topics: Adenosine Triphosphate; Autophagy; Cell Death; Cell Line, Tumor; Cell Membrane; Dimethyl Sulfoxide; Fingolimod Hydrochloride; Humans; Macrolides; Melanoma; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Phosphatase 2; Reactive Oxygen Species; Sphingosine; Vacuolar Proton-Translocating ATPases | 2015 |
Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
Topics: Adolescent; Adult; Aged; B-Lymphocyte Subsets; B7-1 Antigen; B7-2 Antigen; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Young Adult | 2014 |
Recognizing and overcoming potential barriers to oral medications for MS.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Preclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaques.
Topics: Administration, Intravaginal; Administration, Intravenous; Animals; Cervix Uteri; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; HIV Infections; Immunomodulation; Immunosuppressive Agents; Lymphocytes; Macaca nemestrina; Mucous Membrane; Pilot Projects; Propylene Glycols; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Sphingosine; Vagina | 2014 |
FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation Mediators; Kidney Tubules; Lymphocytes; Lysophospholipids; Macrophages; Male; Nephritis, Interstitial; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats, Wistar; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Time Factors | 2014 |
VZV encephalitis that developed in an immunized patient during fingolimod therapy.
Topics: Encephalitis, Varicella Zoster; Female; Fingolimod Hydrochloride; Herpes Zoster Vaccine; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Chronic Progressive; Propylene Glycols; Sphingosine | 2015 |
Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug.
Topics: Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Male; Medication Reconciliation; Propylene Glycols; Sphingosine | 2015 |
Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Kinase Inhibitors; RNA, Small Interfering; Sphingosine; Xenograft Model Antitumor Assays | 2015 |
Blocking lymphocyte trafficking with FTY720 prevents inflammation-sensitized hypoxic-ischemic brain injury in newborns.
Topics: Animals; Animals, Newborn; Atrophy; Blood-Brain Barrier; Brain; Cell Movement; Chorioamnionitis; Cytokines; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Humans; Hypoxia-Ischemia, Brain; Immunosuppressive Agents; Infant, Newborn; Inflammation; Lipopolysaccharides; Lymphocyte Activation; Lymphocytes; NF-kappa B; Pregnancy; Propylene Glycols; Rats; Receptors, Interleukin; Sphingosine; T-Lymphocytes; White Matter | 2014 |
Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier.
Topics: Animals; Blood-Brain Barrier; CD8-Positive T-Lymphocytes; Cerebral Cortex; Claudin-5; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Macrophages; Malaria, Cerebral; Mice; Neutrophils; Occludin; Plasmodium berghei; Plasmodium yoelii; Propylene Glycols; Sphingosine; Zonula Occludens-1 Protein | 2014 |
[Fingolimod treatment in multiple sclerosis].
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
Topics: Animals; Autoradiography; BCG Vaccine; Carrier Proteins; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Freund's Adjuvant; Immunohistochemistry; Immunosuppressive Agents; Inflammation; Ligands; Male; Microglia; Multiple Sclerosis; Positron-Emission Tomography; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, GABA-A; Sphingosine; Time Factors | 2015 |
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sjogren's Syndrome; Sphingosine | 2015 |
Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Influenza Vaccines; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine; Vaccination | 2015 |
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Propylene Glycols; Retrospective Studies; Sphingosine; Treatment Outcome | 2015 |
Delayed cardiac dysrhythmias after fingolimod administration.
Topics: Atrioventricular Block; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Propylene Glycols; Sphingosine; Tachycardia, Ectopic Junctional; Time Factors | 2015 |
Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.
Topics: Animals; Cells, Cultured; Female; Fingolimod Hydrochloride; Lysophospholipids; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Organophosphates; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Spleen; Tandem Mass Spectrometry | 2015 |
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Topics: Blood-Brain Barrier; Cell Line, Transformed; Claudin-5; Endothelial Cells; Fingolimod Hydrochloride; Gene Expression; Humans; Immune Sera; Immunosuppressive Agents; Multiple Sclerosis; NF-kappa B; Propylene Glycols; RNA, Messenger; Sphingosine; Vascular Cell Adhesion Molecule-1 | 2015 |
Synthesis and evaluation of fluorinated fingolimod (FTY720) analogues for sphingosine-1-phosphate receptor molecular imaging by positron emission tomography.
Topics: Animals; Fingolimod Hydrochloride; Fluorine Radioisotopes; Halogenation; Male; Mice; Mice, Inbred C57BL; Molecular Imaging; Positron-Emission Tomography; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2015 |
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; Cell Movement; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Homeodomain Proteins; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Knockout; Multiple Sclerosis; Propylene Glycols; Proto-Oncogene Proteins c-cbl; Sphingosine; T-Lymphocytes | 2015 |
Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
Topics: Adult; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Tachycardia, Ventricular | 2015 |
Sphingosin-1-phosphate Receptor 1: a Potential Target to Inhibit Neuroinflammation and Restore the Sphingosin-1-phosphate Metabolism.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Fingolimod Hydrochloride; Inflammation; Lipopolysaccharides; Lysophospholipids; Male; Maze Learning; Memory Disorders; Oxadiazoles; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Thiophenes; Tumor Necrosis Factor-alpha | 2015 |
Junctional complex and focal adhesion rearrangement mediates pulmonary endothelial barrier enhancement by FTY720 S-phosphonate.
Topics: Acute Lung Injury; Antigens, CD; Antigens, Nuclear; Cadherins; Endothelial Cells; Fingolimod Hydrochloride; Focal Adhesion Protein-Tyrosine Kinases; Focal Adhesions; Humans; Immunosuppressive Agents; Lung; Lysophospholipids; Microscopy, Fluorescence; Nerve Tissue Proteins; Organophosphonates; Proto-Oncogene Proteins c-akt; rac1 GTP-Binding Protein; Receptors, Lysosphingolipid; RNA, Small Interfering; Sphingosine; Transcription Factors; Zonula Occludens-1 Protein | 2015 |
FTY720 mitigates torsion/detorsion-induced testicular injury in rats.
Topics: Animals; Drug Evaluation, Preclinical; Edema; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Lipid Metabolism; Male; Neutrophil Infiltration; Propylene Glycols; Random Allocation; Rats, Sprague-Dawley; Spermatic Cord Torsion; Sphingosine; Testis | 2015 |
The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue.
Topics: Animals; Atrioventricular Node; Dissection; Fingolimod Hydrochloride; Gene Expression Regulation; Lysophospholipids; Rats; Receptors, Lysosphingolipid; Reperfusion Injury; RNA, Messenger; Sphingosine | 2015 |
Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leg; Male; Multiple Sclerosis; Propylene Glycols; Recurrence; Remission, Spontaneous; Sarcoma, Kaposi; Sphingosine; Treatment Outcome | 2015 |
Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3.
Topics: Action Potentials; Anilides; Animals; Cells, Cultured; Dinoprostone; Enzyme Inhibitors; Fingolimod Hydrochloride; Ganglia, Spinal; Gene Expression Regulation; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Inbred C57BL; Organophosphonates; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; RNA, Small Interfering; Sensory Receptor Cells; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazolidines | 2015 |
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2015 |
Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cyclopentanes; Cytokines; Fingolimod Hydrochloride; Flow Cytometry; Immunoenzyme Techniques; Immunosuppressive Agents; Lung Injury; Lysophospholipids; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Reperfusion Injury; Sphingosine; Sphingosine-1-Phosphate Receptors | 2015 |
Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
Topics: Apoptosis; DNA-Binding Proteins; Fingolimod Hydrochloride; Histone Chaperones; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Phosphotyrosine; Propylene Glycols; Protein Interaction Maps; Protein Phosphatase 2; Signal Transduction; Sphingosine; src-Family Kinases; Transcription Factors; Tumor Cells, Cultured | 2015 |
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antigens, Neoplasm; Cytotoxins; Drug Delivery Systems; Fingolimod Hydrochloride; Histocompatibility Antigens Class II; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Propylene Glycols; Receptor Tyrosine Kinase-like Orphan Receptors; Sphingosine; Xenograft Model Antitumor Assays | 2015 |
Sphingosine 1-phosphate signaling at the blood-brain barrier.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Capillary Permeability; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2015 |
FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers; Cell Line, Tumor; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Glioblastoma; Humans; Male; Membrane Proteins; Mice, Nude; Necrosis; Neoplasm Proteins; Propylene Glycols; Reactive Oxygen Species; Receptor-Interacting Protein Serine-Threonine Kinases; RNA Interference; Signal Transduction; Sphingosine; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
Topics: Adult; Encephalitis, Herpes Simplex; Fingolimod Hydrochloride; Herpesvirus 1, Human; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Virus Activation | 2015 |
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Topics: Antibodies, Monoclonal, Humanized; Drug Substitution; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2015 |
Local delivery of FTY720 in PCL membrane improves SCI functional recovery by reducing reactive astrogliosis.
Topics: Administration, Topical; Animals; Delayed-Action Preparations; Fingolimod Hydrochloride; Gliosis; Immunosuppressive Agents; Lysophospholipids; Male; Membranes, Artificial; Polyesters; Rats; Rats, Sprague-Dawley; Recovery of Function; Sphingosine; Spinal Cord Injuries; Treatment Outcome | 2015 |
HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation.
Topics: Animals; Apolipoproteins; Apolipoproteins M; Blood-Brain Barrier; Cell Movement; Cell Proliferation; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cells; Inflammation; Lipoproteins, HDL; Lymphocytes; Lymphoid Progenitor Cells; Lymphopoiesis; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2015 |
[Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
Topics: Antibodies, Monoclonal, Humanized; Disease-Free Survival; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Treatment Outcome | 2014 |
Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Topics: Adult; Astrocytes; Blood-Brain Barrier; Cell Movement; Cell Survival; Cytokines; Endothelial Cells; Fingolimod Hydrochloride; Granulocyte-Macrophage Colony-Stimulating Factor; Healthy Volunteers; Humans; Inflammation; Leukocytes; Lysophospholipids; Microcirculation; Middle Aged; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction; Sphingolipids; Sphingosine; Stress, Mechanical; Young Adult | 2015 |
Safety and efficacy of reduced fingolimod dosage treatment.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Liver Function Tests; Lymphocytes; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult | 2015 |
Fingolimod does not enhance cerebellar remyelination in the cuprizone model.
Topics: Animals; Cerebellum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine | 2015 |
Pulmonary endothelial cell barrier enhancement by novel FTY720 analogs: methoxy-FTY720, fluoro-FTY720, and β-glucuronide-FTY720.
Topics: Calcium; Cell Line; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Fluorides; Glucuronides; Humans; Lysophospholipids; Microscopy, Fluorescence; Permeability; Phosphorylation; Pulmonary Artery; Signal Transduction; Sphingosine | 2015 |
Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Proliferation; Cytarabine; Drug Delivery Systems; Enzyme Activation; Female; Fingolimod Hydrochloride; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipids; Mice; Mice, Transgenic; Nanoparticles; Nanotechnology; Propylene Glycols; Sphingosine | 2015 |
Comment on "Fingolimod effects on left ventricular function in multiple sclerosis" Mult Scler 2015.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Ventricular Function, Left | 2016 |
Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sphingosine; Ventricular Function, Left | 2016 |
Galactosylsphingosine (psychosine)-induced demyelination is attenuated by sphingosine 1-phosphate signalling.
Topics: Animals; Apoptosis; Astrocytes; Demyelinating Diseases; Fingolimod Hydrochloride; Humans; Leukodystrophy, Globoid Cell; Lipopolysaccharides; Lysophospholipids; Mice; Microscopy, Fluorescence; Psychosine; Rats; Signal Transduction; Sphingosine | 2015 |
Fingolimod induces neuroprotective factors in human astrocytes.
Topics: Astrocytes; Chemokine CXCL10; Corpus Striatum; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fetus; Fingolimod Hydrochloride; Heparin-binding EGF-like Growth Factor; Humans; Interleukin-11; Lysophospholipids; Microarray Analysis; Neural Stem Cells; Neuroprotective Agents; NF-kappa B; RNA, Messenger; RNA, Small Interfering; Sphingosine; Time Factors | 2015 |
Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia.
Topics: Animals; Animals, Newborn; Brain; Cognition Disorders; Diffusion Magnetic Resonance Imaging; Female; Fingolimod Hydrochloride; Hyperoxia; Lysophospholipids; Male; Microglia; Nerve Fibers, Myelinated; Oligodendroglia; Oxygen; Pregnancy; Random Allocation; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; White Matter | 2016 |
Exogenous S1P Exposure Potentiates Ischemic Stroke Damage That Is Reduced Possibly by Inhibiting S1P Receptor Signaling.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Fingolimod Hydrochloride; Lysophospholipids; Male; Mice; Mice, Inbred ICR; Microinjections; Neuroglia; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Stroke; Tumor Necrosis Factor-alpha | 2015 |
Mechanism of sphingosine-1-phosphate induced cardioprotection against I/R injury in diabetic rat heart: Possible involvement of glycogen synthase kinase 3β and mitochondrial permeability transition pore.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Creatine Kinase, MB Form; Diabetes Mellitus, Experimental; Diet, High-Fat; Fingolimod Hydrochloride; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Ischemic Preconditioning; Lipids; Lysophospholipids; Male; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Sphingosine | 2016 |
Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction.
Topics: Animals; Animals, Newborn; Cytokines; Fingolimod Hydrochloride; Heart Diseases; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocarditis; Myocytes, Cardiac; Phosphotransferases (Alcohol Group Acceptor); Rats, Sprague-Dawley; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Transfection; Ultrasonography | 2016 |
Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors.
Topics: Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Nervous System; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2016 |
Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; DNA-Binding Proteins; Female; Fingolimod Hydrochloride; Histone Chaperones; Interferon-gamma; Interleukin-2; Interleukin-33; Lysophospholipids; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Oncogene Proteins; Organophosphates; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Phosphatase 2; Sphingosine; Spleen | 2016 |
Cigarette smoke inhibits efferocytosis via deregulation of sphingosine kinase signaling: reversal with exogenous S1P and the S1P analogue FTY720.
Topics: Bronchi; Cells, Cultured; Epithelial Cells; Fingolimod Hydrochloride; Gene Expression Regulation, Enzymologic; Humans; Immunosuppressive Agents; Lysophospholipids; Macrophages, Alveolar; Phagocytosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Pulmonary Disease, Chronic Obstructive; Signal Transduction; Smoking; Sphingosine | 2016 |
Sphingosine 1-phospate differentially modulates maturation and function of human Langerhans-like cells.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cytokines; Endocytosis; Fingolimod Hydrochloride; Humans; Langerhans Cells; Lysophospholipids; Phenotype; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2016 |
The Role of Sphingosine-1-Phosphate in Adipogenesis of Graves' Orbitopathy.
Topics: Adipogenesis; Adult; Blotting, Western; CCAAT-Enhancer-Binding Protein-beta; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cells, Cultured; Female; Fibroblasts; Fingolimod Hydrochloride; Graves Ophthalmopathy; Humans; Immunosuppressive Agents; Lysophospholipids; Male; Middle Aged; Orbit; PPAR gamma; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine | 2016 |
Novel effects of FTY720 on perinuclear reorganization of keratin network induced by sphingosylphosphorylcholine: Involvement of protein phosphatase 2A and G-protein-coupled receptor-12.
Topics: Cell Line; Cell Movement; Fingolimod Hydrochloride; Humans; Keratin-8; Organophosphates; Phosphorylation; Phosphorylcholine; Protein Phosphatase 2; Receptors, G-Protein-Coupled; RNA, Small Interfering; Sphingosine | 2016 |
FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Movement; Chick Embryo; Chorioallantoic Membrane; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Sphingosine; Thyroid Neoplasms | 2016 |
Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2.
Topics: Aldehyde-Lyases; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Drug Synergism; Female; Fingolimod Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lysophospholipids; Male; Middle Aged; Mouth Neoplasms; Phenotype; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2016 |
Interstitial Fluid Sphingosine-1-Phosphate in Murine Mammary Gland and Cancer and Human Breast Tissue and Cancer Determined by Novel Methods.
Topics: Activation, Metabolic; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Extracellular Fluid; Female; Fingolimod Hydrochloride; Humans; Isoenzymes; Lysophospholipids; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Mice, Knockout; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Random Allocation; Sphingosine; Tumor Microenvironment | 2016 |
The Adipose Mesenchymal Stem Cell Secretome Inhibits Inflammatory Responses of Microglia: Evidence for an Involvement of Sphingosine-1-Phosphate Signalling.
Topics: Adipose Tissue; Adult; Cell Proliferation; Cell Separation; Chemotaxis; Culture Media, Conditioned; Cytokines; Down-Regulation; Female; Fingolimod Hydrochloride; Humans; Inflammation; Lipopolysaccharides; Lysophospholipids; Male; Mesenchymal Stem Cells; Microglia; Middle Aged; Phenotype; Proteome; Signal Transduction; Sphingosine | 2016 |
Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Fingolimod Hydrochloride; Heart; Humans; Inflammation; Lipopolysaccharides; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Myocardial Contraction; Myocardium; Peptidoglycan; Phosphatidylinositol 3-Kinases; Phosphorylation; Pilot Projects; Receptors, Lysosphingolipid; Sepsis; Sphingosine | 2016 |
FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fingolimod Hydrochloride; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Lysophospholipids; Mice; Neovascularization, Pathologic; Oxygen Consumption; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Vascular Endothelial Growth Factor A; Vascular Remodeling; Xenograft Model Antitumor Assays | 2016 |
Differential Effects of Long Term FTY720 Treatment on Endothelial versus Smooth Muscle Cell Signaling to S1P in Rat Mesenteric Arteries.
Topics: Animals; Body Weight; Endothelial Cells; Fingolimod Hydrochloride; Gene Expression Regulation; Hemodynamics; Humans; Lysophospholipids; Male; Mesenteric Arteries; Muscle Development; Myocytes, Smooth Muscle; Pressure; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Time Factors; Vasoconstriction | 2016 |
Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.
Topics: Adult; Autonomic Nervous System; Circadian Rhythm; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Sphingosine | 2016 |
High-Resolution Expression Profiling of Peripheral Blood CD8
Topics: Adult; CD8-Positive T-Lymphocytes; Cytokines; Cytotoxicity, Immunologic; Female; Fingolimod Hydrochloride; Humans; Lysophospholipids; Male; Middle Aged; Multiple Sclerosis; Phenotype; Sphingosine | 2017 |
Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis.
Topics: Animals; Capillary Permeability; Cells, Cultured; Cytokines; Fingolimod Hydrochloride; Immunomodulation; Lysophospholipids; Membrane Proteins; Mice; Mice, Inbred C57BL; Phosphoric Monoester Hydrolases; Pyridoxine; Receptors, Lysosphingolipid; Sepsis; Signal Transduction; Sphingosine; Vascular Endothelial Growth Factor A | 2016 |
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-gamma; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Phenotype; Sphingosine; T-Lymphocytes | 2016 |
Characterization of the Anticoagulant and Antithrombotic Properties of the Sphingosine 1-Phosphate Mimetic FTY720.
Topics: Adenosine Diphosphate; Animals; Anticoagulants; Arteriovenous Shunt, Surgical; Biomimetic Materials; Blood Platelets; Carotid Artery, Common; Chlorides; Disease Models, Animal; Ferric Compounds; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Lysophospholipids; Male; Platelet Aggregation; Platelet Function Tests; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Thrombosis; Vena Cava, Inferior | 2017 |
Selective Sphingosine 1-Phosphate Receptor 1 Agonist Is Protective Against Ischemia/Reperfusion in Mice.
Topics: Animals; Cerebral Infarction; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphopenia; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Receptors, Lysosphingolipid; Reperfusion Injury; Sphingosine | 2016 |
Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension.
Topics: Adoptive Transfer; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Bone Marrow Transplantation; Cell Movement; Disease Models, Animal; Fingolimod Hydrochloride; Genetic Predisposition to Disease; Hypertension; Inflammation Mediators; Lymph Nodes; Lysophospholipids; Mesenteric Arteries; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes; Time Factors; Vascular Remodeling | 2017 |
Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
Topics: Animals; Astrocytes; Cell Line, Tumor; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Microglia; Monocytes; Multiple Sclerosis, Chronic Progressive; Primary Cell Culture; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Transcriptome | 2017 |
Analysis of sphingolipids in human corneal fibroblasts from normal and keratoconus patients.
Topics: Cell Line; Ceramides; Cornea; Fibroblasts; Fingolimod Hydrochloride; Humans; Keratoconus; Lysophospholipids; RNA, Messenger; Signal Transduction; Sphingolipids; Sphingosine; Transforming Growth Factor beta1; Transforming Growth Factor beta2; Transforming Growth Factor beta3 | 2017 |
FTY720 Attenuates Angiotensin II-Induced Podocyte Damage via Inhibiting Inflammatory Cytokines.
Topics: Adult; Angiotensin II; Animals; Cell Adhesion; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Humans; Immunohistochemistry; Interleukin-6; Lysophospholipids; Male; Middle Aged; Podocytes; Radioimmunoassay; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Renal Insufficiency, Chronic; Sphingosine; Tumor Necrosis Factor-alpha; Wound Healing; Young Adult | 2017 |
Evaluation and Optimization of
Topics: Algorithms; Animals; Crystallography, X-Ray; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lysophospholipids; Molecular Structure; Multiple Sclerosis; Protein Structure, Secondary; Receptors, Lysosphingolipid; Sphingosine | 2017 |
Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis.
Topics: Actins; Aldehyde-Lyases; Animals; Cell Line; Cell Movement; Chemical and Drug Induced Liver Injury, Chronic; Collagen Type I; Collagen Type I, alpha 1 Chain; Female; Fingolimod Hydrochloride; Gene Expression; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis; Lymph; Lysophospholipids; Macrophages; Male; Membrane Proteins; Mice; Monocytes; Neutrophils; Phosphoric Monoester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); Sphingosine | 2017 |
Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.
Topics: Animals; Ceramides; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Rats; Serine C-Palmitoyltransferase; Sphingosine; Spinal Cord | 2017 |
A Brain-Region-Specific Neural Pathway Regulating Germinal Matrix Angiogenesis.
Topics: Brain; Embryo, Mammalian; Enzyme Activation; Fingolimod Hydrochloride; Guanine Nucleotide Exchange Factors; Hemorrhage; Humans; Integrin beta Chains; Lysophospholipids; Mutation; Neostriatum; Neovascularization, Physiologic; Neural Pathways; Neural Stem Cells; Organ Specificity; p38 Mitogen-Activated Protein Kinases; Phenotype; Receptors, Lysosphingolipid; Reward; Signal Transduction; Sphingosine; Transforming Growth Factor beta | 2017 |
Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion.
Topics: Animals; Cytosol; Excitatory Postsynaptic Potentials; Exocytosis; Fingolimod Hydrochloride; Glutamic Acid; Hippocampus; Male; Multiple Sclerosis; Neurons; Neurosecretory Systems; R-SNARE Proteins; Rats, Wistar; SNARE Proteins; Sphingosine; Synaptic Vesicles; Synaptosomes | 2017 |
Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow.
Topics: Animals; Blood Flow Velocity; Cochlea; Cytokines; Fingolimod Hydrochloride; Guinea Pigs; Immunosuppressive Agents; Lysophospholipids; Microcirculation; Microscopy, Fluorescence; Signal Transduction; Sphingosine; Tumor Necrosis Factor-alpha | 2017 |
Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration.
Topics: Animals; Camphanes; Cell Movement; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indans; Inflammatory Bowel Diseases; Leukocytes; Lysophospholipids; Molecular Targeted Therapy; Oxadiazoles; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sulfhydryl Compounds; Sulfonamides | 2018 |
Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Mammary Neoplasms, Experimental; Mice; Obesity; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Retrospective Studies; Sphingosine; STAT3 Transcription Factor | 2017 |
Fingolimod Suppresses a Cascade of Core Vicious Cycle in Dry Eye NOD Mouse Model: Involvement of Sphingosine-1-Phosphate Receptors in Infiltrating Leukocytes.
Topics: Animals; Blotting, Western; Disease Models, Animal; Dry Eye Syndromes; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Leukocytes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Receptors, Lysosphingolipid; Sphingosine | 2017 |
S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense.
Topics: Adaptive Immunity; Animals; Cell Proliferation; Chemotaxis; Female; Fingolimod Hydrochloride; Homeodomain Proteins; Homeostasis; Immunity, Innate; Immunosuppressive Agents; Interleukin-17; Intestines; Lung; Lymphocytes; Lysophospholipids; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mucous Membrane; Nippostrongylus; Sphingosine; Strongylida Infections; T-Lymphocytes | 2018 |
Targeting the SphK1/S1P/S1PR1 Axis That Links Obesity, Chronic Inflammation, and Breast Cancer Metastasis.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Culture Media, Conditioned; Cytokines; Diet, High-Fat; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Interleukin-6; Lung; Lysophospholipids; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Obesity; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2018 |
The Sphingosine 1-Phosphate Analogue FTY720 Alleviates Seizure-induced Overexpression of P-Glycoprotein in Rat Hippocampus.
Topics: Anilides; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclooxygenase 2; Disease Models, Animal; Drug Resistant Epilepsy; Fingolimod Hydrochloride; Hippocampus; Humans; Immunosuppressive Agents; Injections, Intraperitoneal; Lysophospholipids; Male; Organophosphonates; Phenytoin; Pilocarpine; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Up-Regulation | 2018 |
In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Fingolimod Hydrochloride; Mice; Molecular Structure; Sphingosine; Structure-Activity Relationship | 2018 |
Exploring the Protective Role and the Mechanism of Sphingosine 1 Phosphate in Endotoxic Cardiomyocytes.
Topics: Animals; Apoptosis; Cell Line; Cytokines; Endotoxins; Fingolimod Hydrochloride; Lysophospholipids; MAP Kinase Signaling System; Myocytes, Cardiac; NF-kappa B; Rats; Sepsis; Sphingosine | 2019 |
Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.
Topics: Animals; Astrocytes; Autoantibodies; Behavior Observation Techniques; Behavior, Animal; Brain; Cognition; Cytokines; Depression; Disease Models, Animal; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Lupus Vasculitis, Central Nervous System; Lysophospholipids; Mice; Mice, Inbred MRL lpr; Microglia; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Treatment Outcome | 2018 |
Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide.
Topics: Amyloid beta-Peptides; Animals; Anion Transport Proteins; Cytokines; Fingolimod Hydrochloride; Inflammation; Lipopolysaccharides; Lysophospholipids; Maze Learning; Memory, Short-Term; Mice; Mice, Knockout; Microglia; NF-kappa B; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2019 |
Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism.
Topics: Animals; Cells, Cultured; Chromatography, Liquid; Computational Biology; Fingolimod Hydrochloride; Nerve Regeneration; Organophosphates; Rats; Schwann Cells; Signal Transduction; Smad Proteins; Sphingosine; Tandem Mass Spectrometry; Trichloroacetic Acid | 2019 |
Small molecule of sphingosine as a rescue of dopaminergic cells: A cell therapy approach in neurodegenerative diseases therapeutics.
Topics: bcl-2-Associated X Protein; Calcium Channels, L-Type; Cell Line; Cell Survival; Dopaminergic Neurons; Fingolimod Hydrochloride; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Humans; Immunosuppressive Agents; L-Lactate Dehydrogenase; Nitric Oxide; Propidium; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Receptors, GABA-A; Sphingosine; Tyrosine 3-Monooxygenase | 2019 |
The involvement of blood cells in the phosphorylation of the selective sphingosine-1-phosphate receptor 1 agonist SYL-927.
Topics: Administration, Oral; Animals; Blood Platelets; Erythrocytes; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Rats; Receptors, Lysosphingolipid; Sphingosine | 2019 |
The S1P mimetic fingolimod phosphate regulates mitochondrial oxidative stress in neuronal cells.
Topics: Animals; Antioxidants; Cell Death; Cell Line; Dopaminergic Neurons; Fingolimod Hydrochloride; Humans; Lysophospholipids; Membrane Potential, Mitochondrial; Mice; Mitochondria; Molecular Mimicry; Multiple Sclerosis; Neuroprotection; Oxidative Stress; Oxygen Consumption; Phosphates; Reactive Oxygen Species; Sphingosine; Sphingosine-1-Phosphate Receptors; Vitamin K 3 | 2019 |
FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.
Topics: Acetylation; Animals; Diet, High-Fat; Fatty Acid Synthases; Female; Fingolimod Hydrochloride; Immunoblotting; Insulin Resistance; Liver; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organophosphates; Sphingolipids; Sphingosine; Triglycerides | 2019 |
Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
Topics: Animals; Brain; Brain Ischemia; Fingolimod Hydrochloride; Hemoglobins; Hemorrhage; Lymphocytes; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Reperfusion Injury; RNA, Messenger; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Stroke; T-Lymphocytes; Thrombocytopenia; Up-Regulation | 2019 |
The Intra-nuclear SphK2-S1P Axis Facilitates M1-to-M2 Shift of Microglia via Suppressing HDAC1-Mediated KLF4 Deacetylation.
Topics: Acetylation; Animals; Brain Injuries; Cell Plasticity; Cells, Cultured; Fingolimod Hydrochloride; Glucose; Histone Deacetylase 1; Inflammation Mediators; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lysophospholipids; Microglia; Oxidation-Reduction; Oxygen; Phagocytosis; Phenotype; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Promoter Regions, Genetic; Rats; RNA, Small Interfering; Signal Transduction; Sphingosine | 2019 |
Sphingosine-1-phosphate analog FTY720 reverses obesity but not age-induced anabolic resistance to muscle contraction.
Topics: Aging; Animals; Cells, Cultured; Diet, High-Fat; Fingolimod Hydrochloride; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Muscle Contraction; Muscle, Skeletal; Obesity; Random Allocation; Sarcopenia; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2019 |
Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.
Topics: Adult; Biomarkers; Central Nervous System; Cerebrospinal Fluid; Female; Fingolimod Hydrochloride; Humans; Longitudinal Studies; Lysophospholipids; Male; Middle Aged; Multiple Sclerosis; Peripheral Nervous System; Sphingosine | 2019 |
Sphingosine-1-phosphate (S1P) signaling regulates the production of intestinal IgA and its potential role in the pathogenesis of canine inflammatory bowel disease.
Topics: Animals; Dog Diseases; Dogs; Feces; Fingolimod Hydrochloride; Gene Expression; Immunoglobulin A; Inflammatory Bowel Diseases; Intestines; Lysophospholipids; Male; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2019 |
Cytokine-Induced and Stretch-Induced Sphingosine 1-Phosphate Production by Enthesis Cells Could Favor Abnormal Ossification in Spondyloarthritis.
Topics: Adolescent; Adult; Aged; Animals; Calcification, Physiologic; Cells, Cultured; Chondrocytes; Cytokines; Female; Fingolimod Hydrochloride; Humans; Lysophospholipids; Male; Metabolic Networks and Pathways; Mice; Middle Aged; Osteoblasts; Osteogenesis; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Spondylarthritis; Stress, Mechanical; Synovial Fluid; Tenocytes; Up-Regulation; Young Adult | 2019 |
Sphingosine 1-phosphate but not Fingolimod protects neurons against excitotoxic cell death by inducing neurotrophic gene expression in astrocytes.
Topics: Animals; Astrocytes; Cell Death; Fingolimod Hydrochloride; Gene Expression Regulation; Hippocampus; Humans; Lysophospholipids; Mice; Nerve Growth Factors; Neurons; Neuroprotective Agents; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
FTY720 Protects Against Ischemia-Reperfusion Injury by Preventing the Redistribution of Tight Junction Proteins and Decreases Inflammation in the Subacute Phase in an Experimental Stroke Model.
Topics: Animals; Apoptosis; Brain Ischemia; Endothelial Cells; Fingolimod Hydrochloride; Inflammation; Organophosphates; Rats, Sprague-Dawley; Sphingosine; Tight Junction Proteins | 2020 |
The Immunosuppressant Fingolimod (FTY720) for the Treatment of Mechanical Force-Induced Abnormal Scars.
Topics: Animals; Cell Differentiation; Cicatrix, Hypertrophic; Cytokines; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Macrophages; Mechanical Phenomena; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; RAW 264.7 Cells; Sphingosine; Th1-Th2 Balance; Th2 Cells | 2020 |
Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
Topics: Actin Cytoskeleton; Animals; Azetidines; Benzyl Compounds; Cell Membrane; Chemokine CCL2; Down-Regulation; Fingolimod Hydrochloride; Graft Rejection; Humans; Lysophospholipids; Macrophages; Membrane Proteins; Mice; Multiple Sclerosis; Organ Transplantation; Phosphoric Monoester Hydrolases; RAW 264.7 Cells; Receptors, Interleukin-8A; rhoA GTP-Binding Protein; Signal Transduction; Sphingosine; United States; United States Food and Drug Administration | 2020 |
Selective detection of phospholipids using molecularly imprinted fluorescent sensory core-shell particles.
Topics: Fingolimod Hydrochloride; Fluorescence; Humans; Lysophospholipids; Molecular Imprinting; Nanoparticles; Polymers; Silicon Dioxide; Sphingosine | 2020 |
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.
Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Data Analysis; Dogs; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Haplorhini; Humans; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine | 2020 |
Fingolimod inhibits multiple stages of the HIV-1 life cycle.
Topics: Fingolimod Hydrochloride; HIV Infections; HIV-1; Humans; Lysophospholipids; Phosphorylation; SAM Domain and HD Domain-Containing Protein 1; Signal Transduction; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; T-Lymphocytes; Virus Latency; Virus Replication | 2020 |
Morpholino Analogues of Fingolimod as Novel and Selective S1P
Topics: Animals; Central Nervous System; CHO Cells; Cricetulus; Disease Models, Animal; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Ligands; Lymphopenia; Lysophospholipids; Mice; Morpholinos; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Spinal Cord; T-Lymphocytes | 2020 |
Discordant disability data in multiple sclerosis phase 3 studies among sphingosine-1- receptor modulator drugs.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pharmaceutical Preparations; Sphingosine | 2020 |
Fingolimod (FTY720) prevents chronic rejection of rodent cardiac allografts through inhibition of the RhoA pathway.
Topics: Allografts; Animals; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Mice; Multiple Sclerosis; Propylene Glycols; Rats; Rodentia; Sphingosine | 2021 |
Sphingosine-1-phosphate and its mimetic FTY720 do not protect against radiation-induced ovarian fibrosis in the nonhuman primate†.
Topics: Animals; Female; Fibrosis; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Macaca mulatta; Ovarian Diseases; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2021 |
Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
Topics: Atrioventricular Block; COVID-19; Fingolimod Hydrochloride; Humans; Lysophospholipids; Pandemics; SARS-CoV-2; Sphingosine | 2021 |
Fingolimod attenuates renal ischemia/reperfusion-induced acute lung injury by inhibiting inflammation and apoptosis and modulating S1P metabolism.
Topics: Acute Lung Injury; Animals; Apoptosis; Fingolimod Hydrochloride; Inflammation; Ischemia; Lysophospholipids; Rats; Reperfusion; Reperfusion Injury; Sphingosine | 2021 |
ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P
Topics: Animals; CHO Cells; Cricetulus; Fingolimod Hydrochloride; Humans; Lymphocyte Count; Lysophospholipids; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes | 2021 |
Blocking T-cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity.
Topics: Fingolimod Hydrochloride; Immunologic Factors; Immunosuppressive Agents; Propylene Glycols; Sphingosine; T-Lymphocytes; Vaccines, DNA | 2022 |
Plasma Sphingosine-1-Phosphate Levels Are Associated with Progression of Estrogen Receptor-Positive Breast Cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Female; Fingolimod Hydrochloride; Gene Expression; Humans; Lymphatic Metastasis; Lysophospholipids; MCF-7 Cells; Middle Aged; Plasma; Receptors, Estrogen; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2021 |
S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo.
Topics: Animals; Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interleukin-23; Lysophospholipids; Mice; Neurodegenerative Diseases; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes, Regulatory; Th17 Cells; Thiophenes | 2022 |
Synthesis and Evaluation of Serinolamide Derivatives as Sphingosine-1-Phosphate-1 (S1P
Topics: Fingolimod Hydrochloride; Lymphocytes; Lysophospholipids; Receptors, Lysosphingolipid; Sphingosine | 2022 |
Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment.
Topics: Animals; Central Nervous System; Cisplatin; Cognitive Dysfunction; Fingolimod Hydrochloride; Lysophospholipids; Mice; Mice, Inbred NOD; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2022 |
Resveratrol Affects Sphingolipid Metabolism in A549 Lung Adenocarcinoma Cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Alkaline Ceramidase; Antioxidants; Biochemical Phenomena; Ceramides; Fingolimod Hydrochloride; Humans; Lysophospholipids; Neuroprotective Agents; Polyphenols; Resveratrol; Sphingolipids; Sphingomyelin Phosphodiesterase; Sphingomyelins; Sphingosine | 2022 |
Fingolimod Does Not Reduce Infarction After Focal Cerebral Ischemia in Mice During Active or Inactive Circadian Phases.
Topics: Animals; Brain Edema; Brain Ischemia; Disease Models, Animal; Fingolimod Hydrochloride; Hemorrhage; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Sphingosine; Stroke | 2022 |
Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Fingolimod Hydrochloride; Lysophospholipids; Mice; Mice, Transgenic; Proto-Oncogene Proteins c-akt; Sphingosine; Sphingosine-1-Phosphate Receptors; TOR Serine-Threonine Kinases | 2023 |
Effect of Quercetin and Fingolimod, Alone or in Combination, on the Sphingolipid Metabolism in HepG2 Cells.
Topics: Ceramides; Fingolimod Hydrochloride; Hep G2 Cells; Humans; Quercetin; Sphingolipids; Sphingosine | 2022 |
Sphingosine 1 phosphate lyase inhibition rescues cognition in diabetic mice by promoting anti-inflammatory microglia.
Topics: Animals; Apoptosis Regulatory Proteins; Cognition; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fingolimod Hydrochloride; Mice; Microglia; Neuroinflammatory Diseases; Phosphates; Phosphoric Monoester Hydrolases; Sphingosine; Tumor Suppressor Protein p53 | 2023 |
FTY720-P, a Biased S1PR Ligand, Increases Mitochondrial Function through STAT3 Activation in Cardiac Cells.
Topics: Adenosine Triphosphate; Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ligands; Mitochondria; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; STAT3 Transcription Factor | 2023 |
Targeting L-Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; L-Selectin; Lymph Nodes; Lymphocytes; Mice; Multiple Sclerosis; Pharmaceutical Preparations; Sphingosine | 2023 |
Exploration of Tetrahydroisoquinoline- and Benzo[
Topics: Bradycardia; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Tetrahydroisoquinolines | 2023 |
Glial Sphingosine-Mediated Epigenetic Regulation Stabilizes Synaptic Function in
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Drosophila; Epigenesis, Genetic; Female; Fingolimod Hydrochloride; Histones; Male; Mice; Neuroglia; Neuronal Plasticity; Sphingosine | 2023 |